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Abstract 
Aims: To evaluate the use of public health models in policymaking, with regard to the 
appropriateness and the practicalities of using such models for simulating health 
interventions, and the application of the results of such modelling exercises to public health 
policymaking. 
Methods: In conjunction with policymakers, existing public health models were adapted 
and used for simulating the effects of risk factor interventions on CHD in the England & 
Wales population. These models were evaluated in terms of the limitations of the input 
data, the assumptions underlying the methodology of the models, and problems in 
translating interventions to the simulation environment. 
Results: The simulation of CHD risk factor interventions using the Prevent and POHEM 
models demonstrated how public health models can be used with policymakers to estimate 
the future development of the health of populations; to evaluate alternative routes to 
achieving health goals; to demonstrate the effect of targeting health interventions at 
different sections of a population; to investigate the relationship between risk factors and 
their linked diseases; and for demonstrating the possible effect of health interventions to 
health practitioners. 
Conclusions: Public health models can be used as policy tools, although ultimately they 
may only inform policy, and not drive it, due to other factors which can influence the policy 
agenda. Such models are complex instruments that require a long term commitment in 
terms of funding, and they need to be developed by multidisciplinary teams, whose 
expertise cover the areas of computing, epidemiology and health policy, but most 
importantly policymakers should be involved with their development and use. Although 
public health models may never be validated in terms of a "gold standard", they can be used 
as policy tools as long as one is aware that they are unverified and that they yield results 
of a hypothetical nature. 
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Preface 
I joined the Health Gain Project, based in the Health Promotion Research Unit at the 
London School of Hygiene and Tropical Medicine, in 1992. The aim of the Health Gain 
Project was to combine the expertise of statisticians, epidemiologists, economists and 
computer modellers to explore the effectiveness and resource implications of differing 
strategies for reducing the burden of coronary heart disease. The Project worked alongside 
policymakers within the National Health service, bringing academic knowledge to bear on 
the planning issues which faced practitioners. 
It was felt that public health models could be useful in assessing the relative health gain of 
alternative routes to the attainment of strategic goals, such as The Health of The Nation 
targets, and would be helpful for applying epidemiology to decision making at a population 
level. 
During the course of my work I realised that although such public health models were 
meant to be used as policy tools; they were often developed and used without input from 
policymakers. And so I thought it would be interesting to investigate the extent to which 
such modelling might be used for decision making, what were the issues which hindered 
their use, and whether an "ideal" public health model could be defined. In this thesis I 
discuss the issues that I think are important in terms of being able to use public health 
models for policymaking, as well as trying to answer the above questions. 
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Chapter 1- Simulation Models and Public Health Modelling 
1.1 Introduction 
Usually the effectiveness of intervention strategies are evaluated by experimental or 
observational methods in longitudinal studies, such as randomised control trials or 
cohort studies. The results of these studies would be extrapolated to estimate the effect 
for a given population. Unfortunately the time-scales necessary for such studies can be 
prohibitive. This is particularly true for health promotion strategies which target risk 
factors for diseases with long latency periods, such as coronary heart disease (CHD). 
Current health care demands require policy decisions to be based on evidence, but the 
decisions must be made before there is time to collect evidence from observational 
studies. 
In recent years the use of simulation models has been seen as a partial solution to the 
problem of the evaluation of health interventions, particularly in terms of interventions 
aimed at reducing the risk of non-communicable diseases (Morgenstern 1992 and 
Manton 1988). These computer models allow policymakers to simulate the effects of 
different scenarios within a population, using available data on existing risk factor 
prevalence, the related risks of disease morbidity and mortality, and the likely change in 
risk factor prevalence due to interventions, and then project the results over several 
generations. It is envisaged that these models will be useful in evaluating the relative 
health gain of different approaches to attaining specific health outcomes. These models 
also permit policymakers to apply epidemiology to decision making at a population 
level. 
The aim of this thesis is to evaluate the use of public health models in policymaking, 
with regard to the appropriateness and the practicalities of using such models for 
simulating health interventions, and the application of the results of such modelling 
exercises to public health policymaking. 
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Through the adaptation and use of existing public health models for simulating the 
effects of risk factor interventions on CHD in the England & Wales population, this 
thesis will consider the limitations of the input data, the assumptions underlying the 
methodology of the model, and problems in translating interventions to the simulation 
environment. 
The future role of public health models in policymaking will be discussed in terms of 
how and by whom they should be utilised, and the requirements for producing models 
that are able to address the policy agenda. 
In this chapter I will first give an overview of modelling in general, with examples of 
various types of models used in different areas of health research, but I will 
concentrating on those that were designed for simulating coronary heart disease (CHD) 
interventions as an aid to public health policymaking. While the second part of the 
chapter describes in more detail seven public health policy models that I have identified. 
PART I 
1.2 Definitions 
A model can be defined as a "computerised mathematical description of some system of 
objects and activities", and modelling as "the art of constructing and using such models 
as tools for analysing policy alternatives and evaluating operations" (Lagergren 1995). 
While simulation can be viewed as "the concept of modelling complicated systems by 
simpler ones" (Ackerman 1994). I perceive modelling to be the use of simplified 
theoretical frameworks which allow the simulation of complex dynamic processes. It 
allows one to break down a process into its contributory sub-processes, and to 
investigate the interactions and importance of these sub-processes in relationship to the 
whole process and the other sub-processes. 
The idea of models being a simplified version of reality has meant that there has been a 
widespread suspicion of mathematical modelling within the health and medical 
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communities, as simplification was considered to overlook too many key features of a 
real system (Ackerman 1994'). However, in recent years there has been a growing 
acceptance of mathematical model in health (Royston 1999), particularly with the 
appearance of WHO's Global Burden of Disease model (Murray 1997'). 
Lagergren (Lagergren 1995) identifies three different objectives that can be achieved by 
using models: 
" making prognoses regarding the future development of the system, 
" evaluating decision alternatives by calculating outcomes of different choices, 
" developing a deeper insight into the properties of the system and how it reacts to 
different stimuli as a basis for policy development. 
Whether these objectives are achieved will depend on the purpose of the modelling 
exercise, although some objectives may be achieved through the modelling process even 
though they were not the aim of the exercise. In the course of this thesis I will explore 
whether and how public health models achieve these goals. 
1.3 Types of Model 
Non-communicable disease models have been developed in a number of areas for 
simulating interventions relating to screening (Habbema 1984), medical interventions 
(van Hout 1992), resource allocation (Taket 1992) and risk factor reduction (Gunning- 
Schepers 19922). Many such models have concentrated on various forms of cancer 
(Habbema 1984, Michalski 1992, McPherson 1992 and Rusnak 1992) possibly due the 
availability of data relating to incidence from cancer registries. More recently new 
infectious disease models have been developed relating to HIV (Blower 1992), with 
models simulating transmission among injecting drug users (van Haastrecht 1994 and 
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van Ameijden 1996), distributed incubation and variable infectiousness (lannelli 1992), 
and the cost-effectiveness of prevention targeting (Kahn 1996). 
In terms of CHD health policy there are several models which concentrate on individual 
risk factors (Grover 1992), risk factors and cardiovascular treatment (Capewell 19991), 
secondary care such as blood pressure screening (Selmer 1990 and Norman 1991) and 
cholesterol lowering treatment (Glick 1992), familial aggregation of disease (Aalen 
1991), priority rating systems (Vilnius 1990) and pathways of coronary care (Bensley 
1995), risk estimation and counselling (Thorsen 1979), estimating GP workload 
(Randall 1992), and cardiological treatment (Budde 1997 and Capewell 19992). 
Relative risks, population attributable risks and multiple logistic equations are used as 
the basis of many of these types of model (Chang 1990, Chambless 1990 and Clayton 
1993). These same methods have previously been used to relate data from sub- 
population studies to an individual's risk, as with the Framingham Equation (Anderson 
1990), the Dundee Risk Score (Tunstall-Pedoe 1991) and the British Regional Heart 
Study Risk Score (Shaper 1987). 
1.4 Policy Models 
Individual risk equations are not adequate on their own to relate how the demographic 
characteristics and risk factor profile of a population will determine the outcome of 
interventions on it, since the age and sex distribution will dictate the number of people 
at risk of disease, and with the associated patterns of morbidity and mortality will 
influence the magnitude of the effect of interventions. 
It has been proposed that the following characteristics are essential for models that 
simulate health policy options (Chigan 1992): 
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"a time period during which risk factors may develop, latent periods before risk 
factors affect morbidity and mortality, and lag times during which risk factor 
changes translate into mortality reduction, 
" multi-factorial risk factor/disease relationships, where one risk factor can influence 
several diseases, and one disease may be influenced by several risk factors, 
"a demographic basis by which population changes within the simulation period can 
be considered. 
These are the key features by which I define a public health model. A multiple disease 
environment with multi-factorial risk factor/disease relationships are essential 
components, since interventions on a single risk factor can have an effect on several 
diseases, as with cigarette smoking. In addition premature deaths avoided due to an 
intervention will result in more individuals at risk of other diseases at older ages. A 
demographic component is also necessary if one is to model the effect of interventions 
on specific populations, as not only will the distribution of risk factors within the 
population affect the health gain achieved by interventions, but also the structure of the 
population and how it ages will influence the amount of health gain achieved over time. 
Since my work involved issues concerning the primary prevention of CHD, I chose to 
concentrate on models that conformed to Chigan's criteria and included CHD. 
My review of the literature found quite a number of CHD models as discussed in section 
1.3, but very few models conform to Chigan's criteria. This is partly because CHD is a 
complex multistage disease (Heller 1987) for which there are few registries (Marmot 
1992), particularly in terms of morbidity measures such as incidence, recurrence and 
survival. Models which attempt to simulate risk factor interventions on CHD must to 
some extent rely on informed estimates of these measures due to the lack of data. As a 
result such models are difficult to validate (Kotva 1992), and this raises questions 
concerning the appropriateness of using unvalidated models. 
28 
I have identified seven policy models that incorporate CHD, these are Prevent 
(Gunning-Schepers 1989: 1992: 19922: 1994: 1995, Barendregt 1990 and Wolfson 19922), 
the Coronary Heart Disease Policy Model (Morgenstern 1992, Wolfson 19922, Goldman 
1989: 1991, Hatziandreu 1988, Tosteson 1990, Tsevat 1991, Weinstein 1985: 1987), 
NIMPH/TAM (Bonneux 1992: 1994, TAM Research Group 1992 and Niessen 1993), 
Prevent Plus (Barendregt and Bonneux, personal communications), the CRISPERS 
model (Zhuo 1991': 19912: 19913: 1994 and Ackerman 1994': 19942: 19943: 19944), 
POHEM (Wolfson 1991: 1992': 19922) and the Global Burden of Disease model (Murray 
1997': 19972: 19973: 19974). These models have all been developed for populations other 
than England and Wales, and so it is important to evaluate their appropriateness, in 
terms of their usability, when applied to this population, and their potential use in 
assessing the effect of health interventions. 
PART II 
1.5 Review of CHD Policy Models 
The seven CHD policy models I have identified are either cell-based or micro- 
simulation models. 
1.5.1 Cell-based Models 
Within a cell-based model the population is subdivided into cells, such as by age, sex, 
and risk factor exposure categories, and it is to these separate cells that specific 
probabilities of events are applied. Over a simulated period the events for all the cells 
are summed to produce outcomes for the whole population, such as disease specific 
mortality rates for each age group in the population. 
These models use less computer memory and processing time than the micro-simulation 
models described below, and can therefore be run on less powerful computers. For 
example, the Prevent cell-based model originally ran on an IBM PC with 640KB of 
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RAM and a maths coprocessor running under MS DOS 2.0. In general cell-based 
models tend to be easier for a lay audience to use and understand than micro-simulation 
models. 
However, the methodology of cell based models inherently imposes restraints on the 
complexity of the model, since increasing the number of data sets, risk factors, diseases, 
disease/risk factor relationships, age groups, or exposure categories will produce 
unmanageably large matrices of cells. This is a major disadvantage of this type of 
model. For instance, with Prevent, a risk factor with two exposure categories covering 5 
age groups for both sexes and linked to one disease will produce 20 cells for the 
prevalence of the risk factor, and these are associated with 20 probabilities of disease 
mortality, which equals 40 cells in all. Doubling the number of age groups, exposure 
categories and disease associations it will produce 80 cells for the prevalence, each with 
two probabilities of disease mortality, which equals 240 cells in all. 
1.5.2 Micro simulation Models 
By contrast, micro-simulation models depend upon a monte-carlo simulation, where 
each individual in a cohort is generated separately using a random process, and over the 
simulation period these individuals can be subjected to certain events; the probabilities 
of these events being drawn randomly from distributions. These models, unlike cell 
based models, therefore have the capacity to absorb all the required risk factors and 
interdependencies. The models require powerful computers with large capacity 
memories, since the life of each individual in the population must be generated and 
stored. Statistics Canada run the micro-simulation model POHEM on a dual Pentium II 
266Mhz with 132Mb DRAM. A simulation of 100,000 individuals takes about half an 
hour, while a run of 4 million individuals would take 16 hours. So even though the 
speed and capacity of readily available computers are increasing; technical constraints 
may still hinder such models' use as a policy tool. 
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1.6 Prevent 
Prevent is probably the most accessible of the models, due to its menu driven interface, 
to be reviewed. The model was developed by Professor Louise Gunning-Schepers, who 
is now based in Amsterdam, for her PhD in 1988. 
The minimum system requirements for running the model are an IBM compatible 
personal computer, using MS DOS 2.0 or higher, with 512KB RAM, a hard disk and a 
graphics adapter, although it is recommended to have 640KB RAM and a maths 
coprocessor. 
Prevent is a cell-based simulation model that can estimate the health benefits for a 
population of changes in risk factor prevalence due to trends and interventions, in terms 
of absolute changes in such parameters as disease-specific and total mortality. The 
underlying methodology allows for (Gunning-Schepers 1989): 
" the possibility that one risk factor affects several diseases, and that one disease is 
affected by several risk factors, 
"a time dimension to simulate the reduction in excess risk after cessation of exposure 
to the risk factor, 
" the interaction between the effect of the intervention and the demographic evolution 
in the population. 
After the user has specified the risk factor to be intervened upon the model first 
calculates the autonomous development, using trends. Then the user specifies change in 
risk factor prevalences after the intervention and the model calculates the development 
due to the intervention and the trends. Next the model calculates the autonomous 
development of all other risk factors that share diseases with the intervention risk 
factors. For instance cigarette smoking is a risk factor for CHD, cerebrovascular 
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accident, chronic obstructive lung disease and lung cancer. Finally the results of the 
calculations are applied to two populations - one with only the autonomous 
developments, and the other with both the autonomous developments and the 
intervention effects. The differences between the two populations are attributed to the 
intervention, with the output given in terms of total and disease specific mortality 
(Barendregt 1990). 
The original version of the model includes the following risk factors and causes of death 
(Barendregt 1990): 
Risk Factors Causes of Death 
Cigarette smoking Coronary heart disease 
Hypertension Cerebrovascular accident 
Cholesterol Chronic obstructive lung disease 
Obesity Lung cancer 
Alcohol Cirrhosis of the liver 
Breast cancer 
Traffic accidents 
Accidental falls 
Table 1.1 - Prevent risk factors and causes of death 
The model has a number of restrictions to limit the size of the data sets used (Barendregt 
1990), and consequently the computer memory required, these are: 
PREVENT Restrictions 
A maximum of 9 risk factors 
A maximum of 9 diseases 
A limit of 4 diseases to be influenced by one risk factor 
A limit of 4 risk factors to influence one disease 
A maximum of 6 risk factor age groups 
A maximum of 5 exposure categories 
A maximum simulation period of 50 years 
Table 1.2 - Prevent restrictions 
The programme has recently been updated for use with Windows NT, which has 
removed many of these restrictions, although a full working version is yet to be 
completed. 
The main drawback to Prevent is that it only gives results of modelling in terms of 
mortality. No output information is available on morbidity, or the costs of treatment. 
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1.7 The Coronary Heart Disease Policy Model 
The Coronary Heart Disease Policy Model (CHDP Model) is a state-transition model, 
where individuals move from a well state through a number of disease states before 
death. This cell-based model was developed in 1987 by Dr Milton Weinstein at 
Harvard. It allows the user to simulate the effects of intervention, both preventive, by 
risk factor modification, and therapeutic, by changing case fatality rates, on mortality, 
morbidity and cost for up to a 30 year period. 
The CHDP Model is made up of three consecutive sub-models (Weinstein 1987): 
" The Demographic-Epidemiologic Model (DE Model), which contains the disease 
free population of 30-84 year olds' stratified into cohorts by age, sex and risk factor 
levels. It uses a logistic risk function based on the Framingham equation to calculate 
the annual incidence rates of CHD events for each cohort. 
" The Bridge Model simulates the initial 30 days after the incidence of the first CHD 
event, with numbers having been passed on from the DE Model. First it determines 
the type of CHD event by age range and sex, then applies probabilities of death 
during the first 30 days following the event by age, sex and type of event. The 
survivors then move into the next sub-model. 
" The Disease History Model (DH Model) classifies the population with a previous 
CHD event into twelve CHD states, and by age and sex. In each simulation year 
patients in each strata are subjected to eight CHD event probabilities, which they 
may or may not experience, and each event and state have associated case fatality 
rates for CHD and non-CHD death, depending on disease history, age and sex. 
These case fatality rates are applied to the population to calculate those who survive 
to the next year of simulation and those who die. 
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The main problem with the CHDP Model is that the number of strata can get very large. 
The existing model uses 5400 strata in the DE Model and 1200 strata in the DH Model 
(Weinstein 1987). Adding one risk factor with two levels of exposure will double the 
number of strata used. Another problem is that the Bridge Model has a cardiac arrest 
pathway. This was initially included to highlight the need for paramedic services in the 
USA by demonstrating the effect of increased survival due to resuscitation en-route to 
hospital. These cardiac event have been included under fatal acute myocardial infarction 
in later incarnations of the model as NIMPH (TAM Research Group 1992) and POHEM 
(Wolfson 1992). 
The model was produced in 1987, and therefore the only revascularisation procedure 
included was coronary artery bypass surgery. There is no percutaneous transluminal 
coronary angioplasty. More recently the model has been adapted for use with the 
Australian population (Mui 1999). 
Although called a "policy model" the CHDP Model does not conform to my definition 
of a policy model since it does not simulate a multi-disease environment. 
1.8 The Netherlands Integrated Model of Public Health 
The Netherlands Integrated Model of Public Health (NIMPH), formerly known as 
TAM, was produced by Jan Barendregt, who programmed PREVENT, and Dr Luc 
Bonneux at Erasmus University in Rotterdam. It is a cell-based model that is used to 
simulate a multi-disease environment, where individuals are at risk from 32 disease 
groups, with each disease being part of a separate submodel, the CHD model being just 
one of them. The methodology allows the simulation of the following phenomena 
(TAM Research Group 1992): 
" Co-morbidity - the concurrent prevalence of two or more diseases in one person, 
34 
" substitution of causes of death - where death is caused by more than one diseases, 
and so the age specific mortality rate of one disease will be affected by changes in 
the age specific mortality rate of another disease, 
" population heterogeneity - differences in risk factor exposure by age group and sex, 
" mortality selection - individuals exposed to risk factors have a higher than average 
probability of developing and dying from various associated diseases, and as they 
die over time the risk factor profile of the population changes and so mortality rate 
change, 
" competing death risks - when two or more diseases have a risk factor in common. 
At a first glance the NIMPH coronary heart disease sub-model seems very similar to 
Weinstein's model. It is made up of a number of further sub-models -a population 
model and a disease model, which includes a Bridge Model, as in Weinstein's model, a 
CHD model and a CHF (congestive heart failure) model. However, its methodology is 
different. The model is based on the principle of multi-state life tables, where life 
expectancy in various health states is used. NIMPH has no risk factors so does not use 
the Framingham equation, but calculates the proportional disease prevalences using 
disease specific mortality and incidence rates, and these are applied to a synthetic cohort 
(TAM Research Group 1992). The output figures are calculated as percentages and 
these are applied to the absolute numbers in the population model. 
For each time step the disease sub-model computes the prevalence and the disease 
specific mortality rate from the incidence rate and the relative survival rate in terms of 
percentages, without calculating absolute numbers. Then the disease specific mortality 
rates from the sub-models are combined with the total mortality rate in order for the 
population model to calculate the number of people alive in the next time step. 
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As with Weinstein's model, people in the well population who experience their initial 
CHD event move into the Bridge Model for the first 30 days of illness. However, 
cardiac arrest is not classed as a separate event, but is included with, and classed as, a 
myocardial infarction. Percutaneous transluminal coronary angioplasty is modelled as 
well as coronary artery bypass grafts. Those that survive can then move into either the 
CHD model or the CHF model depending on their CHD events. Within the CHD model 
patients can experience further CHD events over time until they die, or they move into 
the CHF model. Patients in the CHF experience further CHD events until they die; they 
cannot move into the CHD model (TAM Research Group 1992). 
The developers of the NIMPH model are currently working on separating the CHF 
model from the CHD model, and then creating an overall Cardiovascular Disease model 
which will incorporate the CHF, CHD and Stroke models as sub-models. Work is also 
in progress to add a risk factor module. 
1.9 Prevent Plus 
The Rotterdam team, who produced Prevent and have developed NIMPH, have 
produced a version of Prevent that includes morbidity and costs called Prevent Plus. 
Like its predecessor Prevent Plus is a cell-based model. It includes the following risk 
factors and diseases (Barendregt and Bonneux, personal communications): 
Risk Factors Causes of Death 
Cigarette smoking Coronary heart disease 
Hypertension Cerebrovascular accident 
Cholesterol Lung cancer 
Table 1.3 - Prevent Plus risk factors and causes of death 
And produces output on the following: 
0 
0 
0 
0 
Disease specific hospital days, 
Disease specific costs, 
Disease specific unhealthy person years, 
Aggregated hospital days, 
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" Aggregated costs, 
" Aggregated unhealthy person years, 
" Aggregated population hospital days, 
" Aggregated population costs, 
" Aggregated population unhealthy person years, 
" Disease specific incidence (rates), 
" Disease specific incidence (numbers), 
" Disease specific incidence reduction (numbers), 
" Disease specific prevalence (rates), 
" Disease specific prevalence (numbers), 
" Disease specific prevalence reduction (numbers). 
The model initially used survival times and case fatality rates to produce some measure 
of morbidity, but now output from NIMPH on incidence rates and on incidence specific 
prevalence, which is the disease prevalence due to the incident rate, is used to calculate 
morbidity. The underlying methodology is based on a special type of multi-state life 
table called a proportional multi-state life table, which allows for at least one disease 
state as well as the normally used states of alive and dead (Barendregt and Bonneux, 
personal communications). 
As with Prevent, the model was originally produced to run under DOS, but has been 
updated to run using Windows NT. 
1.10 The Population Health Model 
The Population Health Model (POHEM) has been developed by Dr Michael Wolfson at 
Statistics Canada in Ottawa. It uses the micro-simulation technique to model the 
dynamics of multiple risk factors and major diseases, one of which is CHD, under 
various demographic and health-related processes for a heterogeneous population 
(Wolfson 19922). The model was originally written in APL, but has been converted to 
Visual C++ to make the code more accessible to other users. This process was 
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envisioned by Statistics Canada to have been relatively quick and simple, but has taken 
over four years to complete. 
The model uses a monte-carlo process to generate random life tables, where, within 
each year, an individual is randomly simulated to either die, become ill, or stay well. 
The probabilities of changing states are randomly drawn from age specific uniform 
distributions. This process is repeated a considerable number of times to produce a large 
synthetic cohort (Wolfson 1992'). 
As well as the monte-carlo process POHEM uses a number of dynamic algorithms to 
simulate the following processes (Wolfson 1991): 
" Environmental exposures, such as toxic substances or stressful work environment, 
" Socio-economic status, such as income or marital status, 
" Risk factors, such as high blood pressure or cigarette smoking, 
" Diseases, such as CHD and lung cancer, 
" Functional status, such as gross motor function or vision, 
" Health care utilisation such hospitalisation, 
" Summary health status, based on functional status. 
Within the Disease process is the CHD model, which uses Weinstein's model 
transformed to be consistent with the POHEM architecture, and uses Canadian risk 
factor distributions and treatment protocols (Wolfson 1991). Since it avoids having to 
stratify the population by age, sex and risk factor levels, as with cell-based models, 
POHEM does not start off computationally too memory hungry, although it takes longer 
for a simulation run and requires more data storage space, due to its having to generate 
each individual of the cohort separately. 
Overall the methodology of POHEM gives it great flexibility, with its ability to include 
external factors such as social status and environmental exposure, as well as the 
traditional risk factors. In addition, the model seems to produce more detailed 
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information on morbidity, in terms of functional and health status, and cost, in terms of 
health care utilisation. 
1.11 The Chronic Disease Risk Intervention Simulation Program for 
Epidemiological Research Studies 
The Chronic Disease Risk Intervention Simulation Program for Epidemiological 
Research Studies (CRISPERS) model was developed by Dr Park and Dr Zhuo at the 
University of Minneapolis for their Ph. D. 's, submitted in 1987 and 1991 respectively. 
It is a stochastic compartmental model for simulating the effect of risk factor 
interventions on CHD morbidity and mortality for a micro-population (Zhou 1991'). 
The model includes the risks factors cholesterol, diastolic blood and cigarette smoking 
as dichotomous variables, the distribution of which are taken from an actual population 
(Zhou 1991). The risk factor distributions are used by a multivariate risk function, 
derived from the United States Railroad (USR) study population made up of men aged 
40 to 59, to generate disease events (Zhou 19911). These events are: 
" Incident myocardial infarction MI (fatal and non-fatal); 
" Cardiac death; 
" Death from other causes. 
The CRISPER model uses a methodology of disease states, very similar to the CHDP 
Model, while the model generates individuals using a monte-carlo process as used by 
POHEM. At the start of a simulation an individual is generated as being in a "healthy" 
state, meaning that they having no history of MI. In each simulation time interval a 
healthy individual has the probability of experience one of the three events mentioned 
above, or remaining healthy depending on their risk factor distribution. If an individual 
survives the time interval without experiencing an event, then the individual will 
continue in the healthy state until the next time interval. If the individual experiences a 
cardiac death, a fatal MI, or death from other causes they leave the model. However, if 
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an individual experiences a non-fatal MI then he or she will move into a "previous MI" 
state, and in the next time interval they can experience no change, a death from other 
causes with CHD, a prevalent CHD death, or a recurrent non-fatal MI, depending on 
their risk factor distribution and the time since their initial MI. This process continues 
for each time interval until the individual dies, and then the process is begun again with 
a new healthy individual, and repeated until the micro-population has been created. The 
whole process is repeated using a risk factor distribution resulting from an intervention, 
and the two runs are compared to calculate the effect of the intervention on the micro- 
population (Zhou 1991'). 
As with the CHDP Model, the CRISPER does not conform to my definition of a policy 
model since it does not simulate a multi-disease environment, where several risk factors 
influence several diseases. 
1.12 The Global Burden of Disease Model 
The Global Burden of Disease Model was developed by Dr Murray and Dr Lopez at the 
request of the World Bank, and in collaboration with WHO, as part of the Global 
Burden of Disease (GBD) Study in 1992. The three primary goals of the GBD study 
were to provide information on international non-fatal health outcomes for debates on 
international health policy, to develop unbiased epidemiological assessment for major 
disorders, and to quantify the burden of disease with a measure that could also be used 
for cost-effective analysis (Murray 1997'). Within the remit of these goals there were 
four specific objectives (Murray 1997'): 
I. To develop internally consistent estimates of mortality for 107 causes of death 
by age, sex, and geographic region. 
II. To develop internally consistent estimates of incidence, prevalence, duration, 
and case-fatality for 483 disabling sequelae of the 107 causes. 
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III. To estimate the fraction of mortality and disability attributable to ten major risk 
factors. 
IV. To develop various projection scenarios of mortality and disability estimates by 
cause, age, sex, and region. 
The ten major risk factors included in the model were malnutrition, poor water, 
sanitation and hygiene, unsafe sex, alcohol, occupation, tobacco use, hypertension, 
physical inactivity, illicit use of drugs, and air pollution (Murray 1997). 
The regions, defined by the World Bank, that the model was applied to were (Murray 
1997'): 
" High income Organisation for Economic Cooperation and Development (OECD) 
members; 
" Former socialist economies of Europe; 
" Latin America and the Caribbean; 
" China; 
" India; 
" The middle eastern crescent; 
" Other Asia and islands; 
" Sub-Saharan Africa. 
The model can calculate the attributable burden of disease for a specific risk factors, 
population and time, which is defined as "the difference between currently observed 
burden and the burden that would be observed if past levels of exposure had been equal 
to a specific reference distribution of exposure", where the reference distribution of 
exposure is defined as the risk factor exposures with the lowest relative risk (Murray 
1997). 
41 
CHD is included in the model, and is modelled as being caused by tobacco use, 
hypertension and physical inactivity, and reduced by alcohol at all levels of 
consumption. The model uses attributable fractions, taken from reviews and meta- 
analyses, applied to the population of a region to calculate the burden of disease of these 
risk factors (Murray 1997). 
1.13 Applying Models to the England & Wales Population 
Having reviewed the models I decided to proceed with the Prevent and POHEM 
models, since they conformed to my criteria for being classed as policy models, they 
included CHD as one of the diseases they could simulate, they could be adapted for use 
with the England & Wales population, and their developers were willing for others to 
develop their own country versions of the models. 
In the chapters that follow I chronicle my use of Prevent and POHEM models. I 
describe how I have adapted these models for use with the England & Wales population, 
the problems I encountered, and how I have overcome or circumvented these problems. 
In addition I will discuss their use as policy tools, in terms of their ease of use, data 
needs and ability to model policy relevant interventions. 
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Chapter 2- Policy Decisions in Public Health 
2.1 Introduction 
Public health models use simplified theoretical frameworks which allow the simulation 
of complex dynamic processes, and the construction of these frameworks are dependent 
on theoretical models that link biological, environmental, social and economic factors to 
health. It is necessary to understand these theoretical models, and how their factors for 
health relate to the health policy agenda, in order to build public health models that can 
be used as a tool for policymaking. 
This chapter begin with definitions of health, public health and health policy. Then 
continues by outlining the evolution of public health models with the shift from the Old 
Public Health to the New Public Health. The chapter then moves on to a discussion of 
the link between research and policy making, and the problems of translating research 
evidence into policy with reference to the Rational, the Realistic and the Incremental 
models of research. I conclude by discussing the role of mathematical modelling as an 
aid to policymaking. 
2 1.1 The Concepts of Health, Public Health and Health Policy 
Over time new definitions and concepts have been established with regard to health, 
public health and health policy (Berridge 2000). In discussing these concepts one needs 
to first define what is the current meaning of the terms. With regard to health WHO 
defines it as: 
" "a resource for everyday life, not the objective for living ... a positive concept 
emphasising social and personal resources, as well as physical capacities" - Ottawa 
Charter (WHO 1986); 
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" "a resource which gives people the ability to manage and even to change their 
surroundings" - Achieving Health For All (WHO 1979). 
Within these definitions there is a sense of health being the absence of disease and 
disability, as well as a resource which gives individuals the ability to interact with their 
surroundings, both in the social and the physical contexts. 
In addition, WHO defines the "Prerequisites for Health" (WHO 1986), which are the 
fundamental conditions and resources for health. These are peace, shelter, education, 
food, income, a stable eco-system, sustainable resources, social justice, and equity. This 
fits with the definitions of health as being concerned with the individual and their 
environment. 
Public health grew out of 19' century environmentalism which was concerned with 
health hazards in the physical environment. Following on from the work in the 1840s of 
Edwin Chadwick, which, at a time of epidemic diseases, highlighted the link between 
dirt and disease, and its association with overcrowding and sanitation; public health has 
now evolved to include the socio-economic environment (Berridge 2000). The Acheson 
Report (Department of Health 1988) defined public health as "the science and art of 
preventing disease, prolonging life and promoting health through organised efforts of 
society", while Last defines it as "the combination of science, practical skills, and 
beliefs that is directed to the maintenance and improvement of the health of all people 
... through collective or social action" 
(Last 1987). 
Together these definitions regard public health as a phenomenon that can be influenced 
by collective action, and that has significance for the population as a whole, or for sub- 
groups within it, be they by age groups, ethnicity or socio-economic status (RIVM 
1994). 
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Health policy can be defined as the action of government and other players which are 
aimed at maintaining and improving the population's state of health. It can be seen as 
having two goals (HMSO 1992): 
" adding years to life - an increase in life expectancy and reduction in premature 
death, 
" adding life to years - increasing years lived free from ill-health, reducing or 
minimising the adverse effects of illness and disability, promoting healthy lifestyles, 
physical and social environments and, overall, improving quality of life. 
2.2 Public Health Models 
There has been a change in the emphasis of health policy, driven by a shift from the Old 
Public Health model to the New Public Health model. The Old Public Health was 
mainly concerned with the consequences of unhealthy settlements, and in that context 
with the safety of food, air and water. In terms of diseases it was largely concerned with 
infectious, toxic and traumatic causes of death, which were predominant among young 
people and were associated with poverty. In contrast, the New Public Health emerged to 
meet a whole new set of diseases associated with longevity and over-population, with 
industrialisation and industrial decline, with inequalities in health in affluent societies, 
with environmental damage, and with ecological imbalance. This change has been 
influenced by the belief that many of the underlying factors for these diseases can be 
amenable to prevention through social, environmental or behavioural change (Lancet 
1991). 
The shift reflects how the perceived relationship between health, health care and disease 
has changed over time. These changes have been outlined in terms of a number of 
frameworks. The traditional view of the health, health care and disease relationship was 
that disease led to a need for health care, and required access to health care. The role of 
health care was seen as trying to cure existing disease, or care for the consequences of 
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disease, and was not concerned with the factors causing disease. Within this framework 
new or more disease leads to more health care being required, see Figure 2.1. 
NEED. ACCESS 
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DISEASE HEALTH CARE 
CARE, CURE 
Figure 2.1 - Health care activities dominate issues of health policy (Evans 1990) 
The 1970s and 1980s saw a move to investigate the area labelled "Other Factors" as 
health care costs increased, especially since a number of studies indicated the 
considerable scope for improving the efficacy, effectiveness, cost-effectiveness and 
appropriateness of health care utilisation, see Figure 2.2. By 1974, in Canada, the 
increasing costs of health care led the Minister of National Health and Welfare to 
producing a document entitled "A New Perspective on the Health of Canadians" 
(Canada 1974), known as the Lalonde Report. It called for a shift away from focusing 
on health care as the only determinant of health, and proposed consideration of the areas 
of lifestyle, environment and human biology. The Report identified the paradox that 
although most of the burden of ill health was a result of lifestyle, environment and 
human biology; most of the expenditure on health went into health care. And so 
advocated that improvements in the environment and in lifestyle would be the most 
effective means of reducing mortality and morbidity. Essentially, the Lalonde Report 
signalled the shift in emphasis from the treatment of illness to the prevention of illness 
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or, as Lalonde later remarked "more positively, to the promotion of health" (Lalonde 
1977). 
GROWING HEALTH CARE COSTS 
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Figure 2.2 - Health policy of the 1970s and 1980s (Evans 1990) 
The Report contributed to a focus on things individuals could do something about, 
especially in terms of individual risk factors for specific diseases. Interventions then 
began to be aimed at the individual. Underlying this policy development was the 
implicit model that individuals choose unhealthy lifestyles due to ignorance, and that 
once they are provided with the appropriate information they would change their 
lifestyles, and so improve their health status. This ignores the possibility that individuals 
may be informed and still choose unhealthy behaviour due to conditioning, personal 
enjoyment or their social environment. However, this philosophy of individual 
responsibility for health has made the framework politically attractive to conservative 
governments, since more individual responsibility to lead a healthier lifestyle is 
conceived as leading to less demands on health services and to state intervention, and so 
is seen to be a means of saving money for governments. 
Since 1974 a considerable amount of research evidence has amassed which does not fit 
into the Lalonde framework. Evans and Stoddart (Evans 1990) identified new areas 
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which include the positive correlation between health and wealth, with the gradient in 
the relationship of socio-economic status to health which exists across countries, across 
different diseases and other measures of health, and across time. Also, they noted that 
access to health care has not narrowed the inequalities in the distribution of health 
across socio-economic groups. They also identified a strong positive correlation 
between lack of social support and poor health, the importance of self-esteem, the 
ability to exert control over life and coping skills, and the potentially critical role played 
by childhood experiences. In addition, the emerging knowledge about genetic 
predisposition to disease, and the importance of interactions between the genetic 
endowment and the environment, both physical and social, were recognised by Evans 
and Stoddart. As well as considering the preliminary work on biologic pathways linking 
the mind, the nervous system and the immune system. 
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Figure 2.3 - Health policy after the Lalonde Report (Evans 1990) 
In response to these shortcomings Evans and Stoddart (Evans 1990) suggested a model 
(Figure 2.3) which encompasses these issues, with the key addition of the "Individual 
Response" box which includes behaviour as well as biological responses to the 
individuals environment, and includes some factors or processes that were previously in 
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the lifestyle and human biology fields. In addition genetic endowment has been added, 
which includes the concept of predisposition to disease or ill health within certain 
physical or social environments. Finally, a Prosperity box has been added to allow for 
the effects of changes in productivity, income and wealth on living standards, and in 
turn on social environment. This framework has been encompassed by the Social 
Ecological Theory (Stokols 1996), the main concepts of which are (Coombes 2000'): 
" Environmental settings have multiple physical, social, and cultural dimensions that 
can influence a variety of health outcomes. 
" The health promotive capacity of an environment is the cumulative impact of 
multiple environmental conditions. 
" Human health is not only influenced by environmental factors, but also personal 
attributes such as genetic heritage, psychological disposition, and behavioural 
patterns. 
The last framework, along with this theory, attempts to conceptualise the current views 
on the relationship between health, health care and disease. 
2.3 Issues In Current Health Policy 
Since the Black Report (DHHS 1980) on inequalities in health it has been becoming 
increasingly clear that social deprivation provides a major determinant of poor health 
status (Birt 1996). While in the UK and US, although there has been an overall decline 
in death rates, socio-economic differences in death rates have been increasing (Marmot 
1997). 
Social class has been demonstrated to be robust predictor of health outcomes be it 
measured by education, income, or occupation (Marmot 1989), with occupational social 
class being strongly associated with overall and non-cardiovascular mortality, and 
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education being more strongly associated with cardiovascular death (Davey-Smith 
1998'). 
Differing levels of the traditional risk factors by social class only account for a small 
proportion of the differences in health observed (Marmot 1989). It has been suggested 
that these differences may be due to in utero and early life experiences (Barker 1986), or 
psychosocial factors, such as low control of in the work environment and lack of social 
support (Marmot 1989 and Davey-Smith 1998'). 
In recent years the idea of social capital, defined as "the features of social organisation, 
such as civic participation, norms of reciprocity, and trust in others, that facilitate co- 
operation for mutual benefit" (Putnam 1995), has crept onto the policy agenda, being 
mentioned in the Labour government's "Our Healthier Nation" white paper (DoH 
1999). It has been argued that even though much of the rhetoric of public health pays lip 
service to the value of community focus and empowerment, there is less evidence of this 
commitment in service provision (Lomas 1998), and that there is no good theoretical 
account of how to build social capital (Kawachi 1997). 
Clearly with these new areas of interest there is need for aetiological research to explain 
biological pathways (Marmot 1989), as well as for epidemiological research to explain 
their effects on risk (Ben-Shlomo 1996 and Davey-Smith 1998'), and their implications 
for policy (Marmot 1997). 
2.4 The Link Between Research Evidence And Policy Making 
It may seem that once a framework of how various factors influence health and disease 
has been identified; the research evidence would change health policy with the goal of 
improving health. However the process is not so straight forward. There are two 
perceptions of the way that research influences policy (Walt 1995); the idealistic, under 
which the link between research and policy is seen as a rational process, and the 
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realistic, which assumes that research filters into policy through a process of 
enlightenment. 
2.4.1 The Rational Model of Research and Policy Development 
The rational or synoptic model is based on the concept that development of policy is a 
linear process, which is either knowledge driven, or problem driven. If the model is 
knowledge driven, the concept is that basic research will lead on to applied research, 
development of new policy and finally policy application, while if the model is problem 
driven, the concept is that the identification of a problem will lead to a search for 
solutions, which in turn will lead to policy action. 
Walt (Walt 1994) outlines the rational policy making process using the following steps: 
1. The policymaker is faced with a particular problem which can be separated from 
other problems, or compared with other problems. 
2. The goals, values or objectives that guide policymakers are clarified and ranked 
according to their importance. 
3. The various alternatives for dealing with problems are considered. 
4. The consequences (cost and benefits) following from the selection of each 
alternative are investigated. 
5. Each alternative, and its consequences, are compared with other alternatives. 
6. The policymaker chooses the alternative (and its consequence) that maximises the 
attainment of their goals, values or objectives. 
51 
Behind this theory are a number of assumptions that presume researchers follow a 
rational process in asking the right research question, planning and conducting the 
research, and then disseminating their findings, which are objective, quantifiable and 
present solutions. Moreover, it is assumed the policymaker reads the research results, 
understands the findings and implications of the research, and then acts on the results 
(Walt 1994). 
However, in reality, a rational policy development rarely happens; policymakers are 
constrained from behaving rationally in many ways. First of all, policymakers are 
seldom faced with one clearly defined problem, usually they first have to identify and 
define the problem. Even once a problem has been identified it is often difficult to 
identify one or more specific causes of the problem since public health problems are 
often extremely complex. In some cases it is difficult to even define the problem before 
it can be addressed. 
If the problem and its causes are identified, policymakers are still faced with the task of 
clarifying goals and objectives when tackling a problem, and of converting those goals 
into operational policies that can be implemented. One major difficulty they face is that 
predicting the cost and benefits of alternative strategies is a complex task, especially 
when health promotion strategies are intended to have long term effects, for example 
over the lifetime of young children. 
Policymakers are seldom objective in their decision making. They are driven by their 
own priorities, and influenced by other bodies or factors, as in the UK with the 
Conservative government raising the recommended weekly alcohol guidelines, against 
the recommendations of the medical profession (Marmot 1995 and Report 1996) 
possibly due to the influence of the brewing industry. Present policies are often largely 
determined by past policies, since it is easier to implement adaptations of existing 
policies than completely new policies. 
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2.5 Problems in the Relationship Between Research and Policy 
Research fording are not the property of research scientists, the fenders, or the 
respondents in the research, but are part of a shared body of knowledge (Lewando- 
Hundt 2000). Ideally this body of knowledge informs health policy, but there are a 
number of barriers that prevent the link between research and policy being a simple, 
linear and logical process. 
One of the most important influences is political factors. If governments are 
ideologically committed to a policy then research findings may only be of secondary 
interest, especially if the findings conflict with the policy impetus or its ideological 
basis. This was the case in the UK in the 1980's when the Conservative government's, 
under the leadership of Margaret Thatcher, introduced the internal market in health, 
which fitted with its ethos of improving services through competition, but was not 
evaluated in any way prior to its introduction. Policymakers may have different 
priorities from researchers and therefore regard their findings as irrelevant, or it may be 
that policymakers undervalue, or have unrealistic expectations of, the benefits of 
research to policymaking. 
Barriers may also exist due to conceptual confusion. This is particularly the case in 
public health research which often does not provide unambiguous results. This lack of 
scientific certainty can lead to distortion and a lack of clarity in policy. In particular, in 
areas where research findings disagree policymakers may be reluctant to make firm 
decisions (Walt 1994). 
The ways in which different risks are perceived, both at the individual and at the societal 
level, with an imbalance between actual and perceived risk may also impede the 
influence of research on health policy. An example of this is the reaction to the 
uncertainty about the risk of contracting CJD from British beef. This resulted in a 
European trade ban and falls in consumption (McKee 1997), but no such reaction is 
seen to the continued use of tobacco, with its known risks. The media often skew risk 
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information, as illustrated by a study of US network news (Greenberg 1992), which over 
a two year period monitored almost 500 stories on air crashes and only 57 about 
tobacco, when 250 Americans were killed in air crashes and about 800,000 died from 
smoking related illnesses. The media increases conceptual confusion because scientific 
disagreement makes a more interesting story than scientific consensus. 
Since policymakers must often make decisions within a short time scale, research which 
takes a long time to produce results, as in the case of the effects of smoking 
interventions on CHD morbidity and mortality, is less attractive to them than research 
that produces results in the short term. 
Communicability of research findings to policyrnakers is also important, with both the 
research and policy communities accepting that research communications, whether they 
are reports to funders or journal papers, are often esoteric, opaque and unclear. Findings 
are sometimes presented in a form which makes them inaccessible to non-experts, and 
so they do not pass outside tight academic circles. This is taken to the extreme where 
researchers feel that their work should only be written for fellow academics, and should 
not provide policy recommendations, leaving it to others to possibly extrapolate the 
findings into the policy domain. Other researchers feel that they have a public duty to 
disseminate their findings widely, channelling their results through the mass media, 
although the value of this dissemination will be heavily dependent on the accuracy of 
the reporting (Walt 1994). 
2.5.1 The Realistic Model of Research 
The barriers to policy implementation which have been discussed above are recognised 
in the realistic model of research. This model is based on the belief that to seek a direct 
link between research and policy is to misunderstand the nature of the policy 
environment, and that the focus of science on increasing knowledge and solving 
problems do not fit easily with the reality of policymaking (Walt 1994). New 
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information, ideas and knowledge do diffuse through the policy environment, and so 
become part of policymakers' thinking, but not in a clearly defined linear way. 
In looking at the extent to which research influences policy one needs to take a longer 
and wider view, rather than searching for direct links between individual research 
projects and policy options; one needs to consider the accumulation of research 
evidence which leads to a gradual change in the knowledge and action of policymakers 
(Walt 1995). 
2.5.2 The Incremental Model 
The incremental model can be seen as the antithesis to the idealist model, and is 
essentially a hybrid of the realistic model. Walt (Walt 1994) identifies the key points of 
this model as: 
1. The selection of goals and objectives, and the means of implementation are closely 
allied. 
2. Policymakers look at a small number of alternatives for dealing with a problem, and 
they tend to chose options that differ only marginally from existing policies. 
3. For each alternative only the most important consequences are considered. 
4. There is no optimal policy solution. 
Incremental policy making is essentially remedial, and focuses on small changes to 
existing policy rather than implementing major new policies. Policymakers must accept 
that few problems are ever fully solved, and that the process of implementing policy is 
an iterative one. 
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2.6 The Role of Mathematical Modelling as an Aid to Policy Making 
The need to produce policies to tackle complex, chronic diseases such as CHD has 
meant that decisions have been made with incomplete or conflicting evidence (Levine 
1987). Mathematical modelling may be a useful tool for investigating the effect of 
public health interventions, allowing one to consider varying levels of effectiveness and 
efficacy. Modelling can show how the quantification of the health benefits of alternative 
risk factor interventions can help in health policy (Gunning-Schepers 1989). For 
instance, the use of modelling to make estimates of the effect of prevalence changes are 
not only important in assessing the impact of preventive interventions, but also to 
estimate the health needs on which to base decisions about the levels of health services 
required. In addition, models may possibly be used as a tool to investigate different 
assumptions in areas where knowledge is limited, such as the effects of social class and 
early life influences on health, which are increasingly becoming important issues in 
health policy. 
However, modelling will not dictate policy, but will only quantify one step in the 
policymaking process. As outlined, barriers other than the lack of evidence may hamper 
policymaking. In the following chapters I describe my investigations into whether 
mathematical models can be used by policymakers as policy tools, and what factors will 
influence their use. 
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Chapter 3- Health Policy in England Since 1995 
3.1 Introduction 
In 1978 the International Conference on Primary Health Care, meeting in Alma-Ata, 
expressed "the need for urgent action by all governments, all health and development 
workers, and the world community to protect and promote the health of all the people of 
the world" in its ten point declaration (WHO 1978). Then in 1981 the WHO issued its 
Health for All by the Year 2000 document (WHO 1981), the objectives of which were 
"the attainment by all people of the highest possible level of health" and "that as a 
minimum all people in all countries should have at least such a level of health that they 
are capable of working productively and of participating actively in the social life of the 
community in which they live" (WHO 1981). 
This was followed in 1985 by Targets for Health for All 2000 (WHO 1985), in which 
the WHO defined 38 targets for all regions of the world, including Europe, with specific 
figures for reductions in infant mortality, maternal mortality, mortality from diseases of 
the circulatory system, cancer mortality, and deaths from accidents. These targets were 
then updated in 1991 (WHO 1991), since the original targets included goals to be 
achieved by 1990 which needed to be reassessed. 
Although the UK Conservative government of the time had endorsed the Alma Ata 
declaration on primary health care and Health for All by the Year 2000, since 1979 it 
had not acted on the issues raised and was seen to be resistant to setting health targets 
(Catford 1991 and Ashton 1991), but this changed in 1992 with its introduction of 
health targets. 
This chapter describes the health policies for England that were in place, or have been 
implemented since 1995, coinciding with the time period for my work on public models 
detailed in thesis. In particular I will concentrate on the policies and the use of targets 
directed towards the reduction of CHD, and with this view I will discuss their 
implications to public health modelling. 
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3.2 The Health of The Nation Targets 
Throughout Europe there has been a rise in demand for health related interventions, 
which can mean rising health care expenditure. In a world of limited resources this 
means that the most cost effective health strategies need to be identified. 
Followed the lead set by the WHO with its Health for All by the Year 2000 targets, and 
in an attempt to address the problem of the rise in demands on the health care system in 
England & Wales, the Government published its "The Health of The Nation" White 
Paper in 1992 (HMSO 1992), which set out targets for the reduction in the death rates 
for coronary heart disease, stroke, cancers, suicide and accidents, for the reduction in 
the incidence of sexually transmitted diseases and for reductions in the prevalence of 
cigarette smoking, alcohol consumption and obesity. 
In England CHD accounted for about 26% of deaths in 1991 (HMSO 1992), and so was 
identified as an important area for the Government's White Paper. The White Paper 
introduced targets for the reduction in the death rates for coronary heart disease: 
" To reduce annual death rates for both CHD and stroke in people under 65 by at least 
40% by the year 2000 (from 58 per 100,000 population in 1990 to no more than 35 
per 100,000 for CHD). 
" To reduce the annual death rate for CHD in people aged 65 to 74 by at least 30% by 
the year 2000 (from 899 per 100,000 population to no more than 629 per 100,000). 
" To reduce the prevalence of cigarette smoking in men and women aged 16 or over 
to no more than 20% by the year 2000 (a reduction of at least 35% in men and 29% 
in women, from a prevalence in 1990 of 31 % and 28% respectively). 
" To reduce the average percentage of food energy derived by the population from 
saturated fatty acids by at least 35% by 2005 (from 17% in 1990 to no more than 
11%). 
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" To reduce the average percentage of food energy derived by the population from 
total fat by at least 12% by 2005 (from about 40% in 1990 to no more than 35%). 
" To reduce the percentage of men and women aged 16-64 who are obese by at least 
25% for men and at least 33% for women by 2005 (from 8% for men and 12% for 
women in 1986/87 to no more than 6% and 8% respectively). 
" To reduce the mean systolic blood pressure in the adult population by at least 5 mm 
Hg by 2005. 
" To reduce the proportion of men drinking more than 21 units of alcohol per week 
from 28% in 1990 to 18% by 2005, and the proportion of women drinking more 
than 14 units of alcohol per week from 11% in 1990 to 7% by 2005. 
The introduction of these new health targets were widely perceived as a welcome 
change in health policy for the Government (Ashton 1991, Gabbay 1992 and Mooney 
1991). The recognition that intersectoral policy and collaboration is needed to achieve 
these targets was particularly welcomed (Ashton 1991). However, the document was 
heavily criticised for its lack of discussion on poverty and inequalities (Ashton 1991, 
Gabbay 1992, Dean 1992 and Davey-Smith 1994). Underlying this omission was the 
Government's belief that improvements in health would result from telling individuals 
to live more healthily, which ignored the WHO principle of encouraging people to 
participate in decisions (Gabbay 1992). Others argued that unhealthy behaviour did not 
occur in a social vacuum (Davey-Smith 1994), and that there was a need for social and 
economic policies changes that would allow individuals to choose the healthy option 
(Gabbay 1992), without which health inequalities may increase (Davey-Smith 1994). 
As Klepp et al stated "only exceptional, highly motivated individuals will be able to 
confront and cope with the social norms, marketing practices, and economic realities 
which combine to reinforce their current health-compromising behaviors" (Klepp 
1985). 
The Government's desire to improve health was thought to be contradictory to its 
policies on taxation and benefits, which were resulting in increased inequalities in 
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Britain, with the proportion of those living in poverty being twice as high as it was 30 
years previously. Twenty percent of £27 billion in tax savings achieved in the first 
decade of the Conservative government went to the 200,000 highest paid members of 
the population, while only 2% went to the three million lowest paid (Dean 1992). In 
addition, it was felt that the Conservative governments' links to the tobacco industry 
were at odds with its call to fight lung cancer and heart disease, made apparent by its 
reluctance to ban tobacco advertising (Health Education Authority 1991, Dean 1992 and 
Gabbay 1992). 
Review of the Government's 27 targets in 1996 (Langlands 1996) showed that the 
progress of the 23 targets were moving in the right direction, although a later study 
(Troop 1997) showed that only 9 would achieve their actual target values. While it has 
been commented that some of the targets seem to have been calculated based on the 
current trends (Mooney 1992). The trends for the prevalence of drinking amongst men 
and women had showed no change, while the prevalence of obesity in the whole 
population and of smoking amongst 11 to 15 year olds has risen. The Government's 
lack of initiatives to address equalities remained a key concern for researchers. 
3.3 Saving Lives: Our Healthier Nation 
In May 1997 the Labour party won the General Election and replaced the Conservative 
government. In aiming to show continuity with the previous Government's health 
promotion strategy (Maxwell 1998) they issued the "Saving Lives: Our Healthier 
Nation" White Paper in 1999 (DoH 1999), building on the targets of The Health of The 
Nation. The main differences between Our Healthier Nation and The Health of The 
Nation were in the recognition in Our Healthier Nation that health depends on social 
and economic conditions, as well as the environment, lifestyle, access to services and 
fixed risk factors, and in its awareness of the role of inequalities in health (Gabbay 1998 
and Horton 1998). 
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The aims of Our Healthier Nation were: 
" To improve the health of the population as a whole by increasing the length of 
people's lives and the number of years people spend free from illness. 
9 To improve the health of the worst off in society and to narrow the health gap. 
Four priority areas were identified and targets to be achieved by 2010 were set: 
1. Heart disease and stroke - target to reduce the death rate from coronary heart 
disease and stroke and related diseases in people under 75 by at least two fifths - 
saving 200,000 lives. 
2. Accidents - target to reduce the death rate from accidents by at least a fifth and to 
reduce the rate of serious injury from accidents by at least a tenth - saving 12,000 
lives. 
3. Cancer - target to reduce the death rate from cancer in people under 75 by at least a 
fifth - saving 100,000 lives. 
4. Mental health - target to reduce the death rate from suicide and undetermined injury 
by at least a fifth - saving 4,000 lives. 
These priority areas are similar to those of The Heath of the Nation, apart from the 
exclusion of HIV/AIDS and sexual health as a priority area, which is now encompassed 
in a wider action on public health along with drugs, alcohol, food safety, water 
fluoridation, communicable disease, genetics and the health for black and minority 
ethnic groups. 
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Within the section covering heart disease and stroke there are action points for reducing 
risk and staying healthy: 
" major changes in diet, particularly among the worst off, with increased consumption 
of such foods as fruit, vegetables, and oily fish; 
" large reductions in tobacco smoking particularly among young people, women and 
people in disadvantaged communities; 
" people keeping much more physically active - by walking briskly or cycling, for 
example - on a regular basis; 
" people controlling their body weight so as to keep to the right level for their 
physique; 
" avoiding drinking alcohol to excess. 
These less defined action points replaced the more explicit targets of The Health of The 
Nation which gave specific targets for reductions in the prevalence of cigarette 
smoking, the average percentage of food energy from saturated fatty acids, the average 
percentage of food energy derived from total fat, the prevalence of obesity, the mean 
systolic blood pressure, and the prevalence of heavy drinking. While physical activity 
was added to the CHD health agenda. 
The smaller number of national targets were presented as offering greater flexibility to 
focus on particular health problems and on health inequalities. While the broader nature 
of these targets were shown as offering additional challenges and opportunities 
compared to the strategies of The Heath of the Nation. However, the Government has 
been criticised for the document's lack of objectives concerned with the reduction of 
inequalities (Maxwell 1998). There was little point in accepting that socio-economic 
factors influence health if targets were not set for their improvement (Gabbay 1998). 
Although a budget of £96 million had been allocated to public health development; 
none had been allocated to reducing health inequalities (Gordon 1999). 
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The White Paper was also criticised for only using mortality measures in its assessment 
of the disease related targets (Gabbay 1998), its emphasis of disease based health care 
over wider public health concerns (Fulop 1999), and its lacks of plans for the 
implementation of its policies (Maxwell 1998), with its rather vague action points that 
have no targets for the changes recommended. 
3.4 Independent Inquiry into Inequalities in Health Report 
In 1997, the then Minster for Public Health, Tessa Jowell commissioned an independent 
review of inequalities in health under the chairmanship of Sir Donald Acheson. The 
aims of the Inquiry were to review the evidence on inequalities in health in England, 
and to identify areas for policy development likely to reduce inequalities. The Inquiry 
lasted 12 months and its findings were published in 1998 as the Independent Inquiry 
into Inequalities in Health Report (Acheson 1998). 
The Report made 39 recommendations covering 12 areas for future policy 
development. These areas were: 
" poverty, income, tax and benefits; 
" education; 
" employment; 
" housing and environment; 
" mobility, transport and pollution; 
" nutrition and the Common Agricultural Policy; 
" mothers, children and families; 
" young people and adults of working age; 
" older people; 
" ethnicity; 
" gender; 
" the National Health Service. 
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Overall the Inquiry identified three areas of action as being crucial to reducing 
inequalities in health, these were: 
1. all policies likely to have an impact on health should be evaluated in terms of their 
impact on health inequalities; 
2. a high priority should be given to the health of families with children; 
3. further steps should be taken to reduce income inequalities and improve the living 
standards of poor households. 
The Report was widely welcomed as a successor to the Black Report (DHHS 1980) on 
inequalities (Davey-Smith 19982, Black 1999 and Williams 1999), particularly with 
regard to its identification of areas other than the NHS as having a major role in 
reducing inequalities in health (Williams 1999). However, it was criticised for its 
recommendations not having been costed (Davey-Smith 19982, Black 1999 and Birch 
1999), or there being no mention of the resource implications of the recommendations 
(Williams 1999). It was also felt that the recommendations were not presented in a 
hierarchy of priority (Williams 1999), with the under-emphasis of the premise that 
inequalities in health are largely dictated by inequalities in wealth (Davey-Smith 19982). 
In addition, it was thought that the recommendations were too vague, and did not 
specify how their aims would be achieved (Davey-Smith 19982 and Black 1999), 
although this was contested by the Chairman of the Inquiry and others (Acheson 1998 
and Ashton 1999). 
It was seen as being unfortunate that the Inquiry was instructed by the Government not 
to produce targets, and that targets are need if general recommendations are to be turned 
into exact operational plans (Black 1999). 
3.5 The Effect of Targets on the Policy Agenda 
The setting and tracking of health targets help to form a national health agenda and 
identify explicit health policies (Catford 1991), and their popularity has been 
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demonstrated by the WHO and UK Governments. However, the use of targets has been 
criticised in that they result in priority being given to outcomes that can be easily 
measured, such as rates of illness and death, and not quality of life (Adams 1991 and 
Elkan 1998). This is illustrated by the targets of both Our Healthier Nation and The 
Health of The Nation which concentrate on reductions in death from coronary heart 
disease, stroke, cancers, suicide and accidents. The only target addressing incidence 
rates in The Health of The Nation solely relates to sexually transmitted diseases. This is 
arguably because these data are already collected for the UK by the Public Health 
Laboratory Service Aids Centre and the Scottish Centre For Infection & Environmental 
Health, and so are possibly easier to monitor. 
Targets that are perceived to be unrealistic may be dismissed as unattainable (Elkan 
1998). Targets may also lead to "initiative fatigue" when targets are not achieved as 
those responsible for them find it difficult to achieve the other demands of running 
services. This was experienced with The Health of The Nation targets (Gabbay 1998). In 
addition, targets such as those in The Health of The Nation may skew local priorities 
and do not lead to equity between different groups in society (Elkan 1998), when 
variations in health by geographical region, age, sex, socio-economic, or ethnic group 
are not considered (Davey-Smith 1994). 
Some of these criticisms have been addressed by the Our Healthier Nation document, 
with the use of fewer national targets, and by allowing for local flexibility in the setting 
of local priorities and local targets. However, there are still the problems of targets 
being unattainable and being measured solely in terms of mortality (Gabbay 1998). 
3.6 The Implication of Targets for Modelling 
Current health care demands require immediate policy decisions to be implemented 
(WHO 1982), but targets are difficult to evaluate in terms of how they will be achieved 
and how much health gain they will deliver, a problem common to the assessment of 
health promotion policy (Coombes 20002). There is a need for the effectiveness of 
different intervention strategies, or new therapies taken from experimental or 
observational methods, such as randomised control trials, or cohort studies, to be 
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extrapolated to a given population. Using public health models to simulate health 
interventions aimed at achieving such targets has been seen as a partial solution to this 
problem (Gunning-Schepers 1999). 
My work on modelling began during the period of The Health of The Nation. It was felt 
that public health models could be useful in assessing the relative health gain of 
alternative routes to the attainment of strategic goals, such as The Health of The Nation 
targets, and would be helpful for applying epidemiology to decision making at a 
population level. This thesis investigates the extent to which modelling could be used to 
assess health gain and the extent to which such modelling might be used for decision 
making. 
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Chapter 4- Data Sources 
4.1 Introduction 
One of the perceived strengths of public health computer models it that they use 
available data on risk factor prevalence and population demographics, rather than 
requiring new data to be collected specifically for the model (Gunning-Shepers 1989). 
However, different countries may collect different data in their health surveys and 
censuses, which means that a model developed in one country, which uses data 
collected in that country, may not be readily transferable to another country, since these 
same data have not been collected for the second country. Consequently, data from other 
sources, such as from a regional level, or from another country with similar population 
characteristics, are used. This will have repercussions on the validity of the model if the 
data are not representative of the population to be modelled. Mathematical modelling is 
very data-demanding, and the validity of a model will depend heavily on the data used 
by it. In this chapter I will outline the data sources I have used for input to the Prevent 
and POHEM models, the uses of which are described in the following chapters. 
4.2 Census Data 
Census data (OPCS 1995) contain a range of information for Great Britain on 
population and households, including demographic characteristics, students and 
schoolchildren, communal establishments, persons with long-term illness, ethnic 
groups, economic activity, migrants, household composition, tenure, amenities, 
availability of cars, and type of household space. 
The last Census took place on 21st April 1991, and sampled 97.9 per cent of the 
population of Great Britain. In particular there was a one percent short fall amongst 
those aged between 19 and 31, predominantly amongst men, with this discrepancy 
peaking at 6 percent at age 27. This is thought to be due to council tax avoidance 
(Charlton 1997). 
67 
4.3 National Population Projections 
The purpose of the national population projection is to provide future estimates of the 
United Kingdom population, and these have been produced in their current form since 
1949. The projections use population data on current size and age structure taken from 
the most recent Census, then estimate the changes in population size due to births, 
deaths and net migration. Consequently errors in population estimates will mainly be a 
result of errors in the projections of each of these three components. These errors have 
been significant in the past (Shaw 1994). 
I have used the national population projection for England & Wales in 1993 (OPCS 
19952) as the base year population for the models discussed in this thesis, as well as 
using the data as the denominator in calculating rates. Hopefully, as the projected 
population has been calculated only two years after the 1991 Census, errors in the 
estimation of this population will not be significant, as uncertainty is more likely to 
increase with time since the last Census. 
4.4 Mortality Statistics 
Mortality Statistics (OPCS 1995) presents mortality data by cause of death for England 
& Wales. These data have been produced annually since 1837, with the classification of 
causes of death coded using the Ninth Revision of the International Classification of 
Diseases (ICD9) since 1979. Historically there have been inaccuracies in this data due to 
lack of registrations, but today few, if any, deaths escape registration, and the cause of 
almost all registered deaths are certified by a medical practitioner or coroner. However, 
currently only 26 percent of death certificates are signed after a post mortem, which 
gives the most precise diagnosis. This is of particular importance since other studies 
have found marked disagreement between autopsy reports and death certificates 
(Charlton 1997). In addition, it has been documented that converting death certificate 
information to a single cause of death may fail to identify the combination of diseases 
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which have been attributed by the certifier as contributing to death (Ashley 1997). One 
should be aware of these factors when using these data. 
I have used these data for 1993 as the source of total and cause specific mortality rates, 
by age and sex, for input to the models. 
4.5 General Household Survey 
The General Household Survey (ONS 1998) is a multi-purpose survey providing 
information on aspects of housing, employment, education, health and social services, 
transport, population and social security. The Survey has been carried out annually since 
1971 by OPCS, and by the Social Survey Division of the Office of National Statistics 
(ONS) since 1996. It is a continuous survey based on samples of the general population 
of Great Britain resident in private, non-institutional households. The last Survey, 
carried out from April 1996 to March 1997, interviewed 17,043 people aged over 16 in 
9,158 households. 
Although the Survey is carried out every year; it is not a longitudinal survey, but a 
repeated cross-sectional survey with a different sampled population each year. In 
addition, the same sample questions are not asked each year, in particular questions 
regarding cigarette consumption were not asked every other year starting from 1977. 
I obtained the GHS data sets for the period 1973 to 1990 from the ESRC Data Archive 
at Essex University. The data were supplied on CD-ROM as SPSS portable files, from 
which I extracted data in the format required by the models using SPSS Version 8.0. In 
particular, I have used the data on smoking to build up smoking prevalence over time by 
sex, age group and cigarette smoking exposure category for input as trends into the 
models, therefore it is necessary to be aware that one is using these data as a proxy for 
longitudinal data. 
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4.6 Health Survey For England 
The Health Survey for England (Bennett 1995) was first commissioned in 1991 by the 
Department of Health (DoH) from the Office of Population Censuses & Surveys 
(OPCS), and has been produced for each year since. Its objective was to obtain 
information on aspects of health related to cardiovascular disease and associated risk 
factors, and nutrition. The Survey initially aimed to select a representative sample of 
adults (aged 16 or over) living in private households in England; the 1995 and 1996 
Surveys also covered children aged 2 to 15 living in households selected for the survey. 
The sampling was achieved using a multi-stage random probability design. In 1991 
3,242 adults completed a full interview, and by 1996 this sample size had increased to 
20,328 persons (16,443 adults and 3,885 children). 
I have been using the 1993 Survey data set, which has a total of 16,569 adults, as my 
main source of CHD risk factor prevalence data. I obtained the data set from the ESRC 
Data Archive at Essex University. Again the data were supplied on CD-ROM as SPSS 
portable files, and I extracted prevalence data in the format required by the models using 
SPSS Version 8.0. 
The main aims of the 1993 Survey were: 
" to provide baseline data for a nationally representative sample from which to 
monitor trends in the nation's health, 
" to estimate the proportion of people in England in whom specific conditions had 
been identified, 
9 to estimate the prevalence of certain risk factors associated with these conditions, 
" to see how different subgroups in the population vary in their likelihood of having 
specified conditions or risk factors, 
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" to assess the frequency with which particular combinations of risk factors are found, 
and in which groups they predominate, 
" to monitor progress towards some of the specific targets (in connection with blood 
pressure and obesity) relating to CVD in the Health of the Nation initiative, 
" to provide estimates for the above measures for Regional Health Authorities in 
England, 
" to provide more precise estimates for other relatively small subgroups of the 
population, 
" to improve the value of the survey for monitoring purposes by increasing the 
precision of all estimates. 
Although the Survey initially sampled 16,569 adults; of these only 81% had their blood 
pressure measured and only 72% agreed to give a blood sample. There was a particular 
shortfall amongst those aged 16-24 and those aged over 75. Therefore the final sample 
of 12055 does not match the age group distribution of the mid-1993 England population 
exactly. 
4.7 Allied Dunbar National Fitness Survey 
The Allied Dunbar National Fitness Survey (Sports Council and Health Education 
Authority 1992) was conducted in 1990, and its aim was to produce a description of the 
different patterns of physical activity and levels of fitness prevalent among the adult (16 
years and over) population of England. The Survey was carried out by OPCS in 1990 
for the DoH, the Sports Council and the Health Education Authority (HEA), and was 
financed by Allied Dunbar Assurance plc. Overall 4,316 individuals were interviewed, 
however only 56% of these people went on to take part in a physical appraisal (Fentem 
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1994), and there are no figures comparing this group's age and sex structure to that of 
the population of England. A further 2622 interviews were carried out using the same 
questionnaire in 1991 as the Health Education Authority National Survey of Activity 
and Heath, and the reported data have been amalgamated with the data from the Allied 
Dunbar National Fitness Survey. I have used these amalgamated survey data, which was 
supplied to me by the HEA, to obtain the prevalence of physical activity levels in the 
population. 
4.8 Morbidity Statistics from General Practice 
In the 1950s it was recognised that General Practitioners (GPs) consultation information 
could provided useful indicators of the health of the population, and that information on 
prevalence trends in sickness could help inform health service practitioners and 
planners. The first study took place in 1955-6, while the fourth, and most recent, study 
was commissioned by DoH and conducted in 1991-2 under the guidance of a Project 
Board representing DoH, the Royal College of General Practitioners and OPCS 
(McCormick 1995). This study covered a one per cent sample of the England & Wales 
population, which comprised 502,493 patients at 468,042 person years at risk, taken 
from the NHS lists of 60 volunteer practices. 
The main aims of the study were: 
" to examine the pattern of disease seen by GPs, by the age, sex and socio-economic 
status of the patient and to give an indication of the care provided, 
" to provide information to those planning health care resources, 
" to compare the results of this study with those of the earlier studies. 
As this was a self-selected sample of practices their characteristics were slightly 
different from those of all practices in England & Wales. They were larger, employed 
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more ancillary staff and had younger principal doctors. However, the sample population 
was representative of England & Wales in terms of age, sex, marital status, tenure of 
housing, economic position, occupation and urban/rural locations. There were 
differences in the proportions by social class, under-representation of ethnic minority 
groups and of people living alone. 
When interpreting the data one must be conscious of the fact that not everyone consults 
their GP, therefore there is an unknown amount of undetected morbidity in the 
population. Secondly one must be aware of possible errors in the capture, coding and 
processing of the data (Ashley 1997). With the computerisation of practices this may be 
less of a problem, although misclassification of diseases may still exist (Fraser 1997). 
Caution should still be used in interpreting the data (Coulter 1989). 
This survey was used to provide data on the prevalence and incidence of coronary heart 
disease and cerebrovascular disease in the population, although this was done with some 
caution since the incidence measure used counts a person several times if they 
experience more than one distinct episode of a disease during the year. 
4.9 Hospital Episode Statistics 
The Hospital Episode Statistics (HES) (DoH 1995) system was introduced in 1987 to 
provide patient-based data on hospital activity, replacing the Hospital Inpatient Enquiry 
and the Mental Health Enquiry. HES covers all specialities and includes private patients 
treated in NHS hospitals, and is based on consultant episodes, with the clinical 
speciality based on the clinical qualifications of the consultant. FIES data have been 
published for each financial year from 1988-89. 
The data are collated in the Hospital Patient Administration system, and extracts of 
these data are submitted to ONS, formerly OPCS, via the District and Regional 
information systems. The data contains the following three types of episodes: 
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9 unfinished - when a patient is still occupying a bed, 
" incomplete -when the end of data of a patient episode is recorded, but the diagnosis 
has not been coded, 
" completed - when all data items have been coded. 
These data refer to episodes confined to each year separately, therefore a first episode in 
that year cannot be distinguished as a new episode or a recurrent episode. In addition, as 
patients do not have unique identifiers it is difficult to discern new patients from 
patients with recurrent episodes, and this is only possible by fuzzy matching on sex, 
date of birth and post code, which is not ideal. 
As with the GP statistics, not everyone is admitted to hospital for a disease, therefore 
patients admitted may not be representative of all persons with a disease in terms of 
numbers or severity. Also the factors such as accessibility, bed availability, changes in 
diagnostic practices and changes in treatment will affect discharge rates (Fraser 1997). 
These data had been used to obtain first and recurrent myocardial infarction and stroke 
rates for England, and this was done using fuzzy matching by IBM, who supplied me 
with tables of events by age and sex. 
4.10 Cancer Registration 
Cancer registration (ONS 1997) is carried out by ten independent regional registries in 
England & Wales, which collect data on cancers incident in their regions, and submit a 
standard data set of these registrations to ONS. There is a similar system in Scotland, 
which is co-ordinated by the Information and Statistics Division of the NHS in Scotland 
Services Agency. 
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The last published data set for England & Wales was for 1991, which presented data on 
patients who were first diagnosed with cancer by site in 1991 and whose registrations 
were received at ONS by September 1997. 
The main concerns with cancer registration is the level of completeness of 
ascertainment, accuracy of the items registered and the effectiveness of follow-up from 
which survival data are calculated (Charlton 1997), with completeness varying 
according to the period of diagnosis (Smith 1997). It has been shown that in recent years 
completeness has been relatively high, although there is some loss between regional and 
national levels (Swerdlow 1993). Diagnosis is relatively accurate, although errors and 
omissions on items such as date of registration, date of birth, histology and occupation 
still occur, but interpretation of these data is still feasible (Ashley 1997). The 
implementation of recommendations to link registration with information on deaths has 
facilitated the calculation of survival statistics (Charlton 1997). However, this relies on 
the completeness and accuracy of registration being good, but these are improving with 
the development of computer technology. 
I have used cancer registers to obtain data on incidence, stage of diagnosis and survival 
for lung and breast cancer. These data were supplied to me by the Thames Cancer 
Registry and ONS. 
4.11 Oxfordshire Stroke Register 
The Oxfordshire Community Stoke Project (Bamford 1988) was a prospective study of 
acute cerebrovascular disease in a community of about 105,000 people from 1981 to 
1986. The study combined the rapid clinical assessments of patients with accurate 
diagnosis of the pathological type of stroke by computed tomographic scan or necropsy, 
whether they were admitted to hospital or not. Over the study period 675 cases of 
clinically definite first-ever stroke were registered. 
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In terms of comparing the structure of the study population with that for England & 
Wales, the sample over represented the 15 to 44 year olds, and under-represented the 
other age groups. Also due to the study population coming just from Oxfordshire the 
sample was probably not representative in terms of social class and ethnic make up. 
These data were supplied by Dr Mike McDowall of the Oxfordshire Community Stoke 
Project as a Dbase IV file, which I transferred to SPSS Version 8.0 and then converted 
into a SPSS file. From this file I calculated the incidence and prevalence of first and 
recurrent strokes. 
4.12 Scottish MONICA Data 
The WHO MONICA (monitoring trends and determinants in cardiovascular disease) 
Project monitored from the early 1980s, over 10 years, trends in cardiovascular 
mortality and coronary heart disease and cerebrovascular disease morbidity. In addition, 
it assessed the extent to which these trends were related to changes in known risk 
factors, daily living habits, health care, and socio-economic features measured at the 
same time across 37 populations in 21 countries (Tunstall-Pedoe 1999 and WHO/OMS 
1997). 
The Project collected data on (WHO/OMS 1997): 
" standardised coronary and stroke event registration, 
" medical care of patients before, during and after an attack, 
" risk factor measurements, with focus on smoking habits, blood pressure and its 
treatment, serum or plasma total and HDL cholesterol, height, weight, marital status, 
and education, 
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" aspects of recent interest, such as awareness and treatment of high cholesterol, use of 
aspirin and contraceptive pills, and on menopause, 
" population size and mortality, which was routinely available, 
9 medical services data. 
The coronary events recorded in MONICA were defined as non-fatal if the individual 
survived to 28 days from onset, and as fatal if CHD death occurred before or after 
admission or discharge from hospital but with 28 days of onset (Tunstall-Pedoe 1999). 
One of the MONICA populations was all 25 to 64 year old residents of Glasgow city 
north of the river Clyde in Scotland (mean population of 130,000), followed from 1985 
to 1994 (Tunstall-Pedoe 1996), although routine mortality data were missing for 1993 
(WHO/OMS 1997). Table 4.1 describes the coronary events recorded for the Scottish 
MONICA population by sex. 
Official CHD Number of Events 
Sex Deaths Fatal Non-fatal Corona 
Males 2934 2627 2823 5450 
Females 942 1018 1125 2143 
Table 4.1 - Scottish MONICA coronary events by sex (Tunstall-Pedoe 1999). 
Data were supplied from this population on MI and death coronary incidence, and case 
fatality by Professor Simon Capewell in 1998, then at the University of Glasgow. 
The main problem with applying these data to the population of England and Wales is 
that event rates and mortality are some 20-25% higher in Scotland, in addition to 
showing marked North/South gradients and socio-economic gradients (Capewell 
personal communication 1998). As well as this population having a lower socio- 
economic status, and higher risk factor levels and mortality for Scotland (WHO/OMS 
1997). 
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4.13 Discussion 
The data sources described in the chapter are far from perfect. Even national data 
sources that have been routinely collected over a long period, such as the Mortality 
Statistics, are not free of inaccuracies. Although not ideal I think that these data are still 
useable, but one must be aware of their limitations. 
Population data for Census years will be the most accurate, and the further away a 
model's base year is from a Census year the less accurate the data will be. Ideally one 
should base models on, or as close as possible to Census years. For my models I chose 
1993 since it was the last year of the Health Survey for England that data on cholesterol 
levels were collected, as well as alcohol, blood pressure and smoking, and it was only 
two years after the last Census. 
My source of risk factor data was the Health Survey for England 1993. Although this 
was designed to be a nationally representative sample; only 72% of the sample had a 
complete risk factor profile for cholesterol, alcohol, blood pressure and smoking 
measurements. One needs to be aware of this, particularly if modelling interventions 
aimed at the very young and very old, the two groups most under-represented in the 
Survey. 
Sources of morbidity data, such as the Hospital Episode Statistics and the Morbidity 
Statistics from General Practice, are the most problematic in terms of being 
representative, accurate and complete. I would express the need for extreme caution 
when using such data sources. 
Another issue to be aware of when applying regional data, such as those from the 
Oxfordshire Stroke Register and the Scottish MONICA Project, to other regions or 
nationally is that factors like risk factor profiles, social class or ethnic mix, and hence 
disease incidence and mortality, may be quite different, so making the data less 
applicable. 
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In addition to availability of data, the form in which the data are available is important. I 
was fortunate that I was able to obtain many of these data sources in an electronic form, 
and this allowed me to extract data for the models in any format needed. However, had I 
had to rely on just using tables from published reports it would have meant that I would 
have had less flexibility in setting up the categories within the model, and so may not 
have been able to match such things as risk factor exposure categories by age and sex to 
published relative risks. 
When I was working on the Biomed collaboration (see Chapter 9) I was made aware that 
the UK has a far greater range of data available than the Netherlands, Sweden and 
Denmark. In terms of the availability of data important for public health modelling, such 
as representative and continuous risk factor exposure data at a population level, I was not 
constrained by problems of lack of data as the modellers from the other countries were. 
Although the data were not perfect, modellers in the UK are fortunate to have much better 
access to data sets on risk factors and disease, especially in recent years with the 
availability of the raw data from national surveys held by the ESRC Data Archive at 
Essex University. 
Overall, I feel that this chapter highlights the need for the collection of health data at a 
national level. Incredibly, although CHD is seen as the major cause of premature death 
in the UK (Audit Commission 1995), there are no national registers of incidence, 
prevalence or survival. Surveys such as the Health Survey for England should 
consistently measure all the CHD risk factors from survey to survey. Not only are such 
data essential for monitoring the health of the population and for evaluating the effects 
of health interventions (Winkelstein 1981), but are vital for use in public health 
modelling. 
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4.13 Conclusion 
I have already mentioned that the models produced can only be as good as the data that 
are input into them, since they are so heavily reliant on data. However, there will never 
be perfect data sets that are free of all diagnosis and coding error, or that have 100% 
completeness. To some extent one must make do with what data are available. Some 
mainly reliable data are better than no data, although when using these data it is 
important to be aware of their limitations and of how representative the statistics they 
present are. Bad data, which may be estimated or not representative of the population 
they are to be applied to, are not better than no data since one will not be able to support 
the validity of their use to policymakers. I feel that it essential for modellers to 
understand the input data for models, otherwise they will never be able to fully or 
intelligently interpret the results their models produce. 
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Section 2: PREVENT 
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Chapter 5- The PREVENT Model 
5.1 Introduction 
In this chapter I describe my early work on Prevent, when I first adapted it for use with 
an England & Wales population. I encountered a number of problems, and had to revise 
my original plans quite considerably. 
5.2 Getting Started With PREVENT 
5.2.1 Installation 
The Prevent executable programme, PREVENT. EXE, and the data input programme, 
PREVDATA. EXE, are installed on to a personal computer (PC) using the MS-DOS 
operating system by running the PREVINST. EXE programme. This creates a 
PREVENT directory with a DATI subdirectory, which contains the original Dutch data 
set, and a TMPDATI subdirectory, which is used for writing temporary data files that 
Prevent uses during a simulation run. 
The next stage was to create and input an England & Wales data set using the 
PREVDATA. EXE programme. This is a menu driven programme that allows the user 
to create the risk factor and the population data files used by the Prevent programme. In 
addition, the software will, to a certain extent, check for improbable input and errors of 
data entry. Details of the data input process are outlined in the Prevent User Manual 
(Barendregt 1990). 
Prevdata is a useful tool for the initial input of data for a Prevent model since it guides 
the user through the data input process in a structured and methodical fashion. However, 
once this process has been completed and the user wants to return to edit their data files 
it can become quite a laborious task. In particular, when editing risk factor data one 
must run through each input step, in which one will leaves the current data unchanged, 
until one finds the appropriate input screen for editing a specific section of data. After a 
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while, having identified which data file contained which data, I found it easier to edit 
the actual data files in a text editor rather than using the Prevdata programme. 
5.3 PREVENT Input Data Files 
The first step which was necessary before I could edit the data files directly was to 
identify and document the files, since the Prevent Manual only had limited information 
on the files, just specifying that the file names were reserved names, but not giving 
details of their contents. Appendix A outlines the contents of the input files used by 
Prevent. 
The data files can be classified into model settings files, population data files, risk factor 
data files and cause specific mortality data files. 
5.3.1 Model Settings Files 
The settings for each population model are written to a DAT#INST. DAT file, where # 
signifies the number assigned to a population's data set within the model, and is referred 
to in the User Manual as the log file. It is created by Prevdata, but is also used by 
Prevdata and Prevent since it contains details of the following settings: 
" the base year for the model, 
" the number of risk factors, 
" the number of causes of death, 
" the risk factor names, 
" the names of the cause of death, 
" the number of causes of death affected by a risk factor, 
" the cause of death affected by a risk factor, 
" the times for each cause of death to be affected by a change in risk factor exposure, 
" the number of age groups for the risk factor prevalence data, 
" the age group labels, 
" the number of risk factor exposure categories, 
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" the risk factor exposure category labels. 
Appendix B contains the Prevent log file DATIINST. DAT with my comment 
statements explaining each section of the code. 
Once I had become familiar with the Prevent log file I would edit it using a text editor, 
such as Windows Notepad, to change any of the above settings as I found it less 
laborious than using the Prevdata programme. 
5.3.2 Population Data 
The population data were derived from routine data source collected, or projected by 
ONS (formerly OPCS), as detailed in the Chapter 4- Data Sources. These data are: 
" general mortality probability per 100,000 for the base year in one year age groups, 
by sex. 
" birth projections from the base year to the base year plus 50 years as absolute 
numbers, by sex. 
9 life expectancy of the 95 year olds for the base year, by sex. 
" population structure for the base year in one year age groups, by sex. 
It is important to note that mortality probability is used rather than mortality rate. In 
addition, birth projection data for England & Wales are not produced by sex, and so it 
was necessary for me to divide the published figures by the current male to female ratio 
for the population. 
The life expectancy of the 95 years olds is used with the general mortality data by the 
Prevdata programme to produce a data file of life expectancy in one year ages groups, 
by sex, which is used by the Prevent model. Consequently it is essential to use Prevdata 
to input these data, as well as giving a more structured input interface than a text editor. 
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5.3.3 Risk Factor Data 
The risk factor prevalence data were extracted from population surveys, such as the 
General Household Survey and the Health Survey for England, while the relative risk 
data were taken from the original Dutch model, which were obtained from the literature 
(Gunning-Schepers 1989). The data input files for each risk factor were: 
" prevalence of exposure to the risk factor in the base year, by sex, age group and 
exposure category; 
" relative risks of a specific cause of death for a risk factor by sex, age groups and 
exposure category; 
" calculation options: cohort, percentage outflow as a percentage of the exposed to a 
risk factor; 
" calculation options: cohort, percentage inflow as a percentage of the exposed to a 
risk factor; 
" calculation options: age groups, percentage outflow as a percentage of the exposed 
to a risk factor; 
" calculation options: age groups, percentage inflow as a percentage of the exposed to 
a risk factor; 
" percentage outflow as a percentage of the exposed to a risk factor, if separate cohort 
or age groups trends have not been specified; 
" percentage inflow as a percentage of the exposed to a risk factor, if separate cohort 
or age groups trends have not been specified. 
Prevent can be run under one of two risk factor modes. It can be run either in the cohort 
mode when one assumes that the exposure to a risk factor is predominantly a 
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characteristic of a birth cohort, such as behavioural risk factors like smoking and 
drinking, or in the age group mode when one assumes that the characteristics of being 
exposed to a risk factor are predominately age dependent, such as hypertension. 
Separate risk factor trend data files are needed for each of these modes. 
The stratification of these data will be dictated by the stratification of the relative risks 
of mortality for each risk factor, in terms of the number of age groups, the age groups 
categories and the risk factor exposure categories, as input to the log file. 
5.3.4 Cause Specific Mortality Data 
For each cause of death to be included in the model mortality probability per 100,000 in 
five year age groups by sex is required. These data were derived from routine mortality 
data published by ONS. 
5.4 PREVENT Output 
The results of a Prevent simulation run are produced in terms of disease specific and 
aggregated output, and this output can be in either graphical or tabular form. 
5.4.1 Disease Specific Output 
The disease specific outputs produced by Prevent are: 
" Etiologic fraction - the percentage mortality from a disease that can be attributed to a 
risk factor; 
" Potential and Trend Impact Fraction - the percentage mortality from a disease that is 
prevented by the intervention, or the autonomous trends, respectively; 
. Disease specific mortality per 100,000; 
" Disease specific mortality; 
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" Disease specific mortality reduction. 
5.4.2 Aggregated Output 
The aggregated outputs produced by Prevent are: 
" Total mortality - mortality from all causes of death, including those not explicitly 
modelled; 
" Total mortality reduction - the total mortality of the intervention is subtracted from the 
total mortality of the reference population; 
" Potential years of life gained - the years of life gained due to the autonomous trends 
and the intervention; 
" Actual years of life gained - the difference between the reference and the intervention 
population; 
" Survival curve; 
" Expectancy of life at birth. 
Full details of the output are given in Appendix B of the Prevent User Manual (Barendregt 
1990). 
Originally the output could be written to the screen, to a printer, to a graphic or a text 
file. In addition, it was possible to combine the output from several runs in one table or 
graph. However, I found the output formats for the graphs and tables quite limiting, 
such as only one style of graph being available, not being able to change the scales of 
the graphs or the style of the lines, and not being able to change the sub-divisions of the 
tables. I therefore asked Dr Jan Barendregt, Prevent's programmer, to add an output 
option which would write the results to a comma delimited file, which could then be 
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imported into a spreadsheet programme, such as Microsoft Excel. This allowed me to 
produce tables and graphs using a great variety of formatting options, such as using 
different line and bar graph styles, changing the scales of graphs, easily combining a 
number of Prevent runs, and allowing greater sub-division or aggregation of tables by 
age groups or sex. 
5.5 Adapting PREVENT 
Initially I intended to improve the input and output of data for the Prevent model by 
reprogramming the model. I visited Dr Jan Barendregt at Erasmus University in 
Rotterdam to obtain the source code for the programmes, any documentation and to 
discuss the feasibility of reprogramming the model. 
The source code was written in Turbo Pascal, which I am familiar with. However, there 
was no documentation at all for the programme in terms of comment statements, flow 
diagrams or variable glossaries. In addition, the variable names used within the 
programmes were abbreviations of Dutch words, and so would not have been intuitive 
for me to discern. Most importantly Dr Barendregt admitted that Prevent had been his 
first programming exercise, and it had been done within a limited timeframe since it had 
to be completed for Prof. Gunning-Schepers' PhD. Consequently he had not followed a 
structured programming style, which at the time was not seen as important as no-one 
had envisaged Prevent being developed by other researchers. 
After some thought, and discussions with Dr Barendregt, Prof. Gunning-Schepers and 
Dr Margaret Thorogood, I decided that the time that would be needed to unravel the 
source code, and to understand the structure and the workings of the programme was 
not warranted by the expected outcome in terms of the use of Prevent. I therefore 
decided to make the model more easy to use by other, non-programming, changes 
which will be detailed in later chapters, such as developing a spreadsheet model to 
calculate risk factor trends, and allowing the movement of individuals from one risk 
factor exposure category to another, rather than to the non-exposure category. 
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5.6 Validation 
As mentioned in Chapter 2 it is difficult to validate models such as Prevent. Such 
methods as historical testing, where the known changes in risk factor prevalences in the 
past are simulated to verify whether the model can produce current mortality patterns, 
are not possible, because Prevent can only take into account the effect of the reductions 
in the risk factors included in the model to explain changes in mortality. Prevent cannot 
account for risk factors not included in the model, or improvements in medical 
treatment which increase survival and hence reduce mortality. However, I have tried to 
validate the parameters which are used in the model by choosing the most appropriate 
data based on the available literature and data sources. Even this can sometimes be 
problematic, with data from a different population, or only a subgroup of a population 
having to be used when no data are available for the population of interest, which might 
be quite unlike the population for which data are available. 
5.7 Discussion 
One of the attractions of the Prevent model is that it uses input data that are routinely 
available for the England & Wales population. Although some time and effort was 
required to understand and identify the input data files, due to a lack of documentation; 
having done so it is a relatively straightforward procedure to input a new data set, using 
the Prevdata programme and a text editor. 
The lack of documentation for the Prevent source code means that the model can not be 
quickly or easily adapted by other programmers. The original programmer is the only 
person able to make alterations to the model. This is a major weakness in terms of 
developing the model for further use, and for use by other people. On any research 
programme there will be a change in personnel over time. Without adequate 
documentation for a model, when the key individual with the knowledge of its workings 
leaves, or changes research projects, any further development will be almost impossible, 
unless considerable time and effort is spent to rediscover the model's inner workings. 
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Validation of the Prevent model is not possible in terms of historical testing, but, to a 
certain extent, "face-validity" of the parameters used by the model can be checked in 
terms of the appropriateness of the input data used for a particular population. I feel that 
this situation is not ideal, but I would agree with Kotva (Kotva 1992) that due to models 
being unable to capture all the complexities of health interventions and to lack of data it 
may be impossible to validate such models in terms of a "gold standard". However, one 
is justified in using unvalidated models as long as one draws attention to the fact that 
the model is unverified and that its use can only yield results of a hypothetical nature. 
5.8 Summary 
This chapter describes the installation of the Prevent programme, the input data files 
required to run the model, and the types of output produced by the model. In addition, 
the barriers to adapting, by re-programming, and validating the model are discussed. 
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Chapter 6- PREVENT Trends And Limitations 
6.1 Introduction 
On first impressions, Prevent is a seductive computer model, with its "user-friendly" 
menu driven screens for running simulations. The user can believe that it is a simple 
model to use and understand. However, on beginning to use the model to simulate 
actual interventions one becomes aware of the problems with using it in terms of the 
limitations of what it can simulate. These limitations are not made explicit in the 
model's literature. 
The first part of this chapter will concentrate on the Prevent risk factor trends, in 
particular my work on calculating the trend inflow and outflow values used by Prevent 
from past prevalence data, and in producing spreadsheets to aid with the creation and 
input of the Prevent trend files. 
In the second part of this chapter I will identify the limitations I have noted through my 
use of the Prevent model, when I attempting to model risk factor interventions for 
policymakers. In addition, I will outline how I overcame those problems that could be 
solved, and explain why some problems cannot be solved by the user. 
PART I 
6.2 PREVENT Trends 
Some of my earliest work on the Prevent model, while constructing the England & 
Wales version, involved working on the calculation of risk factor trend data. While 
trying to input past changes in risk factor exposure over time into the model I realised 
that I did not understand exactly what had to be input into Prevent, nor was it made 
clear in the documentation what was required. 
Having talked to other researchers who had used the model I realised that defining and 
calculating the trends for Prevent was considered a problematic area. Some of this has 
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been due to a lack of clear documentation concerning what data need to be input into 
Prevdata and how these data are input. In addition, confusion had arisen due to the need 
to define separate trends for using Prevent in the age and the cohort modes, see Chapter 
5, as it was unclear what were the differences required for the calculations using these 
options. Other researchers had just used the default trends which specified no risk factor 
trends in the past and a one percent yearly reduction in prevalence of all risk factors in 
the future. 
Trends within Prevent can be run either in the cohort mode when one assumes that the 
exposure to a risk factor is predominantly a characteristic of a birth cohort, such as 
behavioural risk factors like smoking and drinking, or in the age group mode when one 
assumes that the characteristics of being exposed to a risk factor are predominately age 
dependent, such as hypertension. Consequently separate risk factor trend data files are 
needed for each of these modes, which rely on different methods of calculation. 
Professor Gunning-Schepers explained to me how Prevdata worked, and this clarified 
what data need to be input and how these data are input. The trends can be split into two 
types: 
past trends, which are needed as far back as LAG + LAT years from the base 
year (different for each risk factor/disease combination), 
" future trends, which can be specified for up to 50 years after the base year. 
These trends need only be default trends, since future trends can also be 
specified during each Prevent run. 
LAT is the time between the cessation of exposure and when a person's relative risk 
begins to decrease, while LAG is the time between a person's relative risk beginning to 
decrease and when it reaches its lowest value for the ex-exposed category, the remnant 
relative risk. 
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Prevent also distinguishes between inflow and outflow trends: 
" Inflow trends are the trends from non-exposed to an exposed category, and are 
specified by a positive number, 
Outflow trends are the trends from an exposed category to ex-exposed, and are 
specified by a negative number. 
6.3 Calculating Past Trends 
6.3.1 Cohort Specific Risk Factor Trends 
Ave   X+1 
Pravdanca a P1 
Year - Y+1 
AGE 
Ags-X 
Prevetence - PO 
Yew=Y 
TIMEý 
Figure 6.1 --Ageing of a cohort. 
Trends are defined as the percentage increase or decrease in prevalence of the currently 
exposed. This can be visualised as above in Figure 6.1. 
Cohort trend for age group X from year Y to Y+1= (P1 - P0) / PO 
Dr Perla van de Mheen from the Amsterdam Medical Centre had undertaken some work 
assessing smoking trends using Prevent, during the course of which she produced a 
spreadsheet to calculate trends. However, the way in which she had set up the 
spreadsheet meant that the user had to input values for the trends by trial and error until 
they resulted in the observed prevalences, rather than calculating the trend values from 
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the observed prevalences. This method was unwieldy, and it would entail a considerable 
amount of work if one was to consider using this method to produce a data set for all the 
risk factors and their exposure categories. 
As a consequence Ms Rianne Welvaarts, who was working with Professor Gunning- 
Schepers at the Amsterdam Medical Centre, and I adapted Dr van de Mheen's 
spreadsheet so that the trend values were calculated from the observed prevalences. 
The first step in calculating the past trends is to collect the prevalence data for each risk 
factor category by age group and sex, for each year if possible, as far back as required 
(LAT + LAG years). Most probably there will be years where there are no prevalence 
data, and so the missing prevalences must be interpolated. The method of interpolation 
will be conditional on whether the risk factor in question is age group or cohort 
dependent. I have decided not to use concise mathematical notation for the equations in 
order to avoid confusion, and to make them more explicit for translating to a 
spreadsheet model. 
Age 
Bands Risk Factor Category Prevalence 
H P(Ho) P(Ht) X(H2) P(H3) X(H4) X(H5) P(He) P(H7) 
G P(Go) P(GI) X(G2) P(G3) X(G4) X(G5) P(G6) P(G7) 
F P(FO) P(F1) X(F2) P(F3) X(F4) X(F5) P(F6) P(F7) 
F to J P2(0) P2(1) X2(2) P2(3) X2(4) X2(5) P2(6) P2(7) 
Trend T2(1) T2(2) T2(3) T2(4) T2(5) T2(6) T2(7) 
E P(Eo ) P(EI) X(E2) P(E3) X(E4) X(Es) P(E6) P(E7) 
D P(Do ) P(DI) X(D2) P(D3) X(D4) X(D5) P(D6) P(D7) 
C P(Co ) P(C, ) X(C2) P(C3) X(C4) X(C5) P(Ce) P(C7) 
B P(Bo ) P(B1) X(62) P(B3) X(B4) X(B5) P(Be) P(B7) 
A P(Ao ) P(AI) X(A2) P(A3) X(A4) X(A5) P(As) P(A7) 
A to E P, (0) P, (1) X, (2) P, (3) Xj(4) XI(5) P1(6) PI(7) 
Trend T, (1) T, (2) T, (3) T1(4) T1(5) T, (6) T1(7) 
Year 
_ 
Y(0) 
_ 
Y(1) Y(2) 
- 
Y(3) Y(4) I Y(5) Y(6) Y(7) 
iI 
Table 6.1 - Risk factor prevalence and trends over time by age and age group 
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Prevalences will only be known for age groups rather than single age bands, in the 
above example labelled P1(0), P1(1), P1(3), P1(6) and P1(7) for age group A to E, see 
Table 6.1. In addition, the data may be unavailable for some years, as signified by 
X1(2), X1(4) and X1(5), and so these value will be calculated by linear interpolation: 
X1(2) = P1(1) + (P1(3) - P1(1) / 2) 
and 
X1(4)= P1(3) + (P1(6) - P1(3) / 3) 
and so on. 
Next, starting with year Y(O) one assumes that the prevalence of a risk factor category 
for an age group is distributed evenly across each one year age band. 
Using: 
Pt(O) =( P(Ao) + P(Bo) + P(Co) + P(Do) + P(Eo) )/5 
therefore: 
P1(O) = P(Ao) = P(Bo) = P(Co) = P(Do) = P(Eo) 
As a birth cohort ages each year its prevalence should be tracked diagonally across the 
table, as shown in Figure 6.2 below. 
Figure 6.2 - Ageing of a birth cohort. 
For instance, taking the birth cohort of age band A in year Y(O) which has a risk factor 
prevalence P(Ao); after one year it has a prevalence of P(B1), and after six years it has a 
prevalence of P(G6). 
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The trend is then interpolated for an age group as it ages one year, so T1(1) is the trend 
for age group A to E as it ages to age groups B to F from year Y(O) to Y(1). 
Consequently, from: 
therefore: 
Also: 
TI(1) =( P(13 1) - P(Ao) )/ P(Ao) 
P(BI) = P(Ao) (1+ TI(1) ) 
PI(1) _[ P(Al) + P(BI) + P(CI) + P(DI) + P(EI) J/5 
therefore: 
P1(1) =[P(Ai) + P(Ao) (1+ T1(1) )+ P(Bo) (1+ T1(1) )+ P(Co) (I + T1(1) ) 
+P(Do)(1+Ti(1))]/5 
And so: 
Ti(1) =[( 5*Pl(1) - P(A1) )/( P(Ao) + P(Bo) + P(Co) + P(Do) )]-1 
In Prevent one can set the prevalence of a risk factor for the in-growing cohort, and 
unless data are available it is assumed that the youngest cohort P(A1) in year Y(l) has 
the same prevalence as the youngest cohort P(Ao) in year Y(O), i. e. that the risk factor 
behaviour is the same and that there has been no change in the behaviour between the 
two youngest cohorts in the model in one year. So using: 
P(Al) = P(Ao) 
Therefore: 
TI(1) -ý( 5*Pi(1) - P(Ao) )ý( P(Ao) + P(Bo) + P(Co) + P(Do) )l-1 
While for age groups other than the youngest, such as age group F to J, the following 
applies: 
P2(1)=[P(FI)+P(Gi)+P(HI)+P(Ii)+P(JI)l/ 5 
P20) P(Eo) (1+ Ti(l) )+ P(Fo) (1+ T20) )+ P(Go) (1+ T20) ) 
+ P(Ho) (1+ T20) )+ P(1o) (1+ T2(1))] /5 
T20) _[5* P2(1) - P(Eo) (1+ Ti (1) )/ P(Fo) + P(Go) + P(Ho) + P(1o) l-I 
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For the oldest age group, 65 to 95 years olds, the risk factor prevalence for the whole 
age group is weighted to give a higher prevalence in the 65 to 77 year olds, as follows: 
P65-950) - 12 [ P(651) + P(661) + P(671) + P(681) + P(691) + P(701) + P(71 1) 
+ (721) + P(731) + P(741) + P(751) + P(761) + P(771) ]+[ P(781) 
+ P(791) + P(801) + P(811) + P(821) + P(831) + P(841) + P(851) 
+ P(861) + P(871) + P(881) + P(891) + P(901) + P(911) + P(921) 
+ P(931) + P(941) + P(951) ]}/ 44 
P65-95(1) _{2[ P(64o) (1+ T60-64(1) )+ P(65o) (1+ T65-95(1) ) 
+ P(66o) (1+ T65-95(1) )+ P(67o) (1+ T65-95(1) ) 
+ P(68o) (1+ T65-95(1) )+ P(69o) (1+ T65-95(1) ) 
+ P(70o) (1+ T65-95(1) )+ P(710) (1+ T65-95(1) ) 
+ P(72o) (1+ T65-95(1) )+ P(73o) (1+ T65-95(1) ) 
+ P(74o) (1+ T65-95(1) )+ P(75o) (1+ T65-95(1) ) 
+ P(76o) (1+ T65-95(1) )+ P(77o) (1+ T65-95(1) )] 
+[ P(78o) (1+ T65-95(1) )+ P(79o) (1+ T65-95(1) ) 
+ P(80o) (1+ T65-95(1) )+ P(810) (1+ T65-95(1) ) 
T65-95(1) _ 
+ P(82o) (1+ T65-95(1) )+ P(83o) (1+ T65-95(1) ) 
+ P(84o) (1+ T65-95(1) )+ P(85o) (1+ T65-95(1) ) 
+ P(86o) (1+ T65-95(1) )+ P(87o) (1+ T65-95(1) ) 
+ P(88o) (1+ T65-95(1) )+ P(890) (1+ T65-95(1) ) 
+ P(90o) (1+ T65-95(1) )+ P(910) (1+ T65-95(1) ) 
+ P(92o) (1+ T65-95(1) )+ P(93o) (1+ T65-95(1) ) 
+ P(94o) (1+ T65-95(1) )]}/ 44 
{44*P65-95(1) - 2*P(64o) (1+ T60-64(1)) /[ 2*P(650) + 2*P(66o) + 
2*P(670) + 2*P(680) + 2*P(69o) + 2*P(700) + 2*P(71o) + 
2*P(72o) + 2*P(73o) + 2*P(74o)+ 2*P(75o) + 2*P(76o) + 2*P(77o) 
+ P(780) + P(790)+ P(800) + P(81o) + P(820) + P(830) + P(840) + 
P(850) + P(860) + P(870) + P(880) + P(890) + P(90o) + P(910) + 
P(920) + P(930) + P(94o)]} -I 
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These values for the trend are input to Prevdata. The whole process is repeated for the 
following years, until the latest date that data are available for, always using the same 
initial age groups as they age by one year. Consequently the trend for the youngest age 
group as it ages from year Y(l) to year Y(2) will be: 
T2(2)=[(5*Xi(2)-P(Al) )/ (P(Ai)+P(BI)+P(Ci)+P(Dj))] -1 
or 
T2(2) =L( 5*PI(2) - P(Al) ) /( P(Al) + P(Bi) + P(Cl) + P(Di) )l -I 
and so on. 
6.3.2 An Alternative Method of Calculation 
The technique described in section 6.3.1 can only be used if the data on prevalence have 
used the same age groups over the years, and these are the same age groups as used in 
the model's base year. This was not the case for the England & Wales data on smoking 
used with a 1991 model. Therefore, an alternative method had to be devised. 
Age 
Bands 
Risk Factor Category Prevalence 
H P(Ho) X(H1) X(H2) P(H3) X(H4) X(H5) P(H6) P(HA) 
G P(Go) X(G1) X(G2) P(G3) X(G4) X(G5) P(G6) P(G7) 
F P(Fo) X(F1) X(F2) P(F3) X(F4) X(Fs) P(Fs) P(F7) 
F to J P2(0) X2(1) X2(2) X2(3) X2(4) X2(5) P2(6) X2(7) 
Trend T2(1) T2(2) T2(3) T2(4) T2(5) T2(6) T2(7) 
E P(Eo) X(E, ) X(E2) P(E3) X(E4) X(E5) P(E6) P(E7) 
D P(Do) X(D1) X(D2) P(D3) X(D4) X(D5) P(D6) P(D7) 
C P(CO) X(CI) X(C2) X(C3) X(C4) X(C5) P(C6) X(C7) 
B P(Bo) X(B1) X(62) X(63) X(64) X(B5) P(Bs) X(B7) 
A P(A0) X(AI) X(A2) X(A3) X(A4) X(A5) P(A6) X(A7) 
A to E P1(0) X1(1) X1(2) X1(3) X1(4) X1(5) P, (6) X, (7) 
Trend T, (1) T1(2) T, (3) T1(4) T, (5) T, (6) T1(7) 
Year Y(O) Y(1) Y(2) Y(3) Y(4) Y(5) Y(6) Y(7) 
Tab1 e 6.2 - Risk fac tor prevalence and trends over time by a ge and age group, with differing 
age groups. 
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In this case years Y(O) and Y(6) are the only years with prevalence data for the age 
groups that match the model's base year (A to E, F to J and so on), while years Y(3) and 
Y(7) have prevalence data relating to different age groups (D to H, I to R and so on), 
and years Y(1), Y(2), Y(4) and Y(5) have no prevalence data, (see Table 6.2). 
As before, starting with year Y(O) one assumes that the prevalence of a risk factor 
category for an age group is distributed evenly across each one year age band. 
Using: 
therefore: 
Pi(0) =( P(Ao) + P(Bo) + P(Co) + P(Do) + P(Eo) )/5 
P1(0) = P(Ao) = P(Bo) = P(Co) = P(Do) = P(Eo) 
This assumption is also applied to the other age groups for which prevalence data is 
available in years Y(3), Y(6) and Y(7). Therefore: 
PD to x(3) =( P(D3) + P(E3) + P(F3) + P(G3) + P(H3) )/5 
and 
and so on. 
PD to H(3) = P(D3) = P(E3) = P(F3) = P(G3) = P(H3) 
Pi(6) =( P(A6) + P(B6) + P(C6) + P(D6) + P(E6) )/5 
P1(6) = P(A6) = P(B6) = P(C6) = P(D6) = P(E6) 
Then one assumes that the prevalence of the youngest cohort X(A1) in year Y(1) has the 
same prevalence as the youngest cohort P(Ao) in the previous year Y(O), and so on for 
the next years. Therefore: 
and 
X(Ai) = X(A2) = X(A3) = X(A4) = X(A5) = P(Ao) 
X(A7) = P(A6) 
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Next the missing one year age banding prevalence can be calculated by interpolating 
diagonally across the cells, assuming a linear relationship between the prevalences of a 
single age band as it ages. Therefore: 
X(B 1) = P(Ao) +[ P(Ao) - P(D3) 1/ 3 
X(C2) - P(Ao) + 2*[ (P(Ao) - P(DO) / 3] 
and so on. 
6.3.3 Age Group Specific Risk Factor Trends 
Year 0 Year 1 Year 2 Year 3 
Now 
Age Group @ 
SpeGtic Trends 
Ags N+1 
AgeN 
Year 4 
now 
olow 
001*011' Apo N+ 1 
MON10- Age N 
Figure 6.3 - Ageing oa cohort with age groups specific risk factor trends 
If the risk factor is age group specific rather than cohort specific the missing one year 
age banding prevalences should be calculated by interpolating horizontally across the 
cells, again assuming a linear relationship between the prevalences of a single age band 
as it ages, see Figure 6.3. Therefore: 
X(Al) = P(Ao) +[ P(Ao) - P(A6) 6 
X(DI) = P(Do) +[ P(Do) - P(D3) 3 
X(D2) = P(Do) + 2*( [ P(Do) - P(D3) 1/ 3) 
and so on. 
Ap*N+1 
ApeN 
Age N. 1 
AgeN 
100 
now 
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Consequently, having interpolated the prevalences for the one year age band, the 
prevalence for the age groups can be calculated: 
X1(1) = X(A1) + X(B1) + X(C1) + X(D1) + X(E, ) 
Finally the age group trend for each year can be calculated: 
T1(1) =[ (X(B1) + X(C1) + X(D1) + X(E1) + X(F1) )- P(01) l/ P(01) 
T1(2) =[ (X(B2) + X(C2) + X(D2) + X(E2) + X(F2) )- X1(1) I/ X1(1), and so on. 
6.3.4 Future Trends 
Only default future trends need to be input to Prevent to begin with since future trends 
can be specified during each run. However, the method for calculating these trends for 
input to Prevdata is the same. Future trends are required for at least the time period the 
simulation will be run for (the maximum being 50 years). 
The techniques described for calculating past trends can be used for their calculation. 
One only needs to make an assumption of what the prevalences will be in the year Base 
Year + Simulation Period, and to then interpolate from the last year in which prevalence 
data are available. This interpolation will be carried out diagonally or horizontally 
depending on whether the risk factor is cohort or age group specific. 
Ideally one would set up a number of trend files for each risk factor, with each file 
pertaining to a different assumption concerning future trend development. 
6.4 Spreadsheet Implementation 
As a result of this work I produced a test set of spreadsheets using the first method 
described, which allowed the user to enter the age group risk factor prevalence for one 
exposure category and then calculated the trends for input into Prevent. This was then 
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expanded by Dr van de Mheen to calculate smoking trends using three exposure 
categories, which I subsequently adapted to allow for the input of the future trends. 
6.5 Discussion of Trends 
During the development of these trend calculations it was suggested by Prof. Gunning- 
Schepers and Dr Barendregt, to avoid confusion, that Prevent should only be used in the 
cohort mode, and that any age groups trends should be specified by translating its effect 
to the birth cohorts. 
This work on trends succeeded in clarifying the methods for defining and calculating 
the trends input data file for Prevent, as well as giving the developers an opportunity to 
fully explain the mechanisms by which they are used within the model. Also 
documenting this work has meant that the principles of calculated trends can be 
understood and implemented by others, as demonstrated by Dr van de Mheen. 
The main draw back with using trends as required by Prevent concerns the availability 
of risk factor prevalence data. Prevent requires risk factor prevalence data for 
LAT+LAG years before the base year, which in the case of cigarette smoking linked to 
lung cancer and COLD is 20 years, and 30 years in the updated version of Prevent (see 
Chapter 10). Fortunately I had access to the raw General Household Survey (ONS 
1998) data sets from 1973 onwards (see Chapter 4), which allowed me to extract the 
data in the appropriate form. Even so data were not available for all years, and I had to 
interpolate between years with data to estimate prevalences in missing years. However, 
had I had to rely on published data I would have found that over time different age 
group and exposure categories had been used, and this has been the case for other 
researchers (Biomed II 1999). In addition, as the time periods that data are require for 
increase, one finds such data are not available. Blood pressure and cholesterol data are 
only available at a population level for England since the Health Survey for England 
1991 (White 1993). This means that researchers will increasingly have to interpolate 
from available data, rather than using actual data, which is not ideal. Other methods 
need to be explored for calculating mortality based on available data, such as the 
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method of Peto et al (Peto 1992) for estimating national mortality from tobacco from 
disease mortality statistics. 
PART II 
6.6 PREVENT Limitations 
In the course of using the Prevent model I became aware of several limitations of the 
model. These have particular consequences in that the model is not able to simulate 
certain types of interventions that policymakers may be interested in. These limitations 
were not made explicit in the literature on Prevent. 
6.6.1 Shifting Risk Factor Exposure 
One of most serious limitations of Prevent is that it was not designed to model the effect 
of interventions which move members of one risk factor exposure group into a number 
of different exposure groups. For example, it was designed for modelling movement 
from an exposed to a ex-exposed category, such as heavy or moderate smokers 
becoming ex-smokers, and not for modelling heavy smokers becoming moderate or 
light smokers. This means that it is impossible to shift the risk factor distribution, to 
simulate a population intervention, such as the result of a national campaign to reduce 
individuals' cholesterol. 
This limitation of Prevent is important since preventive strategies may have only small 
effects on the risk experienced by an average individual, but may have large benefits at 
a community or population level. For instance, one person who loses some excess 
weight may only experience a small impact on their personal risk of disease, but if 
many people in a population lose a little excess weight; this may have a substantial 
impact on the population's experience of obesity related disease. This is the so-called 
prevention paradox, where if a large number of people each reduce their risk slightly, 
the entire population may experience a substantial reduction in disease burden (Rose 
1992). 
103 
Exposed 
(Sedentary) 
exposed 
Exposed 
(Light 
Activity) 
Exposed 
(Moderate 
Activity) 
Unexposed 
(Vigorous 
Activity) 
Usual Prevent methodology 
exposed exposed unexposed 
Z-ýý Adapted Prevent methodology 
Figure 6.4 - Movement between exposure categories under Prevent's original and adapted 
methodologies 
I partially solved the problem of not being able to move individuals to another lower 
risk factor exposure by setting up the model so that one of the exposure categories, for 
example moderate physical activity, was treated as the non-exposure category, with the 
remnant risk of the this new non-exposed category set to the value for the actual 
exposed category, and by giving all the individuals already in this category, before the 
intervention, this same remnant relative risk rather than giving them a relative risk equal 
1.0 of the true non-exposed category, see Figure 6.4. 
The work I did with Prevent modelling physical activity targets entailed either 
increasing the prevalence of those people taking moderate physical activity, or 
increasing the prevalence of those people taking vigorous physical activity. Since each 
intervention only involved moving individuals from one exposure group to another 
exposure group; the interventions could be modelled by treating the exposure group that 
individuals move to as an ex-exposure group, although it meant setting up separate 
models for each scenario. A detailed description of this work is given in Chapter 7- 
Modelling the Effects of Increased Physical Activity Using The PREVENT Model. 
However, this method can only be used when the intervention entails moving 
individuals to one category, be it an exposed or non-exposed category, since this 
conforms to Prevent's methodology. It is impossible shift exposure levels, for example 
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with a physical activity intervention it would not be possible to move individuals who 
are sedentary to being lightly active, individuals who are lightly active to being 
moderately active, and individuals who are moderately active to being vigorously 
active; it is only possible to move people who are sedentary, lightly active, or 
moderately active to being vigorously active. 
6.6.2 Relative Risks Less Than One 
Prevent was originally designed in terms of modelling the effect of risk factors which 
have a dose response relationship between level of exposure and risk of disease specific 
death. Using this reasoning the non-exposed group was always used as the reference 
group with a relative risk of 1.0, hence the exposed groups would have relative risks 
greater than 1.0. However, this is not true for all variables which might be of interest to 
health policymakers. For example, moderate alcohol has been argued to be protective of 
CHD (Marmot 1981 and Klatsky 1981), while for the other alcohol related disease such 
as cirrhosis, accidental falls and traffic accidents (Corrao 1999), which are within 
Prevent, a dose-response relationship between alcohol intake and disease has been 
described. 
Ta 
Rela tive Risk of Disease Mort ali 
Alcohol Exposure 
Categories 
CHD Cirrhosis Accidental 
Falls 
Traffic 
Accidents 
Abstainers/Light 
Drinkers 
2.0 1.0 1.0 1.0 
Moderate Drinkers 1.0 1.0 1.0 1.0 
Heavy Drinkers 2.0 9.0 2.0 2.0 
le 6.3 - Relative risks of disease mort ality for alcohol as used by P revent (Gunni 
Schepers 1989). 
ng- 
Due to the methodology of Prevent and the U-shaped risk relationship between CHD 
mortality and alcohol intake the model was originally set up with moderate alcohol 
intake being the non-exposed category with a relative risk of 1.0 for CHD mortality, and 
this meant that the relative risks for cirrhosis, accidental falls and traffic accident 
mortality for moderate alcohol intake were also set to 1.0, which is an underestimation 
of the true relative risks. It would be more realistic to set the relative risks for all 
diseases for abstainers/light drinkers to 1.0, and having increased relative risks for 
cirrhosis, accidental falls and traffic accident mortality for moderate alcohol intake, 
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while for CHD mortality the relative risk for moderate alcohol intake is set to a value 
less than 1.0. 
Unfortunately the Prevdata data input programme was designed by the developer not to 
allow the user to input relative risks less than 1.0 into the model. I discussed this matter 
several times with Dr Barendregt. Initially he was reluctant to say whether Prevent 
could accommodate relative risks less than 1.0 since he had never tried it and was 
unsure what the model would do. However, he finally decided that it would be possible 
to input relative risks less than 1.0 into Prevent, although it would have to been done by 
editing the relative data files directly rather than using Prevdata. Dr Barendregt felt that 
Prevent should be able to cope with such relative risks as long as they were not close to 
zero, since Prevent uses a linear reduction in relative risks to the remnant relative risk, 
but close to zero the reduction is mostly likely as in Figure 6.5. 
Figure 6.5 - Relative risk close to zero 
The time it took to solve these problems was considerable, and highlights how, when 
using a model developed by others, it can be quite hard to solve methodological 
problem or adapt the model if your policy question does not match, or are not perceived 
as important by the developers. This type of problem could not have been foreseen until 
real policy questions were discussed. When different groups have different policy 
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agendas they are trying to address, which do not match the developers' interests they 
may be given a lower priority, and this may slow the modelling process. 
6.6.3 Univariate Risk Factor Distributions 
Prevent uses independent risk factor distributions, where, within the model, the 
prevalence of risk factors are input and used separately. While it can hold prevalence 
data for smoking, hypertension and hypercholesterolaemia individually, it does not hold 
the data for the prevalence of these risk factors in combination. That is, no allowance 
can be made for the clustering of risk factors in individuals when simulating 
interventions. This limitation is of particular concern since it has been shown that 
clustering of cardiovascular risk factors is strongest in those individuals with the highest 
level of these risk factors (Criqui 1980). 
A paper by van de Mheen et al (van de Mheen 1997) attempted to estimate the 
maximum extent of bias in outcome measures of Prevent if an independent risk factor 
prevalence was wrongly assumed. The mortality experiences of a cohort of Dutch men 
aged from 0 to 95 years of age were compared based on the assumptions of independent 
and completely dependent risk factor prevalences, for the risk factors hypertension, 
hypercholesterolaemia and smoking. The researchers concluded that assuming 
independence of risk factor prevalence within Prevent did not greatly affect its estimates 
of life expectancy and potential years of life gained. However, this paper did not address 
the problem that one is unable to identify those sections of the population with 
combinations of risks factors when using Prevent, and hence one is unable to model the 
effect of targeting interventions at these sections specifically. 
This is another important limitation with regard to using Prevent to inform policy, since 
questions are often asked regarding whether health resources should be targeted to those 
at most risk and who might benefit the most from an intervention, rather than using a 
population approach in which health resources are not targeted, but are used to change 
the overall population distributions of risk. 
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6.7 Discussion of Limitations 
The limitations of the Prevent model are serious in terms of restricting its use as a 
policy tool, and will heavily influence one's decision as to whether or not to use the 
model, since there are a range of interventions that the model cannot simulate. I only 
became aware of these limitations after I had used the model for some time, and had 
tried to simulate interventions suggested by policymakers and other researchers. This 
highlights how it is only by using a model to simulate real interventions that one can 
fully understand its capabilities, since the model's documentation may only outline 
interventions that can be simulated with it, which may not be relevant to current policy. 
This also emphasises the importance of developing such models in conjunction with 
policymakers, since they may have more insight than researchers as to what are the 
important policy issues that need to be addressed. 
In the following chapters I discuss how I have used the Prevent model with 
policymakers, and how I have managed to overcome some of the limitations of the 
model, as well as how these limitations restrict Prevent's use as a policy tool. 
6.8 Summary 
The first part of this chapter describes my early work on the Prevent risk factor trends 
model, since this was considered a problematic area, partly due to a lack of 
documentation concerning what data needed to be input into Prevdata, and partly due to 
it being unclear how these data are input. My work involved calculating the trend inflow 
and outflow values, and producing spreadsheets to aid with the creation and input of the 
Prevent trend files. 
The second part of this chapter details how, through my work with Prevent, I identified 
some of the limitations of the model when trying to simulate risk factor interventions 
for policymakers. It outlines how I was able to overcome some of these problems, and 
explains why some problems could not be solved due to the methodology of the model 
and due to the developers resistance to adapting the model. In addition, I discuss how 
these limitation restrict Prevent's use as a policy tool. 
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Chapter 7- Modelling the Effects of Increased Physical Activity Using The 
PREVENT Model 
7.1 Introduction 
I began to work on modelling physical activity when there was a great deal of discussion 
going on about the setting of targets for physical activity (HEA 1994), as well as being a 
time when the number of Prescription for Exercise Schemes, in which general practice 
patients are given free or reduced entrance to exercise facilities, were growing rapidly. 
The previous Government's White Paper "The Health of the Nation" (HMSO 1992) 
introduced targets for the reduction in the death rates for coronary heart disease, taking their 
lead from WHO's "Health For All by the Year 2000" (WHO 1985), see Chapter 3- Health 
Policy for more details. In keeping with this enthusiasm for targets the HEA proposed a set 
of physical activity targets, however it was not clear how the promotion of physical activity 
could most effectively contribute to the Health of the Nation targets. To contribute to the 
debate I modelled the effects of increasing activity in the population, looking at the effects 
of targeting different exercise levels, age and gender groups. This work was undertaken at 
the request of, and in collaboration with, the Health Education Authority. 
7.2 Health Benefits of Physical Activity 
Physical activity, as defined in the report of the Surgeon General on physical activity and 
health (US Department of Health And Human Services 1996), is "bodily movement 
produced by the contraction of skeletal muscle that increases energy expenditure above the 
basal level ". The report concluded that physical activity was beneficial in terms of the 
following health outcomes: 
" Overall Mortality - Higher levels of regular physical activity are associated with lower 
mortality rates for all adults, with even those who are moderately active on a regular 
basis having lower mortality rates than those who are sedentary. 
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" Cardiovascular Diseases - Regular physical activity decreases the risk of cardiovascular 
disease mortality in general and of coronary heart disease (CHD) mortality in particular. 
However, existing data are not conclusive regarding a relationship between physical 
activity and stroke. 
" Blood Pressure - Regular physical activity prevents or delays the development of high 
blood pressure, and exercise reduces blood pressure in people with hypertension. 
" Non-Insulin-Dependent Diabetes Mellitus - Regular physical activity lowers the risk 
of developing non-insulin-dependent diabetes mellitus. 
" Obesity - Low levels of activity, resulting in fewer kilo-calories used than consumed, 
contribute to the high prevalence of obesity in the United States. Also physical activity 
may favourably affect body fat distribution. 
In addition, the report concluded that physical activity was associated with reduced levels 
of colon cancer, osteoarthritis, osteporosis, falling and depression, as well as improving 
health related quality of life. However, this chapter will concentrate on the effect of 
physical activity on CHD with respect to its inclusion as a risk factor within the Prevent 
model. 
Lack of physical activity has been shown to be a strong independent risk factor for death 
from CHD (Powell 1987). In a meta-analysis, Berlin and Colditz (Berlin 1990) calculated 
a 1.9 fold increased relative risk for CHD mortality associated with a sedentary, as 
compared with a vigorously active, lifestyle. This meta-analysis is discussed in more detail 
in section 7.6.1. Population surveys have shown that a small percentage of the British 
population take enough exercise to protect against CHD (Sports Council 1992). Inactivity, 
then, may be an important cause of CHD mortality. 
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7.2.1 Measurement of Physical Activity 
Physical activity is a complex and difficult to accurately measure set of behaviours, with 
studies using numerous approaches such as self-reported surveys, job classification, 
behavioural observation, motion sensors and physiologic markers to quantify physical 
activity levels of individuals. Since physical activity is a continuous variable, and across 
several dimensions such as intensity, frequency, or type (Powell 1994); studies may define 
and report levels of activity differently. This is an important issue to consider since the 
strength of the relationship between physical activity and CHD will be highly dependent 
on the effectiveness, in terms of accuracy and reliability, of the measurements used in 
studies (Haskell 1995). Physical activity is thought to be a blunt proxy for physical fitness; 
a more effective measure for demonstrating the relationship with CHD (Morris 1996). 
However, physical fitness was only measured in 31 % of our population surveys (Fentem 
1994), and so would not be representative if applied to the whole population. 
7.3 Current Activity Levels in the Population 
Before I could develop a model of change in physical activity I first had to determine the 
current level of physical activity in the population. There were very few sources of data 
available. The principle source of information on physical activity in the England & Wales 
population were the Allied Dunbar National Fitness Survey (ADNFS) (Sports Council and 
Health Education Authority 1992) and the HEA's National Survey of Activity and Health 
(HEANSAH), which have been amalgamated by the HEA to increase the power of the 
analysis. 
Unfortunately the levels of physical activity, for which the relative risk were given by 
Berlin and Colditz, were only defined as vigorous, moderate, light and sedentary, and did 
not correspond to those of the ADNFS, which divided physical activity into 6 levels. 
Therefore the ADNFS levels had to be re-analysed by the HEA to conform with the levels 
of vigorous, moderate, light and sedentary exercise. 
Activity levels in the ADNFS were based on 20 minute periods of physical activity in a 
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four week period, and were re-analysed with the following definitions: 
Vigorous - twelve or more occasions of activities at 7.5 kcal/minute and above, such 
as squash, running, football, swimming, tennis, aerobics and cycling, if out 
of breath or sweaty. 
Moderate - twelve or more occasions of activities between 5 and 7.5 kcal/minute, such 
as football, swimming, tennis, aerobics and cycling, if not out of breath or 
sweaty, and table tennis, golf, social dancing and exercises, if out of breath 
or sweaty. 
Light - one to eleven occasions of activities at 5 kcal/minute and above, such as 
table tennis, golf, social dancing and exercises, if not out of breath or 
sweaty, bowls, and fishing, darts and snooker. 
Sedentary - no occasions of activities above 5 kcal/minute. 
This was done for both 20 minute exercise periods at least three times a week and 30 
minute exercise periods at least five times a week. Tables 7.1 and 7.2 show the aggregated 
ADNFS and HEANSAH prevalences of physical activity, which have been taken as those 
for the population, and the readjusted exercise levels. 
MEN Age Groups (%) 
Exercise Level 16-24 25-34 35-44 45-54 55-64 65+ 
Vigorous 28.9 20.4 12.8 8.4 4.1 1.4 
Moderate 37.7 41.6 40.8 38.9 29.8 19.6 
Light 27.8 30.1 36.5 38.1 36.5 35.9 
Sedentary 5.6 7.9 9.9 14.6 29.6 43.1 
WOMEN Age Gro ups (%) 
Exercise Level 16-24 25-34 35-44 45-54 55-64 65+ 
Vigorous 9.7 7.6 4.1 2.9 1.8 0.2 
Moderate 37.1 46.5 46.0 37.3 31.8 19.5 
Light 44.5 39.4 40.0 46.3 45.3 40.3 
Sedentary 8.7 6.5 9.9 13.5 21.1 40.0 
Table 7.1 - Prevalence of physical activity (20 minutes at least 3 times a week) for England and 
Wales by sex and age group (Combined ADNFS and HEANSAH data re-analysed by the HEA) 
112 
Table 7.2 - Prevalence of physical activity (30 minutes at least 5 times a week) for England and 
Wales by sex and age group (Combined ADNFS and HEANSAH data re-analysed by the HEA) 
Care needs to be taken in calculating the prevalence due to the different ways of measuring 
physical activity within and between studies, as mentioned in section 7.2.1. 
7.4 Initial Physical Activity Targets 
This work adopted, as its guidelines, the targets for physical activity proposed by the HEA 
in 1994, which were to be considered by the Task Force on Physical Activity in terms of 
their health effects and the policies needed to achieve them. These targets aimed to increase 
both the frequency and the intensity of people's physical activity. The targets were: 
Target 1: 'To reduce by at least 50% the proportion of men and women aged 16 to 74 
taking no occasion of moderate physical activity of at least 30 minutes, in 
the preceding four weeks, by 2005. ' 
Target 2: 'To increase the percentages of men and women aged 16 to 74 taking a 
minimum of 30 minutes of at least moderate physical activity on five days 
a week by at least 15% by 2005. ' 
Target 3: 'To increase the percentages of men and women aged 16 to 64 taking on 
average three periods of vigorous activity of 20 minutes duration a week by 
at least 9% by 2005. ' 
MEN Age Grou s (%) 
Exercise Level 16-24 25-34 35-44 45-54 55-64 65+ 
Vigorous 10.6 6.5 4.2 1.4 0.4 0.0 
Moderate 53.5 52.6 45.8 44.6 30.5 20.1 
Light 28.9 32.0 39.0 38.0 37.1 35.9 
Sedentary 7.0 8.9 11.0 16.0 32.0 44.0 
WOMEN Age Grou s (%) 
Exercise Level 16-24 25-34 35-44 45-54 55-64 65+ 
Vigorous 2.9 2.8 0.5 0.4 0.4 0.0 
Moderate 40.2 48.2 46.6 36.9 31.4 18.0 
Light 46.0 41.0 42.0 47.8 45.1 39.9 
Sedentary 10.9 8.0 10.9 14.9 23.1 42.1 
ale 7.2 - Prevalence of physical activity (30 minutes at least 5 times a week) for England 
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7.4.1 Threshold or Graded Effect of Physical Activity 
In modelling the targets I tested two alternative hypotheses concerning the relationship 
between CHD risk and level of physical activity, since there was some debate as to which 
theory truly reflected the relationship: 
" Graded effect - that there is an inverse relationship between CHD mortality risk and 
physical activity (Shaper 1991); 
" Threshold effect - that only vigorous physical activity decreases CHD mortality risk 
(Morris 1990). 
Many studies (Kannel 1986, Powell 1987 and Shaper 1991), including Berlin and Colditz's 
meta-analysis, have shown a dose-response relationship between CHD mortality risk and 
level of physical activity, while the work of others (Morris 1990) seemed to show that only 
vigorous activity was beneficial in terms of reducing CHD mortality risk, so I decided to 
investigate the effect of the physical activity interventions under each hypothesis. 
The relationships are illustrated in terms of the independent relative risks of CHD mortality 
by physical activity level in Table 7.3. 
riypoin esis A Hypothesis B 
Physical Activity 
Levels 
Relative Risk Physical Activity 
Levels 
Relative Risk 
Vigorous 1.0 Vigorous 1.0 
Moderate 1.4 Moderate 1.5 
Light 1.7* Light 1.5 
Sedentary 1.9 Sedenta 1.5 
from interpolation 
Table 7.3 - Independent relative risks of CHD mortality using a threshold and a graded 
hypothesis. 
7.5 Initial Exercise Interventions 
The initial interventions that were modelled had been derived from the targets set by the 
Physical Activity Task Force. All the interventions were simulated using the graded effect 
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hypothesis, while those interventions that shift people into the vigorous exercise group 
were also simulated using the threshold hypothesis. 
7.5.1 Initial Scenarios 
Four initial scenarios were modelled: 
A. The three targets described in the section 7.4 would be applied evenly throughout 
the population. 
B. 
C. 
Achieving the targets by concentrating the changes only in the youngest age groups: 
Target 1- 16 to 54, Target 2- 16 to 34 and Target 3- 16 to 34. 
Achieving the targets by concentrating the changes only in those people aged over 
35. 
D. Achieving the targets by concentrating the changes only in the oldest age groups: 
Target 1- 45 to 64, Target 2- 45 to 64 and Target 3- 55 to 64. 
The age inconsistencies of interventions B and D are due to the structure of the population, 
since there were not enough people in some of the age groups to achieve the percentage 
changes that were defined in the targets set for the total population. 
In simulating the Target 1 scenario the intervention increased the level of physical activity 
of the sedentary group to the level of the moderate group. The Target 2 scenario was first 
simulated with an intervention which increased the physical activity of the least active, i. e. 
the sedentary exercisers, and was next simulated with an intervention which increased the 
physical activity of the most active, but were not vigorously active, i. e. the moderate 
exercisers. These two separate model runs were used to provide lower and upper limits for 
the effectiveness of the intervention. The Target 3 scenario was first simulated with an 
intervention which increased the physical activity of the least active, i. e. the sedentary and 
light exercisers, and was then simulated with an intervention which increased the physical 
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activity of the moderately active, i. e. the moderate and light exercisers, again modelled 
separately to provide lower and upper limits for the effectiveness of the intervention. 
7.6 Adapting PREVENT 
I used my 1991 English & Wales version of Prevent model to simulate the proposed 
changes in physical activity levels for the population, modelling the outcomes using the two 
hypotheses and the strategies described previously. Prevent does not normally include lack 
of physical activity as a risk factor, therefore the following data were input for the England 
and Wales population: 
9 physical activity level categories: sedentary, light, moderate and vigorous; 
" prevalence of physical activity by sex, age groups and activity level, using the data from 
the combined ADNFS and HEANSAH data re-analysed by the HEA as described 
above; 
" relative risk of CHD death due to lack of physical activity by sex, age groups and 
activity level adapting the relative risk estimates of Berlin and Colditz and Morris 
described above, 
" two time intervals, the first, LAT, giving the time between taking up physical activity 
and a person's relative risk begins to decrease, and the second, LAG, giving the time 
between a person's relative risk beginning to decrease and when it reaches its lowest 
value for the new level of physical activity, 
the remnant relative risk, which is the lowest possible relative risk that an ex-exposed 
person has after LAT+LAG time has elapsed on taking up a new increased level of 
physical activity. 
LAT and LAG were set to zero and one, the minimum values possible, respectively, since 
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I decided after discussions with Professor Jerry Morris that an individual would experience 
the benefits of increased physical activity within a year. Also as a result of my discussions 
I decided that there would be no excess remnant risk LAT+LAG years after taking up a new 
increased level of physical activity, and that the remnant risk would be the same as the 
actual relative risk for the level of physical activity. 
The main limitation was that Prevent was not designed to calculate the effect of members 
of one risk factor exposure group moving into a number of different exposure groups; it 
was designed solely for modelling movement from an exposed to a non-exposed category. 
For instance, with Prevent changing heavy or light smokers to ex-smokers is possible, but 
changing heavy smokers to light smokers is not. This means that it is impossible to shift 
the risk factor distribution, as would be the effect of a population intervention, such as a 
result of a national campaign to reduce individuals' blood cholesterol or increase exercise 
levels. 
I solved the problem of not being able to move individuals to another lower risk factor 
exposures by first creating two versions of the England and Wales Prevent. The first 
version conformed to the methodology of Prevent with individuals moving from any 
exposure category to the non-exposure category, vigorous physical activity. The second 
version was set up with individuals being able to move from any risk factor category to the 
category of moderate physical activity. I achieved this by setting up the model as if the 
category of moderate physical activity was the non-exposure category, with the remnant 
risk of the category set to the actual value for moderate physical activity, and by giving all 
the individuals already in that category, before the intervention, the same remnant relative 
risk rather than having a relative risk of one. I also consulted the developers of Prevent, 
Professor Gunning-Schepers and Dr Jan Barendregt, to check that this would not interfere 
with the model's other processes, and they thought that this could be achieved without any 
problems. Fuller details of this adaptation are given in Chapter 6. 
7.6.1 Adapting the Relative Risks Estimates 
The relative risks for CHD mortality due to lack of physical activity were taken from a 
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comprehensive meta-analysis (Berlin 1990). The meta-analysis reviewed 27 studies, with 
respect to the quality of the study as measured by Powell et al (Powell 1987), in terms of 
independent relative risk by activity level of the following outcomes: 
" CHD; 
" CHD death; 
" Myocardial infarction (MI); 
" MI plus sudden death; 
" Angina pectoris. 
Relative risks were produced separately for these events from the studies identified by 
Powell et al of occupational and non-occupational activity, then they were recalculated 
including recent non-occupational studies not included in the original review by Powell et 
al. In addition, the relative risks for occupational studies by quality of study were produced, 
using Powell et al's scoring system based on the quality of the measurement of activity, 
the measurement of disease status and the epidemiological method. The relative risks were 
calculated in terms of the following comparisons: 
I. High activity compared with moderate activity groups from studies that reported both 
moderate and sedentary comparison groups; 
II. High activity compared with low activity groups from studies that did not separate 
moderate and sedentary comparison groups; 
III. High activity compared with sedentary groups from studies that reported both moderate 
and sedentary comparison groups. 
In terms of representing the dose response relationship between physical activity within the 
Prevent model the relative risks of interest are those of comparisons I and III, with some 
interpolation needed to derive the relative risk for high activity compared with light 
activity. 
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On closer inspection of the relative risk by occupational and non-occupational studies, as 
reviewed by Powell et al, one finds few studies that calculate the relative risks for MI, MI 
plus sudden death or angina pectoris, see Table 7.4. For CHD and CHD death there were 
more occupational activity studies than non-occupational activity studies reporting the 
associated relative risks. When those studies not originally reviewed by Powell et al are 
included the number of studies of non-occupational activity increases slightly to one study 
reporting CHD and 4 studies reporting CHD death relative risks. For occupational studies 
that were scored according to Powell et al's method for quality; CHD and CHD death 
relative risks were derived from only 2 studies for each of the outcomes that were 
considered satisfactory. 
Table 7.4 - 
Te of Study 
Outcome Occupational 
Activity 
Non-Occupational 
Activity 
CHD 4 0 
CHD death 5 1 
Myocardial infarction 1 2 
MI plus sudden death 1 0 
Angina pectoris 1 0 
Number of studies reaortino CHD outcomes by tvae of activity. as 
Powell et al. 
reported by 
Table 7.5 summarises the relative risks produced by Berlin and Colditz for CHD and CHD 
death for sedentary and moderate activity compared to high activity by their four divisions 
of type of study. 
Sedentary Moderate Activity 
Type of Study CHD CHD death CHD CHD death 
Non-occu ational - 1.6 (1.2-2.2) - 1.3 (1.0-1.7) 
All Non-occupational 0.7 (0.3-1.9) 1.7 (1.2-2.3) 0.9 (0.4-2.0) 1.1 (1.0-1.3) 
Occupational 1.4 (1.0-1.8) 1.9 (1.6-2.2) 1.1 (0.9-1.3) 1.4 (1.2-1.8 
Satisfactory Occupational 1.9 (1.0-3.6) 1.8 (1.5-2.3) 1.3 (0.7-1.3) 1.6 (1.2-2.1 
Table 7.5 - Summary of relative risks with 95% Cl by type of study and level of activity 
compared to high activity for CHD and CHID death. 
In terms of CHD the relative risks do not show clear evidence of a reduction in risk due to 
increased physical activity, whereas there is a stronger association for CHD death with a 
relative risk of around 1.8 associated with a sedentary lifestyle compared to a vigorously 
active lifestyle, with this risk increasing or decreasing depending on the type of studies 
used. 
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There were several problems in using the relative risks of Berlin and Colditz. One problern 
is that there is no mention of how their different levels of physical activity are defined, 
which is a multifaceted issue since it is dependent on intensity, duration and frequency of 
activity. Therefore I had to assume that these levels were similar to those used in the 
ADNFS data, which was not ideal. The only alternative would have been to have used the 
relative risks from just one study, such as the Harvard alumni study (Paffenbarger 1984), 
which is a large well designed study, but limited in that the relative risk are for a population 
of white American college educated men, which may not be appropriate for applying to the 
whole England & Wales population. The Berlin and Colditz relative risks used were similar 
to those produced by Powell et at, see Table 7.6, so I had some confidence in using them. 
Exposure Groups Relative Risk 
Sedentary 2.0 
Irregular 1.5 
Regular 1.1 
Vigorous 1.0 
Table 7.6 - Relative risk of CHD mortality from Powell et al(1987). 
No relative risk for light activity was produced in the meta-analysis, so I derived a 
hypothetical relative risk by linear interpolation. As the Task Force had not specified 
whether the physical activity targets set by were to be achieved through increases in 
occupational or non-occupational physical activity; I chose to use the relative risks from 
occupational studies due to their being based on the largest number of studies. The relative 
risks used are shown in Table 7.3. 
In addition, these relative risks, as well as those used for the threshold effect hypothesis, 
were not calculated separately by age or sex. There are differences in relative risks by age 
and sex for the other risk factors in Prevent (Gunning-Schepers 1989) and it seems probable 
that relative risks associated with physical activity would also vary by age and sex. This 
emphasises how one can only do modelling based on current knowledge, and how one 
important aspect of modelling is that it highlights areas where research is lacking. 
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7.7 Limitations Of PREVENT 
The problems of "fitting" available prevalence and relative risk data to the England & 
Wales population, and then tailoring these for input into Prevent were considerable and 
entailed making compromises. 
The main limitation was that Prevent was not designed to calculate the effect of members 
of one risk factor exposure group moving into a number of different exposure groups; it 
was designed solely for modelling movement from exposed categories to a non-exposed 
category. 
This is an important issue since preventive strategies at a community or population level 
which involve harm minimisation, i. e. moving the population to a lower level of risk 
behaviour rather than the "ideal" least risk behaviour. So in the case of physical activity it 
would be more realistic to expect individuals in the population to increase their levels of 
activity by varying amounts, such as sedentary to moderate, light to moderate, or light to 
vigorous, rather than the whole population becoming vigorously active. 
As Prevent uses the independent risk factor distributions, rather than a multi-variate risk 
distribution, one cannot reduce the prevalence levels of other risk factors that may be 
affected by increased physical activity for the sections of the population that have increased 
their physical activity levels. Only by using a multi-variate risk factor distributions would 
it be possible to identify these sections of the population. 
An additional problem was that only age group divisions beginning with multiples of five 
are permitted, so the youngest age to be intervened upon had to be aged 15, rather than 16 
years. However, this should not have made much of an impact on the effect of the 
interventions since the CHD death rates are very low at these younger ages, and so changes 
in physical activity will have little effect in terms of CHD mortality in comparison with 
older ages groups, as demonstrated later with the modelling. 
121 
7.8 Model Assumptions 
In setting up Prevent the modeller must set certain calculation options and variables, and 
these translate into a number of assumptions about the way in which an intervention would 
affect physical activity in the population, and the process by which physical activity 
influences CHD mortality. 
The assumption was made that the intervention started in 1994 and continued for the next 
eleven years, with the target prevalences of the strategies being achieved in 2005, a target 
year for The Health of the Nation (HMSO 1992). The population was simulated for a 
further fourteen years after the end of the intervention, during which time it was assumed 
that the prevalence of physical activity amongst age groups remained at their new increased 
levels. 
The mechanism by which physical activity affects CHD mortality is described by the time 
periods over which a person's risk decreases, the LAT and LAG times, and the level of risk 
it declines to, the remnant relative risk. Within the model it was assumed that, on increasing 
their level of physical activity, a person's relative risk begins to decrease immediately, and 
that one year after taking up a new level of physical activity a person's relative risk 
decreases to that of people exercising at that level. Some sensitivity analyses were 
performed by increasing these time periods when running the model, but the effect of this 
was only to delay the health gain of the interventions by the increased time period. 
In terms of the remnant risk it was assumed that a person's previously less active lifestyle 
will not continue to have a detrimental effect on their health, and that they will take on the 
relative risk attributed to their current physical activity level. 
As the main interest was to investigate how changing a population's physical activity levels 
might affect its CHD mortality it was decided to assume that physical activity only 
decreased the risk of CHD death and that it did not affect the other diseases mentioned in 
the introduction. In addition, I assumed that physical activity did not affect the other risk 
factors that Prevent includes, such as hypertension, cholesterol and obesity, since the 
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independent risk factor distributions within Prevent mean that one cannot reduce the 
prevalence levels of these risk factors for the sections of the population that have increased 
their physical activity levels. These assumptions that limited the influence of physical 
activity on health meant that the results of the model would have underestimated the true 
effect of the intervention, and needs to be considered when interpreting the results. 
Care needs to be taken in choosing either the age group or the cohort option for the 
calculations in Prevent, since the two options can give markedly different results. The age 
group option should be used when considering a risk factor that is predominately age 
dependent, such as hypertension. An intervention that causes a behavioural change, such 
as cigarette smoking cessation, is more likely to affect a birth cohort which retains the 
change as it ages. I chose to model physical activity as having an age group effect, although 
I also tested the model with the cohort option to see how this affected the results. 
Under the age group option it was assumed that the proposed intervention would change 
the prevalence of physical activity for specific age groups for the entire simulation period 
of 25 years, so that as cohorts aged over time they would take on the prevalence of the 
corresponding age groups when they entered them. For instance, taking the 28.9% 
prevalence of vigorous physical activity for 16 to 24 year old men from Table 7.1, after ten 
years using the cohort option, when these men are 24 to 34, their prevalence of vigorous 
activity would still be 28.9%, that is, the cohort would retain its prevalence from the 
previous age group. Under the age group option after ten years this initial cohort will have 
a prevalence of vigorous activity of 20.4%, as it will acquire the prevalence of the previous 
cohort in the 25 to 34 year age group. 
It was assumed that any changes in the prevalence of physical activity within the population 
would be solely as a result of the interventions, and that there would be no background risk 
factor trends in the population, that is, without an intervention there would be no change 
over time in rates of physical activity. 
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7.9 Initial Intervention Outputs 
I produced the output of the model in terms of the effect of the simulated interventions on 
CHD mortality rate per 1000 per year, total mortality reduction and actual years of life 
gained. 
7.10 Initial Results 
7.10.1 Threshold Versus Graded Effect 
Under the graded effect hypothesis all three targets achieved reductions in mortality. Under 
the threshold effect hypothesis only Target 3, increasing the proportion taking vigorous 
exercise, had any effect. 
A review of physical activity and fitness studies (Blair 1996) investigated the question of 
whether there was a threshold or a graded effect of physical activity on reducing the risk 
of morbidity and mortality, and concluded that the weight of available evidence showed an 
inverse gradient of risk of clinical disease across strata of physical activity. In addition, 
having talked with Professor Morris and Dr Melvyn Hillsdon, at the London School of 
Hygiene and Tropical Medicine, it became apparent that the different findings of a 
threshold or graded effect may have been due to different definitions of physical activity 
levels, with some of Morris et al's vigorous activities being classed as moderate by other 
studies, such as brisk walking, stair climbing, regular cycling and swimming (Morris 1996). 
The majority of studies demonstrated a graded effect and I decided to proceed with the 
modelling using this hypothesis. The remainder of these results are based on the assumption 
that the graded effect hypothesis holds. 
7.10.2 Reduction in CHD Death Rate 
There was a small reduction in the death rate from coronary heart disease associated with 
the achievement of each of the three targets in men and women. This represented a fall of 
between 0.1 % and 0.4% in men, and 0.04% and 0.13% in women. Assuming that all three 
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targets were achieved there might be a reduction of a little less than 1% in the CHD death 
rate in men, and a smaller reduction in women. Targets 1 and 2, which affected many more 
people, but involved lower levels of exercise, showed a much greater potential for 
reductions in CHD mortality. 
In the case of Targets 2 and 3, which involved increasing activity to moderate or vigorous 
levels, the size of the reduction achieved was influenced by whether the people who 
achieved the increased exercise level were drawn from those already taking some exercise, 
lightly or moderately active, or from those who were sedentary, least active. The greatest 
effect would be achieved by moving the sedentary people into the moderate or vigorous 
categories, but, in reality, it is more likely that those already taking some exercise would 
move into the next highest exercise category. This was therefore the assumption used in the 
rest of this initial modelling. 
7.10.3 Reduction in Total Mortality and Life Years Gained 
While the proportional reduction in the death rate appeared disappointing, the actual 
number of deaths under age 65 postponed each year was not insubstantial. The variations 
in the numbers of deaths postponed were a reflection of the expected variation in the size 
and age structure of the population. In general, achieving Target 1 could be expected to 
postpone the deaths of around 1700 people a year, achieving Target 2 would result in a 
slightly smaller number of deaths postponed, while achieving Target 3 would be expected 
to postpone only around 600 or less deaths a year. Overall achieving the targets in men 
would result in a much greater saving in life years than for women. 
7.10.4 Age Groups 
To examine the differing effect of targeting exercise interventions at differing age groups, 
the life years gained were modelled for each of the three targets making the assumptions 
that the target would be achieved by concentrating on the oldest group, over 45, the older 
half of the population, age 35-64, and the youngest group, under 44. It was very clear from 
this work that, for men, the greatest gain could be achieved by concentrating on the oldest 
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men. There was less gain achievable in women, and there appeared to be less difference 
between the effects of targeting different age groups. 
The full results of this initial modelling work are detailed in Moving on - International 
perspectives on promoting physical activity (Health Education Authority 1994) in 
Appendix C. 
7.11 Discussion of Initial Results 
These initial results are far from perfect predictions, given the number of assumptions, 
discussed above, that have had to be made when developing the model. Maybe the most 
important limitation of the data as they stand is the omission of the effects on the 
population aged over 65 year, where the majority of the CHD deaths can be expected to 
occur as the mortality rates at these ages are much higher than 65 years and below. This 
highlights a weakness in the setting of the targets that exclude the age groups where most 
deaths occur, and so underestimate their effect on a population. However, it appears from 
these data that the most effective strategy would involve concentrating on men in older age 
groups, and in particular those men who currently take no physical exercise. 
The Task Force on Physical Activity were surprised at the lack of effect the interventions 
had in the younger age groups with respect to the reduction in CHD mortality, while the 
effect in the older age groups was larger. However, due to the number of targets and 
strategies modelled, I had not really explored the reason why this should be, and so with 
the second phase of modelling I hoped to investigate if some of my initial assumptions 
were responsible for this difference. 
The Task Force's targets were never implemented, as the Government of the time decided 
to have less emphasis on targets since some of its Health of the Nation targets were not 
being met (Prentice 1995 and Troop 1997). Consequently, in 1996 a more general strategy 
statement, rather than specific targets, on physical activity (DoH 1996) was presented, with 
the following objectives: 
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to promote the value of moderate activity on a regular basis for sedentary people; 
" to inform people of the value of maintaining 30 minutes of moderate activity on at least 
5 days a week for those who already take some moderate activity; 
" to advocate, for those already taking some vigorous activity, the maintenance of a total 
of three periods of vigorous activity of 20 minutes a week. 
These objectives made no mention of the proportion of the population to change their 
behaviour, the age groups being addressed, or the time in which the change should occur, 
and were designed to avoid criteria that can be evaluated in terms the achievement of policy 
goals. 
7.12 Final Exercise Interventions 
After this initial physical activity modelling it was decided to refine the strategies to be 
simulated, just concentrating on the one criterion for frequency of three periods of physical 
activity of 20 minutes duration a week, rather than the previous two criteria. This would 
allow for clearer comparisons between interventions. In the previous modelling I was not 
comparing like with like, and this made interpretation of the most effective strategy 
difficult. In addition, by limiting the number of strategies to be modelled it meant that I was 
able to expand the scope of modelling by investigating the effects of targeting by current 
level of physical activity, by more consistent age groupings than before, as well as allowing 
for some sensitivity analysis. In particular I wanted to explore some of the possible 
explanations for the difference in the effect of achieving the physical activity targets 
amongst the younger and older age groups. 
7.12.1 Revised Strategies 
To evaluate the potential effect of different strategies for physical activity promotion I 
explored two options representing interventions targeted at sedentary, lightly active and 
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moderately active people. These strategies were: 
Strategy I- To encourage those who are either sedentary or lightly active to undertake 
moderate activity, thus increasing by 25% the proportion of the population 
aged between 15 and 64 which is moderately active. 
Strategy 2- To encourage those who are either sedentary, lightly active or moderately 
active to undertake vigorous activity, thus increasing by 25% the proportion 
of the population aged between 15 and 64 which is vigorously active. 
The effect of these strategies in men and in women, and in different age groups were 
investigated separately. 
Two scenarios were used to model each strategy to provide lower and upper limits of 
estimated outcomes. For Strategy 1, which aimed to increase the percentage of the 
population with a moderate level of physical activity, I simulated two scenarios that 
targeted either the sedentary group, or those already undertaking light activity. Strategy 2, 
which aimed to increase the number of people undertaking vigorous activity, was simulated 
using two scenarios which assumed that sedentary people would increase their activity to 
this level, or that those already taking moderate exercise would increase their level. 
7.13 Final Intervention Outputs 
I produced the outputs from the simulated interventions in terms of: 
" Percentage reduction in coronary heart disease mortality rate, compared to 1994; 
" Actual years of life gained. 
These output were adapted from the outputs of the initial modelling on feedback from the 
Task Force when the initial results were presented. It was felt that the percentage reduction 
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in CHD mortality rate could be more readily interpreted than CHD mortality rate. Also 
since physical activity only had an effect on CHD mortality within the model; it was felt 
it was not necessary to produce results in terms of total mortality. 
7.14 Final Results 
There would be a very small reduction in the death rate from coronary heart disease 
associated with achievement of each of the two strategies in men and women under 95 
years of age, see Table 7.7. This represents a fall of between 0.03% and 0.15% in men, and 
between 0.01% and 0.06% in women, across all age groups combined. 
Strat aI Strat a2 
Year Lower Upper Lower Upper 
Males 1994 1382.5 1382.5 1382.5 1382.5 
2019 1381.3 1380.5 1382.1 1381.6 
Females 1994 915.0 915.0 915.0 915.0 
2019 914.7 915.4 914.9 914.8 
Table 7.7 - CHD mortality per 100,000 for males and females aged under 95 years achieving 
each strategy. 
While the proportional reduction in the death rate appears disappointing, the actual years 
of life gained by the year 2019 was not insubstantial due to the size of the population 
(Figure 7.1). There was a roughly linear increase in actual years of life gained over time 
from 1994, illustrating that the interventions would be delaying deaths, although not 
enough to affect the mortality rate greatly. There were similar trends for both men and 
women, although the number of deaths postponed for men was about four times greater 
than for women. For both the upper and lower estimates Strategy 1 was the most effective 
in achieving life years gained. See Appendix D for the tables of the figures. 
To examine the differing effect of targeting exercise interventions at various age groups, 
I modelled the life years gained for each of the two strategies making the assumptions that 
the strategy would concentrate on the older age groups, 45 to 64 years of age, or on the 
younger age groups, 15 to 44 years of age. Figure 7.2 shows this comparison in men and 
women in terms of actual years of life gained, using the mean of the two scenarios 
simulated. For both men and women, the greatest gain can be achieved by concentrating 
129 
on the older group. Again Strategy I was the most effective and, as before, there is less gain 
achievable in women than in men. 
Figure 7.1 - Actual years of life gained for men and for women aged under 95 achieving each 
strategy by 2019. 
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Figure 7.2 - Actual years of life gained for men and for women aged under 95 achieving each 
strategy by 2019, targeting by age group. 
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7.14.1 Sensitivity Analysis 
It is possible that the increased relative risk associated with inactivity is attenuated in older 
people, since this was what Professor Gunning-Schepers found for the other risk factors 
within Prevent (Gunning-Schepers 1989). If this is true then the model will overestimate 
the effect of interventions in the elderly. I therefore carried out some sensitivity analysis 
for the simulations targeting those people 45 to 64 years of age, in which they were given 
lower relative risks for each level of physical activity. The relative risks are shown by age 
group in Table 7.8, they were estimated in consultation with Professor Gunning-Scheper 
by decreasing the relative risk by the same magnitude that she had for the other risk factors. 
This change made only a small difference to the number of deaths postponed, and targeting 
the older age groups still produced the greatest benefit (Figures 7.3 and 7.4). Modifying the 
remnant relative risks did not affect the results for those aged 15 to 44 years old. 
Exercise Age Groups 
Level 15-44 45-54 55-64 65+ 
Vigorous 1.0 1.0 1.0 1.0 
Moderate 1.4 1.3 1.3 1.3 
Light 1.7 1.6 1.5 1.4 
Sedentary 1.9 1.8 1.7 1.6 
Table 7.8 - Modified relative risks of CHD mortality in relation to physical activity level and age 
group. 
The interventions were also simulated using the cohort option, as well as the modified 
relative risks, to check if this improved the results for those aged 15 to 44 years old. Under 
this option the intervention would be responsible for changing people's behaviour for the 
entire simulation period, in that those people that take up a new physical activity level will 
continue with this level of activity for 25 years, and not acquire the level of physical 
activity of each age group that the cohorts pass though as they age. Figures 7.3 and 7.4 
shows that this increased the actual years of life gained when targeting the younger age 
group, but concentrating on people 45 to 64 years old still achieved the most health gain. 
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Figure 7.3 - Actual years of life gained for men and for women aged under 95 achieving 
Strategy 1 by 2019, targeting by age group, using modified relative risk and using the cohort 
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Figure 7.4 - Actual years of life gained for men and for women aged under 95 achieving 
Strategy 2 by 2019, targeting by age group, using modified relative risk and using the cohort 
option. 
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7.15 Discussion 
There are a number of problems with using Prevent, most of which have been discussed 
when describing the assumptions I have had to make in order to fit physical activity data 
into the model. Prevent was initially designed for shifting exposure groups to non-exposure 
groups, rather than shifting exposure distribution. In addition, there were constraints on the 
stratification of the population, such as having to use multiples of five for the age group 
divisions, and risk factor exposure. One of the major drawbacks has been the lack of any 
estimate of changes in morbidity, especially if physical activity has much bigger effects on 
the prevalence of non-fatal disease. Work is currently underway to develop a new model 
(Barendregt 1994 and 1997, and Bonneux 1999) which takes into account morbidity, and 
this will greatly increase the applicability of the model. 
The Prevent model may have underestimated the gain in mortality reduction from 
increasing physical activity since it is difficult to quantify the extent to which the relative 
risk of physical activity already accounts for the changes in the other established CHD risk 
factors such as hypertension, hyperlipidaemia, and obesity, as well as quantifying how the 
levels of these risk factors will change due to increased physical activity. I have assumed 
that physical activity will not affect the prevalence of these risk factors. I have also assumed 
that increased physical activity will not affect mortality from any other cause of death 
included in the Prevent model. However, of the causes of death modelled in Prevent, the 
only other cause that is likely to be affected is death from accidental falls (US Department 
of Health And Human Services 1996). This would nevertheless result in some under- 
estimation of the effect of physical activity on mortality. 
Prevent has been used to explore the effect of different strategies which might be 
undertaken to increase physical activity in the population. None of the strategies modelled 
appeared to have much effect on reducing predicted CHD mortality, although the most 
effective strategy appeared to be to encourage sedentary people to undertake moderate 
activity. If the proportion of the population undertaking moderate activity was increased 
by 25% as a result of this strategy, then approximately 12,100 years of life would be gained 
over 25 years. This is very similar to the health gain that could be achieved by a reduction 
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of 2% in the proportion of smokers in the population. The latter might, arguably, be easier 
to achieve (Silagy 1994). 
The reason for the interventions having little effect on the CHD mortality rate for the 
population up to the age of 95 is that the majority of deaths from CHD in the population 
occur in those over the age of 65, while these interventions concentrate on those under 65. 
The most effective strategy would achieve a 2.6% reduction for men and a 2% reduction 
for women in the CHD mortality rate up to age 65 years. 
The greater effect of Strategy 1 as compared with Strategy 2 could be because more people 
receive the intervention, 39.3% of the population aged between 15 and 64 are moderately 
active, while only 10.7% are vigorously active. Increasing each category by 25% results in 
49.1% of the population in this age group undertaking moderate activity and 13.4% 
undertaking vigorous activity. 
The proportion of the population at risk of CHD in the older age group has a significant 
impact on the relative effectiveness of the interventions by age group. This is emphasised 
when using attenuated relative risks for the older age group in the simulation, since the 
actual years of life gained for this age group still outweighs that for the younger age group, 
even though sedentary people in the younger age group have higher relative risks. 
The use of the cohort option in the simulation showed that the targeting of older age groups 
was still more effective, in terms of the actual years of life gained over 25 years, than 
targeting younger cohorts who would retain their new physical activity levels over time. 
Again, this is probably because of the higher CHD mortality rates amongst the older age 
groups in the England & Wales population. A proportionally smaller reduction in a large 
risk may be more beneficial at a population level than a large reduction in a small risk. 
The marked difference between the results for men and women reflects the fact that women 
have a much lower mortality rate for CHD than men, particularly between the ages of 25 
and 64 where the difference in the CHD mortality rate ranges from three to six and a half 
times lower for women. 
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The published account of this modelling work is detailed in Modelling the effects of 
increased physical activity on coronary heart disease in England and Wales (Naidoo 1997) 
in Appendix E. 
7.16 Reflections 
This work was invaluable in terms of my realising the complexity and difficulties, that are 
not apparent in the model's user manual, involved in adding a new risk factor to the 
Prevent. The manual outlines the process as being quite simple. It is not just a matter of 
adding the appropriate prevalences of the new risk factor to the model, and then applying 
the disease specific relative risks to each risk factor exposure category. When adding a risk 
factor questions concerning the accuracy and appropriateness of the risk factor prevalences 
are raised. There is also the problem of finding suitable relative risks which match the risk 
factor exposure categories. The user must consider whether the risk factor is cohort or age 
group specific, what movement between risk factor exposure categories are likely to occur, 
and what is the time period over which an individual's risk will change after moving to a 
new risk factor exposure category. 
The most surprising aspect of the work was my realisation that Prevent could only be used 
for modelling the movement of individuals from risk factor exposure categories to a non- 
exposure category, since this point is never explicitly made in the literature. Fortunately I 
was able to adapt the model in order to simulate the proposed targets, but I would not have 
been able to model any interventions that shifted a population's risk factor distribution, as 
opposed to moving individuals to just one lower risk factor exposure category. 
I found it interesting how the modelling could raise questions concerning the relationship 
between the risk factor and the linked disease which could then be explored more fully by 
adapting the model. For example, investigating reasons why the interventions were more 
effective in the older age groups, allowed me to test a number of alternative hypotheses, but 
also made me think more about feasible explanations for the results. 
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It was disappointing that, although the work was intended to inform the debate on the 
setting of physical activity targets, the fact that health targets became a political hot potato 
had more effect on the targets not being adopted than did the weight of research. This 
shows how difficult it can be for research to keep up with the policy agenda. This can be 
problematic for modelling, since the policy agenda could change markedly in the time it 
takes to develop a model that will address the original agenda. 
The weakest aspect of this modelling exercise in my opinion is the use of the meta-analysis 
by Berlin and Colditz, which was not ideal in terms of its definitions of physical activity 
levels. In addition, the meta-analysis was published 9 years ago, and since then the results 
of several large physical activity trials have been published (Morris 1990, Shaper 1991, and 
Manson 1999) which should be included in an updated meta-analysis. However, it may 
still be difficult to find appropriate relative risks by age and sex; since it is difficult to find 
trials that are applicable to a whole population. This highlights that, sometimes, the best 
obtainable data for modelling must be used to address policy questions when the ideal data 
do not exists. The modellers, and those who are using the results of the model, should 
always be aware of the weaknesses of the data on which the model is based. 
7.17 Conclusions 
Even if Prevent has underestimated the total gain possible from increasing physical activity, 
the relative gain of different strategies carries an important message. My work with Prevent 
indicates that the greatest health gain can be achieved by concentrating on sedentary people, 
on older people and on men. This may seem a contradiction of Rose's argument that 
preventive strategies which concentrate on a minority at high risk produce less health gain 
than strategies which intervene across the whole population, since the minority at high risk 
contribute a small proportion of adverse events (Rose 1992). However, the majority of 
older men, 45 plus, do not undertake even moderate exercise, and older men account for 
about 67% of coronary death under the age of 75. In this case, then, the most effective 
strategy is the one which concentrates on that section of the population which is 
contributing the majority of the deaths. 
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The modelling process was very instructive in terms of gaining a better understanding of 
the works of the model, as well as the difficulties and complexities of updating a model. 
It showed how although Prevent could be used to model these targets; it could not model 
interventions which would shift the risk factor distribution of a population, such as would 
possibly be the effect of a national campaign to increase physical activity overall. Before 
modelling any interventions it is important to decide what is the appropriate model to 
simulate such an intervention. 
7.18 Summary 
This chapter details my work for the Health Education Authority in adapting the Prevent 
model to include lack of physical activity as a risk factor for CHD in the England & Wales 
population. It details how the models has been used to simulate various strategies to 
achieve physical activity targets being considered by the Task Force on Physical Activity, 
targeting by age, sex and current level of physical activity in order to contribute to the 
policy debate in setting such target. 
Prevent was a useful tool in comparing the effect of different strategies to achieving 
physical activity targets in the populations. It demonstrated its ability to make these 
comparisons using various targeting strategies, as well as various hypothesis concerning 
how physical activity affects CHD mortality when current knowledge is open to debate. 
This exercise also highlighted the lack of data for inputting to the model. Modellers 
sometimes have to use the best available data to answer policy questions, while being aware 
of their limitations. 
The chapter illustrates how Prevent could be used to simulate proposed targets or strategies 
in order to inform debate on policy. The chapter also highlights how the politics behind the 
policy of target setting can be a more powerful force than the research results in setting the 
policy agenda, with the proposed targets being turned into a more general strategy 
statement at a time when attention was being drawn to other unmet health targets. 
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Chapter 8- Birmingham Interventions Modelled With PREVENT 
8.1 Introduction 
As a result of my earlier work with Prevent in modelling physical activity targets for the 
Health Education Authority I was approached by Dr Jackie Chambers, Director of 
Public Health, and her colleagues at Birmingham Regional Health Authority who 
wanted the Prevent model adapted to the Birmingham population. They were interested 
in making comparisons between risk factor intervention strategies targeting by age, sex 
and risk factor as a possible aid to policy decision making. In particular they were 
interested in simulating short term risk factor interventions in the Birmingham, Small 
Heath and Sutton Coldfield populations, and assessing their effectiveness in terms of 
actual years of life gained over time (25 years). We decided that this would be best 
achieved as a two stage process, with an initial set of interventions simulated, which 
would give the policymakers at Birmingham Regional Health Authority a better 
understanding of the workings and capabilities the Prevent model, and then to refine the 
set of health interventions modelled to be more specific to the public health issues that 
they wanted to address. 
8.2 Choosing a Version of PREVENT to Adapt 
Having adapted the Prevent model to the 1991 England & Wales population for my 
work on physical activity; I chose to use this model, using the same set of risk factors, 
risk factor exposure categories and diseases, as the basis for the Birmingham models. 
The version of Prevent included the following risk factors: 
" cigarette smoking, 
" hypertension, 
" cholesterol, 
" alcohol, 
" lack of physical activity, 
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and the following diseases: 
" coronary heart disease, 
" cerebrovascular accident, 
" chronic obstructive lung disease, 
" lung cancer, 
" cirrhosis of the liver, 
" breast cancer, 
" traffic accidents, 
" accidental falls. 
8.3 Adaptation of PREVENT 
I adapted my existing 1991 England and Wales model to create three separate models 
for the Birmingham, Small Heath and Sutton Coldfield populations. This entailed the 
input of data for each population on: 
population structure, 
" total mortality probability, 
" birth projections, 
" disease specific mortality probabilities, 
" risk factor exposure prevalences. 
There was no problem with the availability of Birmingham population, birth projection 
and mortality data down to a constituency level, which was supplied to me by 
Birmingham Health Authority. The Authority also supplied risk factor prevalence data, 
from the Pulse Survey, a health survey of the Birmingham region. Most of the risk 
factors related closely to the existing Prevent exposure levels, except for blood pressure 
and cholesterol which were recorded in terms of a yes/no treatment response. 
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Unfortunately these data were problematic at the regional level, particularly in terms of 
smoking data, since the Pulse Survey only had a 35% response rate at region level. 
As a consequence of the lack of blood pressure and cholesterol information by exposure 
level; other data sources needed to be identified to provide this information, otherwise 
national or regional prevalence levels would have had to be used, which may not have 
been appropriate for the Birmingham population. I considered the possibility of using 
different data sources including the data archive for the Health Survey, VAMP data and 
the GP morbidity data, as well as possibly using data on Wolverhampton, which had 
had its own health survey and which was thought to have a similar population to 
Birmingham by those at Birmingham Health Authority. 
In the end I chose to extract data on risk factor prevalences for the risk factors that were 
unavailable, or that were thought to be unreliable, from the 1993 Health Survey for 
England, supplied by the ESRC Data Archive, for the West Midlands and Trent regions, 
and used them as the best approximation available. Data on prevalences were extracted 
for the following risk factors from the 1993 Health Survey: 
" smoking (for Birmingham only, with the constituency data taken from the Pulse 
Survey), 
" hypertension, 
" cholesterol, 
" untreated hypertensives. 
Those at Birmingham Health Authority thought that the smoking data from the Pulse 
Survey was more representative for the constituencies, since there was a better response 
rate at that level, than a the regional level. While for hypertension and cholesterol there 
was a similar poor response rate at both constituency and regional level, possible due to 
these risk factors requiring a medical examination which individuals would be more 
likely to refuse than the questionnaire response required for the measurement of 
smoking, as was witnessed with the Health Survey for England (Bennett 1995). 
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Untreated hypertensives were classed as those individuals with a diastolic blood 
pressure above 95 mmHg who also answered no to the question "Are you currently 
taking any medicines, tablets or pills for high blood pressure? " in the Health Survey 
For England 1993. 
Prevalence data on physical activity levels for Birmingham and the two constituencies 
were taken from the Pulse Survey. Physical activity levels were classified as none, light, 
moderate and vigorous, and these were assumed to match the levels for the relative risks 
used in my previous work on physical activity, which were taken from the meta-analysis 
by Berlin and Colditz (Berlin 1990), see Chapter 7. 
The tables in Appendix F shows this background population data for each of the three 
populations by sex and age groups. 
8.3.1 Importance of Ethnic Mix 
Ideally the ethnic mix of Birmingham should have been taken into consideration, since 
I in 4 members of the population come from an ethnic minority. This is important in 
terms of the prevalence of diabetes amongst the Asian communities and hypertension in 
the Afro-Caribbean community. In theory ethnicity could have been modelled within 
Prevent in two ways: 
1. by stratifying the risk factor prevalences by ethnic group as well as age, sex and 
exposure category, with different relative risks of disease mortality for each cell of 
stratification; 
2. by stratifying the population by ethnic group as well as sex and age, which would 
have involved the input of population data (all cause and disease specific mortality 
probabilities, population structure, birth projections and risk factor prevalences) for 
each ethnic group to be included in the model. 
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I investigated the possibility of implementing these two methods, but due to the 
methodology of Prevent only allowing a limited number of risk factor exposure 
categories, as outlined in Chapter 3, and due to there being no regional risk factor 
prevalence or mortality data by ethnic group, it was not possible to include ethnicity as 
part of the model. 
STAGE ONE 
8.4 Initial Meeting 
The first step was to have an initial meeting at Birmingham Regional Health Authority 
with Dr Jackie Cambers and her colleague Mr Stuart Harris to discuss what they wanted 
modelled. Dr Chambers was already familiar with my work with Prevent for the HEA 
on physical activity, but in order to give a broader view of the capabilities of Prevent I 
gave a presentation on the data requirements of the Prevent model, and on the type of 
simulations that could be run, the range of risk factors that could be intervened on, and 
the targeting within populations that could be employed. 
They identified three areas that they were interested in: 
" Reducing smoking, which they were currently spend £0.3 million per year on, and 
so were interested in estimating the increased health gain due to reducing the 
prevalence of smoking; 
Increasing physical activity, since they were interested in extrapolating the work I 
had done on the England & Wales population to the Birmingham population; 
" Screening and treating hypertension, since it was an area originally highlighted by 
the Health Survey for England 1991 for fuller coverage, with 13% of men and 11% 
of women being hypertensive and not currently taking any drugs that could affect 
blood pressure. 
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In addition, Dr Chambers was interested in modelling the effects of the same 
interventions at constituency level, and in particular comparing the effects of these 
interventions in Sutton Coldfield, the most affluent constituency in Birmingham, with 
Small Heath, the most deprived constituency in Birmingham. Both constituencies have 
roughly the same size population (Small Heath has a population of 84727 people and 
Sutton Coldfield has a population of 92283 people), but have different age and sex 
structure, birth and death rates, and risk factor profiles, and so it would be of interest to 
investigate how these differences affected the outcome of exactly the same interventions 
in each population. Consequently it was decided to build separate models for the Sutton 
Coldfield and Small Heath populations, as well as a model for the whole of the 
Birmingham population. 
8.5 Choosing the Interventions 
The interventions chosen involved simulating the reduction in the prevalence of risk 
factors over time. However, the changes in prevalence of these first set of interventions 
were not chosen on the basis of any policy targets of the Birmingham Health Authority, 
or on what could realistically be achieved by a public health intervention, but what Dr 
Chambers and Mr Harris felt were reasonably achievable reductions in risk factor 
prevalence. 
The first set of interventions decided upon were: 
Smoking: 
. 1.0% reduction in the overall prevalence of cigarette smoking, 
" 2.0% reduction in the overall prevalence of cigarette smoking, 
" 3.0% reduction in the overall prevalence of cigarette smoking. 
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Physical activity: 
" 5.0% increase in the prevalence of moderate physical activity, 
" 10.0% increase in the prevalence of moderate physical activity, 
" 15.0% increase in the prevalence of moderate physical activity. 
These interventions were simulated targeting those people who were sedentary, and 
those who were lightly active as a means of calculating the bounds for what could be 
achieved by such interventions. In a best case scenario all the people who became 
moderately active would have been sedentary before the intervention, and so increasing 
their physical activity level by two categories, which in terms of relative risk of CHD 
mortality translates to moving from a relative risk of 1.9 to a relative risk of 1.4 within 
the model. While in the worst case scenario all those who became moderately active 
would have been lightly active before the intervention, and so only increasing their 
physical activity level by one category, which in terms of relative risk of CHD mortality 
translates to moving from a relative risk of 1.7 to a relative risk of 1.4. 
Hypertension: 
" 20.0% screening and successfully treating of untreated hypertensives in the 
population, 
30.0% screening and successfully treating of untreated hypertensives in the 
population, 
40.0% screening and successfully treating of untreated hypertensives in the 
population. 
These interventions were simulated by first assuming that untreated hypertensives who 
were screened and then successfully treated, so that they became normo-tensive, were 
all severe hypertensives (diastolic blood pressure above 95 mmHg), and then assuming 
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that all were mild hypertensives (diastolic blood pressure between 90 and 94 mmHg). 
Again this was done as a means of calculating the bounds for what could be achieved by 
such interventions, with the best case scenario being that all the people who became 
normo-tensive after screening and treatment would have been severely hypertensive 
before the intervention. In terms of relative risk of mortality within the model this 
translates, for example, to moving from a relative risk for CHD mortality of 2.3 to a 
relative risk of 1.6, and a relative risk for CVA mortality of 5.0 to a relative risk of 1.5 
for men aged under 45 years. In the worst case scenario all those who became normo- 
tensive after screening and treatment would have been mildly hypertensive before the 
intervention. In terms of relative risk of mortality, again as an example for men aged 
under 45 years, this translates to moving from a relative risk for CHD mortality of 1.9 to 
a relative risk of 1.6, and a relative risk for CVA mortality of 3.5 to a relative risk of 1.5. 
For the 40% screening and treating intervention both mild and severe hypertensives 
were screened and successfully treated since the percentage decreases in prevalence 
were larger than each hypertension category prevalence alone. 
Within the model cigarette smoking is a risk factor for lung cancer, chronic obstructive 
lung disease, CHD and cerebrovascular accident (CVA), lack of physical activity is a 
risk factor for CHD, and hypertension is a risk factor for CHD and CVA. 
The same interventions were simulated for the Small Heath and the Sutton Coldfield 
populations as for the Birmingham population. 
8.6 Running the Model 
The simulations were run for 34 years from 1991 (the base year), with the interventions 
beginning in 1996 and the target risk factor prevalences being achieved in 2005 (a target 
year for the Health of the Nation). The simulations then ran 
for a further 20 years, with 
risk factor prevalences at their new level, until 
2025. 
145 
The effect of the interventions was measured in terms of actual years of life gained and 
disease specific mortality. 
8.7 Results of the Modelling 
8.7.1 Birmingham Simulations 
Smoking interventions resulted in a greater number of actual years of life gained for 
males than for females, with the interventions having approximately twice the effect in 
males as in females (see Figures 8.1 and 8.2). For both males and females each increase 
in the percentage reduction in the prevalence of smoking led to a stepwise increase in 
the actual years of life gained. 
Physical activity interventions resulted in a greater number of actual years of life gained 
for males than for females due to the higher CHD mortality rate in men at all ages, and 
targeting the sedentary rather than the lightly active resulted in a greater number of 
actual years of life gained (Figures 8.3,8.4 and 8.5). The intervention on lightly active 
males was equivalent to the intervention on sedentary females. In addition, the actual 
years of life gained continued to increase for males, while for females they increase less 
markedly after 12 years, due to there being more females than males in the population 
only after 62 years of age, and these females still having a lower mortality rate than 
males of the same age. Again each increase in the percentage of those people 
undertaking moderate activity saw a stepwise increase in the number of actual years of 
life gained. 
Hypertension screening interventions, targeting the severe hypertensives, resulted in a 
greater number of actual years of life gained for females, nearly twice that for males, 
while targeting the mild hypertensives had a negligible effect, particularly amongst 
females. Increasing the percentage of treated hypertensives resulted in a stepwise 
increase in the actual years of life gained (Figures 8.6,8.7 and 8.8). 
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Figure 8.1 - Actual years of life gained due to smoking interventions in Birmingham males 
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Figure 8.2 - Actual years 
of life gained due to smoking interventions in Birmingham females 
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Stage One Modelling 
5% increase In The Levels of Moderate Activity In The Birmingham Population 
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Figure 8.3 - Actual years of life gained due to a 5% increase in the levels of moderate activity in 
the Birmingham population 
Stage One Modelling 
10% Increase In The Levels of Moderate Activity In The Birmingham Population 
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Figure 8.4 - Actual years of life gained due to a 10% increase in the levels of moderate activity in the Birmingham population 
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Stage One Modelling 
15% Increase In The Levels of Moderate Activity In The Birmingham Population 
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Figure 8.5 - Actual years of life gained due to a 15% increase in the levels of moderate activity in 
the Birmingham population 
Stage One Modelling 
20% Screening & Treating of Hypertension In The Birmingham Population 
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Figure 8.6 - Actual years of life gained due to a 20% screening and treating of hypertension in the Birmingham population 
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Stage One Modelling 
30% Screening & Treating of Hypertension In The Birmingham Population 
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Figure 8.7 - Actual years of life gained due to a 30% screening and treating of hypertension in the Birmingham population 
Stage One Modelling 
40% Screening & Treating of Hypertension In The Birmingham Population 
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Figure 8.8 - Actual years of life gained due to a 40% screening and treating of hypertension in the Birmingham population 
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8.7.2 Small Heath and Sutton Colditeld Simulations 
Smoking interventions resulted in a greater number of actual years of life gained for 
males than for females, and were responsible for more actual years of life gained in the 
Small Heath population compared to that of Sutton Coldfield (see Figures 8.9,8.10 and 
8.11). However, the number of actual years of life gained was very small for both 
populations, and for all the interventions due to the populations being small, although 
the number of actual years of life did increase with each increase in the percentage 
reduction. 
Physical activity interventions resulted in a greater number of actual years of life gained 
for males than for females, and targeting the sedentary rather than the lightly active 
resulted in a greater number of actual years of life gained (Figures 8.12 to 8.17). When 
targeting the sedentary the interventions were responsible for more actual years of life 
gained in Sutton Coldfield males than compared to that of Small Heath, while for 
females there were a greater number of actual years of life gained amongst those in 
Small Heath compared to those in Sutton Coldfield, although before 2012 the females of 
Sutton Coldfield achieve more actual years of life gained. The interventions aimed at the 
lightly active produced similar results, except that the Small Heath females achieved 
more actual years of life gained for the whole of the simulation period, and in the 10% 
and 15% interventions for the males the actual years of life gained for Sutton Cold field 
peaks in 2020 then begins to fall, while that for Small Heath continues to rise. 
Hypertension screening interventions, targeting the severe hypertensives, resulted in a 
greater number of actual years of life gained for females than for males (Figures 8.18 to 
8.23). While targeting the mild hypertensives had a very small effect, particularly 
amongst females. Again the interventions were responsible for more actual years of life 
gained in Sutton Coldfield males than compared to that of Small Heath, while for 
females there were a greater number of actual years of life gained amongst those in 
Small Heath, which began to level off in 2016, compared to those in Sutton Coldfield, 
which peaked in 2011 and then began to fall. 
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Figure 8.9 - Actual years of life gained due to a I% reduction in the prevalence of cigarette 
smoking in the Small Heath and Sutton Coldfield populations 
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Figure 8.10 - Actual years of 
life gained due to a 2% reduction in the prevalence of cigarette 
smoking in the Small Heath and Sutton Coldfield populations 
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Stage One Modelling 
3% Reduction In The Prevalence of Cigarette Smoking 
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Figure 8.11 - Actual years of life gained due to a 3% reduction in the prevalence of cigarette 
smoking in the Small Heath and Sutton Coldfield populations 
Stage One Modelling 
5% Increase In The Level of Moderate Activity Achieved By Targeting The Sedentary 
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Figure 8.12 - Actual years of life gained due to a 5% increase in the levels of moderate activity 
achieved by targeting the sedentary in the Small Heath and Sutton Coldfield populations 
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Stage One Modelling 
5% Increase In The Level of Moderate Activity Achieved By Targeting The Lightly 
Active 
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Figure 8.13 - Actual years of life gained due to a 5% increase in the levels of moderate activity 
achieved by targeting the lightly active in the Small Heath and Sutton Coldfield populations 
Stage One Modelling 
10% Increase In The Level of Moderate Activity Achieved By Targeting The Sedentary 
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Figure 8.14 - Actual years of life gained due to a 10% increase in the levels of moderate activity 
achieved by targeting the sedentary in the Small Heath and Sutton Coldfield populations 
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Stage One Modelling 
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Figure 8.15 - Actual years of life gained due to a 10% increase in the levels of moderate activity 
achieved by targeting the lightly active in the Small Heath and Sutton Coldfield populations 
Stage One Modelling 
15% Increase In The Level of Moderate Activity Achieved By Targeting The Sedentary 
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Figure 8.16 - Actual years of life gained due to a 15% increase in the levels of moderate activity 
achieved by targeting the sedentary in the Small Heath and Sutton Goldfield populations 
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Stage One Modelling 
15% Increase In The Level of Moderate Activity Achieved By Targeting The Lightly 
Active 
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Figure 8.17 - Actual years of life gained due to a 15% increase in the levels of moderate activity 
achieved by targeting the lightly active in the Small Heath and Sutton Coldfield populations 
Stage One Modelling 
20% Screening of Hypertension Targeting The Severe Hypertensives 
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Figure 8.18 - Actual years of life gained due to a 20% screening and treating of hypertension 
targeting the severe hypertensives in the Small Heath and Sutton Coldfield populations 
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Stage One Modelling 
20% Screening of Hypertension Targeting The Mild Hypertensives 
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Figure 8.19 - Actual years of life gained due to a 20% screening and treating of hypertension 
targeting the mild hypertensives in the Small Heath and Sutton Coldfield populations 
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Figure 8.20 - Actual years of life gained due to a 30% screening and treating of hypertension 
targeting the severe hypertensives in the Small Heath and Sutton Coldfield populations 
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Stage One Modelling 
30% Screening of Hypertension Targeting The Mild Hypertensives 
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Figure 8.21 - Actual years of life gained due to a 30% screening and treating of hypertension 
targeting the mild hypertensives in the Small Heath and Sutton Coldfield populations 
Stage One Modelling 
40% Screening of Hypertension Targeting The Severe Hypertensives 
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Figure 8.22 - Actual years of life gained due to a 40% screening and treating of hypertension 
targeting the severe hypertensives in the Small Heath and Sutton Coldfield populations 
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Stage One Modelling 
40% Screening of Hypertension Targeting The Mild Hypertensives 
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Figure 8.23 - Actual years of life gained due to a 40% screening and treating of hypertension 
targeting the mild hypertensives in the Small Heath and Sutton Coldfield populations 
8.8 Discussion 
Although the various interventions target differing percentage of the population; in 
terms of the ones that results in the most actual years of life gained for all three 
populations targeting sedentary males and severely hypertensive females appear to be 
the most effective interventions. 
Targeting sedentary males, with a 15% increase in the prevalence of moderate physical 
activity, resulted in 724 actual years of life gained for the Birmingham population, 64 
for the Small Heath population and 67 for the Sutton Coldfield population. These would 
be equivalent to the actual years of life gained achieved by 8%, 10% and 11 % 
reductions in the prevalence of cigarette smoking in each population respectively. 
Targeting severely hypertensive females, using the 40% screening strategy, resulted in 
1226 actual years of life gained for the Birmingham population, 141 for the Small Heath 
population and 131 for the Sutton Coldfield population, and these would be equivalent 
to the actual years of life gained achieved by 23%, 35% and 63% reductions in the 
prevalence of cigarette smoking in each population respectively. 
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In terms of the comparison of the effect of the interventions between the Sutton 
Coldfield and Small Heath populations the numbers of actual years of life gained by 
each intervention were very similar due to both populations being of a roughly similar 
size. The Small Health population gained more actual years of life due to the smoking 
interventions since there was a higher prevalence of smoking in this population than the 
Sutton Coldfield population. While for the physical activity interventions the Sutton 
Coldfield men gained more years of life than the Small Heath men due to the larger 
number of older men (over 30 years of age) in the Sutton Coldfield population, but the 
Small Heath women gained more years of life than the Sutton Coldfield women due to 
higher prevalence of sedentary women in the Small Heath population. As for the 
hypertension screening and treating interventions, Sutton Coldfield men achieved 
slightly more actual years of life gained than Small Heath men again due to the larger 
number of older men in the Sutton Coldfield population, while Small Heath women 
achieved more actual years of life gained than Sutton Coldfield women and this was 
achieved after a longer period of time due to the difference in population structure with 
more younger women (under 31 years of age) in the Small Heath population, and hence 
the effects are seen later. 
8.9 Presentation of Results to Birmingham Health Regional Authority 
These results were presented by me to Dr Chambers and Mr Harris, along with their 
General Practitioner group at the Birmingham Regional Health Authority. 
Overall the GPs found the information fascinating, and were interested in seeing how 
interventions and targeting strategies within specific populations could be compared 
using a computer model. In particular they felt that the results of such models would be 
an incentive for GPs in that it gave them an idea of the magnitude of the effect of their 
interventions on individuals when aggregated to the population, and hence gave them a 
sense of their interventions being worthwhile. They were quite surprised by there being 
a small number of actual years of life gained over 35 years when the interventions were 
applied at the constituency level, but I explained that this was a result of the populations 
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being so much smaller than that of the whole of Birmingham. In addition, they thought 
that modelling could be used for risk factor management guidelines that could be 
developed for the city. 
The GPs main concerns were that ethnicity was not included, particularly with 25% of 
the Birmingham population belonging to a ethnic minority group, and that there were no 
measures of morbidity, such as for non-fatal disease since they felt that just measuring 
mortality underestimated the effect of the interventions. They also thought that some 
quality of life measure would have been appreciated. I explained to them about the 
methodological and data problems connected with fitting ethnicity into the Prevent 
model, which made them aware of the lack of health data by ethnic group. I explained 
that Prevent was only designed for output in terms of mortality, and that the resulting 
simulation runs will always underestimate the possible health gain achievable because 
they do not take account of the effects of interventions on morbidity. 
In terms of the interventions that I modelled the GPs raised concerns about whether the 
smoking interventions were smaller than the observed trend in the population, however 
they had no idea what the observed trend was in the Birmingham population, or if this 
trend had been measured, which it had not. So I explained that for the next stage of the 
modelling we would have to make some assumptions on the likely size of the trend. 
During the discussions it became apparent that different definitions for hypertension are 
being used by GPs in the Birmingham area. They were using the 1993 WHO guidelines 
(Subcommittee of WHO\ISM Mild Hypertension Liaison Committee 1993) of mild 
hypertension being classified as having a diastolic blood pressure between 90 and 105 
mm Hg, and moderate and severe hypertension being classified as having a diastolic 
blood pressure above 105 mm Hg, while the Prevent hypertension categories and 
relative risks were based on 1983 WHO guidelines (WHO 1983). However, Dr 
Chambers and Mr Harris wanted to keep the original categories since they conformed 
more closely to the definitions in the Health Survey for England of hypertension being 
classified as having a diastolic blood pressure above 
94 mmHg, and so were, in their 
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view, more relevant for addressing the issue of screening and treating existing untreated 
hypertension, thus allowing them to compare Birmingham with the national figures. 
Amongst the group, questions were raised about compliance in any intervention, and 
whether this should be taken account of before applying reductions in risk factor 
prevalences. I explained that in modelling the interventions I had assumed that the 
reductions achieved were due to complete compliance, but that one should consider 
what percentage of a population needs to be intervened on to produce the desired change 
in risk factor prevalence. 
With respect to forming policy, they were most interested in terms of Birmingham 
hypertensive screening, envisaging that such modelling could be used to decided who is 
it most appropriate to refer and who should be referred back to primary care. They were 
also interested in investigating whether they should treat the "diagnosed but not treated 
hypertensives" rather than screening. With regard to these goals they became aware that 
data not currently available needed to be collected. 
The GPs were also interested in the cost consequences of the interventions, and would 
have liked to have had some economic output to the model so they could investigate 
such areas as what would be the best buy for hypertensives, or what would be the effect 
of an intervention in terms of the avoidable cost to health care. 
Having seen what types of interventions could be modelled with Prevent the group 
discussed other scenarios that they would like modelled. Concern was raised about the 
growing prevalence of teenage smoking in Birmingham, and an interest was expressed 
in simulating what would happen if young people did not give up smoking like the older 
people. There was also interest in modelling reductions in cholesterol in a similar 
fashion to the hypertension interventions. 
The GPs also expressed interest in modelling interventions concentrated on secondary 
disease, in particular for coronary artery disease and interventions on cholesterol, 
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smoking and blood pressure, as well as using aspirin, and so they were disappointed that 
Prevent could only model primary prevention. 
In addition, I raised my concerns about the data on physical activity for Birmingham 
and its constituencies since they showed a marked difference from those for England & 
Wales, with particularly high levels of moderate and vigorous physical activity at older 
age groups (see Appendix F). It was agreed that these data were probably not that 
reliable. Consequently it was decided not to include physical activity in the next stage of 
the modelling. 
At the end of the meeting Dr Chambers and Mr Harris had revised the areas they were 
interested in simulating to: 
" the impact of smoking cessation in adults - simulating a stronger effect on smoking 
cessation with a year on year decrease in the prevalence, as well as taking into 
account the effect of background trends, 
" teenage recruitment to smoking - since this was perceived as major health problem 
in Birmingham, and so they were interested in investigating the long term health 
consequences, 
" interventions directed at hypertension. 
STAGE TWO 
8.10 Revised Specifications for the Modelling 
Following further discussions between myself, Dr Chambers and Mr Harris; we decided 
to adjust the modelling scenarios to the following: 
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The impact of smoking cessation in adults: 
" 0% background trend with -2%, -3% and -4% yearly reductions in smoking 
prevalence over 5 years from 1997; 
-3% background trend with -2%, -3% and -4% yearly reductions in smoking 
prevalence over 5 years from 1997. 
Recruitment to smoking: 
0% background trend with 1%, 2% and 3% yearly increases in the trend amongst the 
15 to 24 age group from 1991 onwards. 
Interventions directed at hypertension: 
20% screening for untreated hypertension targeting treatment to the severe and then 
the mild hypertensives over 5 years from 1997; 
40% screening of untreated hypertension targeting treatment to the severe and then 
the mild hypertensives over 5 years from 1997. 
8.11 Simulations 
As before the simulations were run for 34 years from 1991, but with the interventions 
beginning in 1997 and the target risk factor prevalences being achieved in 2005. The 
simulations then ran for a further 20 years, with risk factor prevalences at their new 
level, until 2025. 
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8.12 Results of the Modelling 
8.12.1 Birmingham Simulations 
As with the first model runs smoking interventions resulted in a greater number of 
actual years of life gained for males than for females, and as before the interventions 
had approximately twice the effect in males as in females (see Figures 8.24 and 8.25). 
Again for both males and females with each increase in the percentage reduction in the 
prevalence of smoking there was a stepwise increase in the actual years of life gained. 
With a background trend of minus 3% reducing the prevalence of smoking the 
interventions only produced approximately half the actual years of life gained as the 
scenario with no background trend, due to the background trend reducing the number of 
people who would be intervened on. This was the case for both males and females. 
For the scenarios simulating the increase in smoking amongst 15 to 24 year olds there 
was no increase in disease specific mortality within the timeframe of the simulation for 
either males or females (Figures 8.26 to 8.29). 
For the hypertension screening interventions, targeting the severe hypertensives resulted 
in a greater number of actual years of life gained for females than for males, over twice 
the number (Figures 8.30). As with the previous modelling targeting the mild 
hypertensives produced a much smaller effect, especially for females. Increasing the 
percentage of treated hypertensives resulted in a stepwise increase in the actual years of 
life gained. 
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Figure 8.24 - Actual years of life gained due to smoking interventions with a 0% trend in the 
Birmingham population 
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Figure 8.25 - Actual years of life gained due to smoking interventions with a -3% trend in the Birmingham population 
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Stage Two Modelling 
Increasing 15-24 Age Group Smoking Trend - Birmingham 
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Figure 8.26 - Lung cancer mortality due to an increasing 15-24 age group smoking trend in the 
Birmingham population 
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Figure 8.27 - COLD mortality due to an increasing 15-24 age group smoking trend in the Birmingham population 
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Stage Two Modelling 
Increasing 15-24 Age Group Smoking Trend - Birmingham 
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Figure 8.28 - CHD mortality due to an increasing 15-24 age group smoking trend in the 
Birmingham population 
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Figure 8.29 - CVA mortality due to an increasing 15-24 age group smoking trend in the Birmingham population 
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Stage Two Modelling 
Hypertension Screening & Treating - Birmingham 
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Figure 8.30 - Actual years of life gained due to screening and treating of hypertension in the 
Birmingham population 
8.12.2 Small Heath and Sutton Coldfield Simulations 
Again smoking interventions resulted in a greater number of actual years of life gained 
for males than for females, and were responsible for more actual years of life gained in 
the Small Heath population than the Sutton Coldfield population (see Figures 8.31 to 
8.36). For all the interventions the number of actual years of life increased with each 
increase in the percentage reduction in the prevalence of smoking due to the 
interventions, and decreased with each increasing reduction in background trend in the 
prevalence of smoking. Although, as before, the number of actual years of life gained 
was very small for both populations. 
Just as with the simulations for the Birmingham population there was no change in 
disease specific mortality due to increased smoking amongst 15 to 24 year olds of both 
sexes within the simulation period (Figures 8.37 to 8.40). 
As with the Stage One modelling, hypertension screening interventions targeting the 
severe hypertensives resulted in a greater number of actual years of life gained for 
females than for males (Figures 8.41 and 8.42). While targeting the mild hypertensives 
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again had little effect, particularly amongst females. Similarly amongst males the 
interventions were responsible for more actual years of life gained in Sutton Coldfield 
than in Small Heath, while for females there were a greater number of actual years of 
life gained amongst those in Small Heath, reaching about 140 years of life gained by 
2016, for 40% screening, and then levelled off, compared to those in Sutton Coldfield, 
which peaked in 2011 and then began to fall. 
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Figure 8.31 Actual years of life gained due to a -2% reduction in smoking with a 0% trend in 
the Small Heath and Sutton Goldfield populations 
170 
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Figure 8.32 - Actual years of life gained due to a -3% reduction in smoking with a 0% trend in 
the Small Heath and Sutton Coldfield populations 
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Figure 8.33 - Actual years of life gained due to a -4% reduction in smoking with a 0% trend in the Small Heath and Sutton Goldfield populations 
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Figure 8.34 - Actual years of life gained due to a -3% reduction in smoking with a -2% trend in the Small Heath and Sutton Coldfield populations 
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Figure 8.35 - Actual years of life gained due to a -3% reduction in smoking with a -3% trend in 
the Small Heath and Sutton Coldfield populations 
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Figure 8.36 - Actual years of life gained due to a -4% reduction in smoking with a -3% trend in 
the Small Heath and Sutton Coldfield populations 
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Figure 8.37 - Lung cancer mortality due to an increasing 15-24 age group smoking trend in the Small Heath and Sutton Coldfield populations 
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Figure 8.38 - COLD mortality due to an increasing 15-24 age group smoking trend in the Small 
Heath and Sutton Coldfield populations 
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Figure 8.39 - CHD mortality due to an increasing 15-24 age group smoking trend in the Small Heath and Sutton Coldfield populations 
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Figure 8.40 - CVA mortality due to an increasing 15-24 age group smoking trend in the Small 
Heath and Sutton Coldfield populations 
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Figure 8.41 - Actual years of life gained due to a 20% screening and treating of hypertension in the Small Heath and Sutton Coldfield populations 
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Stage Two Modelling 
40% Hypertension Screening 
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Figure 8.42 Actual years of life gained due to a 40% screening and treating of hypertension in 
the Small Heath and Sutton Coldfield populations 
8.13 Discussion 
In terms of the interventions that results in the most actual years of life gained for all the 
populations targeting smoking males, and screening and treatment of severely 
hypertensive females appear to be the most effective interventions. 
Dr Jackie Chambers' views were that she thought modelling risk factor interventions in 
the Birmingham population was a useful exercise, particularly with regard to the 
population focus of the model rather than targeting individuals, and the way that models 
translate health promotion strategies into deaths avoided. 
She was concerned with the model's inability to take into account aspects of the local 
population structure other than age and sex, particularly my not being able to include 
ethnicity in the model. However, the discussions around the problem of trying to include 
ethnicity in the model highlighted the absence of data on risk factor prevalence and 
mortality by ethnic group within the Birmingham area. 
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She also felt that the lack of any morbidity measures was a weakness of the model, since 
just concentrating on the effect of interventions in terms of mortality greatly under- 
estimated the possible health gain achievable. 
In addition, Dr Chambers would have wanted the model to be able to simulate the 
delivery of secondary prevention strategies in primary care, particularly with regard to 
interventions on cholesterol, smoking, blood pressure, and using aspirin for individuals 
with CHD, thus taking into account of the ability of GPs to deliver the such 
intervention. 
What she found the results of the modelling most useful for was arguing for resources at 
a Heath Authority level. She had used the estimation that treating hypercholesterolaemia 
with statins at the 3% risk level would cost Birmingham Regional Health Authority £18 
million and save 176 lives per year, compared to her interpretation of the modelling 
results of reducing smoking by 2% per year would save 170 lives per year in the 
medium term (actually it resulted in 194 years of life gained by 2007), and they were 
currently spend £0.3 million per year on that. So the results were used to justify the 
continued spending on their smoking reduction programme, rather than channelling 
spending elsewhere. 
In terms of the future development of the model Dr Chambers thought that the model 
needed to include data on the effectiveness of health promotion, with regard to what 
proportion of a population needs to be targeted to achieve the modelled changes in risk 
factor prevalence, as well as data that gives the impact (uptake x efficacy) of the 
interventions. 
8.14 Reflections 
Overall I felt that the modelling work was an interesting and worthwhile exercise, since 
I feel that models such as Prevent are often developed and used by a modeller in 
isolation from actual policymakers, with the modellers and public health researchers 
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building models and simulating intervention that they think policymakers are interested 
in rather than what they actually want. This exercise gave me an invaluable opportunity 
to present modelling to policymakers, and to find out what issues were important to 
them. It was a means of getting them to develop the interventions to be simulated, which 
in turn makes the results of the modelling more policy relevant. 
I was surprised that the result of the modelling were viewed by the GPs in terms of 
being an incentive to continue with their current practices, or introduce new practices, 
because they saw the effect of translating interventions at an individual level to that of a 
population, I had previously just considered the results in terms of comparing 
interventions. 
My main frustration with the work was the lack of data, particularly with regard to risk 
factor and mortality data by ethnic group, since this was an area of utmost importance to 
Birmingham Regional Health Authority. Even though there were practical difficulties 
with including ethnicity in Prevent, the fact that no relevant data existed meant that I 
could not even consider alternative approaches, as I had applied with the physical 
activity modelling at the national level, to overcome Prevent's limitations. I found it 
interesting that in spite of an issue being seen as so important to policymakers; no data 
had been collected on the baseline health characteristics of the Birmingham population 
by ethnic group. Data on the characteristics of the population as whole were also 
limited, with only a 35% response for the Pulse Survey. This lack of baseline data has 
wider implications with regard to the evaluation of health policies within the 
Birmingham population. It is not possible to properly evaluate the effect of an 
intervention without being able to measure the changes that have occurred. One of the 
unforeseen outcomes of this work was that those at Birmingham Regional Health 
Authority became more aware of the need for such data. 
Policymakers can sometimes be unrealistic about the interventions requested to be 
modelled, as in the case of the smoking interventions, where I was asked to increase the 
change in prevalence due to the intervention since there was a perception that the 
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background trends in the population were greater than the intervention in my Stage One 
modelling. The background trends were increased to at least a 2% yearly reduction. On 
reflection this now seems overoptimistic since in California with very strict tobacco 
control policies and massive investment only a 1% yearly reduction was achieved 
(Glantz 1993). This has led me to realise the need for modellers to review the literature 
on the effectiveness of interventions, particularly with regard to the changes in risk 
factor prevalence due to an intervention that would realistically be achievable in a 
population. Modellers can advise policymakers rather than relying on those 
commissioning the modelling to dictate the changes in prevalence. In future before 
undertaking modelling such as this I would investigate through the literature what 
changes would be achievable by the intended interventions. However, this problem of 
overestimating the effectiveness of public health, or health promotion, interventions 
may be difficult to overcome due to the scarcity of experimental evidence (Winkelstein 
1981) and the lack of evaluation of health promotion studies (Nutbeam 1998), as well as 
the problems of generalising results from studies conducted on different populations to 
one's own (Speller 1997). 
It is important that modellers have information about the current practice of the people 
for whom they are modelling. In this work it would have been useful to model the 1993 
WHO hypertension guidelines, as well as the Health Survey for England hypertension 
categories, since although the latter were relevant to the policymakers at Birmingham 
Regional Health Authority in terms of achieving targets; they were not relevant to the 
GPs in terms of their current practice. Modellers need to be aware that the seemingly 
same intervention in a population can be put into operation using different criteria by 
different groups, and that modellers may need to address the needs of each group 
separately. 
In terms of choosing Prevent as the model to simulate the interventions I think that it 
was very suitable for simulating the interventions derived by Stage Two of the work. 
However, it is possible that if a different model had been used, different interventions 
would have been chosen, and that knowledge of the constraints on the model resulted in 
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our limiting the interventions to those that were possible with the model. The more 
flexible the model, the more varied the interventions simulated would have been. The 
main shortcoming in using Prevent was the lack of any morbidity output, since just 
reporting the effect of primary care interventions in terms of mortality is disappointing 
to policymakers with respect to the size of the health gain achieved, as well as the 
insights that can be gained. 
8.15 Conclusions 
Although Prevent has been used successful in simulating risk factor interventions for 
relatively small populations such as that of the Netherlands (15 million); it had never 
been used for populations as small as Birmingham, Sutton Coldfield and Small Heath. 
My modelling has shown that even when using such small populations it is still possible 
to compare interventions, although the health gained achieved is small. 
The modelling work has also illustrated how targeting the same risk factor intervention 
at populations which have the same risk factor prevalence, as with hypertension, will 
still produce differing outcomes in terms of health gain due to their differences in 
age/sex structure and mortality patterns. 
One interesting aspect of this work has been how presenting results of "what if" 
interventions scenarios stimulated discussion about other aspects of health interventions 
that policymakers and practitioners were concerned with, and about how these 
interventions would be achieved, as well as highlighting the current lack of, and need 
for, accurate baseline data. 
I was particularly interested in how Birmingham Regional Health Authority used the 
model for policy making. The output on smoking was used to back up an existing 
decision to allocate resources to smoking interventions in Birmingham, but the output 
on screening for untreated hypertension which showed potential for large gains was not 
acted on, since it was not on their policy agenda. This is a good example of one the 
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difficulties of turning research into policy, that in spite of the research showing a 
beneficial intervention; policymakers will only pick out the bits of the research that 
support the areas that they already see as important, rather than highlighting new areas 
for the policy agenda as would ideally be the aim of such modelling exercises. It shows 
that policy does not always follow the Rational Model (Walt 1994), as outlined in 
Chapter 3, in which the knowledge gained from research should drive the development 
of policy in a rational and linear process. Instead policymakers will pursue their own 
agenda, which may differ from that of researchers, or may only encompass a portion of 
their research. Ultimately policymakers may only use research that will help sustain 
their current policy agenda, and may not be receptive to research that will requires a 
change in policy. 
8.16 Summary 
This chapter describes my work with Birmingham Regional Health Authority in 
adapting the Prevent model to produce versions for the Birmingham, Small Heath and 
Sutton Coldfield populations. It describes how these models have been used to make 
comparisons between risk factor intervention strategies targeting by age, sex and risk 
factor as a possible aid to policy decision making. In addition, the chapter outlines the 
process of how the interventions modelled were developed in conjunction with 
Birmingham Regional Health Authority, and details their feedback on the work. 
Prevent proved to be a useful tool in comparing the effect of different interventions in 
the Birmingham populations, and in comparing the effect of the same interventions in 
different populations. It demonstrated its ability to make these comparison even when 
simulating relatively small populations, although the health gain achieved may be 
modest. 
In terms of using the model with policymakers the chapter details how important data 
are to the modelling process, particularly how, in the case of ethnicity, the lack of 
appropriate data meant that important policy issues could not be addressed. It also 
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illustrates how policymakers need to be informed on the effectiveness of interventions, 
otherwise they may ask for overoptimistic and unrealistic interventions to be simulated. 
In addition, the chapter highlights how modelling can be used in translating research 
into policy, showing that results of modelling can be used by policymakers to justify 
current policy decisions, while other modelling results may receive less attention. 
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Chapter 9- PREVENT European Collaborative Project 
9.1 Introduction 
In the early 1990s a number of countries in Europe had developed, or had begun to use 
public health models. Epidemiologists in the Netherlands, the U. K., Denmark and 
Sweden had been using Prevent. However, this research had been carried out separately in 
each country, so common problems were being solved independently, causing a 
duplication of work, and was perceived as a barrier to progress. With the development of 
Prevent, and the emergence of other models such as NIMPH and POHEM, there was a 
growing need for an international forum to provide mutual support for modellers and for 
model users with various experiences, which would enhance the development and the use 
of modelling within Europe. 
Discussions about the desirability of collaboration in modelling came to the fore at the 
1994 Conference of the European Public Health Association in Copenhagen at a workshop 
on "Prevent Models and Other Models. " As a result of these initial discussions Professor 
Gunning-Schepers submitted a proposal, for which I wrote the technical section on 
existing public health models, to the European Unions'(E. U. ) Biomed II concerted action 
programme entitled "Public Health Models, " which was accepted for three years of 
funding by the E. U., and work on the collaborative project began in 1996. 
The four objectives of the collaboration which was funded were: 
1. to validate the models in the context of different E. U. countries, 
2. to compare the implementation, the utilisation and the results of Prevent in different 
E. U. countries, 
3. the exchange of data, notably on risk factors, relative risks, new treatments and 
treatment outcomes, for inclusion in such models, 
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4. to explore some methodological issues, such as the comparison of various modelling 
techniques like cell-based modelling as opposed to micro-simulation modelling. 
The project participants were members of the London School of Hygiene & Tropical 
Medicine, the University of Amsterdam, the University of Rotterdam, the Centre for 
Epidemiology - Sweden, the Centre For Studies in Health and Health Services - Denmark 
and Statistics Canada. 
In this chapter I outline the Prevent related work of the project, concentrating on my 
own work with the Prevent model, as well as summarising the cross-country 
comparison modelling work carried out as a result of constructing the four comparable 
Prevent models. I discuss my work on the POHEM phase of the Biomed II project in 
Chapters 13 and 15. 
9.2 Four E. U. Versions of PREVENT 
The collaborative European project entailed producing versions of Prevent for the 4 
E. U. countries involved (England & Wales, The Netherlands, Denmark and Sweden). 
Having set up these versions for Prevent, they were to be used for simulating identical 
risk factor interventions in each country to compare how the differing demographics and 
risk factor prevalences would affect the outcomes. 
As described in Chapter 4- Data Sources, the validity of computer simulation models' 
output depends not only on the methodology and the structure of the model, but also on the 
quality of the input data, and much of the work for this part of the project involved 
resolving issues of using the "best" available data for the model. The aim of this phase of 
the Biomed project was to construct four different country-specific Prevent models, but 
each with comparable data sets and the same relative risks applied. We made joint efforts 
to decide which risk factors to use and that involved searching the literature, with each 
country looking individually for the data that was available. This did not usually involve 
searching the literature, but rather consulting experts. 
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There were substantial cross-country differences in the data that were being used for 
Prevent and in available empirical data. Different ICD codes were being used in the 
definitions of disease, for example we had to decide whether our definition of CHD would 
include "ill defined descriptions and complications of heart disease" (ICD9: 429). In 
addition, risk factor prevalence data did not have the same amount of detail or cut-off 
points. For instance, in Sweden smoking was recorded at a national level as a dichotomous 
(yes/no) variable from 1989 onwards. Much of the effort of this phase of the project was 
spent trying to find the best compromise between uniformity in structure of the four 
countries' data sets and the maximum use of the available data from each country. 
Full details of all the input data are given in the final report of the Biomed project (Biomed 
11 1999). 
9.3 Population Data 
9.3.1 Base Year 
This phase of the project began in 1996. Ideally, the base year should have been the most 
recent year for which population data were available, but it also had to be the same for 
each country. 1993 was chosen as the base year, since it was the most recent year that 
population data were available for the Netherands, Sweden and Denmark, while for 
England & Wales it was the most recent year of the Health Survey for England, from 
which risk factor prevalence data would be extracted, that included the measurement of 
cholesterol. 
9.3.2 General Mortality 
There were cross-country differences in total mortality in the 0-1 year age group due to 
differences in the definition of total mortality, which included or excluded neonatal 
mortality. To keep the definition consistent across the four countries we decided to include 
neonatal mortality in the definition of total mortality. We chose to enter mortality data as 
probabilities of death within 1 year (1993), which had always been the case with older 
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versions of Prevent, but was now made more explicit since the groups from Denmark and 
Sweden were not aware of this definition. 
9.3.3 Disease Specific Mortality 
Specific mortality was defined using the ICD version 9. The risk factors that were to be put 
in the model were smoking, hypertension, and hypercholesterolaemia (see section 9.4.1). 
These risk factors impact largely on cardiovascular and respiratory disease, and we 
therefore decided to include the following diseases in the model: 
" Lung cancer (ICD 9: 162); 
" COLD (ICD 9: 491,492,496); 
" CHD (ICD 9: 410 to 414); 
" CVA (ICD 9: 430 to 438). 
As indicated by its ICD code, the 'COLD' definition included chronic bronchitis, 
emphysema and COLD 'not otherwise specified', as most reported relative risks are 
calculated for these death causes. Asthma (ICD 9: 493) was excluded since it is a clinically 
distinct disease, especially at younger ages. Mortality from CHD was restricted to the 410 
to 414 code, since the studies used to derive the relative risk values utilised this definition. 
Data were specified as 5 year age-group probabilities for base year 1993. 
9.4 Risk Factors 
9.4.1 Choice of Risk Factors 
For public health policymakers, risk factors which contribute substantially to highly 
prevalent, serious diseases or accidents are the most interesting targets for intervention. For 
this phase it was decided to concentrate on those risk factors for which valid quantitative 
data could be obtained relatively easily in all four countries. These risk factors were 
smoking, hypertension and hypercholesterolaemia. Risk factors such as physical inactivity 
and alcohol consumption have been monitored less intensively, implying a wider gap 
between epidemiological data and model input, and so were not included in the model. In 
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addition, physical activity could not be included since prevalence data were only available 
for England & Wales, and did not exist for the other three countries. It was also decided to 
leave out obesity, as the evidence is still unclear as to what extent body mass index has an 
independent association with disease. 
9.4.2 Risk Factor Classification 
Smoking behaviour has been monitored extensively for many years in most countries. In 
contrast, there are fewer detailed empirical data on blood pressure or blood cholesterol 
levels in the general population. For instance, the Netherlands did not have blood pressure 
data at the population level. Not all countries had data on hypertension based on the same 
number of measurements, with the Danish and Swedish data based on one measurement, 
while those for England & Wales were based on three measurements. There were only 
hypertension treatment status data available for the England & Wales population, while 
historical blood pressure trend data were incomplete, in that they were not available, or had 
not been recorded, for long before 1993. Consequently hypertension had to be modelled in 
a rather simple way as a dichotomous variable. Cholesterol was modelled with two 
exposure categories. In addition, it was assumed that treated hypertensives had a relative 
risk associated with their actual blood pressure, irrespective of their treatment status. 
Historical trends in age-specific blood pressure were assumed to be zero due to the lack of 
valid empirical data, and to account for the age dependency of blood pressure and blood 
cholesterol level; age-specific trends were defined. 
The amount of detail entered for the risk factor prevalence by exposure category for 
smoking, hypertension and hypercholesterolaemia was mostly dictated by whether the 
equivalent data on relative risks were available and on the detail to which risk factor 
prevalence was recorded in each country. For instance, to obtain the Netherlands 
hypertension data pooled analysis of various Dutch studies was used to estimate the 
probability of hypertension in the general adult Dutch population, and hence to estimate 
the prevalence of hypertension by age and sex. While for hypercholestolaemia in the Dutch 
population only the lower cholesterol level cut-off to be used was recorded, and so the 
prevalence at the higher cholesterol level cut-off had to be estimated assuming a normal 
distribution. For Sweden the number of cigarettes smoked per day was only available for 
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1980 to 1989, and so the figures for 1990 to 1993 were estimated by multiplying the 
proportion of daily smokers in the population, which was available, with the relative 
distribution of smokers across the smoking exposure categories in 1989. Having access to 
the raw data of the Health Survey for England 1993 allowed me to analysis the risk factor 
exposure categories in any way that was required, and so I was able to adapt the risk factor 
exposure categories to conform with those of the other three countries. 
We decided to define the risk factor exposure categories as follows: 
" Cigarette smoking -3 exposure categories: I to 12 cigarettes, 13 to 22 cigarettes, 23 
or more cigarettes; 
" Hypertension -1 exposure categories: hypertension based on systolic blood pressure 
(160 mm Hg or more); 
" Cholesterol -2 exposure categories: hypercholesterolemia based on total cholesterol 
level (6.5 to 7.9 mmol/l, 8.0 mmol/l or more). 
9.5 Relative Risks, Remnant Relative Risks, LAT and LAG Times 
Prevalence and relative risk data from four different countries will never fit together 
perfectly. Every choice that was made while constructing the models implied a 
compromise between different considerations. 
9.5.1 Smoking 
The relative risks used in PREVENT 2.1 were the same for men and women, and as there 
are interesting differences in number of women smoking between the four countries; a 
search of the literature was made for gender-specific relative risk data associated with lung 
cancer, COLD, CHD and CVA, in addition to being age-specific. As a result of this it was 
decided to use the Framingham risk equation (Anderson 1990) to derive the relative risks 
of CHD and CVA mortality, with the relative risks for lung cancer and COLD taken from 
a systematic review (van de Mheen 1996). The remnant relative risks, and the LAT and 
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LAG times for lung cancer and COLD were determined from the American Cancer 
Society CPS-II prospective study data provided on request by Professor Michael Thun. 
Where these data deviated substantially from what has been reported in previously 
reviewed studies slight adaptations were made. Remnant relative risks for CHD and CVA 
where estimated from a function by Lightwood et al (Lightwood 1997) derived from a 
number of other studies. 
9 . 5.2 
Hypertension 
Hypertension was to be modelled as a risk factor for CHD and CVA. After a search of the 
literature it was decided to derive the relative risks and remnant relative risks from the 
Framingham risk equation, since within the Framingham study hypertension was defined 
using data from several measurements, the relative risks could be estimated for different 
age groups and both sexes, and the blood pressure cut-off points were in line with WHO 
recommendations. The LAT and LAG times for both causes of death were derived from a 
review by Collins et al (Collins 1990). 
9.5.3 Hypercholesterolaemia 
Hypercholesterolaemia was to be modelled as a risk factor for CHD, and based on similar 
arguments to those for hypertension, it was decided to use the Framingham risk function to 
obtain the age-specific relative risks for CHD mortality. After reviewing the literature it 
was decided that the remnant relative risk of formerly having hypercholesterolaemia for 
CHD mortality would be one, if cholesterol was back to a normal level, and this would 
occur after 3 years of LAG time for both causes of death. 
The relative risks, remnant risks and corresponding time lags that were finally decided 
upon were the same in all four models. 
One of the advantages in using the Prevent model is the possibility of repeating 
calculations with different input data. For example, the lower and upper boundary of the 
relative risks as reported in the epidemiological literature can subsequently be entered into 
the model, enabling one to explore how sensitive the results are to these differences in 
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relative risks. However, if these upper and lower boundary for relative risks were included 
automatically in Prevent, the user could get a sense of the sensitivity of the model without 
having to reconstruct and re-run the model. 
9.6 Country Specific Data for the England & Wales Version of PREVENT 
My main task on this phase of the project was to update the England and Wales Prevent 
model. Since I had previously constructed a 1993 model this entailed my checking for the 
most up to date data sources and re-inputting data to conform with the chosen Biomed 
categories. 
9.6.1 Population Data 
All population data for 1993 was obtained from the Office of National Statistics (ONS), 
formerly the Office of Population Census & Surveys (OPCS). These included: 
Population structure in one year age bands by sex was estimated from the 1991 
Census, 
" General mortality in one year age bands by sex, 
" Disease specific mortality in five year age bands by sex, 
. Life expectancy by sex were based on life table data from the 1992-1994 period, 
" Birth projections in period 1993-2043 were taken from population projections for the 
period 1991 to 2061, with estimates given in ten year periods. Using actual births in 
1993 figures until 2043 were calculated by interpolation, and as these data were not 
gender-specific the proportion of boys and girls was calculated using the proportions 
for 1993 (0.512 for boys and 0.488 for girls). 
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9.6.2 Risk Factor Data 
For the base year 1993 risk factor prevalence data on cigarette smoking, hypertension 
and hypercholesterolaemia were taken from the Health Survey for England 1993, and 
extrapolated to the England & Wales population. I had to extract the prevalence data in a 
form that conformed to the risk factor exposure categories and by the age groups that we 
had decided on in discussions as a group. 
Within the Survey current cigarette smokers were only classified as such if they were 
also regular smokers, therefore there may be an over-estimation of never smokers, since 
they are actually those who have never regularly smoked. 
For blood pressure, three readings were taken on one occasion, with the individual in a 
sitting position. The first reading was ignored, and all analysis was based on the average 
of the two subsequent readings. Valid blood pressure measurement were obtained from 
13,565 adults. 
Total serum cholesterol was measured in millimolecules per litre (mmol/1) for the 
Survey, and for 11,840 adults whose blood samples had been taken and were usable. 
For the trends in smoking prevalence since 1973 data were extracted from the General 
Household Surveys (GHS), again the data was obtained from the ESRC Data Archive. 
Smoking was not recorded in 1977,1979,1981,1983,1985,1987 and 1989 by the 
GHS, and the tables in the Health Survey for England in 1991 and 1992 did not yield 
the required age groups, and so the figures were estimated by linear interpolation 
between years with data. 
9.7 Modelling Smoking Interventions Across Four E. U. Countries 
Having set up versions for Prevent for at least 4 E. U. countries, they can be used for 
simulating similar risk factor interventions in each country, and, from the results, cross 
European comparisons can be made. In this case, since data on cigarette smoking were 
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the most complete for all four countries it was decided that the cross-country 
comparison modelling should investigate the differential effect of various anti-tobacco 
measures. The running of the simulations were carried out by Dr Joke Mooy, with input 
from the rest of the Biomed group. 
The group spent some time discussing the type of smoking interventions to be 
modelled, with members providing background information on each country's smoking 
policies and tobacco pricing. The types of interventions discussed centred around 
pricing and advertising policies, although there was some mention of health education 
and legislative interventions, such as the protection of non-smokers and sales restriction 
for youngsters, but these were thought to be difficult to quantify or too specific to each 
population. In addition, the limited time scale of this project and the fact that the 
modelling was being carried out by one person meant that Dr Mooy largely dictated 
what was to be simulated. The following policies were finally decided on as the ones to 
be simulated: 
an absolute price increase of tobacco products by one Euro; 
"a proportional price increase of tobacco products by 10%; 
a hypothetical measure to set prices in all four countries to the same level as in 
Norway in 1995 (4.84 Euro's); 
9a complete ban on tobacco advertising in all four countries. 
The paper (Baan 1999) giving the full account of this modelling work is to be found in 
Appendix G. 
Overall the effect of each of the interventions was small in terms of the percentage of 
premature deaths avoided, although the figures are more substantial when expressed as 
numbers of deaths postponed. However, this is just a reflection of the size of population, 
since a greater number of premature deaths are postponed in a larger population. 
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The modelling did highlight how the different policies would have different effects in 
each of the four counties. In terms of the percentage of premature deaths avoided by the 
year 2035 for the Netherlands the most effective policy would be the Norwegian pricing 
policy with about 4.5% and 2.5% decreases for men and women respectively. For 
England & Wales and Sweden the one Euro price increase and the Norwegian pricing 
policies would be equally effective, with 2% and 1.5% decreases for men and women in 
England & Wales, and a 0.5% decrease for men and women respectively in Sweden. 
While for Denmark the one Euro price increase policy would be the most effective 
resulting in approximately a 1% and 1.5% decrease in premature deaths avoided for 
men and women. 
As with the physical activity modelling in Chapter 7, and the Birmingham model in 
Chapter 8, producing results of risk factor interventions just in terms of mortality is 
disappointing due to the small number of deaths avoided. This could make such work 
unappealing to policymakers since it seems as though drastic policy interventions will 
only make a small impact on health. In reality these interventions will have a greater 
impact due to their reducing morbidity, but this is not captured by Prevent and hence 
not translated in terms of the numbers of events avoided when reporting to 
policymakers. 
Unfortunately I do not think anything new was learnt as a result of these interventions. The 
pricing scenario that would be most effective for each country was the one resulting in the 
largest proportional price increase, while the advertising ban scenario would be most 
effective in the country with the highest prevalence of smoking. These findings were 
simply illustrated by the modelling. The interventions need to be more sophisticated, with 
the pricing scenarios taking into account the relative price of cigarettes in each country, 
since the effect of any price increase will be dependent on the cost of living, and will be 
different for each country. The advertising ban scenario needs to take into account its 
effect on the uptake of smoking, since the modelling assumed that the effect of the 
advertising ban would only be to decrease the prevalence of smoking, and not decrease the 
prevalence of new smokers in the in-growing youngest cohorts. Both types of scenarios 
may also have had a different effect by sex and age groups, such as price increases having 
more effect on younger age groups due to their lower income. In addition, whether people 
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will reduce their consumption by the number of cigarettes smoked, or by switching to 
cigarettes with lower tar content, or whether people will quit due to the interventions needs 
to be considered. 
9.8 Discussion 
Seven years after Prevent's initial development it was important to update the model in 
terms of data concerning the core disease processes, such as the relative risks, remnant 
relative risk, LAT and LAG times, as well as updating the programme's operating systern 
which in turn made the model more powerful and flexible with respect to the amount of 
detail the input data could be described in, see Chapter 10. 
Creating the four E. U. versions of the model gave me an insight into the problems of 
finding appropriate and common population and risk factor data for these different 
countries, and demonstrated how, with such a comparison, one was forced to limit the 
detail of one's model due to limitations in other countries' data. For instance, no matter 
how much detail one's own population data described hypertension, with actual diastolic 
and systolic blood pressure values for each individual in a survey, which would allow one 
to define mild and severe hypertension; if another country's data could only describe 
normo-tensives and hypertensives, then one would have to limit one's own model to just 
normo-tensives and hypertensives to make valid comparisons. 
Reviewing the objectives of the Biomed project: 
1. to validate the models in the context of different E. U. countries: 
The project provided a forum for clarifying how the input data for Prevent are defined, 
such as the definition of general mortality as a probability rather than a rate. The project 
also allowed the developers to explain some of the unclear methodological issues, such as 
understanding how the risk factor trends were calculated and applied. It also provided an 
opportunity to confirm that the variables used in Prevent, such as age groups, diseases, risk 
factors, disease/risk factor relationships, LAT and LAG time were consistent across the 
four country models. 
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As detailed in Chapter 5 it is impossible to validate Prevent in terms of using historical 
data to simulate current disease mortality, the traditional way of validating a model, since 
the model does not account for factors other than the included risk factors that would have 
affected mortality over time, such as other risk factors, or new medical interventions which 
increase survival. However, it was possible to validate the models in terms of "face- 
validity", where we have tried to validate the data which are used in the model. 
2. to compare the implementation, the utilisation and the results of Prevent in different 
E. U. countries: 
The collaboration did give the members an insight into the each country's data, in terms of 
which were available at a national, or regional level, and which needed to be taken from 
country specific studies, as well as the time periods these data cover. Unfortunately, as a 
working version of the updated Prevent was not available for use until the last few months 
of the project; this meant that the utilisation and the results of Prevent were not fully 
explored, aside from the modelling of smoking cessation policies. Since we did not talk to 
policymakers directly we did not get a sense of what were the key health policies relating 
to risk factor reductions in the four collaborating countries, which we should have tried to 
address in our modelling work. 
3. the exchange of data, notably on risk factors, relative risks, new treatments and 
treatment outcomes, for inclusion in such models: 
This was one of the most interesting aspects of the collaboration, giving us the 
opportunity to present and discuss the merits of using data from various studies. In 
addition, it meant that we were not all duplicating the same work in updating our 
versions of Prevent, which we had been doing previously, when working in isolation. 
Unfortunately, although these issues were discussed with all the members of the 
collaboration; it was often one of the developers who made the final decision on which 
data to use, as in the case of the decision to use relative risks derived from the 
Framingham equation rather than from the American Cancer Society CPS-II study, 
which the group had discussed. 
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The modelling of cross-country comparison of smoking interventions, the main 
deliverable of this project, was very disappointing. Simple interventions were simulated, 
and little additional knowledge was gained from the modelling experience, aside from 
illustrating the rather obvious results of the interventions. Unfortunately the 
interventions chosen to be modelled were decided upon without the input of 
policymakers; largely being dictated by the person responsible for carrying out the 
simulations. Ultimately they were not relevant to the current policy debate. This was 
clear from the lack of discussion by invited policymakers at the Biomed conference 
where the results were presented. To them the interventions would have seemed to have 
been devised in a policy vacuum, since they would not have understood why we had 
chosen these interventions. This again highlights how important it is for modeller not to 
be divorced from policymakers, and the need for policymakers to be involved in the 
process of deciding on what interventions are to be modelled. 
Another aspect of modelling that this project did highlight was the importance of the 
availability of data for use within such models, particularly at a population level. 
Whether or not certain risk factor, or population characteristics, such as exposure 
categories and age group division, can be included depends on whether such attributes 
have been recorded in a population. Fortunately for the England & Wales model the raw 
data from the Health Survey for England were available to me, which included all the 
risk factors in Prevent, and gave me enormous flexibility in how I extracted my data for 
the model. Consequently we did not encounter many of the data obstacles that the 
members of the other countries came across, such as having only fixed risk factor cut- 
off measures, or age groupings. 
9.10 Summary 
This chapter describes my work on the BIOMED II project on Public Health Models in 
the period from 1996 until 1999. It outlines the Prevent related work of the project, in 
particular concentrating on my own work with the Prevent model, which involved 
producing a version of the model for England & Wales that was comparable with 
respect to population and risk factor data to models for the Netherlands, Denmark and 
Sweden. The chapter also summarises the cross-country comparison of different 
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smoking interventions modelled across the four countries, which was the aim of 
constructing these four comparable Prevent models. 
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Chapter 10 - The Development of PREVENT Version 2.8 
10.1 Introduction 
Prevent was originally produced in 1989, and since then the programme had not been 
developed to keep pace with the advances in computer technology, such as the 
increasing use of the Windows operating systems. The Biomed project gave Prevent's 
developer Dr Jan Barendregt the opportunity to update the Prevent model. The most 
notable change was that it was ported to Microsoft Windows NT from DOS, which 
meant that the programme could access more computer memory, and hence meant that 
many of the restrictions that were imposed under DOS on limiting the number of risk 
factors, diseases, diseases to be influenced by one risk factor, risk factors to influence 
one disease risk factor, age groups exposure categories and years of simulation were 
now lifted, see Chapter 1. Unfortunately the limited time-scale of the project, coupled to 
the fact that updating the model was not an objective of the project, and that work on 
updating the model was started late in the project, meant that Prevent Version 2.8 has 
not been completed or fully documented, and so is limited in its usability. 
10.2 PREVENT Version 2.8 
Prevent's port to Window's NT has resulted in the model being given a new interface, 
although very similar in structure to the DOS based version. The user now uses "drop- 
down" menus to first select the population data set using the File menu, then using the 
Options menu the user can select the diseases, the risks factors, the risk factor 
interventions, population options and the length of simulation runs for the modelling. 
Under the Disease Options the user can now set disease specific mortality trends as well 
as risk factor trends, although the current version of Prevent does not have the risk 
factor trends implemented yet. 
Using the risk factor intervention option the user can specify the change in risk factor 
prevalence to result from the interventions, now applied to 5 year age grouping, the year 
the intervention will start, and the year the target prevalences will be achieved. 
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The population option allows the user to set total mortality trends, and use a real 
population, or a stationary population. Although it is not explicit what the difference 
between these populations types are since no documentation has been produced on 
using the model and the Help facility has not been implemented yet. Unfortunately, 
neither have the risk factor options been implemented. The user can also access these 
options using the Specifications button. 
Next, on the Options menu, the user selects the Output options which allow one to 
produce result as chart or tables, as rates, population numbers or use a standardised 
population, set the age of life expectancy results, synchronise dynamic charts and save 
output to a file, although this option has not been fully completed making it difficult to 
extract results. 
The user is now set to run the simulation, which is achieved by pressing the Run button. 
After the simulation is completed the results window appears which allows the user to 
view the results by morality, disease specific mortality, population demographic, 
life 
tables and risk factors. Unfortunately only outputs that were available in the earlier 
versions of Prevent have been implemented. However, it is now possible to view the 
charts dynamically since a slider allows the user to animate the yearly changes over 
time. 
All the input data is now entered into one Microsoft Excel spreadsheet file for each data 
set instead of using the Prevdata programme, which used to create a number of data 
files. This Excel file is then used by the Prevent programme, which means the user must 
have Excel installed on their computer to use the model. Since the data input is now 
straight into a spreadsheet it means that there are no constraints to what can be input, so 
relative risks less than 1.0 can be input. However, this does mean that the user must be 
particularly careful when entering data as there are no processes that check for valid 
data, as was the case with Prevdata. 
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10.3 PREVENT Plus 
Prevent, known as Prevent Plus, was also updated to include morbidity, disability and 
cost for the Netherlands; requiring the following data: 
" Disease specific incidence rates by 5 year age groups and sex; 
" Disease specific prevalence rates by 5 year age groups and sex; 
" Disease specific disability weights by 5 year age groups and sex; 
" Disease specific costs per prevalent case by 5 year age groups and sex. 
Some of these data did not exist at a population level for the Netherlands, so they had to 
be derived from limited data in combination with informed "guesstimates" by Dr Luc 
Bonneux and Dr Barendgret. They had originally made these guesstimates for their 
work on the NIMPH model. Much of these required data did not exist for the whole of 
the England & Wales population either. However, I was able to obtain the following 
data: 
" Lung and breast cancer incidence and survival data from the Thames Cancer 
Registry for South East England; 
" Lung and breast cancer registration (incidence) data from ONS for England & 
Wales (ONS 1997); 
" MI and stroke hospital admission and re-admission data for England from the 
Hospital Episode Statistics (DoH 1995); 
" MI and coronary death incidence and case fatality for the Scottish MONICA 
population of Glasgow (Tunstall-Pedoe 1996); 
" Stroke incidence and survival rates from the Oxford Community Stroke Project 
(Bamford 1988) data set. 
Unfortunately, the developers have not documented the process of deriving the 
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appropriate input based on these limited data, and the limited time-scale for the project 
meant that the developers only had time to input the data for Denmark and Sweden, 
which were in the correct form and needed no further manipulation. I was therefore 
unable to implement these features. 
It was frustrating to be so reliant on the developers, in that they were the only people 
who could construct a model and who knew about the assumptions underlining their 
derived data, which may not apply to another country's population. Unless the 
developers have a similar understanding of the health of that other population; it is 
debatable whether the same assumptions can be applied to the new population, and this 
certainly limits the model's usability by others for other populations. I think that a 
model based on data that is unlikely to be available at a population level, as in the case 
of incidence, prevalence and disability is of limited value. This is particularly the case 
when the developers of the model cannot easily convey their assumptions for deriving 
the data. 
This raises the "chicken and the egg" argument about which should come first, the 
model or the data to drive the model. As described in Chapter 1, a model allows one to 
conceptualise a process into its component parts, and so allows one to highlight the data 
needed to simulate that process. This was evident in my modelling work for 
Birmingham Health Authority, which highlighted the lack of risk factor and mortality 
data by ethnic group, and the need for these data if the Authority wanted to simulate 
interventions directed at these groups. At a population level, such data could be 
extracted from the Health Survey for England. In general terms, some of the data 
required by the Prevent model are available from regional and national health surveys. 
At the other extreme is a model like Prevent Plus, which requires morbidity data that are 
not readily available in a form that is representative of the whole population. This 
demonstrates how models can highlight the lack for these data and the need for their 
collection. Due to the lack of these data even in the country for which the model was 
initial developed, assumptions need to be applied to what data are available, but these 
assumptions are undocumented, and possible rely, to some extent, on the developers' 
subjective judgements. These aspects make the derivation of these data for other 
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situations difficult, and so limit the models transferability and usability as a policy too l 
by others. 
10.4 Discussion 
The updating of the Prevent model was an opportunity to address some of the 
limitations of the model, such as not being able to shift risk factor exposure 
distributions, not being able to move individuals to a number of risk factor exposure 
categories rather than just the non-exposed category, and not having univariate risk 
factor prevalences which would allow one to identify high risk sections of the 
population. Unfortunately these limitations were not addressed because different 
priorities were set, and because some of these problems were difficult to solve. 
The morbidity and cost version of Prevent seems very difficult to translate to other 
populations due to the lack of appropriate data and the assumptions used to derive the 
appropriate data. I spent a considerable amount of time identifying, obtaining and 
extracting morbidity data for this part of the project; only to be unable to input the data 
myself due to lack of documentation. The developers did not have the time or the incentive 
to input the data, and so an England & Wales version of Prevent Plus was not constructed. 
The work has illustrated how models should be developed on the basing of using available 
data, even though they can highlight areas where data are lacking. In the case of Prevent 
Plus this scarcity of data and the lack of clear methods for deriving these required data has 
made the model untransferable, and so unusable by others in different situations. 
The main problem with the new version of Prevent is that it is not complete and is 
undocumented to the extent that it is unusable by anyone who has not had considerable 
experience of using the previous version of Prevent and was not party to its recent 
development. The model is less user-friendly due to the lack of documentation and the fact 
that it has not been completed. Three years is too short a time period for even updating an 
existing model, let alone developing a new model, when the developers are only able to 
carry out the work on a part-time basis. 
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The most frustrating aspect of the project was the failure to address some of, what I feel 
are, the fundamental limitations of the Prevent model in terms of being able to use the 
model to simulate policy relevant interventions. Model developers may not be aware of the 
importance of certain issues because they have been working in isolation from 
policymakers. 
10.5 Summary 
The chapter describes the development of the Prevent model which took place during 
the course of the Biomed project, with regard to its move to a Windows NT platform, 
and the problems associated with its update. In addition, the development of Prevent 
Plus, the morbidity and cost version of Prevent, is described, and the reasons why we 
were unable to produce a version for England & Wales are discussed. 
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Chapter 11- Discussion of the PREVENT Model 
11.1 Introduction 
In the last six chapters I have described my work with the Prevent model, using it a tool 
with policymakers. The model was originally designed by Professor Gunning-Schepers 
and implemented by Dr Barendregt. The original aim in producing the model was that it 
would be used as an aid for policymakers who, having been show how to use the model, 
would use it themselves for simulating risk factor interventions. Policymakers would 
then be able to test alternative strategies to achieve their policy goals, or to calculate the 
magnitude of effect of various interventions. 
As a public health model for policymaking Prevent has some positive and negative 
aspects which affect how it can be used and what it can be used for. Within this chapter 
I discuss these aspects with regard to how important I feel they are in affecting the 
model's usability. 
11.2 Positive Aspects of PREVENT 
On first impressions Prevent is an attractive package, with the Prevdata programme 
guiding the users through the data input process, while the simulations model's user- 
friendly menu-driven interface makes the running of interventions a simple process to 
follow. These are important aspects in making the model useable for an individual with 
a non-technical background, such as policymakers may be. The data input process also 
gives the user the opportunity to study and organise their population's demographic and 
risk factor data, which in turns will give them a better understanding of these data that 
underpin the model. This is an important understanding to gain since it is required in 
order to fully interpret the model's output. 
One of the key strengths of Prevent is its ability to link the demographic changes within 
a population over time to risk factor prevalences, since the effect of any risk factor 
interventions will be heavily influenced by the risk factor's distribution by age group 
and sex in a population. This leads on to another of the model's strengths, which is its 
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ability to allow the user to simulate interventions while targeting by age group, sex and 
risk factor exposure level. Such targeting allows a comparison of the effect the same 
interventions in different sections of the population to investigate which will produce 
the most health gain. This is illustrated with the interventions modelled in the 
Birmingham population in Chapter 8. 
I have stated earlier, in Chapter 6, that Prevent's methodology limits one, even using the 
modifications I made when modelling the physical activity targets, to simulate 
interventions that move individuals from exposure categories to the non-exposed 
category, or just one exposure category. However, in spite of this limitation the model is 
effective in modelling certain interventions, such as smoking interventions where the 
aim is to get individuals to stop smoking rather than to cut down their consumption. I 
have shown with the work on physical activity and the work in Birmingham that these 
are some of the types of interventions that policymakers would like to know the effects 
of, and so it means that the model is able to address certain relevant policy issues. 
The model has also been shown to be a useful tool for hypothesis testing when current 
knowledge is incomplete, as in the case of my simulating the attenuation of risk with 
inactivity at older age groups. Prevent allows the user to investigate how changing 
various assumptions concerning the risk factor and disease relationship, which may be 
under debate in the research arena, will affect the outcomes of an intervention. 
Another positive aspect of the model is the way in which it can demonstrate what may 
be achieved if target risk factor prevalences, or screening strategies are met. This was 
the case with the modelling for Birmingham Regional Health Authority where the local 
GP group found the results from Prevent could be an incentive to their work, since they 
only witness the effect on individual patients, while the model showed the overall effect 
on the whole population or constituency. 
11.3 Limitations of PREVENT 
A major limitation of the model is that it is not possible to move individuals to a number 
of lower risk factor categories, nor is it possible to shift risk factor distributions. 
205 
Although with, say, a smoking intervention, policymakers would want smokers to stop 
smoking; in reality smokers may cut down their consumption by smoking fewer 
cigarettes, or cigarettes with a lower nicotine content. It is not possible to model such 
scenarios with Prevent. Health promotion policies at a population level, such as those 
aimed at lowering the population's cholesterol level will cause a shift in the distribution 
of cholesterol level across the whole population to a lower level, rather than all the 
individuals achieving the cholesterol level with the least risk, and Prevent cannot model 
this type of scenario either. 
Another aspect of the model which limits its use for health promotion and public health 
interventions is Prevent's use of univariate risk factor distributions, rather than a multi- 
variate distribution, which means that it is not possible to target high risk groups who 
have a clustering of risk factors, since only the independent risk factor distributions are 
input and used by Prevent. 
Limitations to the number of demographic and risk factor categories that are allowed 
with Prevent means that it is not possible to construct populations in such a way that 
would enable policymakers to address interventions aimed at particular sub-groups of 
the population, as was the case with the Birmingham modelling when it was not 
possible to sub-divide the population by ethnic group. The latest version of Prevent 
overcomes this problem, so when it is completed, the only barrier to such sub-dividing 
of the population will be whether data are available. 
Although it is possible to run Prevent a number of times using upper and lower relative 
risks of mortality estimates from the literature; it would be more helpful to be able to 
input these bounds for the relative risk into the model at the initial data input stage. 
Then the model could calculate the confidence interval for the output in one run. This 
would make Prevent more useful as a policy tool, since having to constantly update 
relative risks, then re-run the model using the bounds of the relative risks, and finally 
amalgamating the results of these runs is a laborious task. 
Lack of morbidity outcomes is another major limitation of the model, particularly since 
for many risk factor interventions the effects are very small in terms of the number of 
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deaths avoided, while changes in disease incidence and prevalence may be substantial. 
Without morbidity in the model it is not possible to present policymakers with the 
whole effect of an intervention, and they may feel that an intervention is not worth 
pursuing since they will only see that it prevents a relatively small number of deaths. A 
methodology for calculating morbidity measures that can easily be transferable to other 
populations needs to be devised, since the new version of Prevent uses a method for 
calculating morbidity outcomes which relies on informed "guesstimates" which only the 
developers fully understand, and which are specific to the Dutch population. I feel that 
this is not an ideal situation if others are to adapt, use and understand the model. If 
assumptions are used in fitting data into the model, then the user must be able to explain 
these assumptions to translate the model's output to policymakers. 
One of the problems of trying to address some of these limitations is the lack of 
documentation for the model. It is easy to see how this has arisen since Prevent was 
developed by others, who initially only looked at the model in terms of being part of a 
PhD thesis, and who expected that it would be used by others in only a limited fashion. 
Due to the lack of documentation it is impossible for others to adapt Prevent in terms of 
reprogramming the model. 
There was never a commitment on the part of the developers to working on the model 
past its initial development. This meant that further development was not a priority and 
as their research agenda moved on; changes to Prevent had a low priority. Fortunately 
the Biomed II project provided an opportunity to develop the model, although in the end 
only the aspects that the developers thought important to update, or that could be 
achieved in the limited time of the project were addressed. Possibly the most 
disappointing aspect is that new version of Prevent is unfinished, and not usable 
because of its lack of documentation, and the need for undocumented information on 
how to use the model and interpret its output. 
11.4 Conclusions 
Over time both Professor Gunning-Schepers and Dr Barendregt have come to the 
conclusion that the model is too complex to be used by policymakers on their own. 
207 
They feel that instead Prevent should be used by modellers who understand its workings 
and its input data. From my experience with the model, I would agree with this method 
for using the model in policymaking, since it is only by using the model extensively that 
I have gained a full understanding of Prevent, and this has taken several years to 
achieve. Although I feel that policymakers should specify the interventions to be 
simulated rather than the modeller. 
Unfortunately Prevent still has a number of limitations as a model for simulating risk 
factor interventions for policymaking, and these I believe are rooted in the fact that 
Prevent was developed, to a certain extent, in isolation from the policy arena. All 
interventions have to be couched in terms of changing an individual's risk factor 
exposure from an exposed category to the non-exposed category. Since the policy 
agenda changes over time, and it is usually dictated by political priorities rather than 
research priorities, policymakers need to be part of the development of models such as 
Prevent. Such models must be able to simulate the interventions that policymakers feels 
are important, rather than those that researcher feel are important. The output of 
modelling will be ignored if it is not relevant to the policy agenda. 
Overall, Prevent is a usable tool for policymaking, although the type of interventions 
that it can simulate are limited. Users need to be aware of these limitations when 
deciding whether or not Prevent is the right model to use for modelling their 
interventions. 
Users of Prevent must also be aware that although it seems a relatively simple model to 
use they need to fully understand the model's input data and its methodology to interpret 
the model's output. 
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Section 3: POHEM 
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Chapter 12 - POPULATION HEALTH MODEL (POHEM) 
12.1 Introduction 
The Population Health Model (POHEM) (Wolfson 1991 and 19922) uses the micro- 
simulation technique to model the dynamics of multiple risk factors and major diseases, 
including CHD, lung cancer and breast cancer, under various demographic and health- 
related processes for a heterogeneous population. 
The micro-simulation technique depends upon a monte-carlo process. Each individual 
in a cohort is generated separately using a random process, and over the simulation 
period these individuals can be subjected to certain events; the probabilities of these 
events being drawn randomly from distributions. These models have the capacity to 
absorb all the required risk factors and interdependencies. Consequently they require 
more processing power than their cell-based counterparts. Statistics Canada run 
POHEM on a dual Pentium II 266Mhz with 132Mb DRAM where a simulation of 
100,000 individuals would take about fifteen minutes. 
The monte-carlo process generates random life tables, where, within each year, an 
individual is randomly simulated to either die, become ill, or stay well. The probabilities 
of changing states are randomly drawn from age specific uniform distributions. This 
process is repeated a considerable number of times, following each individual from 
birth to death, and so producing a large synthetic cohort. 
Since POHEM avoids having to stratify the population by age, sex and risk factor 
levels, as with cell-based models, it does not start off computationally too memory 
hungry. The model does not have to run calculations for the whole population at the 
same time during the simulation period, but only has to keep track of one individual and 
their risk factor levels at a time. However, micro-simulations do take longer for a 
simulation run, and require more data storage space, because they have to generate and 
record the lifetime of each individual of the cohort separately. 
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As well as the monte-carlo process, POHEM uses a number of dynamic algorithms to 
simulate socio-economic status, risks factors, diseases, health care utilisation and 
summary health status, as mentioned in Chapter 3. 
Within the Disease process is the CHD model, which uses Weinstein's Coronary Heart 
Disease Policy Model (Weinstein 1987) transformed to be consistent with the POHEM 
architecture, and uses Canadian risk factor distributions and treatment protocols. The 
CHD module allows the user to simulate the effects of intervention, both preventive, by 
risk factor modification, and therapeutic, by changing case fatality rates, on mortality, 
morbidity and costs over time. The CHD module is made up of three consecutive parts, 
see Figure 12.1: 
A demographic portion, which generates disease free individuals, who are then 
aged. It uses a logistic risk function based on the Framingham equation to calculate 
the annual incidence rates of CHD events for each individual. 
"A bridging portion, which simulates the initial 30 days after the incidence of the 
first 
CHD event, with individuals having been passed on from the demographic model. 
First it determines the type of CHD event by age range and sex, then applies 
probabilities of death during the first 30 days following the event by age, sex and 
type of event. A survivor then moves into the next sub-model. 
"A disease history portion, which classifies the individual with a previous CHD event 
into twelve CHD states. In each simulation year the patient is subjected to eight 
CHD event probabilities, which they may or may not experience, and each event 
and state have associated case fatality rate for CHD and non-CHD death, depending 
on disease history, age and sex. These case fatality rates are applied to the individual 
to calculate those who survive to the next year of simulation and those who die. 
Overall the methodology of POHEM gives it great flexibility, with its ability to include 
external factors such as social status and environmental exposure, as well as the 
traditional risk factors. In addition, the model can produce more detailed information on 
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morbidity, in terms of functional and health status, and costs, in terms of health care 
utilisation. 
12.2 Development of POHEM 
POHEM evolved from what was originally an actuarial model called DEMOGEN, the 
objectives of which were demographic and social policy analysis. DEMOGEN 
modelled the following processes explicitly: 
" educational attainment, 
" union formation, 
" fertility 
" labour force participation / earnings, 
" union dissolution, 
" remarriage, 
" child separation, 
" mortality. 
As a result of this history POHEM also incorporates these mechanisms, and has the 
ability to generate families by first creating an individual who will age, be educated and 
go to work, then marry if the appropriate partner is generated and who is also aged. 
Then, depending on fertility parameters, this couple may have children, which are also 
generated and aged. In addition, the couple may get divorced, or the initial individual's 
partner may die, and the initial individual may remarry, while the children may be 
separated from this individual due to the divorce or death. 
POHEM was originally written in APL with interventions being modelled by editing the 
source code of the programme, then compiling the source code to produce an executable 
programme, which was then executed to run the simulation. In 1994, with a view to 
making POHEM more accessible to other users and to allow more widespread 
development of the programme, Statistics Canada converted it into the Modgen 
programming language, which is a superset of the C++ programming language, running 
in the Windows NT environment. Modgen is modular in form and uses object orientated 
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programming techniques, where each programme is a collection of individual objects 
that interact with each other, and each object has its own programme code and data. 
The Modgen language was developed by the Health Analysis And Modelling Group at 
Statistics Canada specifically for the development of dynamic longitudinal micro- 
simulation models, and has become the language used for all their micro-simulation 
modelling work, not just POHEM. The language is designed to allow application 
developers to simulate the lifetimes of linked individuals and related family members, 
known as actors. In addition, Modgen provides a number of methods for reporting the 
output of simulations, such as cross-tabulated results in ASCII or Microsoft Excel 
spreadsheet formats, or as a relational database of actor information in Microsoft Access 
format. 
As with the APL version, the initial Modgen version of POHEM did not have a user 
interface, as used by Prevent. The user edited the source code to initialise the model and 
to produce results. The ease with which the user can modify the code results from 
Modgen being an object orientated programming language with a modular structure, 
and this means that the user does not have to modify large sections of code, but just the 
appropriate modules to modify the programme for different simulation runs. In addition, 
unlike the Prevent source code, POHEM's is well documented, with comments 
throughout the code to explain the program's workings. 
In order to set up a simulation the user edits MPP files, the Modgen source code files, 
which are processed by the Modgen pre-compiler, and this produces CPP files, which 
are the C++ source code files, and H files, which are the C++ library files, that are then 
compiled with the MODLIB library file by the Visual C++ compiler to produce the 
POHEM. EXE file. This file, when run, reads the input data files (parameter DAT files), 
runs the micro-simulation and finally produces reports of the output, see Figure 12.2. 
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MPP files: 
POHEM. MPP 
FAMILY. MPP 
PERSON. MPP 
OTHERS. MPP 
REPORT. MPP CPP files: 
ACTORS. H 
ACTORS. CPP 
TABINIT. H 
TABINIT. CPP 
MODEL. H 
ý 
MODLIB. LIB 
C++ Compiler 
Parameters 
EXE file] 
Figure 12.2 - POHEM diagrammatic: pre-compilation, compilation and running 
The MPP files are where one enters the definitions of special programming objects in 
the simulation code. There are five such source files, as described in the Statistics 
Canada documentation (Statistics Canada 1998): 
" POHEM. MPP is the main model file, which contains the definitions of general 
purpose classifications, ranges and parameters, such as the type of union, sex 
classifications and the range for the duration of a life. In addition, it contains the 
more complex parts of the actor definitions, such as initialising households and 
creating or removing children from the household. 
" FAMILY. MPP contains the definitions of Household-related classifications, 
ranges and parameters, such as the number of individuals, adults and children in 
the household. It also contains the definition of the Household actor, the code of 
CaseSimulation function and the code of the Household class member function, 
which are used for creating households, and for applying demographic and 
health events to all household members. 
MODGEN. EXE 
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" PERSON. MPP contains the definitions of Person-related classifications, ranges 
and parameters, such as risk factor exposure levels and value ranges. As well as 
containing the definition of the Person actor and the code for the Person class 
member function, such as creating partners, unions and children. 
OTHERS. MPP contains the definitions of Child-related and Ancillary-related 
classifications, ranges and parameters, such as the sex and age of children and 
partners. It also contains the definitions of the Child and the Ancillary actors, 
and the code of the Child and the Ancillary class member functions, such as 
applying demographic and health events to partners and children. 
REPORTS. MPP contains the definitions of required reports, which will produce 
cross-tabulation tables by age and sex of key variables, such as disease events, 
marriage and risk factor levels, as well as the average age of key events. 
12.3 Using POHEM 
The initial version POHEM. EXE ran as a DOS programme, and did not allow any user 
interaction with the programme. It just read the parameter files, ran the simulation and 
produced the output reports. In the next incarnation of POHEM the user used a scenario 
file (SCE extension file) to set up the programme, which is a DOS command line for the 
POHEM. EXE programme. The command line allowed the user to set various aspects of 
the simulation run, such as: 
" the number of cases to be simulated, 
" number of individual cases to be tracked during the simulation to an Access 
database, 
the time to the end of the simulation (simulation period), 
" the random number generator seed value, 
" the output options, such as to Access database, Excel spreadsheet or text files. 
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In addition, the scenario file could be loaded into a visual viewer which was used to set 
the model's inputs data files, as well as viewing and editing the list tables to he output 
and some of the modelling settings. 
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The POHEM. EXE ran as a Windows NT programme that still did not allow the user 
any interaction with the programme, but it did produce an on screen window that 
enabled the user to monitor the progress of the programme in terms of reading the 
parameter files, running the simulation and producing reports, see Figure 12.3. 
The current version of POHEM. EXE has incorporated the file viewing and the 
monitoring programmes into a single programme. Again the user must specify a 
scenario file which will load the appropriate data files to be used by the programme, or 
the user can create a new scenario file by choosing the data files to be used for the 
simulation. The loaded data files are displayed in the viewing window, see Figure 12.4. 
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Although the types of interventions to be simulated are specified in the MODGEN code; 
the latest version of POHEM. EXE does allow the user to change certain variables 
within the data files. By clicking with the mouse on a data file path the user can display 
the variables that can be modified by the user, which will depend on the initial 
MODGEN coding, and clicking on one of this will display the variable. An example is 
shown in Figure 12.5. 
In addition to viewing the data files and modifying certain variables the programme 
allows the user to specify a number of settings for the simulation run. These settings are 
categorised as General, Inputs, Output options, Output parameters and Output tables. 
Each category can be accessed by clicking on the appropriate tab in the Execution 
Control window. 
I. General - within this section the user can adjust such settings as: 
9 The number of cases to be simulated, 
" The number of threads by which a number of different individual can be generated 
and simulated concurrently, depending on the number of processors the computer 
has, 
" The number of sub-samples, 
" The starting seed for the random number generator, 
" Scaling the numbers in the cohort to that of an actual population . 
II. Input - this section allows the user to add, remove and replace the data files that 
are associated with the scenario file, and that are used by POHEM. 
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III. Output Options - the output options that are available to the user are: 
" Standard error values, 
" Coefficient of variation values 
" MS Access tracking and number of cases tracked, 
" MS Excel tables, 
Documentation database, 
" Text tables, 
" Text tracking. 
IV. Output Parameters - this section allows the user to select pre-coded variables to 
be output. The variables are chosen from a list and include such variables as the 
mean and standard deviation of risk factor exposure levels, disease incidences 
and event probabilities. 
V. Output Tables - this section allows the user to select pre-coded tables to be 
output, which are also chosen from a list and includes variable such as the 
number of deaths, cause of death, age of disease onset and disease incidence. 
12.4 Running POHEM 
The model produces standard errors on the outcomes. It does this by randomly 
assigning each case to one of sixteen sub-samples and calculating standard errors on the 
sub-samples for the selected outcomes. Since all interventions are done in a single run, 
it is possible to generate the differences between the interventions and reference case as 
an outcome with the standard errors. Consequently, it can be determined whether the 
reported differences were statistically significant using a 95% confidence interval. 
12.5 Overview of POHEM 
Although POHEM has not been developed as a user friendly executable programme; the 
ability of the user to programme the model and the modular form of its coding gives the 
model great flexibility, and so means it has the capacity to include numerous factors and 
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processes, since they can be programmed in. More importantly the model's ability to 
produce information on morbidity, as well as mortality, makes it an invaluable tool for 
assessing the effectiveness of health interventions where the effect on mortality may be 
small, but the gains in terms of morbidity will be significant. 
In the following chapters I will present how I have used POHEM to model various risk 
factor interventions in the England & Wales populations, and how POHEM compares 
with Prevent, in terms of their different methodology and how that influences the types 
of interventions they can model. 
12.6 Summary 
This chapter describes the POHEM model, in terms of the adaptation of Weinstein's 
Coronary Heart Disease Policy Model for use in its CHD model, and its development 
from an existing actuarial model written in APL to the current Windows NT C++ 
version. In addition, details of how to build and run the model are discussed. 
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Chapter 13 - Developing The England & Wales POHEM 
13.1 Introduction 
POHEM was originally designed for use with data from the Canadian population, and 
was built to address Canadian health policy issues. And so the initial part of the work 
with POHEM involved discussions with Mr Jean-Marie Berthelot and Mr Bill Flanagan 
at Statistics Canada about the type of model I wanted to produce for England & Wales. 
The Canadian version of POHEM has a complex multiple disease/risk factor 
environment with a myriad array of factors which can influence an individual's health 
in a simulation, as previously described in Chapter 12, and which would be difficult to 
replicate for another population within a limited timeframe. This work was carried out 
in conjunction with a European Union Biomed project on public health models, one of 
the aims of which was to compare POHEM with Prevent. It was decided that we should 
try to match the risk factors and the diseases required for duplicating interventions 
between the two models, and in particular the smoking interventions which had been 
modelled as part of the Biomed project, detailed in Chapter 9. Consequently Mr 
Berthelot, Mr Flanagan and I decided on a primary prevention model, which would 
simulate the effects on morbidity and mortality as a result of risk factor interventions. 
We decided not to include secondary care interventions or costs for this initial work. 
The Framingham CHD risk equation is at the core of the CHD module of POHEM, and 
this dictated that we would require data on the risk factors included in the equation; 
which are obesity, cholesterol, blood pressure and cigarette smoking. Chapter 14 details 
the justification for using the Framingham equation with the England & Wales 
population. The Biomed project's interest in simulating smoking interventions meant 
we would also need to model in POHEM the other diseases associated with smoking in 
Prevent, which are CVA, COLD and lung cancer. 
This chapter discusses the building of the England & Wales version of POHEM in 
terms of its data requirements, running the model, and the output to be produced by the 
model. These aspects were to some extent dictated by the interventions that POHEM 
was to simulate, as described in Chapter 15. 
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13.2 Data Requirements 
The minimum data requirements, as specified by Statistic Canada, to build the POHEM 
model outlined in section 13.1 were: 
I. Life tables by sex, 
II. Mortality rates by 5 year age groups and sex for CHD, CVA, COLD, lung cancer 
and all other causes, 
III. Multivariate discrete risk factor distribution by age and sex for smoking, blood 
pressure, cholesterol and obesity, using the following categories: 
" smoking: 1-12,13-22,23+ cigarettes ex-smoker and never smoked, 
" diastolic blood pressure: <95,95-104, >=105 mm Hg, 
" cholesterol: <250.9,250.9-308.7, >=308.8 mg/dl, 
obesity: BMI <25,25-30,30>=. 
IV. Univariate mean and standard deviation for each risk factor distribution by age and 
sex, 
V. Lung cancer incidence and survival by stage, sex and age group. 
13.2.1 Data Sources 
For the England & Wales version of POHEM the only new data that had to be collected 
were the lung cancer data, while producing the multivariate risk factor distribution 
entailed re-analysing the data set from which the Prevent independent distributions had 
been derived. Mortality data were re-analysed to conform with the POHEM age 
groupings. 
For the cancer data no one source was able to supply incidence and survival by stage 
and disease. Incidence data were available for England & Wales from the Office of 
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National Statistics, but not by stage of diagnosis. These data were supplied by the 
Thames Cancer Registry, along with survival data, for South East England, however the 
survival data could not be supplied by age group. 
As detailed in section 12.2, POHEM has the ability to simulated mechanism which 
affect individuals such as educational attainment, union formation, fertility, labour force 
participation, earnings, union dissolution, remarriage, and child separation. However, 
the version of POHEM I have been using has these mechanisms "switched off', since 
the simulations I have undertaken were not dependent on families needing to be 
generated, or on whether the individual was employed. The model was simplified with 
only separate individuals created, aged and followed until death. 
13.2.2 Data Input 
The multivariate risk factor distribution by age group and sex for cholesterol, blood 
pressure and smoking were used to smooth transitions of risk states between age groups. 
This was achieved by treating the transitions as a transport flow problem from one age 
group to the next, constrained by the risk factor distribution and other restrictions 
inherent to the data, and were produced using a programme developed by Statistics 
Canada. The result was a set of transitional probabilities applied to the individuals over 
the course of their synthetic lifetime. The initial risk states were determined directly 
from the initial age group of the risk factor distribution. 
The univariate risk factor mean and standard deviation by age and sex were used to 
assign a specific risk value in POHEM, assuming the risk factors were normally 
distributed within risk states. 
Incidence data for heart disease were derived by inverting the Weinstein model with the 
country specific mortality data provided, by sex and age group. Incidence data were 
provided for lung cancer by sex and age group. Incidence data were not available for 
CVA nor COLD, so the mortality numbers were used as incidence data with 
progression from incidence to mortality being immediate. This assumption does not 
reflect reality, and hence will lead to an underestimation of the effect of CVA and 
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COLD on morbidity, since there will be no period of morbidity. In addition, the 
assumption will cause an overestimation of mortality for these diseases, since an 
individual will die immediately from the initial development of CVA or COLD, while it 
may take some time for them to die from CHD or lung cancer in the model. 
For each disease, "background" incidence rates, the incidence amongst those not 
exposed to the risk factors, were derived by removing the portion of the incidence 
attributable to the explicitly modelled risk factors obtained from the Framingham 
equation. The model applied the relative risks, as used by Prevent for CVA, COLD and 
lung cancer and derived from the Framingham equation for CHD, to the background 
incidence rates to determine an individual's probability of getting a disease at a given 
age. 
13.3 Output 
POHEM allows the user numerous output options, which would result in an 
overwhelming amount of data if all were recorded. Accordingly, some decisions about 
which measures to choose had to be made. Prevent only produces results in terms of 
mortality, so for the POHEM interventions I chose some mortality output to make a 
comparison, as well as some morbidity measures to highlight that aspect of POHEM's 
methodology. The output measures I finally decided on to assess the effect of the 
interventions were: 
13.3.1 Mortality Output: 
I. Changes in life expectancy, 
II. Age and disease specific mortality rates, 
III. Changes in disease free life expectancy, 
IV. Number of people reaching 70 and 85. 
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13.3.2 Morbidity Output: 
I. Number of cases of disease, 
II. Average age of disease onset, 
III. Average number of years lived with disease. 
These outputs can be expressed as yearly totals, or can be aggregated as totals for the 
whole cohort over its entire life-span. These are the outputs used in the risk factor 
intervention simulations described in Chapter 15. 
13.4 Summary 
POHEM was originally produced for a Canadian population, and so had to be adapted 
for use with the England & Wales population. This chapter discuss the building of the 
England & Wales version of POHEM in terms of its data requirements, running the 
model, and the output to be produced by the model. The model produced was used for 
simulating the risk factor interventions described in Chapter 15. 
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Chapter 14 - Using The Framingham Equation With The Population of 
England & Wales 
14.1 Introduction 
14.1.1 The Framingham Study 
Between the 1930s and the 1950s cardiovascular disease (CVD) became the leading 
cause of death in the USA, with coronary artery disease (CAD) being the most common 
cause for this high mortality. At that time, since there were no known treatments 
capable of prolonging the life of those with CAD, it was felt that only a preventive 
approach could substantially reduce the burden of this disease (Kannel 1988). 
At the time the contribution epidemiology had made to the control of infections and 
nutritional diseases led some public health workers to consider applying the approach to 
the investigation of CVD (Kannel 1988). As a result the Public Heath Service through 
the National Heart Institute established a prospective investigation of factors possibly 
related to the development of coronary heart disease and hypertension (Dawber 1966). 
The study was established in 1949 in Framingham, Massachusetts, with an initial 
followed up period of 20 years, but this was changed and the study is still continuing. 
The Framingham Study involved selecting a representative sample of the town's adults 
to be followed up for the development of initial cardiovascular events in relation to 
biennially measured attributes and living habits suspected of contributing to the 
occurrence of CAD (Kannel 1988). Initially 5209 people aged 30 to 62 years were 
examined (Feinleib 1975). 
In the original cohort there were 1644 spouse pairs, the children of whom formed the 
basis of a second study called the Framingham Offspring Study. Over a period of 4 
years, from 1971, these offspring, aged 12 to 60 years, were invited for physical 
examination at the Framingham Heart Study Facilities (Kannel 1979). The aims of the 
Framingham Offspring Study were to determine whether there had been any secular 
changes in risk factors between the two generations of the cohorts, and to examine the 
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presence of familial and genetic effects in determining the level of these risk factors 
(Feinleib 1975). By 1975 5135 offspring were enrolled in the study (Kannel 1979). 
14.1.2 The Framingham Equation 
The Framingham equation is a logistic regression model which provides predicted 
probabilities for several CVD endpoints. The equation is based on the measurement of 
several known risk factors taken from 5,579 members of the Framingham Heart Study 
and Framingham Offspring Study cohorts, with an age range of 30 to 74 years, and who 
were initially free of cardiovascular disease and cancer (Anderson 1990). 
The equation includes the following CVD risk factors: 
" Age; 
" Sex; 
" Systolic blood pressure; 
" Smoking; 
" Total cholesterol; 
" High density lipoprotein (HDL) cholesterol; 
" ECG-left ventricular hypertrophy. 
The equation has been used to calculate the risk of the following outcomes: 
" Myocardial infarction (MI) (MI, including silent and unrecognised MI); 
" Death from coronary heart disease (CHD) (sudden or non-sudden); 
" CHD (consisting of MI and CHD death plus angina pectoris and coronary 
insufficiency); 
" Stroke ( including transient ischaemia); 
" CVD (including all the above plus congestive heart failure and peripheral vascular 
disease); 
" Death from CVD. 
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14.2 Generalisability 
The Framingham equation has been used as the basis of several other public health 
models aside from POHEM, including the Coronary Heart Disease Policy Model 
(Weinstein 1987) and the Netherlands Integrated Model of Public Health (NIMPH) 
(Bonneux 1994), as a means of generating CVD events for simulated populations. The 
cited reasons for its widespread use are its excellent methodology, the long term follow- 
up, and that it allows the estimation of risk in women, unlike many other risk equations 
(Haq 1999). 
However, the issue of the generalisability from a single community population to a 
larger or a different setting is not clear, and the participants in the Framingham studies 
are not necessarily representative of the total US population, with various geographic, 
socio-economic and ethnic groups being underrepresented (Grundy 1998). In addition, 
the baseline measurements for the Framingham studies were in the period from 1968 to 
1975 (Anderson 1991). In the last 30 years CHD mortality rates have declined 
substantially, and the extent to which this decline can be attributed to the major risk 
factors is uncertain (Marmot 1992). Other issues of concern that can make the use of 
such logistic risk functions problematic when applied to new populations are variations 
in the definition of events, the duration of follow up and the definition of the risk 
variables used (Chambless 1990). 
Many of the above models assume that the observations in a specific cohort are 
generalisable to their population of interest, even when the population is that of another 
country, as in the case of NIMPH and POHEM. Nevertheless, how generalisable the 
Framingham equation is to other populations has been an issue of much debate. 
14.3 Problem of Validation 
The main difficulty in being able to justify the use of the Framingham equation is 
validating the event rates generated by the equation for a new population by comparing 
them with the actual event rates for that population. This is problematic due to the lack 
of available data on actual event rates. Although CVD is recognised as contributing to 
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the major burden of disease in developed countries (WHO 1982); there are very few 
registers of CVD events (Marmot 1992), particularly in terms of morbidity measures 
such as incidence, prevalence, recurrence and survival, especially not at national levels. 
As a result the only population comparison that can be made are in terms of mortality 
and of rank ordering of risk, although it is possible to apply the equation to other study 
cohorts for which CHD event data are available. 
14.4 Review of the Literature 
14.4.1 Leaverton et al (Leaverton 1987) 
The Framingham equation was applied to the first cohort of the National Health and 
Nutrition Examination Survey (NHANES I) Epidemiological Follow-up Study 
(NHEFS), which was a national cohort study based on a comprehensive medical 
examination of a probability sample of the United States adults. The Framingham 
equation was compared to a similar regression equation for the NHEFS with respect to 
predicting death from CHD. 
Males Females 
Framingham NHEFS Framingham NHEFS 
Age 0.0781 0.0619 0.1034 0.1059 
Systolic blood 
pressure 
0.0168 0.0133 0.0237 0.0215 
Serum cholesterol 0.0040 0.0049 0.0065 0.0099 
Cigarette smoking 0.4700 0.7815 0.6979 0.8985 
Table 14.1 - Multiple logistic function coefficients by sex and study 
It was concluded that the Framingham equation was generalisable to the white United 
States population, since the coefficients of the equation were very similar to that of the 
NHEFS cohort, see Table 14.1. In addition, both equations produced similar 
distributions when they were applied to the Framingham population, and individuals in 
the population were then ranked in terms of quintiles of multivariate risk. 
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14.4.2 Chambless et al (Chambless 1990) 
Fifteen logistics risk functions, including the Framingham equation, were compared in 
terms of their odds ratios for given changes in risk factor levels for cholesterol, systolic 
blood pressure and smoking. In addition, the ratio of the odds ratios for CHD events of 
cholesterol, systolic blood pressure and smoking were compared as a means of showing 
how much the relative size of the three coefficients differed among populations, e. g. 
ORSBP/ORCHOL, ORSMK/ORCHOL, ORSMK/ORSBP" 
The review concluded that there was sufficient variation between risk equation in the 
value of the coefficients, the odds ratios for risk factors and the ratios of odds ratios to 
suggest that extrapolating these risk equations to new populations was not justified. 
14.4.3 Assman et al (Assman 1990) 
Data from the Prospective Cardiovascular Munster (PROCAM) study was used to 
derive a multiple logistic function including total cholesterol, HDL cholesterol, age, 
systolic blood pressure, smoking, diabetes, angina and family history of MI to predict 
CHD events. Data from the Helsinki Heart Study (HHS) population were applied to this 
model and a version of the Framingham equation which did not include HDL 
cholesterol, and were then compared in terms of their estimates of the number of CHD 
events in a gemfibrozil, which is a lipid lowering therapy, treatment group and a 
placebo treatment group. 
In comparison to the PROCAM equation, which was thought to accurately estimate 
coronary events in the Helsinki Heart Study population, it was found that the 
Framingham equation overestimated the number of events in the treatment group and 
underestimated them in the placebo group, see Table 14.2. However, it was noted that 
this difference probably reflected the fact that the PROCAM equation included HDL 
cholesterol and that the version of the Framingham equation used did not. 
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Number of CHD even ts 
Estim ated Observed 
PROCAM Framingham HHS 
Gemfibrozil 
treatment group 
61 67 58 
Placebo 
treatment group 
82 76 84 
Table 14.2 - Estimated number of CHD events in the Helsinki Heart Study using equations from 
the Framingham and PROCAM studies, compared to the observed number of events 
14.4.4 Laurier et al (Laurier 1994) 
A multi-factorial CHD prediction model based on the Paris Prospective Study, for males 
aged 43 to 53 years, was compared to the Framingham equation by applying data from 
the Prevention Cardio-Vasculaire en Medecine Travail (PCV-METRA) study in terms 
of predicted CHD risk estimates. The PCV-METRA is a prospective study of 
cardiovascular risk factors in workers from several firms in the Ile-de-France region of 
Paris, and was made up of 4131 males and 1635 females aged 30 to 65 years. 
It was found that the Framingham equation's estimated risks were higher than that of 
the PCV-METRA model, showing that the equation tends to overestimate CHD 
morbidity when applied to populations with low CHD mortality rates, such as the 
French. However, it was found that modification of the sole constant term increased 
agreement from 29% to 80%, with the modification reflecting the adjustment in the 
basal CHD risk. 
14.4.5 Grover et al (Grover 1995) 
Using the CHD Prevention Model, which is based on the Framingham equation, each 
individual in the Lipid Research Clinic (LRC) Prevalence and Follow-up Studies cohort 
was assigned a 12 year CHD mortality risk, and ranked according to their risk, and this 
was compared to the screening guidelines proposed by the National Cholesterol 
Education Program (NCEP I and NCEP II) and the Canadian Consensus Conference on 
Cholesterol (CCCC). 
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It was conclude that the equation could be incorporated into CHD prediction charts for 
use by clinicians since it was able to discriminate high-risk and low-risk subgroups 
among whom the incidence of future events will vary substantially (Grover 1999). 
14.4.6 Liao et al (Liao 1998) 
The Framingham equation was compared to two regression models based on systolic 
blood pressure, serum total cholesterol and smoking derived from the NHANES I and 
NHANES II studies in terms of their multivariate regression coefficients for CHD 
death. In addition, the Framingham equation was used to predict the absolute survival 
rate of CHD in the two NHANES studies. 
For the prediction of CHD mortality rate the Framingham equation was thought to 
provide a reasonable rank ordering of risk for individuals in the white US population, 
but it was felt that its prediction of absolute risk was less accurate. The authors noted 
that the equations should be used with caution when generalising to a different 
population, and that it may be inappropriate for use with populations of countries or 
ethnic groups that have much lower or higher CHD incidence and mortality rates than 
the Framingham sample population. 
14.4.7 Wilson et al (Wilson 1998) 
A coronary prediction algorithm was developed using data from the Framingham and 
Framingham Offspring cohorts, using categorical blood pressure measures from the 
Joint National Committee and cholesterol measures from the National Cholesterol 
Education Program, and then comparing the results with that of the Framingham 
equation with its continuous categories. In addition, the generalisability of using data 
derived from the Framingham Study was discussed. 
It was felt that the categorical model could predict CHD risk in a middle-aged white 
population sample. Caution was recommended in generalising to other populations, and 
that the model was most appropriate for individuals who resembled the sample 
population. 
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14.4.8 Grundy et al (Grundy 1998) 
This paper discussed the use of the Framingham risk score in developing national 
guidelines for risk factor management, as well as its appropriate use. 
It was concluded that charts based on the Framingham equation provided a realistic 
picture of a given individual's true absolute and relative risks. Even though one must be 
aware of potential differences among various populations when applying the equation; 
quantitative differences in risk predictions are likely to be small amongst most 
populations. In addition, the authors noted that users should remember that the 
Framingham equation does not take into account all risk factors for CHD. 
14.4.9 Hingorani et al (Hingorani 1999) 
The cardiovascular risk predicted by a computer program based on the Framingham 
equation was compared with actual risk derived from randomised control trials of 
cholesterol reduction. The trials in the comparison were the West of Scotland Coronary 
Prevention Study (WOSCOPS), the Scandinavian Simvastatin Survival Study (4S) and 
the Cholesterol And Recurrent Event trial (CARE). 
The Framingham equation successfully predicted the event rate in the placebo arm of 
the WOSCOPS study, although not for the 4S and CARE studies. This was thought to 
be due to the fact that both the 4S and CARE include individuals with pre-existing 
cardiovascular disease, whereas the WOSCOPS study only included disease-free 
individuals, as did the Framingham studies. It was concluded that the equation was 
applicable to a UK population without clinically evident atherosclerotic disease, and 
that is was clearly appropriate for predicting the effect of primary prevention, but is less 
valid in the setting of secondary prevention, see Tables 14.3 and 14.4. 
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Predicted risk reduction (%) Observed risk 
reduction (%) 
Absolute risk Relative risk Absolute Relative 
risk risk 
95% CI 
End point Non- Smoker Non- Smoker 
smoker smoker 
CHD 2.3 3.3 31 28 2.5 29 
(15-40) 
MI 1.4 2.7 40 31 2.0 27 
(12-40) 
CHD death 0.5 0.9 46 40 0.2 33 
(1-55) 
Stroke 0.0 0.0 0 0 0.16 11 
(-33 - 40) 
Table 14.3 - Effects of cholesterol lowering in primary prevention of cardiovascular disease in 
55 year old men with hypercholesterolaemia: predictions by the Framingham computer program 
compared with observed risk reductions in WOSCOPS 
Pred icted reduction in relative risk Observed 
Males Females reduction 
End point Non-smoker Smoker Non-smoker Smoker (95% Cl) In 
relative risk 
4S 
CHD 50 39 58 47 33 non-fatal 
48 fatal 
CHD death 55 49 62 58 42(27-54) 
CARE 
MI 41 32 49 39 23(4-39) 
non-fatal 
37(-5-39) 
fatal 
Stroke 46 40 56 49 20 -5 - 39) 
Table 14.4 - Effects of cholesterol lowering in secondary prevention of cardiovascular disease: 
predictions by the Framingham computer program compared with observed risk reductions in 
the 4S and CARE trials 
14.4.10 Durrington et al (Durrington 1999) 
For a series of 570 Manchester patients without pre-existing clinical evidence of 
atherosclerosis referred to a lipid clinic the algorithms, charts and tables used by the US 
National Cholesterol Education Program (NCEP), the joint guidelines of the European 
Society of Cardiology, the European Atherosclerosis Society, and the European Society 
of Hypertension, and the report of the UK Standing Medical Advisory Committee were 
compared with the Framingham risk equation in terms of CHD risk. 
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It was found that the Framingham equation broadly agreed with the European charts 
when applied to the same patients. 
14.4.11 Haq et al (Haq 1999) 
The individual CHD event risk estimates for 206 consecutive Sheffield men, aged 35 to 
75 years without pre-existing vascular disease, as predicted by the Framingham 
equation were compared with the PROCAM, Dundee and British Regional Heart Study 
(BRHS) risk functions. 
There was found to be close agreement between the Framingham, PROCAM and 
Dundee risk functions in terms of average CHD risk, and moderate agreement for 
estimates within individuals. The authors felt that there was already ample evidence to 
suggest that the Framingham equation predicts relative risk of CHD with reasonable 
accuracy in diverse populations, while their study suggested that the Framingham 
equation was acceptably accurate for predicting absolute risk in British hypertensive 
men, and this could probably be extended to all British men. 
14.4.12 Statistics Canada (personal communications) 
Dr Michael Wolfson and Mr Jean-Marie Berthelot, who have used the Framingham 
equation to generate events within the CHD module of POHEM, feel that the equation 
can be generalised to the Canadian population. They have used the technique described 
by Assmann et al of modifying the constant term in the equation in order to obtain 
agreement between the observed and predicted mortality in the Canadian population. 
However, they do stress that since there are no national CHD event incidence registers 
to validate the adapted Framingham equation output; one must be aware that the 
predictions could be wrong. There is no way of accurately checking. 
236 
14.5 Discussion of the Framingham Equation 
Table 14.5 summaries the methods for investigating the generalisability of the 
Framingham equation used in the papers reviewed, either by comparing the events 
generated by applying the data from study populations to the equation or, by comparing 
the equation to other risk scores. 
Comp rison 
Paper Study Events Risk Scores 
Leaverton et al   
Chambless et al 
Assman et at  
Laurier et al 
Grover et al 
Liao et al 
Wilson et al 
Grundy et al 
Hingorani et al 
Durrington et al 
Haq et al  
Table 14.5 - Summary of the methods used to investigate the generalisability of the 
Framingham equation 
Overall the papers concluded that the Framingham equations were applicable to 
populations that were similar to the Framingham cohorts, particular predominately 
white populations with high cardiovascular mortality. 
Only one paper, Chambless et al, expressed a view that is was not justifiable to apply 
risk equations to new populations. However, the paper did not specifically investigate 
the generalisability of the Framingham equation, but was a comparison of the 
coefficients of different risk equations. The authors reached their conclusion based on 
the fact that these coefficients were different, and did not apply the equations to 
different populations. The only other paper which expressed some doubt was that of 
Liao et al, which concluded that relative risk derived from the Framingham equation 
could be applied to a US white population, but felt that is was not justifiable to apply 
the absolute risks generated by the equation. This was in keeping with the views 
expressed by Laurier et al and those at Statistics Canada who suggested modifying the 
constant term in the Framingham equation to overcome this problem. 
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One concern with reviewing these papers was that the majority of them were only able 
to investigate the generalisability of the Framingham equation to male populations, due 
to the lack of data on women. Consequently the issue of whether the equation is 
applicable to women as well has not been explored as thoroughly as it has for men. 
Ideally one would like to validate the equation by comparing its predicted risks with 
those of the population of interest, but since no data are available at a national level this 
cannot be done. Some of the papers reviewed have tried to validate the equation by 
applying it to other cohorts, but this can only be seen as a partial solution since one can 
also question how similar these cohorts are to other populations, particularly the British. 
Nevertheless, of the 11 papers and one personal communication reviewed the majority 
expressed the opinion that the Framingham equation could justifiably be generalised for 
use with other populations with some modification, including the British, or England & 
Wales population. 
14.6 Summary 
This chapter begins by describing the Framingham Heart Study and the Framingham 
Offspring Studies. The chapter then outline how data from these studies were used to 
derive the Framingham Equation, and describes the equation in terms of the CVD risk 
factors it incorporates and the CVD event probabilities it generates. 
The chapter also discusses how the Framingham Equation has been used as the basis for 
generating CVD events by several health policy models, as well as discussing its 
generalisability to other populations and the difficulty in validating the equation's 
output when applied to other populations. 
The chapter includes a literature review of applications of the Framingham Equation to 
other populations, where the output from the equation has been compared to the results 
from trial and other risk equations. After discussing the review I conclude that the 
equation can justifiably be used with the England & Wales populations within POHEM. 
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Chapter 16 -A Comparison of the POHEM and PREVENT Models 
15.1 Introduction 
In this chapter I outline the POHEM related work of phase three of the Biomed II 
project, as originally outlined in Chapter 9. The objectives of this phase of the project 
were to compare the performance and output of a micro-simulation model (POHEM) to 
a cell-based macro-simulation (PREVENT) model. The comparison was to concentrate 
on the following aspects: 
" Data needs - comparing the volume and complexity of the data required, 
Generalising and adapting the models for different populations, 
" Flexibility in addressing additional questions, 
" Interpretation - can the results from simulations be easily understood for policy 
making. 
15.2 Differences Between Prevent and POHEM 
In addition to the different approaches to simulation, there are a number of other 
differences between the two models that must be considered in a comparison. 
15.2.1 Cohort Versus Population Model 
The most important of these differences is that POHEM generates a synthetic cohort 
whereas Prevent uses a whole population. With Prevent there is a dynamic population 
made up of all ages, which during a simulation period has individuals dying and being 
born. Although POHEM follows individuals from birth to death through all ages; all the 
individuals simulated are "born" in the same year and so one can only follow this cohort 
over time. It is not possible to simulate the effect of an intervention targeted at the 
whole, or part of the population other than one birth cohort with POHEM. This makes it 
239 
difficult to compare like interventions with like outcomes for Prevent and POHEM, 
since one can only compare the effects of an intervention on the same cohort in the two 
models. 
15.2.2 Shifting Risk Factor Exposure 
Prevent only allows simulations to move people from risk factor exposure categories to 
an ex-exposed category, which has a remnant relative risk, as a result of an intervention. 
For instance, with Prevent changing heavy or light smokers to ex-smokers is possible, 
but changing heavy smokers to light smokers is not. This means that it is impossible to 
shift the risk factor distribution, as would be the effect of a population intervention, such 
as would be the result of a national campaign to reduce individuals' cholesterol, but this 
is possible with POHEM, although only in terms of the effect on a cohort. 
This is an important issue to address since preventive strategies may have only small 
effects on the risk experienced by an average individual, but may have large benefits at 
a community or population level. This is the so-called prevention paradox, where if a 
large number of people each reduce their risk slightly, the entire population may show a 
large reduction in adverse events. 
15.2.3 Univariate Versus Multivariate Risk Factor Distributions 
Prevent uses independent risk factor distributions, where within the model the 
prevalence of risk factors are input and used separately. Although there may be 
prevalence data for smoking, hypertension and hypercholesterolaemia individually; 
there are no data for the prevalence of these risk factors in combination. That is, no 
allowance can be made for the clustering of risk factors in individuals. POHEM, by 
contrast, does use this type of multivariate distribution, and so allows the user to 
simulate high risk intervention strategies that target those individuals who have a 
clustering of risk factors. This helps to address important policy questions regarding 
whether health resources should be targeted to those at most risk and who might benefit 
the most from an intervention, rather than using a population approach in which health 
resources are not targeted, but used to change population distributions of risk. 
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15.2.4 Relative Risks Versus the Framingham Equation 
For each risk factor/disease combination Prevent uses the independent relative risk of 
disease specific mortality, whereas POHEM was designed to use a logistic regression 
equation, the Framingham equation, to calculate the probability of CHD morbidity and 
mortality events, and incidence and survival rates to calculate the probability of cancer 
morbidity and mortality. 
In the version of POHEM used in this work country-specific mortality figures were used 
as a proxy of incidence for CVA and COLD, with progression to death following 
immediately. 
Since there would obviously be differences between the output of the two models due to 
their using different methods to calculate risk, POHEM also was adapted for use with 
the Prevent relative risks to calculate mortality, so allowing me to make a closer 
comparison. 
15.2.5 Past and Future Trends Versus Present Trends 
For certain risk factors, such as smoking, on cessation of exposure an individual's risk 
will not immediately reduce to the lowest possible risk level (the remnant relative risk), 
but will take a number of years to reach this level. In addition, this reduction in risk may 
not start instantaneously on cessation of exposure. It may take a number of years before 
the elevated risk due to the individual's previous risk factor exposure begins to decline. 
Within Prevent these time dimensions are known as LAG and LAT respectively. 
This concept of LAG and LAT times implies that there will be a slow reduction in risk 
over time, and means that not only will the effect of interventions be seen in the future, 
but also that the prevalence of risk factors in the past will determine the incidence of 
disease in the present. As a result past risk factor trends need to be input for Prevent. In 
the case of smoking and COLD this means that risk factor trends as long as 20 years ago 
are required. Such trends may be difficult to calculate due to the limited availability and 
reliability of data. In addition, future trends need to be input to simulate how risk factor 
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levels will change during the course of the simulation period due to factors other than 
the interventions being modelled. These trends can only be guessed. 
The original version of POHEM does not take these LAG and LAT times into account. 
It generates individuals and follows them for their whole life-span, and so generates a 
life-time's risk factor history. POHEM uses the multivariate risk factor transition 
matrices, that is the probability of moving from one category of risk factor exposures 
between age groups, to calculate how risk factor levels change over time. These 
matrices are calculated using the multi-variate risk factor distribution from existing 
cross-sectional data. This means that POHEM assumes that changes in risk factor level 
over time will match the current changes between age groups. 
These differences between the two models were taken into consideration when I chose 
the interventions to be simulated, and the interventions chosen include both population 
and high risk strategies. 
15.3 Interventions 
Since Prevent only simulates the effect of risk factor interventions on mortality and 
POHEM is a cohort model, the only interventions that could be used to compare the two 
models would be risk factor interventions aimed at one birth cohort. 
The interventions to be modelled were chosen after discussion and a search of the 
literature for achievable risk factor changes. The first intervention is a direct comparison 
with one of the Prevent smoking interventions modelled for the Biomed project as 
described in Chapter 9, while interventions II and III highlight POHEM's ability to 
simulate high risk and population strategies. 
I. Ban on cigarette advertising 
" Advertising ban scenario: A total ban on cigarette advertising in England & Wales 
would result in a6% reduction in the prevalence of cigarette smoking (Baan 1999). 
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The effect of such a scenario aimed at those aged 20 to 24 was simulated, and 
modelled in terms of the lifetime impact for the cohort. 
II. High risk approach 
The high risk approach targets individuals who are at high risk of CHD due to a 
combination of risk factors, and attempts to reduce these risk factors at the same time. 
Individuals with a clustering of high levels of smoking, blood pressure and cholesterol 
at age 50 were chosen, using the Prevent cut-offs for the high risk factor levels: 
" 10% reduction amongst those individuals who smoke so that they become ex- 
smokers at age 50, 
" 23% reduction in cholesterol levels amongst those individuals with a level greater 
than 260 mg/dl at age 50, 
" 6% reduction in diastolic blood pressure levels amongst those individuals with a 
level greater than 95 mm Hg at age 50. 
The percentage reductions in risk factor levels were taken from the literature, and were 
attributed to the effects of nicotine replacement therapy (Foulds 1996), statin therapy 
(4S Group 1994 and Shepard 1995), and antihypertensive drug therapy (Collins 1990). 
III. Population based interventions, which reduce the risk factor distributions of all age 
groups the cohort will pass through. 
Shifting the risk factor distribution: 
" 2% reduction in cholesterol levels. 
"2 mm Hg reduction in diastolic blood pressure. 
" 6% reduction in the number of smokers. 
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The reductions in risk factor levels were taken from the literature, and were attributed to 
the effects of dietary changes on cholesterol (Brunner 1997), lifestyle changes on blood 
pressure (BMJ 2000), and a cigarette advertising ban on smoking (Baan 1999). 
It was assumed that the changes in risk factor prevalence due to the interventions would 
persist for the rest of the cohort's lifetime, which probably will lead to an over- 
estimation of the true effect of the interventions, since in reality some individuals may 
revert to an increased risked over time. The alternative would have been to have made 
some assumptions about what percentage of the cohort that would revert to an increased 
risk state over time, but these assumptions may also be unrealistic. 
15.4 Output 
POHEM allows the user numerous output options, which would result in an 
overwhelming amount of data if all were recorded. Accordingly, some decisions about 
which measures to choose had to be made. Prevent only produces results in terms of 
mortality, so for the POHEM interventions I chose some mortality output to make a 
comparison, as well as some morbidity measures to highlight that aspect of POHEM's 
methodology. The output measures I finally decided on to assess the effect of the 
interventions were: 
15.4.1 Mortality Output 
I. Changes in life expectancy, 
II. Age and disease specific mortality rates, 
III. Changes in disease free life expectancy, 
IV. Number of people reaching 70 and 85. 
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15.4.2 Morbidity Output 
I. Number of cases of disease, 
II. Average age of disease onset, 
III. Average number of years lived with disease. 
15.5 Initial Adaptation of POHEM 
In order to make the two models as comparable as possible, POHEM was adapted to use 
the relative risk approach used in PREVENT. It was necessary to reassign the risk states 
in POHEM to match those in PREVENT. The risk state determined the relative risk to 
be used, but in POHEM it was applied to the incidence data whereas in PREVENT it 
was applied directly to mortality. Disease progression for CHD used the Canadian 
model, however, the country-specific mortality rates were reproduced. Survival time 
from incidence of lung cancer from country-specific data was used to reproduce the 
overall mortality. 
The LAT and LAG effects modelled in PREVENT for the impact of smoking on disease 
were adapted for use in POHEM. In particular, they were applied to the incidence rather 
than mortality. In PREVENT, the LAT and LAG are applied when an individual moves 
from a risk factor exposure category to the non-exposed category. In POHEM, it is 
possible to move more smoothly between risk categories and increase or decrease the 
level of risk. Consequently, the LAT and LAG effect was applied whenever there was a 
decrease in risk state and the relative risk of the lower risk state was used where 
remnant risks were not applicable. An increase in risk state immediately negated any 
LAT and LAG currently in effect. 
In addition, the interventions described previously were implemented into POHEM's 
architecture. 
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15.6 Results from the Initial Adaptation 
The smoking intervention was run with both Prevent and POHEM, then the results from 
each simulation were combined in an Excel spreadsheet, and the figures for each disease 
modelled were produced showing the number of deaths postponed during the simulation 
period, see Figures 15.1,15.2,15.3 and 15.4. 
Having produced the figures, I noticed that for the reductions in lung cancer and COLD 
deaths, as shown in Figure 15.1 and 15.2, the output from Prevent peaked much later 
than that produced by POHEM. The results from Prevent showed that the greatest 
benefits from the smoking intervention would be seen when the cohort was 90 to 94 
years old for lung cancer and 100 to 105 years old for COLD. This seemed far too late 
considering the current burden of mortality for these disease in the population of 
England & Wales, with the number of deaths peaking for lung cancer at 70 to 74 years 
and for COLD at 80 to 84 years (OPCS 19952). One would expect the intervention to 
have a greater effect 20 years earlier, which is reflected in the results from POHEM. In 
addition, the Prevent output showed a much greater number of CVA and CHD deaths 
postponed for females than for males, which was also at odds with current CVA and 
CHD mortality patterns. 
Although POHEM was producing the more plausible results, it was using a new 
methodology that had been transferred to its architecture. I checked with POHEM's 
developers that they had implemented the current Prevent LAT and LAG times, as well 
as relative risks and remnant relative risks, in the model. Mr Flanagan checked POHEM 
and confirmed that he was using the same values for these variables. Therefore I 
concluded that they may be a problem with the updated version of Prevent, and so 
contacted Dr Barendregt to ask if there could be a problem with Prevent. He ran the 
same intervention and confirmed that there was something wrong with the results 
produced by the new version of Prevent when intervening on a single cohort rather than 
the whole population. Unfortunately he has not yet been able to correct this problem, so 
some other method for comparing these models had to be considered. 
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Reduction In Lung Cancer Deaths For England & Wales 
Due To A Cigarette Advertising Ban 
Year 
L--7-PREVENT Men .. -- " PREVENT Women -POHEM Men --- POHEM Women 
Figure 15.1 - Reduction in lung cancer deaths for England & Wales due to a cigarette 
advertising ban: Prevent Model versus POHEM 
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Figure 15.2- Reduction in COLD deaths for England & Wales due to a cigarette advertising 
ban: Prevent Model versus POHEM 
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Reduction In CVA Deaths For England & Wales 
Due To A Cigarette Advertising Ban 
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Figure 15.3 - Reduction in CVA deaths for England & Wales due to a cigarette advertising 
ban 
Prevent Model versus POHEM 
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Figure 15.4 euction in CHID deaths for England & Wales due tö ä cigarette advertising ban: 
Prevent Model versus POHEM 
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15.7 Second Adaptation of POHEM 
Since the new version of Prevent was unusable for the comparison, I next considered 
using an older version of the model. However, due to the restrictions of the original 
Prevent model, with respect to the number of age groups and the maximum LAG time 
allowed, it would not be possible to implement the updated risk factor information, 
which now requires 10 age group divisions and a LAG time of 30 years. The next 
possible solution would have been to convert POHEM to conform with the original 
version of Prevent, but I felt this would have been a step backwards, especially having 
spent a considerable amount of time and effort in updating the Prevent input data. In 
addition, it was felt that it would require a considerable amount of work for Statistics 
Canada, which may not have been possible in the short time available, to produce a 
model that would only be used once, and so this solution was decided against. 
Finally I decided on comparing the version of POHEM with the Prevent methodology 
with the a version of POHEM which used the Framingham equation for CHD events, 
cancer incidence rates for England, and the Prevent methodology for CVA and COLD 
since these disease were not currently implemented in POHEM. I had also by this stage 
realised that a comparison of the two epidemiological methodologies was the aspect of 
most interest to my work, since these would essentially dictate the differences in the 
number of deaths postponed and the relative importance of each disease modelled 
between the two models. In addition, comparing the two models' implementation could 
be achieved without having to compare the same interventions simulated by each 
model. 
In the rest of this chapter I will refer to the version of POHEM that uses the Prevent 
methodology as the Prevent methodology model, and the version of POHEM that uses 
the Framingham equation, lung cancer incidence and Prevent relative risks for COLD 
and CVA as the Framingham methodology model. 
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15.8 Results from the Second Adaptation 
Although for the Biomed Project the comparisons between Prevent and POHEM were 
run for both the England & Wales and Denmark populations; this chapter will only 
discuss the comparison using the England & Wales population since I was not involved 
with preparing the Danish data. 
15.8.1 Comparing POHEM and Prevent Methodologies 
Figures 15.5,15.6,15.7 and 15.8 show the yearly disease specific mortality output 
resulting from the cigarette advertising ban simulation from the two versions of 
POHEM by sex. For lung cancer, COLD and CVA both methodologies produced 
similar shaped curves, with approximately corresponding peaks for yearly deaths 
postponed by year. While for CHD the Prevent methodology produced a peak in yearly 
deaths postponed at about 2043, while the Framingham methodology resulted in a slight 
rise in deaths postponed, with an excess in deaths from about 2043, and then producing 
a similar pattern of excess deaths to the Prevent methodology for the rest of the 
simulation period. I discuss the reasons for these differences in section 15.9 Discussion 
of Results. 
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Figure 15.5 - Reduction in lung cancer deaths for England & Wales due to a cigarette 
advertising ban: Prevent versus POHEM methodology 
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Reduction In COLD Deaths For England & Wales 
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Figure 15.6 - Reduction in COLD deaths for England & Wales due to a cigarette advertising 
ban: Prevent versus POHEM methodology 
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Figure 15.7 - Reduction in CVA deaths 
for England & Wales due to a cigarette advertising ban: 
Prevent versus POHEM methodology 
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Reduction In CHD Deaths For England & Wales 
Due To A Cigarette Advertising Ban 
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Figure 15.8 - Reduction in CHD deaths for England & Wales due to a cigarette 
advertising ban: 
Prevent versus POHEM methodology 
The cumulative output for the whole of the simulation period is presented in Table 15.1 
for each methodology by sex. Columns 2,4,6 and 8 represent the male and female 
reference cohorts which evolve without intervention, while columns 3,5,7 and 9 
represent the changes due to the intervention. Negative numbers represent a decrease 
and positive numbers represent an increase in numbers from the reference cohorts, 
while the figures in bold signify that the difference from the reference population is 
statistically significant, using 95% confidence intervals. 
For males the Framingham methodology model resulted in 46 more deaths being 
postponed for COLD than by using the Prevent methodology model. For CVA, the 
Framingham methodology model resulted in 96 deaths postponed, as opposed to an 
excess of three deaths with the Prevent methodology model, which was not statistically 
significant. For both models the intervention resulted in deaths postponed for lung 
cancer, but the Framingham methodology models produced nearly twice as many deaths 
postponed (1456) compared to the Prevent methodology model (879). 1lowever, for 
CHD the Prevent methodology model produced 513 deaths postponed, while the 
Framingham methodology model produced an excess of 396 deaths. 
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A similar pattern was seen among females. With the Framingham methodology model 
88 more deaths were postponed for COLD than with the Prevent methodology model, 
while for CVA the Framingham methodology model resulted in deaths postponed (340), 
as opposed to 83 excess deaths using the Prevent methodology model. The Framingham 
methodology model produced a slightly higher number of lung cancer deaths postponed 
(81) than the Prevent methodology model, and for CHD the Prevent methodology 
model produced 1032 deaths postponed, while simulating the intervention with the 
Framingham methodology model resulted in 521 excess deaths. 
15.8.2 POHEM Specific Interventions 
The cumulative outputs by sex for the high risk and population interventions are 
presented in Table 15.2 for the whole simulation period. Columns 2 and 5 represent the 
male and female reference cohorts which evolve without intervention, while columns 3, 
4,6 and 7 represent the changes due to the interventions. Again negative numbers 
represent a decrease and positive numbers represent an increase in numbers from the 
reference cohorts, and the figures in bold signify that the difference from the reference 
population is statistically significant. 
The high risk intervention would result in only 3.5% of males and 1.8% of females 
being intervened on at age 50. For both males and females the intervention would result 
in deaths postponed from CHD and CVA, and an excess of deaths from lung cancer and 
COLD. The greatest number of deaths postponed would be from CHD, with 1431 and 
426 deaths postponed for males and females respectively, while a similar number of 
CVA deaths would be postponed on both sexes, 283 for males and 265 for females. The 
intervention would result in a smaller number of excess deaths in females than males, 
with 22 females COLD deaths compared to 142 males deaths, and an excess of 21 
female lung cancer deaths compared to 145 for males. For all diseases, and both sexes, 
there would be an increase in the average age at death. 
In terms of the effect on morbidity, disease incidences reflected disease mortality, as 
would be expected. The decrease in CHD deaths results from a decrease in CHD cases, 
and the increase in lung cancer deaths results from an increase in lung cancer cases, for 
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both males and females. For both diseases there would be increases in the average age 
of onset for both sexes, while for CHD there would be an increase in the average years 
lived with the disease, again for males and females. 
The population intervention would target 100% of the cohort, and would result in deaths 
postponed from lung cancer, CHD and stroke for both males and females, while there 
would be a reduction in COLD deaths for females (-576) and an excess in these deaths 
for males (+530). The greatest number of deaths postponed would be from CHD, with 
8714 and 5081 deaths postponed for males and females respectively. The next largest 
reduction would be from CVA deaths postponed, with more females benefiting than 
males, 1498 to 708 deaths postponed respectively. This would also be the case for lung 
cancer deaths postponed, with 941 for females and 665 for males. In addition, there 
would be an increase in the average age of disease onset for lung cancer, CHD, CVA 
and COLD. 
In terms of the effect on morbidity of the interventions, for both males and females, 
there would be a decrease in the averaged age of disease onset for lung cancer, while 
there would be an increase for CHD. For both these diseases there would be an increase 
in the average number of years lived with the diseases, for both sexes. 
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15.9 Discussion of Results 
15.9.1 Comparing POHEM and Prevent Methodologies 
The two models produced similar patterns for the yearly disease specific mortality over 
time for lung cancer, CVA and COLD, although there are differences in the magnitude 
of the number of deaths. The pattern for COLD deaths are similar in magnitude across 
both models since they both used the Prevent methodology for this disease, and 
smoking was the only risk factor associated with COLD. The Framingham methodology 
resulted in more lung cancer deaths postponed for males and females than the Prevent 
methodology model. This is probably due to the Prevent methodology using the Prevent 
relative risks of lung cancer mortality to generate lung cancer incidence, while the 
Framingham methodology uses actual lung cancer incidence data. Since the majority of 
individuals with lung cancer will die from the disease, one can arguable use mortality as 
a proxy for incidence; the Framingham methodology model is probably more realistic. 
The most marked difference in deaths between the models were for CHD and CVA. The 
Framingham methodology model had only a small effect on preventing CHD deaths and 
a greater effect on CVA deaths, and so showed an excess of CHD deaths. On the other 
hand, the Prevent methodology model had a greater effect on CHD deaths than CVA, 
and so resulted in an excess of CVA deaths, but only slightly. In the Prevent 
methodology model the intervention has more effect on CHD than CVA since the 
relative risks of CHD mortality due to smoking are higher than for CVA up to the age of 
75 years. 
This difference in the importance of CHD and CVA with respect to smoking in each 
model is a result of the interaction between the Framingham equation, used for CHD 
events, and the Prevent methodology, used for CVA events, in the Framingham 
methodology model. Since the model uses the assumption that the progression from 
incidence to mortality was immediate for CVA; it means that the intervention has a 
greater effect on CVA as there is no morbidity period within which an individual can be 
at risk from other diseases. The output of the models are presented for the life-spans of 
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the synthetic cohorts; so a reduction in deaths from one disease will lead to an excess in 
deaths from other diseases. 
15.9.2 POHEM Specific Interventions 
In the high risk intervention strategy a much smaller number of individuals were 
intervened on, only 3.5% of males and 1.8% of females in the cohort. The high risk 
strategy resulted in deaths postponed from CHD and CVA, with an excess of deaths 
from lung cancer and COLD. This is due the reductions in hypertension and 
hypercholesterolaemia, which have an immediate effect on CHD and CVA, while the 
effect of the reductions in smoking on COLD and lung cancer take longer to produce an 
effect. This leads to an increase in deaths from these causes among those at high risk. 
The high risk strategy had a smaller effect than the population strategy, probably 
because so few people qualified for the intervention. 
In contrast the population strategy intervened on 100% of individuals in the cohort, and 
resulted in an increase in the number of persons alive to age 70 and 80, average age of 
death, reductions in CHD and lung cancer cases and deaths, CVA deaths for both sexes, 
as well as a reduction in COLD deaths in females, although there was an increase in 
these deaths for males. 
The difference between males and females in deaths from COLD may be due to the 
interaction between the Framingham equation used for CHD events and the Prevent 
methodology for CVA and COLD events using the Framingham methodology model. 
Males have a high probability of CHD, as derived from the Framingham equation, and 
so interventions that target all the CHD risk factors in the equation will have a greater 
effect in the reduction of CHD in males than females. More males will then be at risk 
from other diseases related to these risk factors. In the model CVA is influenced by 
blood pressure and smoking, whereas lung cancer and COLD are only influenced by 
smoking. The Prevent methodology gives CVA a stronger influence on mortality, with 
the progression from incidence to death being immediate, and so the result is an excess 
in CVA deaths for males. 
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Of the two POHEM specific interventions the population based strategy would produce 
the most health gain, even though the shift in risk factor prevalences were small, since it 
affected the whole cohort, whereas the other interventions only targeted a very small 
percentages of the cohorts. This reflects and reinforces Rose's argument that preventive 
strategies which concentrate on a minority at high risk produce less health gain than 
strategies which intervene across the whole population, since the minority at high risk 
contribute a small proportion of adverse events (Rose 1992). The effects of the high risk 
strategy could be improved by reducing the values of cholesterol and diastolic pressure 
levels at which individuals would be intervened at, and by reducing the age at which the 
intervention would begin. These changes to the high risk strategy would increase the 
number of individuals within the cohort affected by the intervention, and would increase 
the time those individuals would be affected for. An area of further work would be to 
investigate the risk factor levels and the age groups that high risk strategies would need 
be targeted to produce similar effects as population strategies. 
15.10 Discussion 
Although it was not possible to use the Prevent model for a direct comparison with 
POHEM; it is still possible to compare the performance and output of the two models in 
terms of the objectives of the Biomed project from using the models separately, with 
respect to: 
" Data needs, 
Generalising and adapting the models for different populations, 
" Flexibility in addressing additional questions, 
" Interpretation. 
15.10.1 Data Needs 
The data needs of Prevent and POHEM are very similar, particular in terms of 
population and mortality data. The most marked difference between the data sets of the 
two models is that POHEM requires risk factor data in the multivariate form, while 
Prevent uses univariate distributions. Univariate distributions of risk factors by age and 
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sex are usually produced in reports, such as those for the General Household Survey and 
the Health Survey for England, whereas producing multivariate risk factor distributions 
by age and sex will require access to the raw data from such surveys, which will then 
need to be reanalysed. These data must also be reanalysed to calculate the univariate 
mean and standard deviation for each risk factor distribution by age and sex, which are 
require for input to POHEM. Other data needs of POHEM that are additional to those of 
Prevent are lung cancer incidence and survival by stage, sex and age group. 
15.10.2 Generalising and Adapting the Models for Different Populations 
The generalisability and adaptability of both models are highly dependent on the 
availability and generalisability of their input data. If the required input data are not 
available, or possible to derive, for the new population, as for example the use of 
Prevent Plus as discussed in Chapter 10, then it will not be possible to produce a version 
of a model. Secondly, the user must decide if the model's methodology and the data 
used by this methodology, such as the relative risks of mortality in Prevent and the 
Framingham equation in POHEM, can be applied to the population of interest. With 
respect to both of these issues my work has involved considering the suitability of 
applying these to the population of England & Wales, as detailed in Chapters 7,9 and 
14. 
15.10.3 Flexibility in Addressing Additional Questions 
Of the two models POHEM is the most flexible with respect to addressing additional 
policy questions. Not only is it possible to simulate high risk and population 
interventions strategies with POHEM, which are not possible with Prevent, but it also 
has the ability to include Prevent's methodology into its structure, as detailed in this 
chapter. This flexibility and adaptability allowed me to compare the face-validity of the 
outputs of the two models, and so discover an error in Prevent that its developers were 
unaware of. 
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15.10.4 Interpretation 
Conceptually the results of Prevent may be easier to interpret, since one applies 
interventions to the whole, or part of a real population, then monitors the development 
of this population over time. With POHEM one has to understand that interventions are 
applied just to one cohort, which is monitored over time, and this then requires the user 
to employ some method for applying the results from the artificial cohort to their real 
population. However, for both models the user must have a good understanding of their 
methodologies and input data in order to interpret their results. 
The stochastic nature of POHEM's output when producing yearly events results in 
jagged graphs which may be confusing for policymakers to interpret, particularly if one 
year there are events postponed and the next there is an excess of events when 
compared to the reference cohort. On the other hand, Prevent's results can be used to 
produce smooth curves, which are more intuitive to follow, since there are no sharp 
changes in the signs of values, as with POHEM. Consequently one needs to consider 
how best to present POHEM's results clearly. It is clearer to present results from 
POHEM in the form of tables, such as Tables 15.1 and 15.2. However, it may have been 
more informative to produce results in terms of premature deaths postponed, possibly 
concentrating on deaths before 75, since a reduction in deaths from one disease will 
always lead to an excess in deaths from other diseases if the output are presented for the 
whole life-span of the synthetic cohort. 
15.10.5 General Discussion 
Comparing two models that have different methods of implementation and 
methodologies is a difficult task, even with my work in which I have had the 
methodology of one model transposed into the structure of another. 
There is no gold standard for comparison. Neither methodology can be validated, or 
classified as producing a "right" answer. This means that in order to interpret the output 
produced by the two models one needs to have a good understanding of the assumptions 
and the methodologies used, the data input, the disease epidemiology, the simulation 
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processes, the translation of the intervention to the modelling environment and the data 
output processes. In comparing the models it is not possible to say that one model is 
right and another is wrong, or even that one model is better than another. However, it is 
important to be able to explain why different models produce different results, and how 
the factors responsible for these differences affect a model's results. Unfortunately this 
kind of knowledge is not easy to obtain, and can only be gained with experience of the 
whole modelling process. 
15.11 Reflections 
Originally I hoped to be able to produce and run an England & Wales version of 
POHEM myself, but due to delays in the redevelopment of POHEM it was not in a state 
that anyone other than the developers at Statistics Canada could input the data, set up 
the model, or run the simulations. This meant that running POHEM simulations was 
dependent on staff at Statistics Canada being free from other work commitments. To a 
certain extent, this limited the scope of the work with POHEM, since it was not possible 
for me to investigate the effect of targeting different risk factor and age groups, or the 
impact of different assumptions concern risk factor/disease relationships in the time 
available, as I have done with Prevent. 
In addition, the fault in the Prevent model meant that it was not possible to make a full 
comparison of the two models; only a comparison of the two models' methodologies 
within the POHEM framework could be made. Since POHEM had the ability to 
incorporate the methodology of Prevent, I was able to identify the fault. This could be a 
use of flexible models such as POHEM, to at least validate the implementation of other 
models, in the absence of being able to validate their results. 
The comparison of the two models' methodologies within the POHEM framework 
suffered from trying to make the two models as similar as possible. The inclusion of 
CVA and COLD in the Framingham methodology model using the Prevent 
methodology led to the increased importance of these diseases when interacting with the 
model's original methodology. It would have made for a clearer comparison if CVA and 
COLD had been excluded from POHEM, concentrating on the effect of interventions on 
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CHD and lung cancer. However, this statement can only be made with hindsight since 
the other Biomed members who developed Prevent wanted these diseases included in 
the comparison. 
Having gone through the process of trying to compare two models I do not think that 
much can be learnt from comparing the results of simulating the same intervention with 
such models. Ultimately users will chose a model that can simulate the interventions 
that policymakers want simulated. I would not choose Prevent to model a high risk 
strategy, or POHEM if I wanted to investigate the effect of an interventions with the 
demographic development of the whole of the England & Wales population, since each 
models cannot simulate these interventions, but the other can. What this work has 
highlighted is the need for those who use models to be able to explain why different 
models may produce different results. 
15.12 Conclusions 
As mentioned earlier in the chapter POHEM and Prevent are quite different models, 
aside from the macro/micro-simulation distinction, with regard to how they model 
interventions and the type of interventions they can simulated. Consequently one cannot 
say that one model is better than the other, but rather that Prevent is better suited for 
simulating interventions in conjunction with the demographic evolution of a population 
in terms of mortality, while POHEM is best suited for modelling interventions that 
simulate high risk and population strategies in terms of morbidity and mortality. 
Therefore the type of intervention one wishes to simulate will dictate the type of model 
one will use, rather than one being able to simulate any intervention using any model. 
Ultimately the user must be able to explain why different models may produce different 
results. 
15.13 Summary 
This chapter describes my work on phase three of the BIOMED II project on Public 
Health Models, the aim of which was to compare a micro-simulation model, POHEM, 
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to a cell-based model, Prevent. A number of other differences between the two models, 
aside from the different approaches to simulation, are also discussed. 
Unfortunately, due to a fault in the updated version of Prevent, it was not possible to 
compare the models directly. Instead the Prevent methodology was transposed to the 
POHEM framework, and then the two models' methodologies were compared within 
the POHEM framework. This comparison was made simulating the effects of the 
cigarette advertising ban detailed in Chapter 9. In addition, the chapter describes how 
POHEM can be used to simulate risk factor interventions that use high risk and 
population strategies, involving a shift in risk factor distributions, which are not 
possible with Prevent. 
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Chapter 16 - POHEM Discussion 
16.1 Introduction 
In the last couple of chapters I have described my work with POHEM. Although I have 
used the model less extensively than the Prevent model my experiences of using it have 
still given me an insight to its usability as a policy tool. POHEM is a technically, 
methodologically and computationally complex model, which is reflected in the effort 
needed to understand and use the model. 
As with the Prevent model, POHEM has some positive and negative aspects in terms of 
its use as a model for public health policymaking, and these aspects will affect how it 
can be used and what it can be used for. Within this chapter I discuss these aspects with 
regard to how important I feel they are in affecting the model's usability, as I have with 
the Prevent model in Chapter 11. 
16.2 Positive Aspects of POHEM 
Some of the positive aspects of POHEM were highlighted in the last chapter in which it 
was compared to the Prevent model, particularly with respect to POHEM being able to 
simulate certain strategies that I consider important to public health policy, which 
Prevent cannot do. The first of these aspects is POHEM's ability to shift risk factor 
distributions, and so simulate the effect of population interventions. The example given 
in Chapter 11 of a health promotion policy aimed at lowering the population's 
cholesterol level, which would shift the distribution of cholesterol level across the 
whole population to a lower level, is possible to simulate with POHEM. POHEM's 
ability to model this type of intervention was demonstrated in Chapter 15 by simulating 
an intervention that reduced cholesterol levels by 2%, reduced diastolic blood pressure 
by 2 mm Hg and reduced the number of smokers by 6%. 
Secondly, since the model holds risk factor prevalence data as multivariate distributions 
it allows a user to target individuals who have a cluster of risk factors, and so allows 
one to simulate high risk intervention strategies, unlike Prevent. This was demonstrated 
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by a simulation described in Chapter 15 where individuals who smoked, had cholesterol 
levels greater than 260 mg/dl, and diastolic blood pressure levels greater than 95 mmHg 
were targeted at 50 years of age. 
And thirdly, POHEM's use of the Framingham equation for CHD incident events and of 
available cancer incidents data allows it to generate morbidity measures, as well as 
output in terms of mortality. This is a particularly important aspect. I have shown with 
my modelling with Prevent of physical activity targets and the Birmingham population 
that for many risk factor interventions the effects are very small in terms of the number 
of deaths avoided. Therefore, by including morbidity, with POHEM it would be 
possible to present policymakers with a more complete picture of the effect of an 
intervention. Although not covered in this thesis, the model has the ability to include 
costs, and so one would be able to present some measure of the relative cost- 
effectiveness of various interventions. 
Another positive aspect of POHEM is its flexible structure which allows the 
methodologies of other models, such as Prevent, to be implemented into the POHEM 
architecture. This enables one to test other models, as detailed in Chapter 15. I was able 
to compare the face-validity of the outputs of the two models, and to discover an error 
in Prevent that may otherwise have gone unnoticed for some time by its developers. 
This also illustrates how POHEM, like Prevent, can be used for hypothesis testing, since 
the model's flexibility allows the user to investigate how changing various assumptions 
concerning the risk factor and disease relationship within the model will affect the 
outcomes of an intervention. 
POHEM usability as a policy tool is greatly enhanced by its ability to model up to ten 
different simulations per run, which allows the user to carry out sensitivity analysis of 
the input variables. Although this is possible in Prevent, it would require each 
sensitivity run to be simulated separately. 
In addition, POHEM generates confidence 
intervals and tests for statistical significance of its results. 
Even though POHEM was originally developed from an actuarial model, written in an 
out of date language, Statistic Canada's long term interest in modelling has meant that 
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they have committed resources to its development and usability. This was shown by 
their conversion of the model's source code from APL to MODGEN, the C++ like 
language used by all the models in its Health Analysis and Modelling group. This has 
meant that the model is understood and can be developed by a number of people, and 
so, unlike Prevent, does not rely on a single individual. This need to make POHEM 
more accessible has meant that the methodology and coding has had to be well 
documented. Not only can new people joining Statistics Canada understand and use the 
model, but it also allows greater accessibility to those outside the institution. 
16.3 Limitations of POHEM 
Although POHEM has many advantages over the Prevent model; there are some aspects 
where Prevent uses methodologies more appropriate for policymaking. The most 
notable of these is that while Prevent can simulate the development of the whole 
population; POHEM can only simulate the development of one birth cohort over time, 
although the cohort can be intervened on at any point in its life span. One would have to 
run POHEM for each birth cohort, each simulated for a different length of time, to build 
up a population profile. 
In addition, the age dependent risk factor prevalence data used by the model is derived 
from cross-sectional surveys. This means that as the simulated cohort ages it takes the 
age specific risk profiles of the population the data is derived from. This may be true for 
age dependent risk factors such as blood pressure or cholesterol, but will not be so for 
behavioural risk factors such as physical activity or smoking. This has implications if 
one is trying to build up a population from cohorts. Within POHEM one is using the 
assumption that changes in risk factor distribution as a cohort ages will be the same for 
all cohorts as they pass through the same age groups, which may not be true due to 
cohort or period effects. 
POHEM, in comparison to Prevent, is more computationally intensive, with one 
reference simulation and one intervention simulation each of 4 million individual taking 
as long as sixteen and a half hours when run on a dual Pentium II 266Mhz with 132Mb 
DRAM, although simulations of about 100,000 individuals only take about fifteen 
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minutes. The three scenarios simulated in Chapter 13 would have taken over 66 hours to 
run had I used a4 million person cohort. Eventually this will be come less of a problem 
as the computational power of affordable and readily available computers increases over 
time, but presently the time taken to run simulations may prove to be a barrier to 
POHEM's use as a policy tool. This would be a particular problem if one was to try to 
build a population by generating each cohort. 
Unlike Prevent, POHEM is a very technical model without a "user-friendly" interface. 
In order to run simulations the user must edit the model's MODGEN source code, 
compile the MODGEN source code to C++ source code, next compile the C++ source 
code into an executable file, and then run this file. Although, the developers are adding 
Windows interfaces to make the model more user-friendly it is not seen as a priority for 
Statistics Canada. As a consequence I have had to rely on staff from Statistics Canada to 
input the data and run the model for me. Although in the long term I will be able to use 
the model without relying so heavily on Statistics Canada; the investment in time and 
effort may be a barrier to using the model as a policy tool, especially when policy 
questions need to be answered in a shorter time-scale. 
Although Statistics Canada are committed to the long term development of POHEM it 
has taken a long time to reach its current stage of development. The conversion from 
APL has taken well over three years to complete. At times, Statistics Canada had to halt 
development of the new version and use the APL version in order to deliver simulations 
addressing current governmental policies. This longer than expected development time 
was also one of the factors contributing to the difficulty of its use by others outside 
Statistics Canada, since each updated version had different features and mechanisms for 
setting up and running the model, and so one needed to wait for some stability in the 
methodology used before embarking on learning to use the model. 
Another aspect of POHEM which could be seen as a barrier to it use as a policy tool is 
that care needs to be taken in presenting the output from the model. As seen in Chapter 
15, the stochastic nature of the model's output when producing yearly events results in 
jagged graphs, which may be confusing for policymakers to interpret, particularly if one 
year there maybe events avoided and the next there is an excess of events when 
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compared to the reference cohort. Consequently one needs to consider how best to 
present POHEM's results clearly. This is true for any model, but more so for the 
stochastic output of micro-simulation models. 
16.4 Conclusions 
The flexibility and complexity of POHEM can be viewed as both strengths and 
weaknesses of the model. They give POHEM the ability to simulate interventions that 
are impossible to model with Prevent, especially the ability to simulate and compare 
high risk and population strategies, which are important issues in public health policy. 
In addition, POHEM's ability to incorporate multiple methodologies make it a powerful 
tool for testing the output of other models, as well as being adaptable to include any 
process that a modeller may wish to simulate. However, these aspects also make the 
model highly technical. The user must understand the source code and compilation 
processes of the model to use the model without the assistance of its developers. 
The model is even more complex than Prevent, and so, like Prevent, is too complex be 
used by policymakers on their own. However, unlike Prevent, the model require a 
greater commitment, in terms of time and effort, by others modellers who wish to use it. 
Modellers still need to fully understand its workings and its input data, in order to 
translate POHEM's results to policymakers. Fortunately the implementation 
methodology used by POHEM is common to all the models used by the Health Analysis 
and Modelling group at Statistics Canada, and so it is well supported in terms of its 
documentation and the number of people who can advise on the model. This makes it 
easier for those outside Statistics Canada to develop and use the model. However, 
policymakers may not realise the time and effort needed before one is able to use it, and 
so may not be prepared to invest the necessary resources to the model. 
POHEM still has a number of limitations that cause it to fall short as an ideal model for 
simulating risk factor interventions for policymaking. Most notably that it can only 
simulate interventions on a cohort, rather than a population, which I feel is more 
relevant for policy. The modelling with Prevent in Birmingham (Chapter 8) showed 
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how the demographics of a population contributed to the effect of an intervention, as 
well as the risk factor profiles of the cohorts in that population. 
This limitation it coupled to the computational demands of the model which currently 
dictates very long simulation run-times for sizeable cohorts. This may be prohibitive in 
terms of the practicality of simulating whole populations. As technology improves this 
will become less of a problem, making the possibilities of a population version of 
POHEM more feasible. 
Overall, POHEM is a usable tool for policymaking, since its flexibility allows the 
implementation of numerous types of interventions, mechanisms and methodologies, 
although one it limited to applying the simulations to individual birth cohorts. Most 
importantly users of POHEM need to be aware of its complexities, and of the time and 
effort they need to invest before they will be able to use the model. 
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Section 4: Discussion 
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Chapter 17 - Discussion 
17.1 Introduction 
The aim of this thesis was to evaluate the use of public health models in policymaking 
in terms of the appropriateness and the practicalities of using such models for 
simulating health interventions, and the application of the results of such modelling 
exercises to public health policymaking. And through this process one would be able to 
define the requirements for public health models that are capable of addressing the 
policy agenda. 
To this end I have described the adaptation and use of the Prevent and POHEM public 
health models for simulating the effects of risk factor interventions on CHD in the 
England & Wales population, particularly the effect of targeting various sections of the 
population. The results of these modelling exercises were intended to contribute to the 
debate of setting priorities for reducing CHD and to enable policymakers to make more 
informed decisions concerning public health strategies. 
I have considered the limitations of the input data, the assumptions underlying the 
methodology of the models, and problems in translating interventions to the simulation 
environment. In addition, I have discussed the link between research and policy, with 
respect to the issues that influence the implementation of research findings to the policy 
agenda, and the need for modellers to be aware of these issues in developing public 
health models. 
Within this chapter I review my work, and then discuss the future role of public health 
models in policymaking, in terms of how and by whom they should be utilised, and the 
requirements for producing models that are able to address policy questions. 
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17.2 Model Development 
17.2.1 Review of Models 
When I began this work I reviewed several suitable health policy models, particularly 
ones that included coronary heart disease. I found that non-communicable disease 
models have been developed in a number of areas such as screening, medical 
interventions, resource allocation and risk factor reduction. Many such models have 
concentrated on various forms of cancer, while new infectious disease models have 
been developed relating to HIV in terms of transmission, incubation, variable 
infectiousness, and the cost-effectiveness of prevention targeting. Several models for 
CHD concentrated on such areas as individual risk factors, cardiovascular treatment, 
secondary care, familial aggregation of disease, priority rating systems and pathways of 
coronary care, risk estimation and counselling, estimating GP workload, and 
cardiological treatment. 
In the course of reviewing the literature I concluded that the essential characteristics for 
models that were to simulate public health policy options, derived from Chigan (Chigan 
1992), were: 
"a time period during which risk factors may develop, latent periods before risk 
factors affect morbidity and mortality, and lag times during which risk factor 
changes translate into mortality reduction, 
multi-factorial risk factor/disease relationships, where one risk factor can influence 
several diseases, and one disease may be influenced by several risk factors, 
"a demographic basis by which population changes within the simulation period can 
be considered. 
However, I discovered that few of the models I had identified conformed to these 
criteria. The ones that matched these criteria the closest were Prevent, the Coronary 
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Heart Disease Policy Model, NIMPH/TAM, Prevent Plus, the CRISPERS model, 
POHEM and the Global Burden of Disease model. 
After more appraisal of these models I decided to proceed with the Prevent and 
POHEM models because they conformed to my criteria for being classed as policy 
models, included CHD as one of the diseases simulated, could be adapted for use with 
the England & Wales population, and their developers were willing for others to 
develop their own country versions of the models. In addition, since Prevent was a cell 
based model and POHEM was a micro-simulation model I could also compare their 
methodologies. 
17.2.2 Prevent 
Initially I had intended to improve the input and output of data for the Prevent model by 
reprogramming it. However, there was no documentation in terms of comment 
statements in the programme, flow diagrams or variable glossaries to demonstrate how 
the programme worked. In addition, the variable names used within the programme 
were abbreviations of Dutch words, and the source code did not followed a structured 
programming style. Consequently I decided to make the model more easy to use by 
other, non-programming, changes such as developing a spreadsheet model to calculate 
risk factor trends, and allowing the movement of individuals from one risk factor 
exposure category to another, rather than to the non-exposure category. 
My work on trends succeeded in clarifying the methods for defining and calculating the 
risk factor trends input data files for Prevent, as well as giving the developers an 
opportunity to fully explain the mechanisms by which the trends were used in the 
model. Documenting this work meant that the principles of calculated trends could be 
understood and implemented by others. 
In the course of my work with Prevent I became aware of its limitations in being unable 
to shift risk factor exposure, use relative risks less than one and use univariate risk 
factor distributions. However, I realised these problems after I had used the model for 
some time, and had tried to simulate interventions suggested by policymakers and other 
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researchers. I have outlined how I was able to overcome some of these problems, and 
explained why some problems could not be solved due to the methodology of the model 
and due to the developers' reluctance to adapt the model. 
I modelled changes in physical activity in collaboration with the Health Education 
Authority. At the time there was a great deal of discussion about setting targets for 
physical activity, and my work on modelling the effects of increasing activity in the 
population, targeting differing exercise levels, age and gender groups, contributed to the 
debate. This work led to my being asked by Birmingham Regional Health Authority to 
adapt the Prevent model to the Birmingham population. Their interest was in making 
comparisons between risk factor intervention strategies as a possible aid to policy 
decision making. In particular they were interested in simulating short term risk factor 
interventions in the Birmingham, Small Heath and Sutton Coldfield populations. My 
modelling showed that the interventions that resulted in the most actual years of life 
gained for all three populations were targeting male smokers and screening for and 
treating severe hypertension in females. 
The Biomed project stressed the need to update a model, seven years after its initial 
development. In three years the project achieved its aims of validating the models in the 
context of different E. U. countries, comparing the implementation, the utilisation and the 
results of Prevent in different E. U. countries, and exchanging data on risk factors, relative 
risks, new treatments and treatment outcomes, for inclusion in models. 
The implementation of the new version of Prevent was less successful; some limitations 
of the original model were not addressed, and the scarcity of data and the lack of clear 
methods for deriving these required data have made the Prevent Plus model difficult to 
transfer to other populations. 
Many of the constraints I experienced in the modelling work carried out with Prevent 
stemmed from the limitations of the model, as outlined in Chapter 6. It was possible to 
simulate the HEA's physical activity targets, since they only entailed moving individual 
from one exposure category to one other, but it would have been more realistic to have 
simulated shifts in the population's average physical activity levels. The more realistic 
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the simulation of interventions; the more informative to policymakers are the results. 
This limitation also affected the choice of interventions modelled for Birmingham 
Regional Health Authority, since Prevent's inability to simulate shifts in risk factor 
distributions meant the policymakers were constrained in their policy options. 
Since Prevent used only univariate risk factor distributions I was not able to simulate 
the effects of interventions on those people at high risk due to a combination of risk 
factors. The interventions modelled may have had more effect if targeted at these high 
risk individuals, and so resulted in different policy implications. Limited targeting, in 
terms of age and sex, was possible, and this demonstrated how interventions would have 
different effects in different groups. 
Prevent was only able to produce output in terms of mortality, and this made the results 
of the interventions modelling seem disappointing, as well as underestimating the true 
effect of the interventions by excluding reductions in morbidity. Ideally, I would have 
wanted to produce results in terms of both mortality and morbidity, as this would have 
given a more complete view to policymakers when comparing interventions. 
Lack of data also affected the scope of the modelling carried out with Prevent, and this 
applied at various stages in the modelling process. One important limitation of the data 
concerned the risk factor prevalences in Birmingham, Coldfield and Small Heath. There 
was a poor response rate to the local Pulse Survey, which meant that data for Trent and 
the West Midlands region had to be used. There were also missing variables such as 
social class and ethnic groups. If these variables had been available, I could have 
stratified the population by them and then modelled interventions targeted at these 
groups, thus addressing key issues on the health policy agenda. 
A less obvious, but still important problem was the lack of data on the effectiveness of 
interventions in changing risk factor levels, such as blood pressure or cholesterol, and 
in changing the proportion of the population which would take up moderate physical 
activity or quit smoking. For the interventions modelled with Prevent I relied on the 
policymakers who commissioned the work to suggest the changes to be achieved by the 
interventions. However, they were not the best source for such information. In 
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retrospect it would have been better to have carried out a review of the literature to find 
out the effectiveness of interventions, and what changes in prevalences would have been 
realistically achievable. With unrealistic estimates of effectiveness, the output of the 
model may under or over-estimate the effect of interventions, which in turn will result 
in policy decisions based on incorrect results. 
Gaps in knowledge also exist in terms of the relative risk of disease associated with 
exposure to risk factors. This is highlighted in my discussion of the Berlin and Colditz 
meta-analysis (Berlin 1990) in Chapter 7. The meta-analysis seemed to be the best 
available source for the relative risks of CHD mortality by physical activity level, but it 
was published 10 years ago and so did not include the results of several large physical 
activity trials that have been published since its publication (Morris 1990, Shaper 1991, 
and Manson 1999), which need to be included in a new updated meta-analysis. In 
reviewing my work I feel that in the future one should also use relative risks from such 
studies as a means of carrying out sensitivity analysis on one's modelling results. 
Possibly this procedure should be carried out with any modelling work, since there will 
always be some uncertainty surrounding the effect of risk factors or interventions on 
disease. 
The smoking interventions simulated as part of the Biomed II project, as described in 
Chapter 9, highlighted the need for policymakers to be involved in the choice of 
interventions to be simulated. The facts that Prevent could model smoking interventions 
and we had the required data on smoking for the four participating countries were not 
enough justification for modelling the interventions described. Ultimately smoking 
should have first been identified as an area of interest for policymakers, and then those 
interventions for reducing the prevalence of smoking that policymakers thought were 
relevant to their populations needed to be addressed. In future, I would always 
investigate what the important issues for policymakers were before proceeding with any 
modelling work, as otherwise the work will not be relevant to the policy agenda. 
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17.2.3 POHEM 
I described the POHEM model, in terms of the adaptation of Weinstein's Coronary 
Heart Disease Policy Model for use in its CHD module. Then I described the building 
of the England & Wales version of POHEM in terms of its data requirements, running 
the model, and the output to be produced by the model, as well as discussing the 
justification for using the Framingham equation with the England & Wales population. 
I outlined my work comparing the performance and output of POHEM, a micro- 
simulation model, to Prevent, a cell-based macro-simulation model. In making such a 
comparison one must consider a number of differences aside from their different 
approaches to simulation. These differences were that of a cohort versus a population 
model, the ability to shift risk factor distributions, multivariate versus univariate risk 
factor distributions, using the Framingham equation as opposed to relative risks of 
mortality to generate events, and using current age group trends as opposed to using 
actual past and hypothetical future trends. 
Due to problems with the updated Prevent model I was forced to compare the Prevent 
methodology transferred to the POHEM framework with the version of POHEM using 
the Framingham equation. The outputs of each model's simulation of a ban on cigarette 
advertising were compared in terms of mortality. I demonstrated how in comparing such 
models it will not be possible to say that one model is better than another, but that one 
needs to be able to explain why different models may produce different results, and how 
the factors responsible for these differences affect a model's results. 
In addition, I describe my work using the Framingham methodology model to simulate 
high risk and population based interventions to demonstrate the model's ability to target 
individuals with a clustering of risk factors and to shift risk factor distributions, and to 
produce results in terms of morbidity. The simulation of the population based strategy 
produced the most health gain, thus reinforcing Rose's argument that preventive 
strategies which concentrate on a minority at high risk produce less health gain than 
strategies which intervene across the whole population (Rose 1992). 
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The main limitation of the work on POHEM was the need to use the modellers at 
Statistics Canada to input data and run the simulations, and so work progressed when it 
was possible for them to spend time on the model, rather than when the work was 
needed. This over-reliance on Statistics Canada was a result of the unexpectedly long 
time-scale for the conversion of POHEM from APL to MODGEN and the numerous 
updates of the model once this conversion had been completed. These meant that the 
features and mechanisms for setting up and running the model have only recently 
stabilised to an extent that allows others to use the model. Ideally I would have wanted a 
version of POHEM that I could have updated and run myself; unfortunately there was 
no way of predicting the time the redevelopment would take, but at least in the near 
future this will be possible. 
In the context of the Biomed II project the interventions modelled with POHEM were 
chosen to mirror one of the Prevent smoking interventions and to demonstrate some of 
the limitations of Prevent, for which they proved to be adequate. Although the changes 
in risk factor prevalence that were simulated were taken from the literature, and so 
could be assumed to be realistic and achievable; the interventions really should have 
been developed with policymakers to make them more policy relevant. This lack of 
consultation with policymakers was partly due to the limited time-scale of the project 
and to POHEM not being completed early on in the project. This meant that it was not 
possible to show the model to policymakers. In future a demonstration of the model to 
policymakers, similar to the one of Prevent to Birmingham Regional Health Authority 
described in Chapter 8, should be undertaken before embarking on the modelling 
process. 
Having concluded that the type of intervention one wishes to simulate will dictate the 
type of model one will use, I feel that little can be gained from the straight comparison 
of models, as attempted in Chapter 15, other than highlighting what each model can or 
cannot do. However, this work did demonstrate how one can try to reproduce the results 
of one model with another model such as POHEM, which has the flexibility to 
incorporate the other model's methodology, and so could be used for validating the 
mathematical processes within the model. 
279 
17.2.4 The Role of Policymakers in Model Development 
The most important aspect in the development of public health policy models is that 
policymakers should be consulted at the inception of the model, and should then 
participate at all the stages of development. They will have more insight than 
researchers as to what are the important policy issues that need to be addressed, and 
hence incorporated into a model. In addition, policymakers will then gain a better 
understanding of such models, and so will be in a better position to commission 
modelling work, understanding the assumptions and limitations underlying the models, 
and to understand the output of these models. My experiences with Prevent and Prevent 
Plus have shown that model developers may not be aware of the importance of certain 
issues because they have been working in isolation from policymakers. While 
policymakers may feel that the results from modelling exercises have no relevance to their 
policy agenda, as seen on the Biomed II project. These problems would be overcome to 
some extent by having closer links between modellers and policymakers during the 
development of models. 
17.2.5 Other Important Aspects of Model Development 
Another important aspect that should be considered in the development of health policy 
models is the need for information on morbidity, as well as mortality. My experiences 
with the HEA and Birmingham Regional Health Authority have shown that 
policymakers will view small changes in mortality as disappointing, even if one states 
that by excluding morbidity one is underestimating the true effect of the interventions. 
Producing results in terms of both mortality and morbidity would give policymakers a 
more complete view when comparing the effects of interventions. 
Good documentation is also important in developing a better understanding of a public 
health model, by policymakers and by other modellers who wish adapt the model to 
their own population. By documentation I mean literature explaining the workings and 
assumptions of the model, explaining the data requirements of the model and the 
assumptions needed to derive data if the required data are unavailable in the correct 
format, explaining how to use the model, and explaining the programme source code, 
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which itself should be commented. My experiences with Prevent and Prevent Plus have 
shown how the lack of documentation has meant that models cannot be easily adapted 
by other programmers, or used by other modellers. Further development will be almost 
impossible without considerable time and effort being spent on rediscovering a model' s 
inner workings. 
17.3 The Data Need of Models 
One of the perceived strengths of public health computer models it that they use 
available data on risk factor prevalence and population demographics, rather than 
requiring new data to be collected specifically for the model (Gunning-Schepers 1989). 
However, different countries have different available data sets, which means that a 
model developed in one country may not be readily transferable to another country. 
Mathematical modelling is very data-demanding, and the validity of a model will 
depend heavily on the data used by it. Modellers need to know which data are available 
for their populations, and be aware of the quality and applicability of these data. 
This idea of using available data for models relies on there being an absolute data set 
available for any country. Ideally one would want the collection of yearly data on risk 
factor prevalences, disease incidence and mortality by age, sex, social class, ethnic 
group and regional grouping. My modelling work has highlighted the need for the 
regular collection of such health data at a national level. These data are not only vital for 
use in public health modelling, but also for the monitoring of the Nation's health and for 
the evaluation of health interventions. 
Data on morbidity is difficult to obtain at the population level, and therefore developers 
need to be aware that the scarcity of such data, and that the lack of reproducible 
methods for deriving these data can make models untransferable, as with Prevent Plus. 
Consequently if model developers are to include morbidity they need to use 
methodologies that can be translated to other populations, and if data need to be 
derived, then the methods used and the assumptions involved need to be made explicit. 
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As well as the availability of data, the form in which the data are available is important. 
If one is to use public health models to address issues such as the effect of intervening 
on those individuals at high risk, who have a clustering of risk factors, or those of a 
certain ethnic or socio-economic group, one must be able to identify the number of such 
individuals in the population in the data and be able to produce risk factor prevalence 
data in a multivariate format. Consequently, survey data need to be available to 
modellers in an electronic form, and so allowing them to extract data for the models in 
any format needed. If they have to rely on just using published tables they will have less 
flexibility in setting up the categories within the model, and may not to able to address 
important policy issues such as the effect of ethnicity and socio-economic level. In 
addition, demographic data need to be in a format that allow modellers to identify 
individual groups, and ideally one would need to know the risks associated with risk 
factors in these different groups. 
Ultimately to produce accurate CHD public health models one would want annually 
collected data on the main risks factors for CHD by age and sex, as well as information 
relating to ethnicity and social class. This is being realised for England with the 1998 
Health Survey for England (TSO 2000), which collected information on alcohol 
consumption, cigarette smoking, eating habits, body mass, blood pressure and blood 
analyses, including total and HDL cholesterol. However, there are no plans to set up 
national register of CHD and stroke, as there are for cancer, or to collect data on 
incidence, prevalence and survival, which would further the development of morbidity 
modelling. In addition, the Hospital Episode Statistics (DoH 1995) system needs to be 
improved to allow the identification of patients during and across years so that first and 
recurrent episodes can be identified, although this may be difficult to achieve due to 
problems of patient confidentiality. 
I have stated that public health policy modelling is very data-demanding, and that the 
validity of a model will depend heavily on the data used by it. Due to this importance of 
data to modelling it is essential for modellers to understand the input data for models. 
The data input process will give modellers a partial insight to the quality of the data, 
since one has the opportunity to inspect, then organise and stratify the data into the form 
required by a model, although this would not be the case for those who use a model set 
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up by others. Although, ideally a modeller would want information on how the data 
were collected, the response rates, the measurements used, and how representative the 
data are of their population. Without a proper understanding of a model's input data the 
user will never be able to filly or intelligently interpret the results their models produce. 
17.4 The Policy Arena 
My work on modelling began during the period of The Health of The Nation (HMSO 
1992). At that time it was felt that public health models could be useful in assessing the 
relative health gain of alternative routes to the attainment of strategic goals, such as The 
Health of The Nation targets. However, over the course of my work in the UK there was 
a change of government, and hence a change in health policy. The new policy, outlined 
in Our Healthier Nation (DoH 1999), had different aims, areas of priority and health 
targets. Modellers need to aware that health policy can change over time, and that 
models need to have the flexibility and adaptability to incorporate such changes if the 
outputs of such models are to remain relevant to the health policy agenda. 
One of my most important conclusions from my work is that models should be only 
used by modellers who understand their workings and their input data, and should not 
be used by policymakers alone. Having spent the last five years working on two 
different models I think that it would be too difficult to translate the assumptions and 
the methodologies underlying the data input, the epidemiology, the simulation 
processes, the translation of intervention to the modelling environment and the data 
output processes in order for policymakers to use such models appropriately without 
input from modellers and in a short timeframe. 
However, although I feel policymakers should not run the models themselves; they must 
be an integral part of the modelling process. Policymakers need to be specifying the 
interventions to be simulated rather than relying on researchers to decide them, 
particularly since it can be difficult for researchers to keep abreast of the policy agenda. 
My work with Birmingham Regional Health Authority demonstrated how developing 
the interventions in partnership with policymakers meant that issues important to them 
were addressed. This in turn made the results of the modelling more policy relevant. In 
283 
addition, since the policy agenda will change over time, and is usually dictated by 
political priorities rather than research priorities (Walt 1994), policymakers need to be 
constantly involved, otherwise over time models will not be able to address the new 
policy agenda which will emerge. 
My work also highlighted how it is only by using a model to simulate real interventions, 
such as the HEA physical activity targets and the risk factor interventions in the 
Birmingham population which were envisioned by policymakers, that one can fully 
understand a model's capabilities and limitations, which may not be described fully in 
the model's documentation. I only became aware of the limitations of the models I used 
after trying to simulate interventions suggested by policymakers and other researchers. 
In the course of my work I realised that those using models should not be overly reliant 
on policymakers to advise on such areas as the effectiveness of interventions, as with 
the overly optimistic risk factor interventions modelled in the Birmingham population, 
since researchers may be the best suited for supplying such information. And so, as well 
as consulting policymakers, there is a need for a review of the literature concerning 
what changes would be achievable by the intended interventions to be simulated. 
17.5 The Potential Impact of Models on Policy 
Public health models use simplified theoretical frameworks which allow the simulation 
of complex dynamic processes. The construction of these frameworks is dependent on 
theoretical models that link biological, environmental, social and economic factors to 
health. I feel that it is necessary for modellers to understand these theoretical 
frameworks, and how the factors influencing health within these frameworks relate to 
the health policy agenda, in order to build public health models that can be used as tools 
for policymaking. 
The emphasis of health policy has shifted from the Old Public Health model, which was 
largely concerned with infectious, toxic and traumatic causes of death, to the New 
Public Health model, which is influenced by the belief that many of the underlying 
factors for these diseases could be amenable to prevention through social, 
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environmental or behavioural change (Lancet 1991). Inequalities, in utero and early life 
experiences, psychosocial factors, and social capital, are part of the current health policy 
agenda (Acheson 1998 and DoH 1999). These new areas have implications in terms of 
the need for aetiological research to explain their biological pathways, epidemiological 
research to explain their effects on risk, and how policy will address them. 
However, even when biological and epidemiological evidence is convincing there are 
barriers that prevent research evidence informing health policy through a simple, linear 
and logical process, as described by Walt (Walt 1994 and 1995). These barriers include 
political factors, where findings conflict with the policy impetus or its ideological basis, 
conceptual confusion, when research does not provide unambiguous results, differences 
in risks perception, when there is an imbalance between actual and perceived risk, 
imbalances in the timeframes, when research takes a long time to produce results and 
policy demands decisions within a short time scale, and inappropriate communication of 
research findings to policymakers. Modellers need to be aware that the results of their 
modelling work may not ultimately inform policy, even if the results are convincing, 
due to these barriers. 
17.6 The Implications for Future Research 
The time and effort required to develop a new public health model, or to even convert 
an existing model to another population can be considerable. Even for an existing model 
the user must gain an adequate understanding of its methodologies, underlying 
assumptions, data needs and limitations before being able to run the model, and then to 
fully interpret its output. These time scales may be problematic for policymakers, not 
only because the policy agenda could change markedly in the time it takes to develop or 
convert a model, but also because such work requires a long term commitment from 
funders. Consequently those commissioning modelling work need to be aware of these 
issues. 
I have argued that it is necessary for model developers to understand theoretical 
frameworks of health, and how their various determinants of health relate to the health 
policy agenda, in order to build public health models that can be used as a tool for 
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policymaking. In addition, I have stated that as new issues appear on the policy agenda, 
as inequalities, early life course and social capital have; models require the flexibility 
and the capacity to include these factors into their methodology. However, modellers 
must be aware that there may be a long time before issues which are already on the 
research agenda appear on the policy agenda. For example, socio-economic factors had 
been highlighted in the Black Report (DHHS 1980) in 1980, but have only recently 
been addressed in Our Healthier Nation (DoH 1999), this process was dependent on 
political factors rather than the weight of knowledge, as described in Chapter 2. 
Unfortunately, highly technical models, such as POHEM, which have the flexibility and 
capacity to evolve with health policy, require investment in time and effort from funders 
and researchers. The Biomed project and Statistics Canada's experiences have 
demonstrated how long time periods are required to develop models. But model 
developers must also be aware that models which are computationally intensive may be 
difficult to use as a policy tool. For example, some simulations can take days to run, as 
with the case of POHEM when simulating four million individuals. Eventually the 
computational burden of modelling will become less of a problem as the power of 
affordable and readily available computers increases. However, at present this may be 
seen as a barrier to using particular models as policy tools, and at times it may be more 
appropriate to use simpler models, such as the smoking cessation model of Lightwood 
et al (Lightwood 1997), to address policy issues within a shorter time frame. 
To be able to bridge the gap between epidemiological research and health policy, public 
health models need to be used by individuals who understand the modelling, 
epidemiological and policy environments. Since public health models rely heavily on 
health data, epidemiological measurement of risk, estimations of the effectiveness of 
interventions and theoretical frameworks of health, and then the translation of these into 
a computing environment, I feel that someone with a strong grounding in epidemiology 
and an understanding of computing would be best suited for the role of developing 
models. In addition they must be able to liase with modellers and policymakers, and be 
able to translate issues from each of these arenas to the other, and so will require good 
negotiating and presentation skills. 
However, they need to ensure that the model can 
address the current policy agenda, since ultimately the output of modelling will be 
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ignored if it is not relevant to the policy agenda. The most plausible strategy for model 
development, in my opinion, would be to have a team of individuals, whose skills cover 
the areas of expertise required, working together, as seen at Statistics Canada. Although 
each individual within the team needs to be able to effectively communicate their ideas 
to the others in the team, as well as to policymakers. 
Having witnessed the development of two models in two settings, with Prevent 
developed in an academic environment and POHEM developed in a governmental 
environment, I feel that future public health models should be developed at a 
governmental level, for instance by the Department of Health in the UK. The experience 
of Statistics Canada has show that when modelling is perceived as a key area of policy 
development there will be a commitment to fund the building of a team with the 
required expertise to develop models, and over a long time-scale, as well as leading to 
the development of an institutional methodology for modelling. By this I mean that the 
institution holds the knowledge of the methodology used rather than individuals, and so 
when individuals leave the institution knowledge is not lost, and new individuals joining 
the institution can gain the required knowledge for model development from 
documentation and from having a group of individuals they can consult. This 
methodology also benefits those outside the institution who wish to use that institution's 
models. This is in contrast to the development of Prevent at the Universities of 
Amsterdam and Rotterdam, where short term funding meant that the model has not 
continually been developed over time, and where only a few individuals can develop the 
model, and so without these key individuals no future development of Prevent can take 
place. 
In addition, I feel that the developers of POHEM at Statistics Canada have closer links 
to policymakers than the developers of Prevent, and so the terms of their modelling 
work is always dictated by policymakers, whereas much of the work with Prevent at 
University of Amsterdam has been divorced from policy, reflected in its inability to 
simulate the targeting of high risk individuals, or shifting population risk factor 
distributions, which are key policy issues. I still think the input of researchers from 
academia is vital for the development of public health models; those developing models 
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need to have closer links with policymakers to ensure that these models can always 
address the current policy agenda, which will be evolving over time. 
There is definitely a role for large complex multi-purpose public health models, such as 
Prevent and POHEM, that can be used at as tools for policy development, but these 
should be developed at a governmental level and should be able to be used to answer a 
variety of policy questions. The time and effort required to develop such models are not 
warranted if they can only be used to answer questions on a single issue relevant at one 
particular time. In such instances the use of simpler models that are quicker to develop 
and adapt should be used, such as the smoking cessation model (Lightwood 1997) 
mentioned earlier, or using the Framingham equation for estimating the cost 
effectiveness of reducing coronary risk factors in primary care (Field 1995). 
17.7 Conclusions 
My work has shown that public health models can successfully be used as policy tools, 
and their use can be regarded as a means for bridging the gap between epidemiological 
research and health policy. I have shown how these models can be used: 
" for estimating the future development of the health of populations, 
" to evaluate alternative routes to achieving health goals, 
" to demonstrate the effect of targeting health interventions at different sections of a 
population, 
" to investigate the relationship between risk factors and their linked diseases, which 
may be under debate in the research arena, 
" for demonstrating the possible effect of health interventions to health practitioners. 
288 
At the same time models allow one to develop a deeper insight into the theoretical 
frameworks of health, as well as demonstrating the need for the collection of routine 
health data. 
In terms of the requirements for public health models intended for use as policy tools, I 
think that such models need to fulfil the following criteria: 
1. Models should be based on readily available data, or in the absence of such data 
should use a documented method for deriving these data, since otherwise it will not 
be possible to transfer the model to other populations. 
2. Models should have a multi-factorial risk factor and disease environment, where 
each risk factor can influence several diseases, and each disease can be influenced 
by several risk factors, otherwise models will underestimate the effect of risk factor 
interventions. 
3. Models should have the ability to produce output in terms of both morbidity and 
mortality, since models that exclude morbidity will underestimate the true effect of 
interventions. 
4. Models should include a demographic basis by which population changes within the 
simulation period can be considered, since the effect of a risk factor intervention in a 
population will not only be dependent on the prevalence of the risk factor, but also 
on the prevalence by age group, and that population's age structure, with its 
associated disease patterns. 
5. Models need to be implemented in a flexible and adaptable fashion that allows the 
inclusion of new risk factors and interventions as they appear on the research and 
policy agendas, otherwise models will become obsolete if they cannot address 
changes in the policy agenda over time. 
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6. Models should have the ability to shift risk factor distributions and to target high 
risk individuals, since these are key strategies in public health that need to be 
addressed if the model is to be used for informing policy decisions. 
7. Models require a user guide which documents the programme sources code, the 
methodologies used, the underlying assumptions, the data needs and data derivation, 
the limitations, the computing requirements and the running of the model. Otherwise 
it will be difficult, if not impossible, for other modellers to adapt, use, or understand 
a model. 
The validation of such public health models may always be difficult due to the lack of 
available data to compare their output with, and there will probably never be a "gold 
standard" for such models. The "face-validity" of the parameters used by the model can 
be checked to a certain extent, and their methodologies can be verified using other 
models. This is not an ideal situation, but I feel that one is justified in using unvalidated 
models as long as one draws attention to the fact that the model is unverified and can 
only yield results of a hypothetical nature. Such models are probably best used in 
comparing the effect of various interventions, based on the same data and assumptions, 
rather than for estimating the effect of individual interventions viewed in isolation. 
However, if data are available, modellers should always attempt to validate their models 
by using historical data to simulate current disease patterns (Kotva 1992). 
Modellers must understand that modelling will not dictate policy, but will only quantify 
one step in the policymaking process. My work has shown that barriers other than the 
lack of evidence may hamper policymaking, and policymakers may only pick out the 
bits of the research that support the areas that they already see as important, rather than 
highlighting new areas for the policy. At the same time it is important for modellers not 
to be divorced from policy. In order to use models as tools for policy, policymakers 
must be involved in the processes of developing the models and deciding on the 
interventions to be modelled. 
290 
To summarise, the key conclusions from my work are that: 
" Public health models can be used as policy tools, although ultimately they may only 
inform policy, and not drive it, due to other factors which can influence the policy 
agenda. This was demonstrated by the HEA's dropping of the modelled physical 
activity targets due to the political sensitivity of the unmet Health of the Nation 
targets at the time, and by Birmingham Region Health Authority's use of only the 
results from the smoking simulations since smoking was already on their policy 
agenda. 
" Public health models need to be developed and used in conjunction with 
policymakers, although models need to be developed, adapted and run by 
researchers who fully understand their workings. This was demonstrated by 
Prevent's inability to simulate high risk and population risk factor intervention 
strategies due to its being developed in isolation from policymakers. 
Public health models are complex instruments that require a long term commitment 
in terms of the funding required to build and retain the modelling expertise of those 
researchers involved in the development of such models. This is shown by the 
differences in the development of Prevent and POHEM, with Prevent's lack of 
development resulting from being dependent on one individual whose research 
priorities were no longer to work on the model, while POHEM uses methodologies 
that are consistent across all Statistics Canada's modelling work, and which has 
been committed to over a long time scale, as well as Statistics Canada investing in 
the training of a large group of individuals who are able to develop the model. 
Public health models need to be developed by multidisciplinary teams, whose 
expertise cover the areas of computing, epidemiology and health policy, since an 
understanding of health data, epidemiological measurement of risk, estimations of 
the effectiveness of interventions and theoretical frameworks of health, and the 
translation of these into a computing environment is required. In addition, the 
members of the team need to be able to communicate their ideas effectively to each 
other and to policymakers. 
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" Public health models may never be validated in terms of a "gold standard", but they 
can be used as policy tools as long as one is aware that they are unverified and that 
they yield results of a hypothetical nature. Although ultimately modellers should 
always attempt to validate their models by using historical data to simulate current 
disease patterns, if such data are available. 
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Appendix A- Prevent Input Files 
" DATIINST. DAT - Prevent Log 
Population Data: 
" AMORT. DAT - general mortality per 100,000,1 year age groups. 
" BIRTH. DAT - birth projections from the base year to base year + 50, absolute 
numbers. 
" EXPECTAT. DAT - expectation of life in the base year, 1 year age groups. 
" POP. DAT - population structure in the base year in 1 year age groups. 
Risk Factor Data: 
" RFIBEMI. DAT - percentage outflow as a percentage of the exposed to cigarette 
smoking. 
" RFIBEPL. DAT - percentage inflow as a percentage of the exposed to cigarette 
smoking. 
" RF 1 EXP. DAT - exposure to the risk factor cigarette smoking, England and Wales 
1991,6 age groups, 3 exposure categories: 0-9,10-19,20 or more cigarettes. 
" RFIRRI. DAT - relative risks of lung cancer, risk factor smoking, standard Dutch 
data set, 6 age groups, 3 exposure categories. 
" RF1RR2. DAT - relative risks of COLD, risk factor smoking, standard Dutch data 
set, 6 age groups, 3 exposure categories. 
" RF 1 RR3. DAT - relative risks of CHD, risk factor smoking, standard Dutch data set, 
6 age groups, 3 exposure categories. 
" RF2COMI. DAT - calculation options: cohort, percentage outflow as a percentage of 
the exposed to hypertension. 
" RF2COPL. DAT - calculation options: cohort, percentage inflow as a percentage of 
the exposed to hypertension. 
" RF2LFMI. DAT - calculation options: age groups, percentage outflow as a 
percentage of the exposed to hypertension. 
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" RF2LFPL. DAT - calculation options: age groups, percentage inflow as a percentage 
of the exposed to hypertension. 
" RF2EXP. DAT - exposure to the risk factor hypertension, England and Wales 1991, 
6 age groups, 2 exposure categories: hypertension based on diastolic blood pressure 
- mild (90-94 mmHg), severe (95 mmHg or more). 
" RF2RRI. DAT - relative risks of CHD, risk factor hypertension, standard Dutch data 
set, 6 age groups, 2 exposure categories. 
" RF2RR2. DAT - relative risks of CVA, risk factor hypertension, standard Dutch data 
set, 6 age groups, 2 exposure categories. 
" RF3BEMI. DAT - outflow trends for exposure to cholesterol. 
" RF3BEPL. DAT - inflow trends for exposure to cholesterol. 
" RF3EXP. DAT - exposure to the risk factor cholesterol, England and Wales 1991,6 
age groups, 2 exposure categories: hypercholesterolemia - mild (6.6 - less than 7.8 
mmol/1), severe ( 7.8 mmol/1 or more). 
" RF3RRI. DAT - relative risks of CHD, risk factor cholesterol, standard Dutch data 
set, 6 age groups, 2 exposure categories. 
" RF4BEMI. DAT - outflow trends for exposure to alcohol drinking. 
" RF4BEPL. DAT - inflow trends for alcohol drinking. 
" RF4EXP. DAT - exposure to the risk factor alcohol drinking, England and Wales 
1991,6 age groups, 2 exposure categories: low (0 - 10 units), high (22 units or 
more). 
" RF4RRI. DAT - relative risks of CHD, risk factor alcohol drinking, standard Dutch 
data set, 6 age groups, 2 exposure categories. 
" RF4RR2. DAT - relative risks of cirrhosis, risk factor alcohol drinking, standard 
Dutch data set, 6 age groups, 2 exposure categories. 
" RF4RR3. DAT - relative risks of accidental falls, risk factor alcohol drinking, 
standard Dutch data set, 6 age groups, 2 exposure categories. 
" RF4RR4. DAT - relative risks of traffic accidents, risk factor alcohol drinking, 
standard Dutch data set, 6 age groups, 2 exposure categories. 
" RF5BEMI. DAT - outflow trends for exposure to obesity. 
RF5BEPL. DAT - inflow trends for obesity. 
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" RF5EXP. DAT - exposure to the risk factor obesity, England and Wales 1991,6 age 
groups, 2 exposure categories: mild (BMI over 25 - 30), severe (BMI over 30). 
" RF5RRI. DAT - relative risks of breast cancer, risk factor obesity, standard Dutch 
data set. 
Disease Mortality Data: 
" ZMORSI. DAT - mortality/100,000 from lung cancer, 5 year age groups, England 
and Wales 1991. 
" ZMORS2. DAT - mortality/100,000 from COLD, 5 year age groups, England and 
Wales 1991. 
" ZMORS3. DAT - mortality/100,000 from IHD, 5 year age groups, England and 
Wales 1991. 
" ZMORS4. DAT - mortality/100,000 from CVA, 5 year age groups, England and 
Wales 1991. 
" ZMORS5. DAT - mortality/100,000 from cirrhosis, 5 year age groups, England and 
Wales 1991. 
" ZMORS6. DAT - mortality/ 100,000 from accidental falls, 5 year age groups, 
England and Wales 1991. 
" ZMORS7. DAT - mortality/100,000 from traffic accidents, 5 year age groups, 
England and Wales 1991. 
ZMORS8. DAT - mortality/100,000 from breast cancer, 5 year age groups, England 
and Wales 1991. 
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Appendix B- The Prevent Log File: DAT1 INST. DAT 
1989 
58 
cig. smoking 
- base year of simulation 
-5 risk factors, 8 diseases/outcomes 
hypertension 
cholesterol - risk factors 
alcohol 
obesity 
lung cancer 
COLD 
IHD 
CVA 
cirrhosis 
accidental fall 
traffic accidents 
breast cancer 
3- number o 
1 10 4 
2 10 10 
350 
20-24 
25-34 
35-49 
50-59 
60+ 
19 
24 
34 
49 
59 
95 
- causes of death (1: lung cancer, 2: COLD, 3: IHD, etc) 
causes o death linked to the I" risk. factor: cigarette smokin 
- cause of death number, LAG and LA T, 
e. g. 1104 signifies lung cancer, LAG =10 years, LAT =4 years. 
- number of age groupings 
- age grouping labels 
- end years of age groupings 
3- number of risk factor exposure categories 
1-12 
13-22 - risk factor exposure category labels (number of cigarettes smoked per day) 
23+ 
2 
320 
410 
5 
35-44 
45-49 
50-54 
55-59 
60+ 
34 
44 
49 
- the above sections repeated for the next risk factor: hypertension 
324 
54 
59 
95 
2 
mild 
severe 
1 
330 
6 
35-39 
40-44 
45-49 
50-54 
55-59 
60+ 
34 
39 
44 
49 
54 
59 
95 
2 
mild 
severe 
4 
310 
514 
610 
710 
2 
20-39 
40+ 
19 
39 
95 
2 
excessive 
abstainers 
1 
811 
2 
40-49 
50+ 
39 
49 
95 
1 
QI>30 
- cholesterol settings 
- alcohol settings 
- obesity settings 
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Appendix C- Moving on - International perspectives on promoting 
physical activity (Health Education Authority 1994) 
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Appendix D- 
Table D. 1 - Actua 
Chapter 7: Tables of the Figures : 
Modelling the Effects of Increased Physical Activity 
Using the Prevent Model 
Stra I Strat 2 
Limit Lower Upper Lower Upper 
Males 5613 9537 1866 4167 
Females 1511 2556 501 1129 
I years of life gained for men and for women aced under 9 5 achieving each 
strategy by 2019 
strata I strata 2 
Age Grou 15-44 44-64 15-44 44-64 
Males 968 20437 401 8238 
Females 155 5675 64 2265 
Table D. 2 - Actual years of life gained for men and for women aged under 95 achieving each 
strategy by 2019, targeting by age group 
Relative Risks Meta Analysis Mod ified 
Mode Age Group Cohort 
Age Groups 15-44 44-64 15-44 44-64 15-44 44-64 
Strategy 1 1123 26112 1123 23283 5573 29484 
Strategy 2 465 10503 465 9104 2130 14321 
Table D. 3 - Actual years of life gained tor men and for women aged under 95 achieving each 
strategy by 2019, targeting by age group, using modified relative risk and using the cohort 
option 
339 
Appendix E- Modelling the effects of increased physical activity on coronary 
heart disease in England and Wales (Naidoo 1997). 
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Jý-d4Apihwpkv .. / Cw. wrww H.. rA 1997p1: 144-1 so 
Modelling the' effects of increased physical 
activity on coronary heart disease in England 
and Wales 
Bhnh Naidoo, Masptet TboroSood, Klim 1NcPberron, Louise 1 C3unninQ-Schepen 
ro: 
Abstract 
Ooboalfee - To lavssd ate the use otcom- 
puter modsb as took tar Policy mashers in 
evahwdsg physlcal nativity intsrvsndom 
absurd at reducing dads from coronary 
heart Amme (CHD). 
Design - The CCU-band computer model 
Prevent, adapted to simulate rich lentos 
iotsrvadoss ftr as FngMch and Welsh 
popalatba, was used to dmulate the seat 
of two stratsgies hr Increasing pbyslcd 
activity levels in respect of CHD mortality 
ov r 25 years. The Mt wstew involved 
a 25% Increase is the proportion of 15-64 
year rids who were modwat* aodve, 
while the second eaategy Involved a da- 
liar lncrsass In the proportion who were 
vigorsudy active. The Rect. of bcudop 
on narrower age ranges and on people at 
different Initial activity levels were she 
explored. 
Mein swwbe - The dmutadosu showed a 
email reduction in rho CHD death rates - 
lees than 0.15% and 0.06% for men and 
won respectvely. The strategles would 
poe[pons or to 12100 deaths over 25 years, 
comparable to the effect eta 2% reduction 
IS amskfag prevalence. The strategies 
eaeaeed as If they would be more effective if they concentrated an mss rat er than 
women, on thus. over 45 years of age as 
apposed to all or younger age poops, and 
on the last active mashers of the papu- 
hulen rather than than already taldag 
some exerelse. 
Conchm ow - The are of c mprter mod- 
eting for simulating physical activity 
wwgin has shown that concentrating 
these interventions on older sedentary 
men will produce the greatest hakth gain, 
but efforts to encourage smoking cessation 
may be more effective in terms of years of 
oft saved. 
(1 Bpibwiol CwasrNiy Ha4M 1997; 51: 144-130) 
It is often dilbcult to evaluate the effectiveness 
of health promotion interventions by ex- 
perimental or observational methods since the 
time scales necessary are too long. An interim 
solution is to use computer models which will 
simulate the effects of different Interventions 
within a population, using available data on 
risk factor prevalence and the attributable risks 
of disease mortality, and projecting the results 
over several generations. Such models are po- 
tentlally useful in assessing and comparing the 
relative health gain of alternative intervention 
strategies. This Is a new methodology, and 
this work should be seen as an early step in 
attempting to explore the application of these 
tedwitIm. 
Lack of physical activity has been shown to 
be a strong independent risk factor' for death 
from coronary hear disease (CHD). Ina mea- 
anslysis, Berlin and Coldits' calculated a 1.9 
fold increased relative risk for CHD mortality 
associated with a sedentary lifestyle compared 
with a vigorously active lifestyle. Population 
surveys have shown that only a small percentage 
of the British population take enough exercise 
to protect against CHD. 3 Inactivity, then, may 
be an important cause of CHD morality. The 
promotion of physical activity is currently the 
focus of discussion. ' The number of "pre- 
scription for exercise" schema, in which gen- 
eral practice patients are given free or reduced 
entrance to exercise ficilide% Is growing rap- 
idly. 
The Govenment's white paper The Health 
pf tb Narier' in 1992 introduced targets for 
the reduction in the death rates for CHD. It is 
not clear how the promotion of physical activity 
could most effectively contribute to these tar- 
gets. To contribute to the debate we have 
modelled the effects of increasing activity in the 
population, looking at the effects of targeting 
differing exercise levels, age and gender groups. 
This work was undertaken as part of the 
health gain project. funded jointly by the 
Health Education Authority and North 
Thames Regional Health Authority, which aims 
to provide policy makers with predictions of 
the effects of changing resource priorities, sim- 
ulating the effect of shifts in resource allocation 
using computer modelling. 
Medwds 
CUUINT ACTMTY LSVar. a 
Table I has been adapted from the Allied 
Dunbar national fitness survey (ADNFS), and 
shows the proportion of men and women in 
England and Wales by age group who are active 
at different levels. Activity levels were based 
on 20 minute periods of physical activity in a 
four week period, and defined as: 
Vqprotu - 12 or more occasions of activities at 7.5 kcal/minute and above, such as squash, 
running, football, swimming, tennis, aerobics, 
and cycling (if out of breath or sweaty). 
Moderot, - 12 or more occasions of activities between 5 and 7.5 kcal/minute, such as foot- 
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factor. Finally the results of the calculations 
are applied to two populations - one with only 
the autonomous developments and the other r.. t 16-24 23-34 33-0 43-34 33.44 as+ with both the autonomous developments and 
Mew 
fd. 9 ý 
37.7 
27.8 
SedeaueY 5.6 
ý 9.7 
Madam 37.1 
Ii& M. i 
gedmry If. 7 
20.4 13.3 3.4 4.1 1.4 
41.6 40.3 36.9 39.3 19.6 
30.1 36.5 36.1 36.3 35.9 
7.9 9.9 14.6 29.6 43.1 
7.6 4.1 2.9 1.6 02 
46.5 46.0 37.3 31.9 19.5 
39.4 40.0 46.3 45.3 40.3 
6.5 9.9 13.5 21.1 40.0 
ball, swimmin& tennis, aerobics and cycling (if 
am out of breath or sweaty), table tennis, golf, 
social dancing and eeacises (if out of breath 
or sweaty). 
Light - one to II occasions of activities at 
5 kallminute and above, such as able tennis, 
golf, social daacieg and wicisa (if not out of 
breath or sweaty), bowls, Sshsta, dam and 
snooker. 
Sadeaay - no occasions of activities above 
5 kcal minntra. 
Tsta fTMATaßtaa 
To evaluate the potential effect of different 
strategies for physical activity promotion we 
explored two options representing inter- 
ventiaoos targeted at sedentary, lightly active, 
and moderately active people. These strategies 
were as follows: 
Sc, wgy !- to encourage those who are either 
sedentary or lightly active to undertake mod- 
erate activity, thus increasing by 25% the pro- 
portion of the population aged between 15-44 
which is moderately active. 
Swwrcy 2- to encourage those who sea either 
sedentary, tightly active or moderately active to 
undertake vigorous activitY, thus b acing by 
25% the proportion of the population aged 
between 15 and 64 which is vigorously active. 
We have investigated separately the effect of 
these strategies in men and in women, and in 
different age groups. 
"rtmvstir" 
plswnr' was developed by one of us (1. j Gun- 
niWSchepas) in 1988. It is a cell-based sim- 
ulation model that can estimate the health 
benefits for a population of changes in risk 
factor prevalence due to trends and inter- 
ventions over a maximum period of 50 yeas, 
both in terms of proportional changed in disease 
specific incidence and in terms of ablohne 
changes in such parameters as disease specific 
and total mortality. 
After the user has specified the risk factor 
to be modified, the model first calculates the 
autonomous development of risk factor pre- 
valences due to existing trends. Then the user 
specifies change in risk factor ptevalaxxs after 
the intervention and the model calculates the 
development due to the intervention and these 
trends. Next the model calculates the auto- 
nomous development of all other risk factors 
that share diseases with the intervention risk 
tee Intervention effects. 
The differences between the two populations 
are attributed to the intervention, with the 
output given in terms of total and disease spe- 
cific mortality (details of the calculations are 
presented in Appendix 1). It was originally 
produced to simulate a Dutch population with 
but year 1985, but we have adapted it to 
simulate an English and Welsh population with 
base year 1991. 
We have used Pºrwnt to simulate proposed 
changes for the English and Welsh population, 
modeling the hypotheses of a graded effect for 
the health benefits of physical activity, using 
high risk and population strategies to achieve 
the set strategies. 
ADAPTING PURVMT 
Prevfmt does not normally include lack of phys- 
ial activity as a risk factor, therefore the fol- 
lowing data were input for the England and 
Wales population: 
" Physical activity level categories: sedentary, 
light, moderate, and vigorous, 
" Prevalence of physical activity by sex, age 
groups and activity level, 
" Relative risk of CHD death due to lack of 
physical activity by sex, age groups, and 
activity level, 
" Two time intervals, the first, LAT, giving the 
time between taking up physical activity and 
a person's relative risk begins to decrease, 
and the second, LAG, giving the time be- 
tween a person's relative risk beginning to 
decrease and when it reaches its lowest value 
for the new level of physical activity, 
" The teamant relative risk, which is the lowest 
possible relative risk that an et-exposed per- 
son has after LAT+LAG time has elapsed 
on taking up a new level of physical activity. 
LA OP PHYSICAL ACTIVITY AND CHD DEATH 
RISK 
'The way in which lack of physical activity 
affects CHD mortality Is not frilly understood. 
Although it has been shown to be an in- 
dependent risk factor, the actual mechanism 
by which risk of CHD death decreases with 
increased levels of physical activity is not clear. 
We used the hypothesis that there is an inverse 
and graded relationship between CHD risk and 
physical activity, as proposed by Shaper. ' 
ULATIYa RISR3 
The relative risks for CHD mortality due to 
lack of physical activity were taken from a 
comprehensive mets-analysis. ' No relative risk for light activity was produced in the meta- 
Analysis, so we derived a hypothetical relative 
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As our main interest was to investigate how 
changing a population's physical activity level. 
e: p,;  ro tr RR might affect its CHD mortality, we chose to 
vpnow t. o assume that physical activity decreased the risk Atoaente 1.4 of CHD death only and did not affect other 
sedgy i: y diseases. In addition, we assumed that physical 
S From intapoivfon. 
risk by interpolation. The relative risks are 
shown in table 2. 
'These relative risks are unfortunately not 
known separately by age or sex, and moreover 
the definition of exercise levels is not completely 
dear with respect to duration and calorific 
output. We have assumed that these levels are 
similar to those used in the ADNFS data. 
The problems of "fitting" available pre- 
valence and relative risk data to the English 
and Welsh population, and then tailoring these 
for input into Flavenr were considerable and 
entailed making compromises. Arum was not 
designed to calculate the effect of members of 
one risk factor exposure group moving into a 
number of different exposure groups; it was designed solely for modelling movement from 
an exposed to a non-exposed category. The 
remnant risks in the model had to be adapted 
to permit movement between different levels 
of exposure. An additional problem was that 
only age group divisions beginning with mul- 
tiples of five are permitted, so the youngest age for intervention had to be 15 rather than 16 
years. 
MODEL ASSUMPTIONS 
In setting up li v. nt we have to set certain 
calculation options and variables, and these 
translate into a number of assumptions about 
snow 1 30000 2 
yiv 1, aw uep. Law vyp. 
1994 1)e2.1 1382. s 1387.1 1782.9 
2019 1381.3 1390.5 1381.1 1381.6 
decrease immediately, and that one year after 19% 915 915 911 915 
taking up a new level of exercise a persons 2019 914.7 9141 914.9 911.9 
the way in which an intervention would affect 
physical activity in the population and the pro- 
cess by which physical activity influences CHD 
mortality. 
We assumed that the intervention started in 
1994 and continued for the next 11 yeah, with 
the prevalencea of the strategies being achieved 
in 2005, a target year for the Health of the 
Nation. ' The population was simulated for a 
further 14 years after the end of the inter- 
vention. 
The mechanism by which physical activity 
affects CHD mortality is essentially described 
by the time periods over which a person's risk 
decreases and the risk it declines to. Within 
our model we have assumed that on taking 
up exercise a person's relative risk begins to 
relative risk decreases to that of people ex- 
ercising at that level. We have performed some 
sensitivity analysis by increasing these time 
periods when running the model. 
In terms of the remnant risk we have assumed 
that a person's previously less active lifestyle 
will not continue to have a detrimental effect 
on their health, and that they will take on the 
relative risk attributed to their current physical 
activity level. 
acuvny era not arrest the other risk factors 
that Aswnr includes, such as hypertension, 
cholesterol, and obesity. 
We assumed that the proposed interventions 
would change an age group's behaviour for the 
entire simulation period (25 years), so that as 
cohorts age during the simulation period and 
move from one age group to the next, some 
people will take up a new physical activity level 
which may be at a lower or higher level than 
the level they achieved in their previous age 
group. 
We have also assumed that any changes in 
the prevalence of physical activity within the 
population would be solely as a result of the 
interventions, and that there would be no back- 
ground risk factor trends in the population - 
that is, without an intervention there would be 
no change over time in rates of physical activity. 
Care needs to be taken in choosing either 
the age group or the cohort option for the 
calculations in P*ve t, since the two options 
can give markedly different results. The age 
group option should be used when considering 
a risk factor that is predominately age de- 
pendent, such as hypertension. An intervention 
that causes a behavioural change, such as ci- 
garette smoking cessation, is more likely to 
affect a birth cohort which retains the change 
as it ages. We chose to model physical activity 
as having an age group effect, although we also 
tested the model with the cohort option to see 
how this affected the results. 
Two scenarios were used to model each strat- 
egy to provide lower and upper limits of es- 
timated outcomes. For strategy 1, which aimed 
to increase the percentage of the population 
with a moderate level of physical activity, we 
simulated two scenarios that targeted either the 
sedentary group, or those already undertaking 
light activity. Strategy 2, which aimed to in- 
crease the number of people undertaking 
7»k3 Coonary A. an dü. au Monolid pr 100 00o for 
Men and for woM. n Dyed weder 93 ackwvint each 
fA1 tw 
MOL. 
Vbnm: 
Tab k4 Modified rdadw risk of coronary Juan dwaie 
mortdiry in 'lotion to exoni o in. and age gory 
Bxemix 4arü 
Ap ~ 
1i44 13-31 l3-61 65+ 
V1Loron 1.0 1.0 1.0 1.0 Modena 1.4 1.3 1.3 1.3 Light 1.7 1.6 1.3 1,4 Sedsn 1.9 1.8 1.7 1.6 
343 
Modelling the effects of inneased physical activity on CHD 
Table S Example calculation of potential impact factor (PIF) for the risk /actor, lack of 
physical activity, in men aged 55-64 under strategy 1, using the lower limit of the 
intervention 
Euniv 
kw 
Oryinal lmnvtntion Rlatiw 
Orrvak: nre (0) ynrvalinu (1) risk 
Vigorous 0.041 0.041 1 PIDR(0) 1.6411 
Moderau 0.298 0.391 1.4 PIDR(1) 1.6132 
light 0.365 0.272 1.7 
Sedentary 0.296 0.296 1.9 
Sum II 
PIDR=Proportion incident dauity ntio. 
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Figure 1 Actual yeah of life gained for men and for women aged under 9S years and 
achieving each intervention strategy by the year 2019. 
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Figure 2 Actual years of life gained for men and women aged under 95 years and 
achieving each intervention strategy by the year 2019, targeting by age groups. 
PIP 0.017 
vigorous activity, was simulated using two scen- 
arios which assumed that sedentary people 
would increase their activity to this level or that 
those already taking moderate exercise would 
increase their level. 
INTERVENTION OUTPUTS 
The outputs from the simulated interventions 
have been produced in terms of: 
" Percentage reduction in CHD mortality rate 
(compared with 1994), 
" Actual years of life gained. 
Strategy 
1 
Strategy 
2 
Strategy 
2 
= Men 16-44 
D Men 44-84 
= Women 15-44 
Cl Women 44-64 
Strategy 
1 
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Results 
There would he a very small reduction in the 
death rate from CHD associated with achieve- 
ment of each of the two strategies in men and 
women under 95 years of age, see table 3. This 
represents a fall of between 0.03% and 0.1Sgt, 
in men and between 0.01% and 006% in 
women, across all age groups combined. 
While the proportional reduction in the death 
rate appears disappointing, the actual years of 
life gained by the year 2019 are not in- 
substantial (fig 1). The time trajectory is 
roughly linear from 1994, showing that the 
interventions are delaying deaths, although not 
enough to affect the mortality rate greatly. 
There are similar trends for both men and 
women, although the number of deaths post- 
poned for men is about four times greater than 
for women. For both the upper and lower 
estimates strategy I is the most effective in 
achieving life years gained. (Appendix 2, tables 
6,7, and 8 gives the data for the figures). 
To examine the differing effect of targeting 
exercise interventions at various age groups, we 
modelled the life years gained for each of the 
two strategies making the assumptions that the 
strategy would concentrate on the older age 
groups (45-64 years of age) or on the younger 
age groups (15-44 years of age). Figure 2 shows 
this comparison in men and women in terms of 
actual years of life gained, using the mean of 
the two scenarios simulated. For both men and 
women, the greatest gain can he achieved by 
concentrating on the older group. Again strategy 
I was the most effective and, as before, there is 
less gain achievable in women than in men. 
SHNSITrvrrv ANALYSIS 
It is possible that the increased relative risk as- 
sociated with inactivity is attenuated in older 
people. If this is true then the model will over- 
estimate the effect of interventions in the elderly. 
We therefore carried out some sensitivity ana- 
lysis for the simulations targeting those people 
aged 45-64 years of age, in which they were 
given lower relative risks for each level of phys- 
ical activity (See table 4). This change made 
only a small difference to the number of deaths 
postponed, and targeting the older age groups 
still produced the greatest benefit (figs 3 and 
4). Modifying the remnant relative risks did not 
affect the results for those aged 15--44 years old. 
Age group interventions were also simulated, 
using the cohort option as well as the modified 
relative risks, to check if this improved the 
results for those aged 15--44 years old. Under 
this option the intervention would be re- 
sponsible for changing people's behaviour for 
the entire simulation period, in that those 
people that take up a new physical activity level 
will continue with this level of activity for 25 
years and not revert to a lower level of physical 
activity. Figures 3 and 4 show that this in- 
creased the actual years of life gained when 
targeting the younger age group, but con- 
centrating on people 45-64 years old still 
achieved the most health gain. 
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Discussion 
We have used the F rw u cell-based computer 
simulation model to explore the effect of 
different strategies which might be undertaken 
to increase physical activity in the population. 
This is a new methodology, and much of the 
work is still of an exploratory nature. None of 
the strategies modelled appeared to have much 
effect on predicted CHD mortality, although 
the most effective strategy seemed to be to 
encourage sedentary people to undertake mod- 
erate activity. If the proportion of the popu- 
lation undertaking moderate activity were 
increased by 25% as a result of this strategy, 
then approximately 12 100 years of life would 
be gained over 25 years. This is very similar to 
the health gain that could be achieved by a 
reduction of 2% in the proportion of smokers 
in the population. The latter might, arguably, 
be easier to achieve. ' 
The reason for the interventions having little 
effect on the CHD mortality rate for the popu- 
lation up to the age of 95 is that the majority 
of deaths from CHD in the population occur 
Nadoo, 771oro/ond, McPheno., nd 
in those over the age of 63, while these in- 
terventions concentrate on those under 65. The 
most effective strategy would achieve a 2.6% 
reduction for men and a 2% reduction for 
women in CHD mortality up to 65 years. 
The greater effect of strategy I as compared 
with strategy 2 could be because more people 
receive the intervention, since 39.3% of the 
population aged between 15 and 64 are mod- 
erately active, while only 10.7% are vigorously 
active. Increasing each category by 25% results 
in 49.1% of the population in this age group 
undertaking moderate activity and 13.4% un- 
dertaking vigorous activity. 
The proportion of the population at risk of 
CHD in the older age group has a significant 
impact on the relative effectiveness of the in- 
terventions by age group. This is emphasised 
when using attenuated relative risks for the 
older age group in the simulation, since the 
actual years of life gained for this site group 
still outweighs that for the younger sac group, 
even though the younger age group has higher 
relative risks. 
The use of the cohort option in the sim- 
ulation showed that the targeting of older age 
group, was still more effective, in terms of the 
actual years of life gained over 25 years, than 
targeting younger cohorts who would retain 
their new physical activity levels over time. This 
again may be an implication of the influence 
of the higher CHD mortality rates among the 
older age groups in the England and Wales 
population on the impact of these interventions. 
The marked difference between the results 
for men and women reflects the fact that women 
have a much lower mortality rate for CHI) 
than men, particularly between the ages of 
25 and 64 where the difference in the CUD 
mortality rate ranges from three to six and a 
half times lower for women. 
There are a number of problems with using 
Prevent, most of which have been discussed 
when describing the assumptions we have had 
to make in order to fit physical activity data 
into the model. These include the fact that 
the model was initially designed for shifting 
exposure groups to non-exposure groups and 
having to use multiples of five for the age group 
divisions. One of the major drawbacks has been 
the lack of any estimate of changes in morbidity, 
especially if physical activity has much bigger 
effects on the prevalence of non-fatal disease. 
Work is currently underway to develop a new 
version; which takes into account morbidity, 
and this will greatly increase the applicability 
of the model. 
The Prey nr model may have underestimated 
the gain in mortality reduction from increasing 
physical activity. Since there is no clear under- 
standing of the relationship between physical 
activity and other established CHD risk factors 
such as hypertension, hyperlipidaemia, and 
obesity, we have assumed that physical activity 
will not affect the prevalence of these risk fac- 
tors. We have also assumed that increased phys- 
ical activity will not affect mortality from any 
other cause of death included in the Prevent 
model. new are cerebrovasculsr accident, 
chronic obstructive lung disease, lung cancer, 
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cirrhosis of the liver, breast cancer, traffic ac- 
cidents, and accidental falls. 
Even if Aswm has underestimated the total 
gain possible from increasing physical activity, 
the relative gain of different strategies carries 
an important message. Our work with Auvart 
indicates that the greatest health gain can be 
achieved by concentrating on sedentary people, 
on older people, and on men. This may seem 
a contradiction of Rose's" argument that pre- 
ventive strategies which concentrate on a mi- 
norky at high risk produce less health gain than 
strategies which intervene across the whole 
population, since the minority at high risk con- 
tribute a small proportion of adverse events. 
However, the majority of older men (45 plus) 
do not undertake even moderate exercise, and 
older men account for about 67% of coronary 
death under the age of 75. In this case, then, 
the most effective strategy is the one which 
concentrates on that section of the population 
which is contributing the majority of deathsl. 
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Appsaft I 
DMC MIT1IODOLOGY OF THE fEEVEWP MODEL 
Figure 5 Wustntes the buic version of the 
Pmvem model. 
a 
AIDIý''""- 
PID R"" "" ý- PIDR; ""' A ýýý PID14 
PIP'"'ý' 
PIDR"ý-P1DM'-"A 
ý PIDR: 
M! ""ýM'"- TIP"-"M""' 
Ma''- M""- Ii[i-(TTP, '")(I-PIP; °-)jM.. - 
Where: 
A: index for ape. 
t: index for time. 
is index for ex-exposure level. 
P: proportion. 
ID: total number of ex-exposure levels. 
IDR: incidence density ratio. 
PIP: potential impact fraction - the incidence 
that is avoided by a preventive intervention as 
a Proportion of the incidence that would have 
occurred in that population without the inter- 
vention. 
TIF: trend impact friction - the incident cases 
prevented at S certain moment in time, by an 
autonomous change in risk factor prevalence, as 
a proportion of the incident cases that would have 
occurred at that time in the absence of change. LAT: the period between the end of exposure 
to the risk factor and the first effect on disease 
specific mortality. 
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at: total number of exposure categories. 
n: index for exposure category. 
r. index for risk factor. 
j-0,1: index for trend (0) or intervention 
population (1). 
a: index for sex. 
z: index for disease. 
M"": constant overall mortality quotient. 
Mj'": adjusted overall mortality quotient. 
M--': disease specific mortality quotient. 
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Table 5 exemplifies an intervention on 
one risk factor for one age group with no background trends for that risk factor. It 
shows that this intervention will result in a 
reduction of 1.7% in CHD mortality for men 
aged 55-64. 
Appendix 2 
Tables 6,7, and 8 below give the data on which figures 2,3, and 4 am based. 
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Appendix F- Input Data for the Birmingham, Small Heath and Sutton 
Coldfield Versions of the Prevent Model 
Birmin gham Small Heath Sutton Coldfleld 
Age Male Female Male Female Male Female 
0 7901 7388 979 889 535 503 
1 8002 7492 983 906 525 490 
2 8033 7529 980 913 522 482 
3 8000 7507 970 912 526 479 
4 7914 7434 954 903 532 480 
5 7782 7319 934 887 540 484 
6 7614 7170 909 866 548 491 
7 7418 6996 882 841 553 501 
8 7203 6805 852 813 555 512 
9 6983 6609 822 784 554 525 
10 6771 6421 792 754 552 538 
11 6583 6253 763 726 552 551 
12 6436 6122 737 701 558 564 
13 6344 6040 716 681 573 576 
14 6316 6014 700 667 593 586 
15 6269 5971 680 650 616 597 
16 6275 5979 666 637 635 607 
17 6505 6188 673 651 649 607 
18 7021 6658 708 700 653 594 
19 7730 7303 763 771 651 574 
20 8511 8014 826 853 647 549 
21 9199 8642 879 923 643 528 
22 9699 9106 906 960 640 517 
23 9921 9330 896 951 636 520 
24 9920 9358 858 907 633 534 
25 9869 9342 811 853 629 550 
26 9808 9315 769 804 624 565 
27 9610 9161 727 758 621 579 
28 9261 8866 691 719 621 593 
29 8803 8466 657 686 622 605 
30 8282 8010 622 651 626 621 
31 7768 7559 584 612 630 637 
32 7312 7151 550 576 629 646 
33 6955 6821 523 542 622 647 
34 6683 6560 500 512 612 642 
Table F. 1a - Population structures of Birmingham, Small Heath and Sutton Coldfield by age (0 to 34 
years) and sex 
348 
Birmin gham Small Heath Sutton Coldfleld 
Age Male Female Male Female Male Female 
35 6409 6291 479 482 598 632 
36 6138 6026 459 453 588 625 
37 5962 5859 437 429 594 633 
38 5906 5816 411 411 623 662 
39 5935 5859 385 396 666 703 
40 6014 5954 359 384 714 750 
41 6074 6024 337 374 755 788 
42 6064 6015 319 362 779 807 
43 5947 5886 309 349 780 802 
44 5752 5671 303 335 763 777 
45 5545 5438 300 322 742 748 
46 5370 5241 299 311 723 721 
47 5213 5075 302 307 697 691 
48 5086 4960 312 309 664 659 
49 4986 4886 325 318 626 628 
50 4888 4821 341 328 585 593 
51 4794 4756 357 338 545 559 
52 4733 4710 370 345 517 537 
53 4713 4685 379 350 506 530 
54 4722 4678 386 352 508 535 
55 4741 4683 390 354 512 544 
56 4759 4695 395 356 513 550 
57 4780 4714 399 356 517 555 
58 4801 4739 403 354 520 555 
59 4819 4768 407 349 524 551 
60 4836 4796 410 345 529 549 
61 4843 4825 411 340 533 546 
62 4822 4862 403 331 528 542 
63 4767 4909 386 320 512 533 
64 4682 4958 361 306 488 522 
65 4585 5009 332 290 461 509 
66 4478 5044 305 275 435 497 
67 4341 5038 282 264 410 487 
68 4171 4980 266 259 387 480 
69 3975 4880 254 259 367 474 
70 3760 4758 244 259 346 470 
Table F. 1b - Population structures of Birmingham, Small Heath and Sutton Goldfield by age (35 to 70 years) and sex 
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Birmin gham Small Heath Sutton Coldfleld 
Age Male Female Male Female Male Female 
71 3543 4633 231 257 324 463 
72 3339 4511 218 255 305 454 
73 3160 4402 202 251 289 442 
74 2997 4297 185 245 277 428 
75 2839 4185 169 239 266 412 
76 2668 4052 153 233 254 397 
77 2475 3896 138 224 239 381 
78 2254 3712 123 211 219 363 
79 2014 3505 109 195 196 345 
80 1774 3292 95 177 173 323 
81 1545 3072 82 160 151 302 
82 1321 2827 70 146 132 285 
83 1106 2552 60 136 118 275 
84 904 2258 52 131 107 269 
85 748 1996 36 94 86 203 
86 613 1759 30 83 71 179 
87 484 1496 23 71 56 152 
88 378 1248 18 59 44 127 
89 286 1036 14 49 33 105 
90 218 845 11 40 25 86 
91 148 648 7 31 17 66 
92 102 486 5 23 12 49 
93 72 361 3 17 8 37 
94 49 270 2 13 6 28 
95+ 103_ 1 654 5 31 12 67 
Table F. 1c - Population structures of Birmingham, Small Heath and Sutton Coldfield by age (71 to 95 plus years) and sex 
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Birmin gham Small Heath Sutton Coldfleld 
Age Male Female Male Female Male Female 
0 1175.23 1009.97 1560.96 1074.27 559.19 634.26 
1 59.96 77.38 121.96 88.26 0.00 0.00 
2 44.81 37.18 40.80 65.67 38.28 0.00 
3 42.49 50.61 123.61 21.93 0.00 0.00 
4 20.22 21.52 20.95 22.15 0.00 41.67 
5 15.42 27.32 42.82 45.07 0.00 0.00 
6 18.39 8.37 43.98 23.08 0.00 0.00 
7 18.87 14.29 22.68 0.00 0.00 0.00 
8 24.99 11.75 70.38 24.59 0.00 0.00 
9 5.73 12.10 0.00 0.00 0.00 0.00 
10 20.67 12.46 25.26 53.05 0.00 0.00 
11 21.27 12.79 26.21 27.56 0.00 0.00 
12 34.18 9.80 27.12 0'. 00 71.67 0.00 
13 47.27 16.56 55.84 0.00 0.00 69.46 
14 15.83 26.60 0.00 29.96 0.00 0.00 
15 44.66 20.09 88.14 0.00 64.95 0.00 
16 38.24 20.07 60.08 31.39 31.47 0.00 
17 43.03 9.70 59.44 30.72 30.82 0.00 
18 71.19 36.04 0.00 28.58 61.21 0.00 
19 67.25 32.86 104.83 25.94 153.52 69.72 
20 65.77 29.94 96.76 46.86 61.84 36.43 
21 45.65 27.77 45.47 21.67 31.08 113.51 
22 72.15 26.35 88.22 104.10 93.75 0.00 
23 74.56 32.15 66.94 63.07 62.85 0.00 
24 68.53 38.46 116.52 44.07 31.59 0.00 
25 101.28 36.39 295.51 23.44 63.59 72.66 
26 61.16 27.91 78.01 0.00 32.04 70.83 
27 60.34 37.11 82.45 52.76 96.53 0.00 
28 77.71 22.56 173.63 0.00 32.21 0.00 
29 79.49 37.79 152.02 29.17 128.53 33.03 
30 103.79 27.46 128.57 30.73 127.72 0.00 
31 72.06 66.13 102.68 97.93 63.50 0.00 
32 101.15 69.90 36.33 138.81 31.79 0.00 
33 86.23 49.83 152.89 36.87 64.27 30.92 
34 104.69 82.29 40.01 117.22 32.67 124.54 
35 115.40 108.04 125.06 0.00 100.34 126.56 
Table F. 2a - Mortality probability per 100,000 in 1 year age groups for Birmingham, Small Heath 
and Sutton Coldfield by age (0 to 35 years) and sex, 1989-1993 
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Birmin gham Small Heath Sutton Coldfleld 
Age Male Female Male Female Male Female 
36 127.01 76.31 43.57 0.00 170.00 127.90 
37 187.68 109.18 228.75 93.10 134.56 157.81 
38 216.48 116.86 388.21 146.03 96.32 30.22 
39 205.34 139.85 363.35 201.92 90.07 85.27 
40 199.34 127.57 222.75 156.04 55.98 79.97 
41 233.52 139.34 296.65 373.98 211.83 126.88 
42 224.03 109.66 374.94 55.17 153.99 49.53 
43 255.29 156.18 258.80 228.79 102.55 99.72 
44 288.19 225.47 197.50 238.19 157.21 205.67 
45 349.23 213.09 597.81 310.23 188.45 187.05 
46 364.31 282.01 400.95 448.67 110.59 166.31 
47 386.75 228.30 396.19 195.47 200.71 202.40 
48 408.14 269.78 384.31 451.39 210.73 181.80 
49 536.12 253.47 979.26 690.03 350.65 159.16 
50 591.58 298.24 817.47 607.61 341.58 235.89 
51 685.97 386.17 1115.08 236.67 366.19 392.54 
52 673.78 381.45 861.05 519.68 770.06 297.42 
53 916.71 430.22 1361.09 171.16 630.07 225.96 
54 872.86 588.22 1134.40 791.19 510.91 298.48 
55 1032.33 515.43 1172.00 450.66 390.18 367.07 
56 1061.90 658.12 958.60 839.37 698.78 615.96 
57 1139.97 739.67 1147.26 951.04 501.92 539.39 
58 1361.14 702.27 1721.92 788.77 460.04 503.45 
59 1499.32 868.61 1416.30 1307.70 836.48 362.05 
60 1669.16 896.69 1787.62 923.32 1053.15 545.44 
61 1991.33 1006.33 2072.18 1170.90 1305.94 801.94 
62 1893.83 1181.80 2352.32 1080.62 1242.61 1065.13 
63 2317.96 1299.33 2255.38 1429.18 1704.20 896.18 
64 2472.34 1386.02 3431.05 1236.17 1384.53 801.11 
65 2723.43 1537.25 3719.78 1914.48 1551.08 898.95 
66 2805.18 1928.29 3286.00 3431.22 1733.30 1438.25 
67 3614.61 1786.26 3891.02 2096.69 2172.88 1468.62 
68 3837.92 2180.99 4845.60 2737.81 3401.62 1325.86 
69 4418.32 2469.15 4386.16 2895.94 3640.16 1589.22 
70 4578.81 2765.20 5198.63 3194.26 3970.98 1730.99 
Table F. 2b - Mortality probability per 100,000 in 1 year age groups for Birmingham, Small Heath 
and Sutton Coldfield by age (36 to 70 years) and sex, 1989-1993 
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Birmin gham Small Heath Sutton Cold- 
field-Age Male Female Male Female Male Female 
71 4605.25 2582.51 4895.80 3884.77 3758.35 1670.17 
72 5271.44 2702.97 6920.69 3769.40 3419.42 2349.37 
73 5740.98 2932.49 7061.27 3524.93 4062.56 2588.88 
74 6112.86 3367.72 8169.98 2897.94 4867.10 2356.76 
75 6364.13 3719.26 7517.96 4097.24 5422.39 3196.84 
76 7170.87 4094.99 8370.29 4778.03 4397.20 3512.49 
77 7758.45 4373.27 8325.64 5732.20 5939.55 3712.28 
78 8527.20 4744.32 9865.13 6523.10 8316.12 4259.40 
79 9560.19 5310.94 13339.32 6073.42 9596.77 4869.52 
80 9912.49 6159.67 12413.89 9275.54 8958.76 5707.15 
81 11391.51 6597.32 12152.06 7250.67 13716.57 5850.32 
82 12183.49 7641.40 14527.97 8677.99 12228.94 6838.21 
83 12950.24 8495.98 14430.46 10021.85 10742.00 6806.87 
84 14698.74 8937.31 15868.31 9059.75 14504.09 7926.16 
85 14991.60 9362.27 5993.39 2753.73 13304.20 10344.13 
86 15952.62 10715.52 6397.54 3167.64 14165.34 11830.50 
87 17103.65 11927.55 6884.93 3541.90 15198.05 13159.87 
88 17277.42 13024.29 6958.83 3883.50 15354.09 14361.27 
89 19662.69 14455.06 7981.77 4333.39 17499.27 15926.40 
90 20661.29 15231.70 8414.82 4579.64 18399.19 16774.95 
91 23577.60 17350.89 9696.01 5258.99 21033.67 19086.67 
92 25830.06 18873.26 10702.76 5753.84 23074.88 20744.04 
93 24629.51 21185.86 10164.28 6516.71 21986.22 23256.45 
94 29194.57 24195.71 12235.28 7530.30 26134.36 26516.84 
95+ 25699.53 22780.68 10644.00 7050.82 22956.44 24985.35 
Table F. 2c - Mortality probability per 100,000 in 1 year age groups for Birmingham, Small Heath 
and Sutton Coldfield by age (71 to 95 plus years) and sex, 1989-1993 
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Table F. 3 - Birth proj 
Year Birmingham Sutton 
Coldfleld 
Small 
Heath 
1991 8180 488 1147 
1992 8188 463 1097 
1993 8150 418 1071 
1994 8078 432 1109 
1995 7970 423 1066 
1996 7829 434 1142 
1997 7676 429 1128 
1998 7527 422 1110 
1999 7389 413 1086 
2000 7268 405 1064 
2001 7163 396 1043 
2002 7072 389 1023 
2003 7006 382 1005 
2004 6956 376 989 
2005 6930 371 976 
2006 6924 367 966 
2007 6932 365 959 
2008 6954 363 955 
2009 6983 362 954 
2010 7021 361 949 
2011 7065 360 947 
2012 7108 360 946 
2013 7149 360 946 
2014 7181 360 946 
2015 7205 355 935 
2016 7205 351 923 
2017 7205 346 911 
2018-41 7205 341 897 
tions for B irmingham. Small Heath a nd Suttoi Coldfield, 1991-2041 
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Age 
Birmi 
Male 
ngham 
Female 
Sutton Coldfield 
Male Female 
Small Heath 
Male Female 
0 72.0 78.1 75.6 80.4 69.8 76.5 
1 71.9 77.9 75.2 80.0 69.8 76.3 
2 70.9 77.0 74.2 79.0 68.9 75.4 
3 69.9 76.0 73.2 78.0 68.0 74.5 
4 69.0 75.0 72.2 77.0 67.0 73.5 
5 68.0 74.0 71.2 76.0 66.1 72.6 
6 67.0 73.1 70.2 75.0 65.1 71.6 
7 66.0 72.1 69.2 74.0 64.1 70.6 
8 65.0 71.1 68.2 73.0 63.1 69.7 
9 64.0 70.1 67.2 72.0 62.1 68.7 
10 63.0 69.1 66.2 71.0 61.1 67.7 
11 62.0 68.1 65.2 70.0 60.1 66.7 
12 61.0 67.1 64.2 69.0 59.1 65.7 
13 60.1 66.1 63.2 68.1 58.2 64.8 
14 59.1 65.1 62.2 67.1 57.2 63.8 
15 58.1 64.1 61.2 66.1 56.2 62.8 
16 57.1 63.2 60.2 65.1 55.2 61.8 
17 56.2 62.2 59.3 64.1 54.3 60.8 
18 55.2 61.2 58.3 63.1 53.3 59.9 
19 54.2 60.2 57.4 62.1 52.4 58.9 
20 53.3 59.2 56.4 61.1 51.4 57.9 
21 52.3 58.2 55.4 60.1 50.4 56.9 
22 51.3 57.3 54.5 59.1 49.5 56.0 
23 50.3 56.3 53.5 58.2 48.5 55.0 
24 49.4 55.3 52.6 57.2 47.6 54.1 
25 48.4 54.3 51.6 56.2 46.6 53.1 
26 47.5 53.3 50.6 55.2 45.7 52.1 
27 46.5 52.3 49.7 54.2 44.8 51.1 
28 45.5 51.4 48.7 53.3 43.8 50.1 
29 44.6 50.4 47.8 52.3 42.9 49.1 
30 43.6 49.4 46.8 51.3 42.0 48.1 
31 42.6 48.4 45.8 50.3 41.0 47.1 
32 41.7 47.4 44.8 49.3 40.0 46.2 
33 40.7 46.5 43.9 48.4 39.1 45.2 
34 39.7 45.5 42.9 47.4 38.1 44.3 
35 38.8 44.5 41.9 46.4 37.1 43.3 
Table F. 4a - Life expectancy in 1 year age groups for Birmingham, Small Heath and Sutton Coldfield by age (0 to 35 years) and sex, 1990-1992 
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Birmin gham Sutton Coldfield Small Heath 
Age Male Female Male Female Male Female 
36 37.8 43.6 40.9 45.5 36.2 42.3 
37 36.9 42.6 40.0 44.5 35.3 41.4 
38 36.0 41.6 39.0 43.6 34.3 40.4 
39 35.0 40.7 38.1 42.6 33.4 39.5 
40 34.1 39.8 37.1 41.7 32.5 38.5 
41 33.2 38.8 36.2 40.7 31.6 37.6 
42 32.3 37.9 35.2 39.8 30.7 36.7 
43 31.4 36.9 34.3 38.8 29.7 35.7 
44 30.5 36.0 33.3 37.9 28.8 34.8 
45 29.5 35.1 32.4 36.9 27.9 33.9 
46 28.6 34.1 31.5 36.0 27.1 33.0 
47 27.8 33.2 30.5 35.0 26.3 32.1 
48 26.9 32.3 29.6 34.1 25.4 31.3 
49 26.0 31.4 28.6 33.1 24.6 30.4 
50 25.1 30.5 27.7 32.2 23.8 29.5 
51 24.3 29.6 26.8 31.3 23.0 28.6 
52 23.4 28.7 26.0 30.4 22.2 27.7 
53 22.6 27.8 25.1 29.4 21.5 26.8 
54 21.8 26.9 24.3 28.5 20.7 25.9 
55 21.0 26.1 23.4 27.6 19.9 25.0 
56 20.2 25.2 22.5 26.7 19.1 24.2 
57 19.4 24.3 21.6 25.8 18.3 23.4 
58 18.6 23.5 20.7 25.0 17.5 22.6 
59 17.9 22.7 19.8 24.1 16.7 21.8 
60 17.1 21.9 18.9 23.2 15.9 21.0 
61 16.4 21.1 18.2 22.4 15.2 20.2 
62 15.7 20.3 17.4 21.5 14.5 19.5 
63 15.0 19.5 16.7 20.7 13.9 18.7 
64 14.4 18.7 15.9 19.8 13.2 18.0 
65 13.7 18.0 15.2 19.0 12.5 17.2 
66 13.1 17.3 14.5 18.2 12.0 16.6 
67 12.4 16.6 13.8 17.4 11.4 15.9 
68 11.8 15.9 13.2 16.7 10.9 15.3 
69 11.3 15.2 12.5 15.9 10.3 14.6 
70 10.8 14.6 11.8 15.1 9.8 14.0 
Table F. 4b - Life expectancy in 1 year age groups for Birmingham, Small Heath and Sutton Coldfield by age (36 to 70 years) and sex, 1990-1992 
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Table 
Birmin gham Sutton Coldfleld Small Heath 
Age Male Female Male Female Male Female 
71 10.4 14.0 11.2 14.4 9.3 13.4 
72 9.8 13.4 10.7 13.7 8.9 12.8 
73 9.3 12.8 10.1 13.0 8.4 12.2 
74 8.8 12.1 9.6 12.3 8.0 11.6 
75 8.3 11.5 9.0 11.6 7.5 11.0 
76 7.9 10.9 8.5 11.0 7.1 10.5 
77 7.4 10.4 8.1 10.4 6.7 10.0 
78 7.0 19.8 7.6 9.9 6.3 9.4 
79 6.7 9.3 7.2 9.3 5.9 8.9 
80 6.3 8.8 6.7 8.7 5.5 8.4 
81 6.0 8.3 6.5 8.2 5.2 8.1 
82 5.6 7.8 6.3 7.7 5.0 7.8 
83 5.4 7.4 6.1 7.2 4.7 7.4 
84 5.1 7.1 5.9 6.7 4.5 7.1 
85+ 5.0 6.7 5.7 6.2 4.2 6.8 
F. 4c - Life e xpectancy in 1 year a ge groups f or Birmingh am, Small Heath and Goldfield by age (71 to 85 plus years) and sex, 1990-1992 
Alcohol Male Male Male Female Female Female 
Age 
Groups 
<10 
units 
11-21 
units 
>21 
units 
<7 
units 
7-14 
units 
>14 
units 
15 - 24 63.6 29.1 7.3 50.9 41.4 7.7 
25 - 34 46.6 42.1 11.3 48.0 47.3 4.7 
35 - 44 35.9 49.5 14.6 51.9 43.1 5.0 
45-54 31.1 53.7 15.2 62.1 33.7 4.2 
55 - 64 34.0 53.4 12.6 73.7 23.1 3.2 
65+ 38.7 50.6 10.8 82.5 14.3 3.2 
Table F. 5 - Prevalence of alcohol consumption in the Birmingham population 
Male Sedentary Light 
Activity 
Moderate 
Activity 
Vigorous 
Activity 
15 - 24 14.1 15.4 34.6 35.9 
25 - 34 15.9 20.3 29.5 34.2 
35 - 44 19.3 28.9 24.6 27.3 
45 - 54 23.6 30.6 23.6 22.3 
55 - 64 30.6 26.4 20.8 22.3 
65+ 36.3 24.6 18 21.1 
Female Sedentary Light 
Activity 
Moderate 
Activity 
Vigorous 
Activity 
15 - 24 18.9 25.3 28.4 27.4 
25 - 34 19.8 28.2 27.2 24.8 
35 - 44 22.2 32.4 25.5 20.0 
45 - 54 23.8 32.9 23.1 20.1 
55 - 64 29.4 31.2 19.3 20.1 
65+ 39.8 27.1 16.6 16.5 
Table F. 6 - Prevalence of physical activity levels in the Birmingham population 
utton 
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Male Never 
Smoked 
Ex- 
Smokers 
1-9 
cigarettes 
10 - 20 
cigarettes 
20+ 
cigarettes 
15 - 24 65.3 6.0 11.1 14.1 3.5 
25-34 51.9 17.0 6.3 10.7 14.1 
35 - 44 41.7 28.6 7.1 8.8 13.8 
45-54 32.9 36.8 5.1 7.6 17.7 
55-64 24.2 50.2 3.1 8.8 13.7 
65+ 21.1 62.7 4.9 6.0 5.3 
Female Never 
Smoked 
Ex- 
Smokers 
1-9 
cigarettes 
10 - 20 
cigarettes 
20+ 
cigarettes 
15 - 24 63.3 13 7.7 10.1 5.8 
25-34 56.8 13.7 9.8 11.4 8.3 
35-44 49.4 18.4 7.1 11.6 13.5 
45-54 46.4 27.7 5.0 7.6 13.3 
55-64 52.8 24.3 6.9 11.0 5.0 
65+ 57.0 28.9 6.7 4.6 2.8 
Table F. 7 - Prevalence of cigarette smoking in the Birmingham population 
Cholesterol Male Female 
Age Groups Normal Mild Severe Normal Mild Severe 
15-24 97.5 2.5 0.0 93 5.3 1.8 
25 - 34 83.3 12.1 4.5 87.4 12.1 0.5 
35 - 44 73.3 20.7 6 88.2 10 1.8 
45 - 54 66.0 25.1 8.9 59.4 33.3 7.3 
55 - 64 62.8 29.3 7.9 50.0 37.3 12.7 
65+ 67.0 28.0 4.9 43.2 36.6 20.2 
Table F. 8 - Prevalence of hypercholesterolaemia levels in the Birmingham population 
Hypertension Male Female 
Age Groups Normal Mild Severe Normal Mild Severe 
15 - 24 96.0 2.9 1.1 99.4 0.6 0.0 
25 - 34 92.8 4.7 2.5 97.2 0.8 2.0 
35-44 83.2 7.8 9.0 92.3 5.5 2.2 
45 - 54 68.8 15.0 16.3 86.0 6.0 8.1 
55-64 68.4 11.8 19.8 84.9 7.6 7.6 
65+ 66.7 13.1 20.3 73.5 11.0 15.5 
Table F. 9 - Prevalence of hypertension levels in the Birmingham population 
Hypertension Male Female 
Age Groups Untreated 20% 
Screening 
40% 
Screening 
Untreated 20% 
Screening 
40'/6 
Screening 
15-24 3.6 0.7 1.4 0.0 0.0 0.0 
25 - 34 5.3 1.1 2.1 2.5 0.5 1.0 
35 - 44 10.7 2.1 4.3 3.5 0.7 1.4 
45 - 54 14.5 2.9 5.8 
9.5 1.9 3.8 
55 - 64 23.3 4.7 9.3 15.8 3.1 6.3 
65+ 
T, mkIo C in 
37.3 
- Provnipnr. 
7.5 14.9 34.6 
p of untreated hvaertensives in the Bir 
6.9 13.8 
minaham nonulation I 
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Alcohol Male Male Male Female Female Female 
Age 
Groups 
<10 
units 
11-21 
units 
>21 
units 
<7 
units 
7-14 
units 
>14 
units 
15 - 24 75.7 24.3 0.0 75.4 24.6 0.0 
25 - 34 75.7 21.0 3.3 66.2 33.8 0.0 
35 - 44 55.6 16.0 28.3 72.4 23.4 4.2 
45 - 54 65.6 9.4 25.0 82.3 13.5 4.2 
55-64 87.5 12.5 0.0 90.6 9.4 0.0 
65+ 72.1 27.9 0.0 92.3 7.7 0.0 
Table F. 11 - Prevalence of alcohol consumption in the Small Heath population 
Alcohol Male Male Male Female Female Female 
Age 
Groups 
<10 
units 
11-21 
units 
>21 
units 
<7 
units 
7-14 
units 
>14 
units 
15 - 24 16.3 45.5 38.2 34.3 41.4 24.3 
25 - 34 21.5 49.8 28.6 49.3 46.9 3.8 
35 - 44 26.1 55.1 18.9 45.7 51.9 2.4 
45 - 54 30.5 49.1 20.4 56.7 41.1 2.2 
55 - 64 44.6 40.7 14.6 72.8 25.2 2.0 
65+ 55.7 37.5 6.8 84.6 12.5 2.9 
Table F. 12 - Prevalence of alcohol consumption in the Sutton Coldfield population 
Male Sedentary Light 
Activity 
Moderate 
Activity 
Vigorous 
Activity 
15 - 24 18.8 17.6 44.9 18.8 
25 - 34 27.0 33.5 24.0 15.5 
35 - 44 32.1 30.5 20.7 16.8 
45 - 54 33.3 10.7 23.0 33.0 
55 - 64 34.8 18.5 20.6 26.1 
65+ 39.6 22.3 22.5 15.6 
Female Sedentary Light 
Activity 
Moderate 
Activity 
Vigorous 
Activity 
15 - 24 21.2 26.6 34.0 18.2 
25 - 34 25.9 22.8 25.6 25.7 
35-44 40.9 19.1 15.6 24.3 
45 - 54 54.9 18.9 11.5 14.7 
55 - 64 66.5 14.2 12.1 7.1 
65+ 75.7 9.7 9.7 4.9 
Table F. 13 - Prevalence of physical activity levels in the Small Heath population 
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Male Sedentary Light 
Activity 
Moderate 
Activity 
Vigorous 
Activity 
15 - 24 9.1 12.7 41.4 36.7 
25 - 34 13.4 18.3 32.7 35.6 
35 - 44 20.8 31.7 23.1 24.4 
45-54 24.0 35.6 23.5 16.8 
55-64 30.5 27.1 21.4 21.0 
65+ 44.0 17.2 17.5 21.3 
Female Sedentary Light 
Activity 
Moderate 
Activity 
Vigorous 
Activity 
15 - 24 9.6 31.8 23.9 34.6 
25-34 22.6 35.8 22.6 19.1 
35 - 44 23.9 32.6 22.6 20.9 
45 - 54 22.9 33.5 20.8 22.8 
55 - 64 30.9 33.2 19.2 16.6 
65+ 48.4 25.9 14.0 11.8 
Table F. 14 - Prevalence of physical activity levels in the Sutton Coldfield population 
T 
Male Never 
Smoked 
Ex- 
Smokers 
1-9 
cigarettes 
10 - 20 
cigarettes 
20+ 
cl arettes 
15-24 61.8 12.9 4.9 12.7 7.7 
25-34 50.9 19.8 18.2 9.4 1.6 
35 - 44 31.1 24.5 27.7 11.8 4.9 
45-54 22.0 24.6 19.3 19.3 14.8 
55 - 64 27.4 34.9 18.3 9.7 9.7 
65+ 26.0 39.7 13.4 17.8 3.1 
Female Never 
Smoked 
Ex- 
Smokers 
1-9 
cigarettes 
10 - 20 
cigareftes 
20+ 
cigarettes 
15 - 24 77.0 3.7 2.4 16.1 0.8 
25 - 34 63.3 8.7 6.6 18.7 2.7 
35 - 44 56.5 18.0 6.0 18.1 1.4 
45-54 59.1 18.8 5.9 16.2 0.0 
55 - 64 60.1 10.8 16.3 12.9 0.0 
65+ 50.8 22.0 18.2 9.1 0.0 
hip F15- PrPvalAnce of cigarette smokina in the Small H eath conulati n 
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Male Never 
Smoked 
Ex- 
Smokers 
1-9 
cigarettes 
10 - 20 
cigareftes 
20+ 
cigarettes 
15 - 24 47.2 13.4 26.2 11.7 1.5 
25 - 34 64.3 11.5 12.3 8.6 3.4 
35-44 54.3 24.7 10.2 7.2 3.6 
45 - 54 34.7 40.9 12.1 8.6 3.7 
55 - 64 26.5 55.0 7.9 9.2 1.5 
65+ 20.4 70.2 6.2 2.7 0.5 
Female Never 
Smoked 
Ex- 
Smokers 
1-9 
cigarettes 
10 - 20 
cigarettes 
20+ 
cigarettes 
15 - 24 41.9 22.6 25.2 10.4 0.0 
25-34 60.8 19.7 8.9 7.5 3.0 
35 - 44 62.3 23.5 5.0 7.0 2.2 
45 - 54 58.9 29.1 5.7 5.1 1.2 
55 - 64 48.5 37.8 6.9 4.1 2.8 
65+ 48.8 38.0 8.2 3.8 1.3 
Table F. 16 - Prevalence of cigarette smoking in the Sutton Coldfield population 
Age 
Groups 
Lung Cancer COLD IHD CVA 
Males Females Males Females Males Females Males Females 
0-4 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000015 0.000011 
5-9 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000005 . 000000 
10-14 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000006 
15-19 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000012 0.000006 
20-24 0.000004 0.000000 0.000000 0.000000 0.000017 0.000000 0.000013 0.000013 
25-29 0.000000 0.000000 0.000000 0.000000 0.000017 0.000004 0.000017 0.000022 
30-34 0.000011 0.000006 0.000000 0.000000 0.000032 0.000006 0.000011 0.000011 
35-39 0.000040 0.000013 0.000000 0.000000 0.000237 0.000047 0.000033 0.000080 
40-44 0.000141 0.000061 0.000000 0.000014 0.000590 0.000095 0.000107 0.00 1115 
45-49 0.000313 0.000141 0.000015 0.000008 0.001305 0.000234 0.000191 0.000227 
50-54 0.000855 0.000288 0.000067 0.000068 0.002784 0.000567 0.000436 0.000271 
55-59 0.001397 0.000517 0.000251 0.000212 0.004393 0.001466 0.000678 0.000517 
60-44 0.002422 0.001027 0.000668 0.000312 0.007457 0.002678 0.001403 0.000945 
65-69 0.004845 0.001555 0.001494 0.000938 0.011963 0.005082 0.002348 0.00 6667 
70-74 0.005786 0.001823 0.003155 0.001274 0.017083 0.008159 0.004762 0.003133 
75--79 0.006073 0.001705 0.004980 0.001426 0.023690 0.012362 0.008980 0.00 7718 
80-84 0.007880 0.001929 0.007579 0.001729 0.034105 0.020714 0.014105 0.013514 
85-90 0.007400 0.001020 0.010437 0.002640 0.044498 0.028866 0.021851 0.021342 
90- 44 0.005608 0.000832 0.013503 0.003621 0.058896 0.041925 0.032798 0.035038 
95+ 0.003268 0.000835 0.014254 0.004053 0.069096 0.050799 0.035781 0.043263 
able F. 1 7a - Disease specmc mortainy prouaomq in 1 year age groups Tor csirmmgnam oy age 
and sex, 1989-1993 
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Age 
Groups 
Cirrhosis Accidental Falls Traffic Accidents Breast 
Cancer 
Males Females Males Females Males Females Females 
0-4 0.000005 0.000000 0.000000 0.000000 0.000010 0.000016 0.000000 
5-9 0.000000 0.000000 0.000000 0.000000 0.000032 0.000000 0.000000 
10-14 0.000000 0.000000 0.000012 0.000006 0.000025 0.000026 0.000000 
15-19 0.000000 0.000000 0.000012 0.000000 0.000077 0.000025 0.000000 
20-24 0.000004 0.000000 0.000021 0.000004 0.000063 0.000036 0.000000 
25-29 0.000004 0.000004 0.000017 0.000000 0.000046 0.000000 0.000022 
30-34 0.000027 0.000011 0.000022 0.000000 0.000043 0.000000 0.000072 
35-39 0.000079 0.000054 0.000020 0.000007 0.000086 0.000007 0.000161 
4pý4 0.000121 0.000068 0.000013 0.000020 0.000040 0.000000 0.000237 
45-49 0.000176 0.000102 0.000038 0.000016 0.000053 0.000039 0.000516 
50-54 0.000252 0.000101 0.000084 0.000017 0.000050 0.000008 0.000710 
55-59 0.000167 0.000085 0.000042 0.000017 0.000017 0.000051 0.000720 
60-44 0.000167 0.000107 0.000092 0.000041 0.000050 0.000025 0.001076 
65-69 0.000204 0.000152 0.000084 0.000152 0.000084 0.000048 0.001283 
70-74 0.000167 0.000097 0.000179 0.000142 0.000131 0.000071 0.001327 
75-79 0.0 00261 0.000176 0.000294 0.000341 0.000147 0.000083 0.001798 
80-84 
X 
0.000120 0.000186 0.000902 0.000986 0.000241 0.000214 0.002471 
85-90 0.000228 0.000079 0.002099 0.001958 0.000134 0.000131 0.002867 
90-94 0.000049 0.000066 0.003219 0.003956 0.000107 0.000077 0.003952 
95+ 0.000000 0.000048 
able F. 17b - Disease specific mort 
0.004277 
ality probab 
0.005985 0.000000 0.000022 0.005012 
ility in 1 year age groups for Birmingham by ag T 
and sex, 1989-1993 
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Age 
Groups 
Lung Cancer 
Males Females 
COLD 
Males Females 
IHD 
Males Females 
CVA 
Males Females 
0-4 0.000000 0.000000 0.000000 0.000000 0.000000 0.00 0000 0.000000 0.000044 
5-9 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
10-14 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
15-19 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
20-24 0.000004 0.000000 0.000000 0.000000 0.000000 0.000000 0.000046 0.000000 
25-29 0.000000 0.000000 0.000000 0.000000 0.000055 0.000000 0.000000 0.000052 
30-34 0.000000 0.000000 0.000000 0.000000 0.000000 0.000069 0.000000 0.000069 
35-39 0.000000 0.000000 0.000000 0.000000 0.000461 0.000000 0.000092 0.000092 
40-44 0.000123 0.000000 0.000000 0.000000 0.000738 0.000332 0.000123 0.00 2222 
45-49 0.000520 0.000000 0.000000 0.000000 0.001951 0.000893 0.000520 0.000766 
50-54 0.000873 0.000350 0.000109 0.000000 0.004255 0.000817 0.000546 0.000117 
55-59 0.001505 0.000791 0.000401 0.000000 0.004014 0.002261 0.000702 0.001357 
60-64 0.002740 0.001706 0.000507 0.000244 0.007813 0.001950 0.002131 0.001097 
65-69 0.004583 0.001782 0.001250 0.000742 0.012778 0.006978 0.002778 0.002079 
70-74 0.006296 0.002526 0.004630 0.001105 0.016481 0.009313 0.008704 0.003157 
75-79 0.006926 0.002725 0.006061 0.001998 0.024820 0.015259 0.010390 0.007629 
80-84 0.015000 0.002136 0.012778 0.003738 0.036667 0.020828 0.015556 0.017089 
85-90 0.009635 0.001664 0.016950 0.005252 0.045514 0.025845 0.020875 . 019043 
90-94 0.007302 0.001357 0.021927 0.007203 0.060241 0.037539 0.031332 0.031264 
95+ 0.004248 0.001362 0.023145 0.008062 0.070674 0.045484 0.034182 0.038603 
Table F. 18a - Disease specific mortality probability in 1 year age groups for Small Heath by age 
and sex, 1989-1993 
363 
Age 
Groups 
Cirrhosis 
Males Females 
Accidental Falls 
Males Females 
Traffic Accidents 
Males Females 
Breast 
Cancer 
Females 
0-4 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
5-9 0.000000 0.000000 0.000000 0.000000 0.000136 0.000000 0.000000 
10-14 0.000000 0.000000 0.000000 0.000000 0.000000 0.000057 . 000000 15-19 0.000000 0.000000 0.000057 0.000000 0.000000 0.000000 0.000000 
20-24 0.000000 0.000000 0.000046 0.000000 0.000046 0.000044 0.000000 
- 25-29 0.000000 0.000000 0.000000 0.000000 0.000055 0.000000 0. -0-00105 
30-34 0.000000 0.000069 0.000000 0.000000 0.000072 0.000000 0.000069 
35-39 0.000184 0.000092 0.000092 0.000000 0.000184 0.000000 0.000000 
40-44 0.000123 0.000111 0.000000 0.000000 0.000123 0.000000 0.000443 
45-49 0.000390 0.000128 0.000000 0.000000 0.000000 0.000000 0.000511 
50-54 0.000873 0.000000 0.000109 0.000000 0.000109 0.000000 0.000583 
55-59 0.000201 0.000226 0.000000 0.000000 0.000000 0.000113 0.000339 
60-64 0.000203 0.000122 0.000101 0.000122 0.000000 0.000000 0.000731 
65-69 0.000139 0.000297 0.000000 0.000297 0.000000 0.000297 0.001633 
70-74 0.000556 0.000158 0.000000 0.000000 0.000185 0.000000 0.001894 
75-79 0.000289 0.000000 0.000577 0.000000 0.000577 0.000182 0.001635 
80-84 0.000556 0.000267 0.001111 0.000534 0.000000 0.000000 0.002937 
85-90 0.000000 0.000000 0.002281 0.002006 0.000000 0.000000 0.002419 
90-94 0.000000 0.000000 0.003497 0.004052 0.000000 0.000000 0.003335 
95+ 0.000000 0.000000 0.004648 0.006131 0.000000 0.000000 0.004230 
able F. 18b - Disease specific mort ality probabi lity in 1 yea r age groups for Small Heath by at T 
and sex, 1989-1993 
364 
e 
Age 
Groups 
Lung Cancer COLD IHD CVA 
Males Females Males Females Males Females Males Fema es 0-4 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
5-9 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.0 00000 0.000000 
10-14 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
15-19 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
20-24 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 
25-29 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.000064 0.00 9 
30-34 0.000000 0.000000 0.000000 0.000000 0.000064 0.000000 0.000000 0.000 0 
35-39 0.000000 0.000000 0.000000 0.000000 0.000196 0.000000 0.000000 0.000061 
40-44 0.000053 0.000000 0.000000 0.000000 0.000422 0.000000 . 000053 0.000 5 45-49 0.000174 0.000000 0.000000 0.000000 0.000695 0.000232 0.000058 0.000000 
50-54 0.000601 0.000000 0.000000 0.000000 0.001954 0.000073 0.000301 0.000218 
55-59 0.000541 0.000073 0.000000 0.000000 0.002243 0.000799 0.0 0309 0.000073 
60-64 0.001390 0.000966 0.000077 0.000000 0.004712 0.001412 0.000541 0.000520 
65-69 0.003691 0.000572 0.000874 0.000163 0.008159 0.003433 0.001651 0.001389 
70-74 0.003636 0.001241 0.002208 0.000620 0.014156 0.004608 0.003636 0.00204 
75-79 0.003581 0.001686 0.002387 0.000843 0.021654 0.009905 0.006650 0.006428 
80-84 0.005580 0.002062 0.004993 0.001924 0.040822 0.018557 0.014391 0.01 5546 
85-90 0.007516 0.000963 0.006103 0.002757 0.042262 0.028981 0.019485 0.026011 
90-94 0.005696 0.000786 0.007895 0.003781 0.055936 0.042093 0.029247 0.042703 
95+ 
Table F. 1 
0.003314 
9a - Diseas 
0.000789 0.008333 
e specific mortality pro 
0.004232 0.065623 0.051002 
bability in 1 year age groups for Su 
0.031907 
tton oldfle 
0.052278 
d by anA 
and sex, 1989-1993 
-a- 
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Tab 
Age 
Groups 
Cirrhosis 
Males Females 
Accidental Falls 
Males Females 
Traffic Accidents 
Males ema s 
-- 
nest 
Cancer 
ema es 
0-4 0.000000 0.000000 0.000000 0.000000 0.000000 o-0000 00 0.00 0 
5-9 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.00 0 
10-14 0.000000 0.000000 0.000000 0.000000 0.000000 0.0 00071 . 00 15-19 0.000000 0.000000 0.000000 0.000000 0.000125 0.000000 0.000000 
20-24 0.000063 0.000000 0.000000 0.000000 0.000125 0-000000 -106.10-50-0-W 
25-29 0.000000 0.000000 0.000000 0.000000 0.000000 0.000000 0.0 
30-34 0.000000 0.000000 0.000000 0.000000 0.000 228 0.000000 0.00 0 
35-39 0.000000 0.000000 0.000000 0.000000 0.000065 0.000000 0.56012 
40-44 0.000053 0.000000 0.000000 0.000000 0.000 00 0.000000 OVOO 
45-49 0.000058 0.000058 0.000058 0.000058 0.000000 
- - 
0.000058 0.029 
50-54 0.000075 0.000000 0.000000 0.000000 0.050 07 5 0.000000 . 0010 
55-59 0.000077 0.000145 0.000077 0.000000 0.000000 0.000000 08 
60-64 0.000154 0.000074 0.000000 0.000000 0.000000 0.000000 6.00126 
65-69 0.000291 0.000000 0.000000 0.000082 0.000000 0.000000 0.000736 
70-74 0.000390 0.000000 0.000260 0.000000 0.000130 0.00 0 
75-79 0.000000 0.000211 0.000341 0.000632 0.000000 0.000000 0.0021 07 
80-84 0.000000 0.000000 0.000881 0.000687 0.000294 0.000137 0.0023 37 
85-90 0.000000 0.000000 0.000000 0.001460 0.000000 0.0 0214 0.003382 
90-94 0.000000 0.000000 0.000000 0.002949 0.000000 0.000125 0.0046 
- 95+ 0.000000 0.000000 0.000000 0.004462 0.000000 0.000036 0. O W5--87 7 
le F. 1 9b -D isease specific mortali ty probability in 1 year age groups for Sutton oeyE 
nd sex, 1989-1993 
go 
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Appendix G- Biomed II Project: Smoking Interventions Modelling 
Paper (Baan 1999) 
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